Compositions and methods for altering a nucleobase in a lipoprotein(a) polynucleotide

Abstract

The disclosure features compositions and methods for treating cardiovascular disease by introducing one or more alterations into a lipoprotein(a) (LPA) polynucleotide in a cell. In particular embodiments, the disclosure provides a base editor system (e.g., a fusion protein or complex comprising a programable DNA binding protein, a nucleobase editor, and gRNA) for modifying an LPA polynucleotide, where the modification is associated with reduced expression, and / or reduced activity of the LPA polypeptide encoded by the polynucleotide.

Description

[0001] COMPOSITIONS AND METHODS FOR ALTERING A NUCLEOBASE IN A LIPOPROTEIN(A) POLYNUCLEOTIDE

[0002] CROSS REFERENCE TO RELATED APPLICATIONS

[0003] The present application claims priority to U.S. Provisional Application No. 63 / 583,795 filed September 19, 2023, the entire contents of which are hereby incorporated by reference in their entirety.

[0004] SEQUENCE LISTING

[0005] This application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The Sequence Listing XML file, created on September 12, 2024, is named 180802-056102PCT_SL. xml and is 2,559,791 bytes in size.

[0006] BACKGROUND

[0007] Cardiovascular disease (CVD) is the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Over three quarters of CVD deaths take place in low- and middle-income countries. Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs. Therefore, improved methods for treating cardiovascular disease are urgently required.

[0008] SUMMARY

[0009] As described below, the disclosure features compositions and methods for treating cardiovascular disease by introducing one or more alterations into a lipoprotein(a) (LPA) polynucleotide in a cell. In particular embodiments, the disclosure provides a base editor system (e.g., a fusion protein or complex comprising a programable DNA binding protein, a nucleobase editor, and gRNA) for modifying an LPA polynucleotide, where the modification is associated with reduced expression, and / or reduced activity of the LPA polypeptide encoded by the polynucleotide. Non-limiting examples of alterations include base edits and / or double-strand cuts.

[0010] In one aspect, the disclosure provides a method of editing a nucleobase of a lipoprotein A (LPA) polynucleotide in a cell. The method involves contacting the LPA polynucleotide with a base editor system containing a guide RNA, or a polynucleotide encoding the guide RNA, and a base editor containing, or one or more polynucleotides encoding the base editor, where the base editor contains a fusion protein or a protein complex. The base editor contains a nucleic acid programmable DNA binding protein (napDNAbp) domain and a deaminase domain. The guide RNA targets the base editor to effect an alteration of the nucleobase of the LPA polynucleotide.

[0011] In another aspect, the disclosure provides a method of treating atherosclerosis and / or cardiovascular disease in a subject in need thereof. The method involves contacting a cell of the subject with a base editor system containing a base editor, or one or more polynucleotide encoding the base editor, where the base editor contains a fusion protein or protein complex. The base editor contains a nucleic acid programmable DNA binding protein (napDNAbp) domain and a deaminase domain. The base editor system further contains a guide RNA, or a polynucleotide encoding the guide RNA, where the guide RNA targets the base editor to effect an alteration of a nucleobase of an LPA polynucleotide.

[0012] In another aspect, the disclosure provides a modified cell containing an alteration in a nucleobase of a LPA polynucleotide. The alteration is prepared by the method of any aspect of the disclosure, or embodiments thereof.

[0013] In another aspect, the disclosure provides a base editor system containing a fusion protein, or one or more polynucleotides encoding the fusion protein, where the fusion protein contains a nucleic acid programmable DNA binding protein domain (napDNAbp) and a deaminase domain. The base editor system further contains a guide RNA, or a guide RNA encoding the guide RNA. The guide RNA targets the base editor to effect an alteration of a nucleobase of an LPA polynucleotide.

[0014] In another aspect, the disclosure provides a polynucleotide or set of polynucleotides encoding the base editor system of any aspect of the disclosure, or embodiments thereof, or a component thereof.

[0015] In another aspect, the disclosure provides a lipid nanoparticle containing the base editor system, the polynucleotide, or the set of polynucleotides of any aspect of the disclosure, or embodiments thereof.

[0016] In another aspect, the disclosure provides a pharmaceutical composition containing the modified cell, the base editor system, the polynucleotide, the set of polynucleotides, or the lipid nanoparticle of any aspect of the disclosure, or embodiments thereof, and a pharmaceutically acceptable excipient.

[0017] In another aspect, the disclosure provides a kit containing the modified cell, the base editor system, the polynucleotide, the set of polynucleotides, the lipid nanoparticle, or the pharmaceutical composition of any aspect of the disclosure, or embodiments thereof, for use in the method of any aspect of the disclosure, or embodiments thereof. The kit further contains a container. In another aspect, the disclosure provides a guide RNA containing a sequence listed in Table 1A-1, 1A-2, 1B-1, 1B-2, 1C-1, or 1C-2. In any aspect of the disclosure, or embodiments thereof, the cell is in vivo or in vitro. In any aspect of the disclosure, or embodiments thereof, the cell is a mammalian cell. In any aspect of the disclosure, or embodiments thereof, the cell is a liver cell in a rodent or human. In any aspect of the disclosure, or embodiments thereof, the cell is a hepatocyte. In any aspect of the disclosure, or embodiments thereof, the cell is contacted with or the base editor system contains two or more guide RNAs, where each guide RNA binds a different location within the LPA polynucleotide. In any aspect of the disclosure, or embodiments thereof, the guide RNA is selected from the guides listed in Tables 1A-1, 1B-1, and 1C-1. In any aspect of the disclosure, or embodiments thereof, the deaminase domain is an adenosine deaminase or a cytidine deaminase. In any aspect of the disclosure, or embodiments thereof, the adenosine deaminase contains an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine and contains one or more amino acid alterations selected from one or more of I76Y, V82S, Y123H, Y147R, and Q154R compared to the following amino acid sequence: TadA*7.10 MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1). In any aspect of the disclosure, or embodiments thereof, the adenosine deaminase contains the amino acid alterations I76Y, V82S, Y123H, Y147R, and Q154R. In any aspect of the disclosure, or embodiments thereof, the adenosine deaminase has at least about 95% identity to SEQ ID NO: 1. In any aspect of the disclosure, or embodiments thereof, the cytidine deaminase contains an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine: ppAPOBEC1 MTSEKGPSTGDPTLRRRIESWEFDVFYDPRELRKETCLLYEIKWGMSRKIWRSSGKNTTNHVEV NFIKKFTSERRFHSSISCSITWFLSWSPCWECSQAIREFLSQHPGVTLVIYVARLFWHMDQRNR QGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPC LKISRRWQNHLAFFRLHLQNCHYQTIPPHILLATGLIHPSVTWR (SEQ ID NO: 23). In any aspect of the disclosure, or embodiments thereof, alteration of the nucleobase is associated with a reduction in transcription of a polynucleotide sequence encoding the LPA protein. In any aspect of the disclosure, or embodiments thereof, alteration of the nucleobase in the LPA polynucleotide results in a missense mutation. In any aspect of the disclosure, or embodiments thereof, alteration of the nucleobase in the LPA polynucleotide disrupts a splice site. In any aspect of the disclosure, or embodiments thereof, the alteration introduces a single nucleotide polymorphism (SNP) into the LPA polynucleotide, where the SNP is associated with reduced serum concentrations of LPA in a subject and / or reduced incidence of atherosclerosis and / or cardiovascular disease in a subject. In various embodiments, the SNP is selected from one or more of, chr6:160531784:T>C, chr6:160532531:C>T, chr6:160548552:G>A, chr6:160532610:A>G, chr6:160591049:A>G, chr6:160635134:G>A, and chr6:160547886:A>G. In any aspect of the disclosure, or embodiments thereof, the alteration results in a premature STOP codon. In any aspect of the disclosure, or embodiments thereof, the alteration is associated with a reduction in incidence of cardiovascular disease in a subject. In any aspect of the disclosure, or embodiments thereof, the napDNAbp domain is a Staphylococcus aureus Cas9 (saCas9) or a Streptococcus pyogenes Cas9 (spCas9). In any aspect of the disclosure, or embodiments thereof, the napDNAbp has specificity for a protospacer adjacent motif (PAM) selected from one or more of: NG, NGA, NGC, NGG, NNGRRT, NNNRRT, and NRCH, where “N” indicates A, C, G, or T, “R” indicates A or G, and “H” represents A, C, or T. In any aspect of the disclosure, or embodiments thereof, the Cas9 is a dead Cas9 (dCas9) or Cas9 nickase (nCas9). In any aspect of the disclosure, or embodiments thereof, the base editor contains an amino acid sequence with at least about 90% identity to a sequence listed in Table 2. In any aspect of the disclosure, or embodiments thereof, the guide RNA contains a nucleic acid sequence containing at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of a spacer nucleic acid sequence listed in Table 1A-2, 1B-2, or 1C-2. In any aspect of the disclosure, or embodiments thereof, the guide RNA contains a nucleic acid sequence listed in Table 1A-1, 1B-1, or 1C-1. In any aspect of the disclosure, or embodiments thereof, the guide RNA contains a nucleic acid analog. In any aspect of the disclosure, or embodiments thereof, the guide RNA contains one or more of a 2′-OMe and a phosphorothioate. In any aspect of the disclosure, or embodiments thereof, the base editor further contains one or more uracil glycosylase inhibitors (UGIs). In any aspect of the disclosure, or embodiments thereof, the base editor further contains one or more nuclear localization sequences (NLS). In any aspect of the disclosure, or embodiments thereof, the base editor contains two NLS. In any aspect of the disclosure, or embodiments thereof, the method involves altering the nucleobase of the LPA polynucleotide at a rate of greater than 50%. In any aspect of the disclosure, or embodiments thereof, the method is associated with at least a 50% reduction of serum concentrations of LPA in the subject. In any aspect of the disclosure, or embodiments thereof, the method is associated with a reduction of serum concentrations of LPA in the subject to less than about 50 mg / dL. In any aspect of the disclosure, or embodiments thereof, the method is associated with at least a 10% reduction of incidence of coronary heart disease in the subject. In any aspect of the disclosure, or embodiments thereof, the deaminase domain is inserted within the napDNAbp domain. In any aspect of the disclosure, or embodiments thereof, the base editor system is administered to the subject using a lipid nanoparticle containing the guide RNA and an mRNA molecule encoding the base editor. In any aspect provided herein, or embodiments thereof, the method is not a process for modifying the germline genetic identity of human beings. Definitions Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise. By “atherosclerosis” is meant a pathology associated with the deposition of plaques of fatty material on the walls of blood vessels. By “cardiovascular disease” is meant a pathology affecting the heart and / or blood vessels. By “lipoprotein(a) (LPA or LP(a)) polypeptide” is meant an LPA protein or fragment thereof having at least about 85% amino acid sequence identity to a polypeptide sequence provided at Ensemble Transcript Accession No. ENST00000316300.10 and capable of stimulating secretion of plasminogen activator inhibitor-1. An exemplary LPA polypeptide amino acid sequence from Homo Sapiens is provided below (Ensemble Transcript Accession No. ENST00000316300.10): MEHKEVVLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTVTGRTCQAWSSMTPHQHNRTTENYPNA GLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQ ECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVR WEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAW SSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVP SLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCR NPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQ SYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQ CSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSH SRTPEYYPNAGLIMNYCRNPDAVAAPYCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQ APTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDAVAAP YCYTRDPGVRWEYCNLTQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYST TVTGRTCQAWSSMTPHSHSRTPEYYPNAGLIMNYCRNPDPVAAPYCYTRDPSVRWEYCNLTQCSDAEGTA VAPPTITPIPSLEAPSEQAPTEQRPGVQECYHGNGQSYQGTYFITVTGRTCQAWSSMTPHSHSRTPAYYP NAGLIKNYCRNPDPVAAPWCYTTDPSVRWEYCNLTRCSDAEWTAFVPPNVILAPSLEAFFEQALTEETPG VQDCYYHYGQSYRGTYSTTVTGRTCQAWSSMTPHQHSRTPENYPNAGLTRNYCRNPDAEIRPWCYTMDPS VRWEYCNLTQCLVTESSVLATLTVVPDPSTEASSEEAPTEQSPGVQDCYHGDGQSYRGSFSTTVTGRTCQ SWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEISPWCYTMDPNVRWEYCNLTQCPVTESSVLATSTAVS EQAPTEQSPTVQDCYHGDGQSYRGSFSTTVTGRTCQSWSSMTPHWHQRTTEYYPNGGLTRNYCRNPDAEI RPWCYTMDPSVRWEYCNLTQCPVMESTLLTTPTVVPVPSTELPSEEAPTENSTGVQDCYRGDGQSYRGTL STTITGRTCQSWSSMTPHWHRRIPLYYPNAGLTRNYCRNPDAEIRPWCYTMDPSVRWEYCNLTRCPVTES SVLTTPTVAPVPSTEAPSEQAPPEKSPVVQDCYHGDGRSYRGISSTTVTGRTCQSWSSMIPHWHQRTPEN YPNAGLTENYCRNPDSGKQPWCYTTDPCVRWEYCNLTQCSETESGVLETPTVVPVPSMEAHSEAAPTEQT PVVRQCYHGNGQSYRGTFSTTVTGRTCQSWSSMTPHRHQRTPENYPNDGLTMNYCRNPDADTGPWCFTMD PSIRWEYCNLTRCSDTEGTVVAPPTVIQVPSLGPPSEQDCMFGNGKGYRGKKATTVTGTPCQEWAAQEPH RHSTFIPGTNKWAGLEKNYCRNPDGDINGPWCYTMNPRKLFDYCDIPLCASSSFDCGKPQVEPKKCPGSI VGGCVAHPHSWPWQVSLRTRFGKHFCGGTLISPEWVLTAAHCLKKSSRPSSYKVILGAHQEVNLESHVQE IEVSRLFLEPTQADIALLKLSRPAVITDKVMPACLPSPDYMVTARTECYITGWGETQGTFGTGLLKEAQL LVIENEVCNHYKYICAEHLARGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYARVSRFV TWIEGMMRNN (SEQ ID NO: 426). By “lipoprotein(a) (LPA or LP(a)) polynucleotide” is meant a nucleic acid molecule encoding an LPA polypeptide, as well as the introns, exons, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, an LPA polynucleotide is the genomic sequence, mRNA, or gene associated with and / or required for LPA expression. An exemplary map of a LPA polynucleotide sequence is provided at FIG.2. An exemplary LPA nucleotide sequence from Homo Sapiens is provided below, where underlined text represents untranslated regions, regular text represents introns, and bold-faced text represents exons (Ensemble Transcript Accession No. ENST00000316300.10): GTAAGTCAACAATGTCCTGGGATTGGGACACACTTTCTGGGCACTGCTGGCCAGTCCCAAAATGGAACAT AAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTAAGACATAGTTTTTTTAAATTATAAGAA TTATTTTTTCTCCCACAATGTAGTAAAAATACATATGCCATGGCTTTATGTGCAATTCATTTAATTTTTG ATTCATGAAATTCCCAGTTCAAAATCTTGTATATGATTGAAAAATTCTTAAAAAAATAAGTTTAATTTCC CCGTGAAGACTGTCACGGTGCTGGAATGAATGGGCAGAAAAAATAATGGTTGATTTTTCTAATCTAAAAG AGTGTGCCTACATGATGGCCAGTCTGGCTGAAAAATAAATAGCCATTGTAGCTAACTATGCAAAGGATGG CTAAGCTCTTCGCTTGGTTCTCAGTTTCATTAATTTATATCATCTCTGTTCAGGTGCCATGCTCCCCTCA CTAGCAAGTTGAAACAATGAAATAACTCTTTGAATATGTTTGGTTCCTTGACCTGTTCATGGAGTGGGAC TCAGCATTTCTCTCTTTGTTATGGCCTGAGTAAGGCTTTCCATCGGTATACATTTGCTTCTTATCCCTGG AGAAATTATACACATCCATTTGCCAGATGATATACGCATATAATGATTCAACAAATACTCAGGGTATTTG TTGAGTGGGTTAGGTCCCCACATTTTTATACATACATACACACATACACACCGTGTGTGATTGTGAATGT AAGTGTGTGTCCTTTACAAATACTAGCTTATTTAGCTCATGGTATAGGTAGGGTAGCATAGTCATCCCCA TTTTATAAACAAAGAAATCTAGACTTAGGAAAATCATGTTATTTGTCTCGTGACCAAATTCCCAAATCAA GGAAATAAAGAAACCTGGATTTAAGCCAGATTTCCAAGAAAAAATCTAGGGCTCTTCTCACTTTTTCATC TTTGTTCCAACATTTGAAAAAATAAATCTAAACACATTCCAATGTAACTGAAGAGCAGGTTAATTGTTTG CCACTTGCAGAATCCAATTAAGAAGAGAGAAGTCTGGTATAAAGAAAGTGATTTGCTTCCAAAGCTAGCT TAGGGGAAGAAATGCAGCAGTCCTGCCGTACTACTTCACTTTAGGAGCAGAAAGTGGCACTTTTAAAAGG CAACAGAGGAGGCGAGCAAGGATTCAGGGGTCCATGCTAGCTTGGGCACCTTATCCACCAGGTAGTTGAG CAGTTGCCTGCTGGTGCCTTTGTGAGCAGGGTGTTGTCCCTTGAGGCAAATCTCTGGAGGGTGAGAGTTT TGTAGTGGGCATGCTTTGGTTTATAAATCACCTGTGAACTCAGGAGTTCCATCTTGAAGCACATACATAG TTAGATGAACTTGCCCTGCAGGGAGAGTCTGATGAAAGGGAGGTAGATGCTTGCAATTTAATCTATAAAT TACCAGATAAAATTTTACAAGTTGACTTTAAAGTCAAACACATTTGAATTTAGTGGAAGCCATTCAAGAA AATATCAAAGAAAATACAGAGCAGGAGAAGATTAAGCAAAGAGTTTTTTGGGGAAATTGGTGTCTATGTC TGTGTGTGTAGGGAGTGCAGGGGATATGAATATTCTATTTCAGCCCATGGAAACTAGGATGTAGATCACT GTGAACTTATTCAGCAGGCTACACCCAAAGGCTAGAACAAACTTCTCTGCCACAGGATTAACATATGTTT TAATCGACCTGGGGGGCACATTCTCTGATAAGCTCTTTTGGAAAGCCAGGCTTTCTGTGGACGTGTTATC TTTCCAATGTGTGCTGGAATGCCCGGGGAGAGGAAAAAGTTTCTTTTACAGCCATGCTCAGTGAGAAGCG GAGAAACATCTTCTATTCACAAATTGCTAAGTCTTTTACACATGCAAATATGCATACACATTCACACACC ACAGTGAGGAAGAAATTCTCACACCATTAATAAAATACATTTACTTCAGTAGCAATATACATCTACATTT TGCCTATAATATAAAAGTATTTTTCCTATTAAAAGATTTGTTTAATGTTTCTTCACCAACAAATAAACCC TATTAAATCCCCATTGCCATATGAGCCCTGGAGGTGAATCAGAGAAACAAAAGGATTGTGGAAAAATCAT CAGGTTAAAAAAAGAAAAATTGATTCTGTTTTGGGATATTTCCTAGCAACATGAGCTGGGGAGGGGATCT CAGCAGTGATGCTCTATGAAGCATAATAAAATGACACAGTTACAGGTAACTTAGTTAAAGGGGGAAATAA ATGGAAGTTTCCTCTTTTTGAATATCAATTGTAGCCTGCTCTGCTACATTTCAAAAACACTCTTCAAAAT GTTTAACTGAACTCACTGTAGGAAGCACCTTATTAATTTATTGTGTGTTTTGAAGTCACACTGTGAGCTA TAGAATTTACCCAAGCACAACTCTTCCTGGAAAAGAGAGTTCAAATGAGAAACAGTGCGGGGTGAAGACA TGGATATGGGCCTAAAATATCTATTTCTCAATGATATTTTGATATATCTATCAAGTGCTTTTTAGTGGAT TAGGTTCAGAATGCATCAGCCAATGCCTGTTCAATAATCCAGTTTTCCAGCATAGAGCATATTAAATTGA GGAAGGACAAAGTCACAGAGGTGGGGAGCAGGTGGACTGTGGCCAAGGACTTTGCATGAAACAGTGAGCG TGCATCCTCCTCCTTGCCCTGCCCTCATGGTCTGTGTACTCTCAGGAGGTCAGGACAGGCCTTTCTGAGA ATGAGAATCTGTTCATCTGCCTTTCTACTGGATACTTGTCATCGGCATACAAACACATGTTCTCTGCAGT GTGTCATCTTTCAGAACCTCCCCTGACCCTGTATTCCCTAGAAGTCTCGCTGCTTTCAGAGCCAGGCTTC TCTCCTGCTGCCACCCCCACTGCTCTTCTAGTCACTCTTTAACCCACTCCATCTGCATGTGGCCCCCACC ACACCCCTCAAAGTGGTCAAGGTTGTCCTGTTGCTTAATTCCATGGAAGCTTGGCTATCTTCATTTTATT AGCCTCTTTTGGCCTCTCACCCTGTGAAAATCACTACATTTTGTGCCAGAGATGGAGCTGGCATCTCCAG GCTTGGAAGAGGGCTGCTGAAGCTCAGCCAGGTGTCCTAAGGAGCCTCAGGACAGGGGATGCTCAGTAGC CTTGCAATGGGAACACAGCTGAGCCCCACTTGGCCACCCTTTGCCACAACCAGGCAGAAAGCAGCTTTTG AACAGATTTGTTGCCTCAGATTTGATCTCAAAGAAAAATCGTGGGCAGTATTGGTCCCAGGTTCTGCTTT TTTACAATTTCCTCTGAAATCTGGATGCCTATCAACACCTTGGAAAAACTGAATTCTCCCCAACTAATAG TGGTGTGTCACTGTAGTAAGCCTAGTACAAAAATGGCCTTCTTTGTGGAGGAGCTTCATATCCTCCATTT TTTTTTTGCTTAATTTTTGCCCAAGATGAGAACATAATTTAGTTCACTTTTTATTTATTCCCAACATCAT CCATGCACCAACATTTTTGTAACTAAAGGAGGGACCATTCAGAAGATGCTTATCAACTGTCAAAGTGACA GTGTTACAACCAATGCACATATTGTAAGAAATCAAACAATGGCCTCCAAGGTTCATTTCTACACAGGGAT TAGCAGATCAACATCAATCTTGGCAACACAGTTGCCACTGATGGTGTCTTATTTTTTTTATCATGACATG GCAATCAAGAGCAAACATGATTTATTCTTATTTAAGATTTTATGGTTAGACTAGGCAGATAGCTAGATAT GAGCAGGAGGTGGAAGCCCCTGAGAGAATGGAGGTCTGGAGAATCTGAAACCCCAGAGATTACCCAAGTC CTGCATGCTAGACATGAGTGGAGGAGGGGGAATACCTAGGTAGAAAAGAATGCCCCTTAAGATGCCCAGC AGTCGCTCACTGTGCAGTTAACTTTTCAGAATGCTGCTAGATACATGCTGATAGGGAGGGAAGAGGGCAA AGGAGAAATTCCTAAGAGATACACGGTTGCAGTTAGTATACATCTGAGTGCTATACAACCTTCTTTGGGT GGTGGCAAGAAGCAATGCAGCCATTACGTAGAATTCATATCAAACACCTGTATCACAGGTGTTAAAGAAA CAAGAAACATTGTACTTCTTGTATTCTTAATAATGATTTGCAATATTGTCTTTAGTATCACTGCAAACCT CTATAAATATGATTTTTAAAAAGTATTTCTTTAGGTTGGAATTACTTCTACGCATTGACTTATCTTCCTG GGTTTCATTAGCCGTACCCGTTGTACTTTCTTCCTTACCACTGTTTATCTCAAACTCTTGAGATTAAAGT ATGGGCTCAGGAGGGAGCGAGGAGCTTCAGGACTCTCACGGACCTCCAGCACAGTGTAGCTGCCTTATGG AAAAGTGGCCACACTGTTTTCTGCACTGGTCCCTGCCCCTACTATTCCTCACTGGGCAGAGCACAGCCAC CCTGGCCCTGCCTGAACATTTTAGTCAGTGTTGGCTCTGTGCTTCTCTGGGGAGGAAATCCAAGAGACAA CCCACAGCCCCTCTGCCATTTCAGCTGCAGCAGTACCACCGTTAATGCCCTTGGGCTTGAGAAAGAAGGG ACCTGGCCACTTCCCTGACACCTCCAGCACACAGCAGGGAAAGAATTCCAGTTTCTCTTTCTTGTGAGCT TTCACCTGCTACTCTTCACCAGGCAAGGCTCCTGGCTTGGGCCCACAGTGCAGGCACCTCGAACTCAGTT GAACATTTCCACTGGCTGCACTCTGTGTTTTTGTGGGGTGAAGCTCCCAGAGGTGACTGAAAGTCCTTCT GCCACTAACACTGCAGTCATACTGCCCTTGCTGTACTTGGACTAGGGAAGGAAAAAAGATCCTGAGTGCT TTACTCACACCCCAGTGTGCCCCAGCCACCCTATGGAAAAGAGGCCAGTGTGTCATCCCTGCAAGCACCC TGAGGCCCCTGCCCCTGCTGCCCCCAAGCTGTAGAGCCAGAATATAAAGCTGGCAGAAAAATGTAAAAAG GCTAGACTGGCTTAGCCTCCCAGCCTACATCTTTCTCCTGTGCTGGATCCTTCCTGCTCTTGAACATCGG ACTCCAAGTTCTTCAGCTGTGGGACTTGGACTGTCTTCCTTGCTCCTCAGATTGCAGGTGGCCTATTATG GGACCTTGTAATCTTGTGAGTTAATACCACTTAATAAGCTCCCCTTTGTGTGAGTATATCTATATCTATA GATAGATATAGGTATACTCACTATATATACACATATATACATATACTCTCTCTCTCTCTCTCTCATATAT ATATATATATAATCTCCTATTAGTTCTGTCCCTCTAGAGAACCCCGACTAATACAGATTTTCATACCAGA AGTGGTTCTTGAGGAACAGAATATTAAGGATGGAATTCTTTCATTGGTTTTGGGACTTCTGGTGTTGGCT GATTAATATGATTAGACCAAAAAATGCTAAGGACTCTACTTCTAATAGTATGGAGAACACTGATAGTACT TGGCCTGAATTGTTTAGAGAGTTATGCAAAATAAATGCATTTGACACTACTGATTCATCACTTATGAGAG GCAAGGAGTTTAGTGACTCTATACATAATACCTTTGACTATATGTGGAGAACCAAGGAACATAATGAAGT TGGTTGATTGCTCCTAAGTTCTCTGGAGAAAGAGATGAAAGAAAATGATGATCTCAGGGGATCTGTCTCC CACCTTCAGAAGCAGATACTGAGCCACAAATCTGCTAAGATTGCCCTGAATGAGAGTTTTAACTCCTGTA GAGAAAGAGTTGAAATTGTGAAAAAACAGAGACAAGCTGTTATCATGCGAGTAGCTGATCTGCAACAAGA GGTGCATGCACAGCCTTGCCAGGTGTTTACTGTTAAAGTGAGGGCATTGACTGGAAAAAAATGGGACCCT GGAACTTGGAGTGGGGATGTGTGGGAGAACCCTGATGAAGCTGAGGACACTGAGTTTGTGAACTCTGATG AAACTTTTTTGCCAGAAGAAACAGTTTCCCCATCCCCAGTAGTGGTAACATCCCCTCCCTGACCCGTGCT GCCATTAGCCTTTCCACCTTTGTCTGAGGATGTAAACCCTGCACTGCTTGAGGCAACAGTGATGGCCTTC CCTGAGGCAGCTGCCAGGCAAGATAATGTTGATTCTCCTCAAGAGGCACCCCTAATGCCCCTGAATGCTT CTAGACCTATAACTAGGCTAAATTCCTTGCGGGCCCCAGAGGTGAGGTTCAGAGTGTGACCCATGAGGAG GTGCATTATACTCTAAAAGAACTGCTTAAGCTTTCTAATTTATATTGGCAGAAATCTGGAGAACAGGCAT GGGAATGGATATTAAGGGTAAGGGATAATGGTGGAAGGGACATAGAGTTGGATCAAGCTGAATTTATTGG TTTGGCCCTACTAAGTAGGGATTCTGCATTTAATGTTGCAGCTCGGGGACTTAGAAAAGGTTCTGATAGG GCCGGGAGCAGTGGCTCACGCCTGTAATCCCAGCACCTTGGGAGGCGGGGGCGGGCAGATCACGAGATCA GGAGATTGAGACAATTCTGGCTAAAATGGTGAAACCCCATCTCTGCTAAAAATACAAAAATTAGCTGGGC ATGGTGATGCGTAACTGTAATCTCATCTACTTGGGAGGCTGAGGCAAGAGAACTGCTTGAACCTGTGAGG CAGAGATTGCAGTGAGCCAAGATCGCCCCACTGCATTCCAGCCTGGTAACAGAGCAAGACTCCATTTCCA AAAAAAAAAAAAAAAAAGTTATAATAGTTTATTTGCTTGGTTAGCTGAAATATGGATTAAAAGATGGTCC AATGTTAGTGAGCTGGAAATGCCTTGGTTTAATGTAGAGGAAGTGATCCAAAGGCTTAGGGAGATTAGGA TGGTGGAGTGGATTAGTCACTTTAGACCTACTCATCCCAGCTGGGAGGGTCCAGAAGATACACCCTTGGC CGAAGCTTTGTGAAATAGATTTGTGAGAGCAGCACCTGTATTTTTGAAGAGCCCGTAATTGCTCTTCTCT GTATGTCAGATCTAACAGTAGGAACCACAGTCACTCAACTACAAAATTTAAATACAATGGGAATAATTGG ATCCTGAGGTGGCAGGGGCCAAGTGTTGGCACTGAACCATCAAAGGCAAGGTGGGCATAACTACCATAAT AGACAGCAGAGGCAAAGCAGCCATCAGAATAGTCTGACTCATGTAGAGCTCTGGCATTGGCTAATTAATC ATGGTGTTCCTAGAAGTGAAATTGATGGGAAACCTACTGTATTCCTACTTGATTTATATAAACAAAAAAC TGCCAGGTAGAATGGACTAAAGACTAATCTGAATTATAAAAACAGAGAATCATGGGCCCTCAATCAATTT CCAGACTCGAACCTGTTACAGTTCCAGAACCCACTGAATGAAGGGGAGGCTGGATCCCCTTGAGGAAGGA CACCACTAGGCTACTGACAACTTATGCTGTTACTCTTTCTCCCATCCTTCCCTAAGGAGACCTCTGGCCT TTTACCAGGGTAACTGTGTGTACTGGAGAAAGGGAAGTAATGAGACATTTCAGAAAGTACTGGACACTGG CTCTGAGCTGACGTTGATTCCAGGGTACCCAAAACGTTATTGTGGTTCCCCAGTTAAAGTAGGGGCTTAT GGAGGTTAGGTAATTAATGGAGTTTTAGCTCATTTCTGACTTACAGTGGTTCCAGTGGGTCCCTGGACTT ATCCTCTGGTCATTTTCCCAGTGCCAAAATGCATAATTTGTATAGACATACTTATTAGCTGGCAGAAATG CCACATTGGCTCCCTGACTGGTAGGATGAGGGCTATTATGGTGGGAAAGGCCAAACAGAAGCCATTAGAG CTGTCTCTACCTAGAAAAATAAAAAAATCAAAAACAATATCCCATCCCTGGAGGGACTGAAGTGATTAGT GTCACCATCAAGGACTTGAAAGACGCAGGGGTGGTGATTCCCACCACATCCCTGTTCAACTCTCCCATTT GACCTGTGCAGAGGACAGATGGATCTTGGAAAATGATGGTGGATTATTTTAAGCTTAACCAAGTGGTGAC TCCAATTGCAGCTGCTCTACCAGTTGTGGTTTTGTTGCTTGAGCAAATTAACACATCTCCTGGTGCCTGG TATGCAGCCATTGGCTTGGCAAGTGGCTTTTTCTCCATTCCTGTCCATAAGACCCACCAGAAGCAATTTG CCTTCAGCTGACAAGGCCAGCATTATACCTTTACCACCCTACCTCAGGGGTGTATCAACTCTCCAGCTTT GTGTCATAATCTTATTTGGAGAGACCTTGCTCGCTTTTCACTTCCACGAGATATAACACTGGTCCATTAC ATTCATGACATTATGATGATTGGATACAGTGAGCAAGAAGTAGCAAACACACTGAACTTATTGGTGAGAC ATTTGTATGCCAGAGGATGGGAAATAAATCCAGCTAAAATTTAGGGACTTTCTACCTCGGTAAAATTTCT AGGGTTCCAGTGGCATGAGACCTATGGAGATATTCCTTCTAAGGTGAAGCATAACTTGCTGCGTTTGGCC CCTCTTACAACCAAGAAAGAGGCACAATGCCTGGTGGGCCTATTTGGATTTTGGAGGCAACACATTCCTC GTTTGGGTGTGTTACTCTGGCCCATTTATCGAGTGACCTGAAAGGCTGCCAGATTTAAGTGCAGTCTAGA ACAAAAGAAGGCTCTGAAACAGGTCCAGGCTGCTGTGAAAGCTGCTCTGCCATTTGGGCCACATGACCCC GCAGATCCAATGGTGCTTGAGGTGTCAGTGGCAGATAGGGATGCTGTTTGGAGCCTTTGGCAGGCCCCCA TAGGTGAATCACAGTGGAGACCTCTAGGATTTTGGAGCAAGGCCCTGCCACTTCTGCAGATAACTACTCT CCTTTTGAGAGACAGCTATTGGTCTGTTATTGGGCTTTGGTGGTAACTGAACGTTTGACTGTGGGTCATA AAGTCACCATGCTACCTGAACCTGCCTATCATGAACTGGTTGCTTTCTGACCCATCTAGCCATGAAGTGG GTCAGCACAGCGGCATTTCATCATCAAATTGAAGTGGTGTGTATGTGATCGGGCTTGAGCAGGTCCTGAA GGCACAAGTAAGTTACATAAGGAAGTGGCTCAAATGCCCATGTTCTCCACTCATGCCACCCTGCCTTCCC TCCCCCAGCCTGCACCAATGGCCTCATGGGGAGTTCCCTATGATCAGTTGACAGAGGAAGGGAAGACTAA GGACTGGTTCATAGATGGTTCTGCACGATATGCAGGCACCACCCGAAAGTGGACAGCTGCAGCACTATAT CCACTTTCTAAATGCATGTGTACACTTGTGCTAAGAAAATATCTTTATTTTATTTCCTTTATTTTTCCTT TATCATGTGACCTTAGATTTATGGACTTCACATCAGCATTTAAGCATTTAAGTGTTGTTCATATCAGCAT TTAAATATTGTTAACCTTATGTAATAACTTTTGGTTTGGGGATTGGTGCGTTTCTGGTTGTATGAGGATA GTTGTATTATATTAGGCATAATTATGACCTTATTATTGTCTTTATTTGAAGATTATGTATGATTTCAGGA TGTGTGTATGGGTTCAAGTTGACAAGGAGTTGGACTTGTGATGGTTAATACTGTCAACTTGATTGGATTG AAAGATGCAAAGTATTAATCTCGGTTATGTCTGTGAGGGTGTGGCAAAAGGAGATTAACATTTGAGTCAG TGGGCTGGGAAGGCAGACCCACCCTTAATCTGGGTACACACCATCTAATCAAGTTCCAGTGTGGCCAGAT TGTAAAGCAGGGAGAAAAATGTGAAAAGACTAGACTGAATTAGCTTCCCAGCCTACATCTTTCTCCTGTG CCAAATGCTTCCTGCTCTTGAACATCGGACTCCAAGTTCTTCAGCGTTGGGAGTTGGACTGGCTTTCTTG CTCCTCAGCTTGCAGAGGGCCTGTTGTGGAACCTTGTGATCCGCTGAGTTAATACTACTTAATAAGATCC CCTTTATATACATATAATATATTATATTATATATAATATATATAATATATATTATATATAATATATATAA TATATTATATATTATATATAATATATATTATATATTATATATAATATATATTATATATAATATATATTAT ATATTATATATTATATATAATATATATTATATATAATATATATAAAATATATATATATCCTATTAGTTCT GTCCCTCTAGAGAACCCTGACTAATACAATTTATGTCATTAATCTCATTTATTGATTTGTATACATTGAA CCAACCTTATATCCCAGGAATAAAACCTACTTGATTGTGGTGGATTAGCTTTTTGATGTACTCTTGGATT CAATTGCTGGTATTTTATTGAGAATTTTTGCATCTGTGTTCATCAAGGATATTGGCTTGAAGTTTTCTTT TTTTGTTGTTCCATATCAGAATGATGACGACCTCATAGAATGAGTTAGTCTGTCCTCTTTTATCTTTTGG AATTGTTTCAGGAGGCTTGATATCAGCTCTTCTTTATATGACTGGTATACTTTGGCTAGGAATCTCTCTG GTCCAGGGGTTTTTCTGGTGTAGGTTTTTAATTACTGATTCAACTTCAGAACTCATTACTCATTATTGAG TTCTAAAACTCACTTTCATGTACTCTTCAAAAGACTGTCTTCTTCTGTTGTTGAGCGGGGTGTTCTCTCA AGGTCGTTTAGGTGAAGGTGGTTGCTGGTGTTCTTCTGTATCCTTACTGCTTGTCTTTCTCTTTTTTTAT TGACTACTGAGGATTAATGGTGATGTGTCCAACTTTAACTCTAGATTAGTCTATTTCTCTTTTAGATTGT AACTCTGTTTTATATATTTTGAAGCTCTGTTGTTAGGCATGTGTATTTGGATTGTTAGGTCTTCTTGATG ATGACCTTTATCATTATGTAATGTTTCTTCTTATCTCTGGAAGTATTCGTTGTTCTGAAGTCTATTTGTG CTGATATGAATACAGCCTTCACAGCTCTATTTTCACTAGTATTTGTATATCTTTTTCTCAGCTTTTAAAT TGAGATGTTCAGACCATTTGCATTAAAGTAGTTGTTAATAGGATTAAATTTAAATCTACCATTAAGTTGG TTATTTCTCTTTGTCCCATTTAAACTTTGTTCCTTTTTTCATATTTTTCTGCCTTCATTTATATTGAGTT TATCTCCACGACTTACTTATTAAATTAATTTTTAATGGTTTTAGTATTTTCCACAATGTTTATAATATAT ACTTTGATTTTTTCACATTCCACCTTCAAATGACAGAATTATACTGGATATATAGAAATCTTACATCATT GCACTTCTCCTTCCTCCCTCTCAAAATGTTGTGCTATTGCTCTTTGTAATAGAGGCTTACTTCTATTATG TTATAGCTCTCATAATACATTGACACTATTTTTACCCTGAATAATCAGTTGTTTTTTAAAGTGATTATGA CTACAAATATTTTGAATAATTTCTTTATTTTACCATTTCTGGTGCTCCTTATCTTTTACAGTAGATCCCA ATTTCCATCTGGAGTCACATTCTTTCTGTGAAAAACAACCTTTAGCATTTCTTATAGCACGGGACTGCTG TTGCTGTTGTCTTTCAGCTTTTCTTTGTCTGAAGAAGTCTTTATTTTGCCTTCAGTTTTTAAAAGTGATT TTGCTGAGTATAGATACTGGGTTGAGAGTTTCATTCCTTGTATCATTTTAACAATGATGTTCCATTATAT TCCGTTTTGAATAGTTTCTGACTAGAAATCTGATCTTTGTTTCTTTGTATTCAATAGTTCCTTTTTCTCT GACTGCCTTTAAGATATTCTCATCTTTGTTTTTCAACAGTTTGACTATAATTTGTTTATTATTAACTTTT TGTATTTATTCTGCTTGAGGTTTCCTGAGCTCCTTGGATTTGCAGATTGTTGATTTTTATTGTTTTTGTA AAATTCATAGCCATTATCTATTCTACTGTTTTGTTTTTTTTTTCACTTCTCTCTCTCTGTATTCTTCTTT TTGGACTGTAAGTATTCAAATGTTAGATCATTCATATTGCTTCATAAACCTTATATGCTTCTTCTGCTTT TTTTTTTTTGTCAGGAACTCTTTTTTTGTATCTGTGTTGGTTTGGATAAGTTCTAGTAGACTATGTTCAA GTTTATGGATTATTTTGTTAGTTGTGTCTAATTGACTCCTCAGTGCATTCAGAGAATTCTTCATCTCTGA TATTATAAATCTCTTCCTAGCATTTTCATGTTACTCTTTTCTATAGTTTCCATCTCTTTGCTGAAATTCT CCCCCTATCCATGGATATTGTCCACCTTTACCACAAGATTCTTTAACATATTAACATAGGTATCATACAA ACCCAAACTGATAGTTTCCAGATGGTGTCTTTTCTGAGTCTGTCTGTCTTGATTGCTTTATTATTTAACA GTGACTTATCTTCCCTCTTCAGCTTTTGGTGTGTCTTGTAATTGTTTAATCAAACACTGGGTATCATAAA TGGAGGAACAGTAGAGATTGCAGTAAATATTATTTATGCTTTGAAATGGGCACCCATCTTCTGTTGAAAA TATGTTTTGTGGTCAATTGAGTCAACCTAGTAACTGGTTGAACTGAATTTGGCATTTGTGCTTGTTGCTT TTATCTTAAATGCACCACAGGTTTAAATTCCTCCAGTGATGGGTTGCTGCTATCTTTTGCTTAGAGTGGG GCCTGGGGTGTGGAAGAATTTTCTCAGTGTTCCTATCTATTATTAGATTTTAGCAGTCACTGCATGCCTG CACTACAGAGGGGATATCTTCATACACATAATCTAACCCCATTGAAACTGCTGTTTCTTCTTAATGAATG CTCAATCTTTGGTGGAAATAAACAAATGCTGTATCTCCTGGAGCCACTTCAGTCTTAGTCAGGTTCTGCA GGGCTTTGAAGGGAATGCATTCTCAGTATTCTTGTGCCTTATTTGGATGGAACTTGAACCTGTGGTGGGT TTGGAGAGAAAGAGTAGCAGACGTCTGCTATGTTGCAATGCAGGATGCTGGGCACAAGAAAATTTCCAGT CTCTCCTCCAAGGAAATAAGATTTGATCATCTACCTATCCCTGAGAAGTGAAGGGCTTTGCCTGCGGTGC TAGATGCAAAACCATTTTTCTCCCCCCATTGCCCAGAAACTTAAGGCTTTGGCTTTTCTGAGCAGTGGTC TAGGGAATTGTGCAAGGTTTTCATATTTGACCCTGACAGCCCATCACCACCTACAGCTTGCAGTGCCAAA TGTATCTCCCTCTGATCTCTCCTGTCCTGTGGTCCTCATGAACATTAAGAAGAGATTTCTAAAAAAGAGC TTGCACATGAGCATAGTTTCTGGTGAGAAGAATTCTGATATGTTAACTTCCTCTAAACTTTTAAATAAAA TATTTCTAAGAATTAAATAAAGTTCTAGAATGATATGAATCTATTCCTTTGGTTTTTTGCACGTCTGTCT GCCTGCTAATCAAGAGAAGAGAATGGTCGTAATTCTCAGAGACTTTTTCCTGTTTGTGTCATAAATGACT TCACATTTTTTTCTGTTCTAAGAACTATTCAGCTTGATTTCTTCTGTTTTAATTTTAGCAGCACCTGAGC AAAGCCATGTGGTCCAGGATTGCTACCATGGTGATGGACAGAGTTATCGAGGCACGTACTCCACCACTGT CACAGGAAGGACCTGCCAAGCTTGGTCATCTATGACACCACATCAACATAATAGGACCACAGAAAACTAC CCAAATGCGTATGTCATTAATCTTACAGTAAGCAAAACAAGGTCCAAGTAAAATTTGTCTTAGAAAAGGT GTGCGTCAAGCTAACTTCTTATGATTAAATTTTTCTCACACATAGAATGCATGGCAAAATGTCTGAGAAA CATTACTTTGAGCAAAGAGTATGATAGAAGAGAAATGTTAAGCTGGCTCTCTTTCCTGAGAGTTTGATAA AATCAGGAGAATATCTGGCGGTGGTGAGGCCACAATAATGGAAAATCAGAATGTTTAGACAGAGTCAGCT TCAACAACACTCACTAAAGGTCAATGTGATCTTTACCCCTTGAAATTCTATAATTCTAATCTCCAATTCC TGAAGTGAAGGTTGTGTTGGCCTTTTCTGTCTTGGCTCACAAGTAAATGATATGTGCATATCTATGGAAA GGCGAATCTATCTTTTTCTATATCTATGTCTATTCCAACGGGTAGAAACACCCTGGGTCCTGAGCACCAG TGGTCTGAAGGAATACGGGTTGCCAGGAAGAGAGAAGCAAAGGCAGGAAGGCAGATGAAAGTAAGAAATG AGACAGATGCTAAACAATAAAAAGTGCGGGAAGATAGACAGAAGCTGGGGTCTGACCACACCATGGCCAG TCTTTCACACATAAGTGACTACCAAAGACAAGAAAAAATGATTTCCGCTTGTTGGACAATAGATGGTAGA GGACCAAGGGAATTGCGAGAGAGAGAACAATGAGATCAACTCAACAGATGCACTGGTTTTCTTCCTGGAG ACCCTTCCTGCACTGAAGGGCAGGAGATGGAGCCCAAAAAAAACTGTAGCCATCTTGCTGAACAGAGGAG GGACATTGGAGTTTGGGATTATTCAGGTGGCTAGGATTTTCTAGGCCTGCTAACAATGAGAACAGATTTG TGGAGGAAAGGAGTTCTAGAAATATGCATAGAAATCTCCTCGAGTCATTGGCTAAACATGAAGCTGCATG TACACAGAAAATAGATCCACAAGAAAGTAGGGCAAAGAACATCTACGGAAGAGCAGCAACTACAATGGAA CAGTGAGCTCAATAAACATGACAGAGCTCAAATAGCACTAAGGGATATTGGAGTTTGGACCACACAGAGG AGAGAGACTTCACTGAACATCTTGGGCATTCAGTAGAGACCCAGGAAAAGCCATACTTTAGGAGTAGAAT TAGTATATTCTTAGAATAAAGGCAGCTCCACACAAACAATAGCAAAACTGAAAAGGAAGTCTCCAAGCAT CAGAATGATGTCCAAGTCAATGAACTGCCTCTGAGAGGAAAACTCAACCATCTTTAGAGGTAAACATCAA AGTCAAGTGGCTCAGCTATGCAGTATCCACAGTGTGAGGCCTAAATATAAAACTTGACTACACATAGAAA CCTTTTAGTGTGACCCACAAGCAGGAGGAAAATCAGCCAATACAAACAGACCCAGAAGAGACAGAAATGA TTAGAATGGCATAAAAATTTGACATATCACTATATAATAATTGAGTTCTAGGATTTAAGAAAACATGAAT ATAGAATGCAACAGACACCTTATCCAGAGACAGTAAGAGTATAAAGAGCCAAATCGAAGAACTACTAAGA GATATGTCTTAAATGAAAAAATTACTAGATGGCCTCCCCATCTAGTTAGACATTTCAGAAGAAAATACCA AATGAAAAATAATTGCATAGAACCTACAGAACCAGATACACACATACAAAACACACGCATGCATACACAC ACACTCAAACATGTATAAGCTTACAAACACACACACACATCCACAAATGCTGAAAAATGAAATCAACCGA GCCACACAGACATAAAGGAAAACATAAAAAGATTTCCTACATGTGGGAAGCAAGTCACAGAAAGGGGGAA GGAGATTGGAACAGAAATATATACTGAAAGCAAGGATGGCTGAAAATTTTCCAAATATAAAGAAGATTAA AAAATCACGGACTCAAGAAGCTCAATGGATCAGAAAAATAATTTCTAAAATGACAATTATAGGATGCCAC TGGGTACATAGCAGTTCAACTGTCAGAGGGCAAAGACATAATACACAGAAAAATCTCGTAAGGAACGGGA AAAACAAAAAGCTGTGTCTTGCTAGAGGAACAGTGATACAAGTGACTAATGTGTTCCCATCAGAAACACT GCAACCTGGACACAAAAGAATAACATTAAAGTAATAAACGTAAGAAAGAAGAGCTCAACTGAGAAGGCTA CATCCAGCAATAAAATGCCTTGAAGTTCATCCATGTTGGAGGAATGCACATTGTGCACTCCCCTAAACAA AGAAACCGGAAACTGTAAGACTTTGGAATCAGCAGGCTTATGTAACAAAAGAGGTGACCCTAAGGAATTA AGGAGAAGAAGAATAGAACAAGAAGGGAACTTTCTGCAGCCTATATAATGAAGAACCTAGCAATTGGCAA ATGTAGATGAAAATGCTACATGTTTTCTTGATCAAACGTTTATATCTTTTTAAATGAGAGTTGACGAGTT GAAGCAAAATGATACCAATATATTTAACTTTACCATATGTAGAAGTAAAAATTTGAACATGTAGCATAAA TCATGTAGGGATTAATTGGAAGTGTACCACTGTAAGTTTCTTACCTCATGCACGATAGTATGTAATACTA ATAAAAGGTTAATGTGTGGGTTCAAAGGGATATTGCAAATCCTAGAGCAATCACAAAGTTTTTAACTCTG AGGTTTGTTGTATAATAACAATATTTTATGTATTCAAAAGAGGGAAGCCAAGGAAGAAAAAAAAGTCTTT AAAGAGCTCTGGCTCTTAGTACATCCAGTTGCTCATTGAATGAGCTTCCTGGAATGGAGGGTCTGGGACT GAGACTAGGCCACATGTGTAGAGCCACTAGAGACACAATGTTGGATCCCCATGGCCCATAATACATTTCC CATTTTCTCAGGCAGCCACAGGTCATGAATGTGAGGATACTGAGAGGTTGGAGCAACGTTCTTGGGAGGC ATAAGGAAGAGCGAATGCTTCAAGATCCCCGCAGCCCAAACTCCTCAGCTGCTTTGCCTCCTAATTCATT GTTTTTTGCTCCTCCATAGCTGTCCGACCTCTTCAGATCTCTTAGTCTTCCTGCCATCTTCCTTTATGCC ATGGGACCCACTGTTCTTTCAACTCATCCCCCAGTTCTGGAGTGGCTGTGGACAGCAGAGGATAGACTGA GAGCAGGAGAGAAGGTCCTGCCCAGGAACCCATTCTAGAGATACTGCATTCTGCCTGGGAGCAAGTTTTC CAGGGCAGCTTTGAGAAGTCTTGCAGAAACAAACCTACTTGACCGACATGATATGGGAATGACAGACAGT AATACTATTTGCACAATGCTTTTCCATGGGAAAGGTAGAGCCTTTTCACTAGGTTTTGAGTACATGGAGT GTGAGAGTTGACCTGGAAAGGTTATCCTCCTTGATGCCATGTTTTCTCTGAAGAACTACATGTTCGTTGC AACTCCCACATTAGAATATGAAGTCCTACCGAGAGAGATACGGAGACTAGACAGATACAGATGCATTTGC ATGTGAATACACAATCCCACAATACAGACGTCAAAACCCATACCAGTTATTCCAGAGAGATGGATTGGGC AGAAGGCAGAAGGAGAATACTCTGATCGTTTTTCGGCCACGTGTGTGTGTTATCTCAGTGTTTCTAAGAA GCGTTTGCTACTTTAGATTTTTTATTTAAAAAAAATAGTAATAATCTATTAAGTATGAGAGATGTGCAGA GAGGATTAGTGATCGAGAGCCATTTTTGCTGGTGGCAATCATATGGTACTTTTAATGGGAATATTAGAAA GGCACCGGTAATGACCTTGTTGCAGCACAAAGGAGAGAGTGTGGGGTGCCCCTGCATGTTGTCCCACCTC TTGTGACGTGTATCGTTTTGGAATTTCCAGTGGCTTGATCATGAACTACTGCAGGAATCCAGATGCTGTG GCAGCTCCTTATTGTTATACGAGGGATCCCGGTGTCAGGTGGGAGTACTGCAACCTGACGCAATGCTCAG ACGCAGAAGGGACTGCCGTCGCGCCTCCGACTGTTACCCCGGTTCCAAGCCTAGAGGCTCCTTCCGAACA AGGTAAGGAGTCTGTGGCCAGACATCTACACGCTTCGATGCTGGGATGAAAAGCCATGGAAATTCCCACT GATGCAGCCGCCTTCAATGGTAAACGGATGCTCGAGTGTTGCCTGAGTTCTACCATGTAGGAGGAAGCCT CCGTGCACTCTCTGGGGGAGCCAGCGGAGTGATTTCTGGTGCAACGTGGTTGGGCTTTGTCTTTAGGATG GGCACAAACCCTCCAGGGGGATCGACTTCAAAATTCACCTTGTTGTAAAACGGGCTACCTCAGTGTCCCA GCCAAAATTTTTATTGTAACATGCTGTCAGGTGTGTCACTCTTTCCAAGCCAGTAAGCTTTTCCGGGGAT TTCTTCAAGTAGCCAGCATTCAGAGCAATCTTCAGCATTGCAGATTCTGAGAAATGTGGCTCTGGAGCCT GTCACCCTCGAGAAACCTAAGAGGGCTGCATTGATTCCATGTGGCCCTGGGTCTATGGAGCAGTACATGA GCTCCCAGTGCTCTAAGGCTCTTCAGCCCTAGGCTTTGAAGGGAGTGATTTCTCAGTATTCTTAAACCTC TTTCTGATGACACTTGTACCTGTGAGGGGTCTAGAGAGAAAGAGTAGTAGACTCCTACTTTACTACAATT CAGGATGCAGGGCATGAGAGGATTCCCTCTCTCCTCCAAGGGAAGAAGCTTTTGGCGTGCACACATCCCT GAGAAGCAAAGTGTCTTTGTCTTCAGTCAGATACATAGGACCGTTTTCTGCCCCATGGCCCGGAAGCCAA AGGCCTTGGCTTTCATGATCAACGGTCTAGGGAAACATGCAAAATTTCCATGTCTGTCCCAAACTCTGCC CCCGACAGCCAATTACCACCTGCAGCCCGCATTGCCAAATGCGGTGCCGTTTGCATGAAGATTCAGTAGA GTTTCCTAGAAAGGTGCTACCTCGTGAGCTCACTTTCCAATGAGGAATCTGATCTGTTGTGTTTCTCTAA GGTGTCAGGTGAAATATTTCCAAGAACTTACTACAGTTCTAGAATGGGAGGAATCTGTTGCTTTGGTGTT TGTTTGTTGGTCGGTTTTCTCACATCCATCTGCCTATGGATAAGGAAAAGAGAACGGTCGTAATTCTCAT AGACTCCTTTCTGGTTGTGTCACAAATGGCTTCACATGTTTCTCTATGCTCAGAGATACTCAGCTTGATT TCCCGTGTTTTCATTTCAGCACCGACTGAGCAAAGGCCTGGGGTGCAGGAGTGCTACCATGGTAATGGAC AGAGTTATCGAGGCACATACTCCACCACTGTCACAGGAAGAACCTGCCAAGCTTGGTCATCTATGACACC ACACTCGCATAGTCGGACCCCAGAATACTACCCAAATGCGTATGTCTTTGTTCTTTACCATAAGAGAAGA AAGGGCCAAGTGAAGTTTCTGTTACAAGAGATGTGTCTCAAGCTGAGTTCTCCGAACTCAACTTGTGACA GATGCAGATGGCGTAGCAAAATGTCTCAGGATGATTGCCTTGGAGCTAAGGGTCTGAGAGAAGGGAAATG TTAAGCTCCCTCTCCTTCCTCCTAGTTCTATTGAGCAGAAGGGAAATCTGGAGGTGAGGAGATCACATTA TGAAGAAAGTCAGAATGACAAAGGACCAGACACTTAGATTACCCTTCCACAACACCAACTAAACGTCAAT GGAGACTTTCCAGTTGGAATTCCGTTATTCTGGCTTCCACTTCCTGAAGGGAAGGTTGCGTTTGCCTTTT CTCTCTGGGTTCAAGAGGAAAGAATAGGTGCTTATTTATGGACAGGTGAATTGATCTGTTTCTATATCTA CGTATATTCCGATTGTCAGAAAAACACTCGTTCCTAAGTACCAGTGGCCTGAAGGGATACAGGTTCCCAG CAAGAGAAGATCCAAGGAAGGAAGGCAGATGAGAGTCAGCACAGAGAGGGATGCTGAAAAGTAAAAGGGA TGGGTGGATGGAGAGAAGCCCGGGTCTGACCACCCAATGGCCAATATTTTGGCCACAAGCGACTACCAGA GACATGGAAAAATGGTTTCTACATGTGGGACAACAGATGGTAGAGGACCTAGAGAATTGAGAGAGGGGCA ATGATGGGCTCCACTCCGCAGATGCCTTGGCTTTCTTCCTGGATACCCTTCCTGCACTGAATAGCAAGGA GATGGAGCCCAAGCAGACTGTAGCCATCTTGCTGAATGGAGGAGAGGGATTGGAGTTTGGGATGACTGTG GTAGCTGAAATTTTTCTAGGTCTGCTAGAAATAAGAACTGGTTTGTGTGGAGGAAAAGAGCTCTACAAAT ACGCATAGAAGTCTCCTCCAGTCGTTGGCCTGACATGACGCTGCCTGTGCACAGGAAATGGTTCCACGAG AAAGTGTGGCAAAGAACATTTACTGAGAAACAGCAAGTACAAGAGCACAGGAAGCTCAATAAAGAAGAGA GAGATCACATAGCACTCTGGGATACTGGAGTTCTTCCCAGCTAGACCAGAGAGTCCTCACGGAGCACATT GCCAATTCAGTGGAGACCCCAGAACAGCCGTAATTTAAAGGTACACTTAGTATATTACTAGAATAAAGTC AGCTGCAGACAACCCCTTGCACAGCTGGAAAGCAAGTGTCCAAGCATCAAATCGGTTTCCAATCAATGAA GTGCCTGTGAGAGGAAATCTCAACTCTCTTTAGAAGTAAACAACAAAGTCGATTGCCTCAGCTATGCGGT ATCCGCAGAGTGAGTCCTAAATTTAAAATCTGACTACATGTAGAAAAGCGTTTCGTGTGACCCATGACCA GGAAATAAATCGGGTAATACAAACAGGCTCAGGAATGAGAGAAATGATTAGAATTGCGTGAAAATTTGAC ATATCAGTATGATAACTGATTTCAAATATTTAAAAAAACAACATGCAAGAAAGCAGATATCATATCAAGA GAAATTAACAGTACAGAATAGCCAAATTAAATTAAAGAGGTAGTATAAAAAAAGTATGTCTTAATTGAAA AAAATTACTGTATGGCCGGCTGATCAATTTAGACGTTTCAGAGGAAAACATTACCCAACACACAATTCTA GAGAACCTACAGAATGAGCTACACACACACACACACACACACACACACACACTGAAAACACACCCATACT CACACACACGCAGAAACTCACAAGTTCTAACACACACAGACACGCGCACCCCTGAAGAAACAGTGAAATA TAAAATTAAGCGAGCCTCACAGACATGTAGGAAAATATGAAAAGATTTCCTGCATGTGGGAAGCAAGTCA CAGTAAAGAGCAAGGGAGTTTATAATAGAAACAAATACCAGAATCAAGGATGGCTGATAACTTTTCAATT ACGAAGAACATTAAAAAAAATCACAGAATCGTGAAACTCAAGGGATCATATAGGGAATTTCGGAAAAAAA ACCCAACCTGTATGATGTACTTTTGTACATCACAGTTCGAAGGTAACAAGGCAAAGATGTAATAAGAAGA AACCTGTCACGAGAAACTGGAGGAAAAAGAGCTGTGTCTTCCTACAAGTACACTGATACAAATTGCCAAT GTGTTCACCTCAGAAACACTGGAAGCCAGATACCAGGGAATATTGTTAAAATGATAATCAGGAACAAAAA GAGATCAACCGGGAATGCTGAATCCAGCAATAAAATGCCTTGAAGGTCATCCATGTCGGATAAATGCATA TTGTGCACTGCCCCAAAGAAAGAAACCGGAAACTGTAAGAATTGGAAATCAGCAGGCTTATGTAACAAGA GAGGTGACCCGAAGGAATTAGGTAGAAGAAGAATTGAACAAGAAAGGAACTTTCTGCAGCCCACGTAATG AAGAATCCAGCAATTGGCAAATGTAGATAGATGTAAATGCAAAATATTTTCTTGATCAAATTTCTATATC TTTGTAAATGAGAGTTGACTACTTGAAACAAAATGATAGCAAGATATTTAACTTCAGCATATGTAGAGGT AAGAATTTGAAATGGTAGCATAAATCACGAAGGGATTAATTCGAAGTGTACCGTTGTAAGTTTCTTTACC TCATGCACGATGGTGTGTCATATTAATAAAAGGGTACTGTGCGGGTTCGAAGGGATATTGCAAATCCTAG AGCAATCACAAAGGTTTGAACTCTGAGGTTTTTGGTATAATAAGAATAGTCCATGCATTCAAAAGAGGGA AGCCAAGGAAGAACTAGAAGTCTTTCAAGAGCTCAGGCTCTTATACATCCAGTTGCTCATTGAACCAGCT TCCTGGAATGGAGGGTCTGGGGTTGAGACTAGGCCACAAGTCTAGAGTCTCTAGAGAGACAGTGTTGGAA CCCCATGGCCCATAATACATTTCCCATTTTCTCAGGCAGCCAGAGGTCATGAATGTGAGGATACTGGGAG GTTGGAGCAACGTTCTTGGGAGGCATAAGGAAGAGCGAATGCTTCAAGATCCCCGCAGCCCAAACTACTC GCCTGCTTTGCCCCCTAATGCATTTTTCTCTGCTGCTCCGTAGCTGTCCGACCTCTTCAGATCTCTTAGT CCACCCTGCCGTCTTCCTTTATGCCATGGGTCCCACTGTTCTTTCAACTCATCCCCCTTTCCCTCAGTCC CGGAGTAGCTGCGGCCAGCAGAGGGTAGACTGAGAGCAGGAGAGAAGGACCTGCCTAGGAACCCCTTCTA GAGATACTGCATCCTGCCTGGGAGCAAGTTTTCCAGGGCAGCTTTGAGAAGTCTTGGAGAAACAAACCTA CTAAACCTGACAGACAGTAATACTATTTGCACAATGCTTTTCTGTGGGAAAGGTAGAGCCTTTTCACTAC GTATTGAGTACATAGAGTGTGAGGGTTGACCTGGAACGGCTATCCTCCTGGATGACGTGTGTTTTCTGAA GAACTACATGTTCGTTGCAACTCCCACATTAGAATATGAAGTCCTACCGAGAGAGATACGGAGACTAGAC AGATACAGATGCATTTGCATGTGAATACACAATCCCACAATACAGACGTCAAAACCCATACCAGTTATTC CAGAGAGATGGATTGGGCAGAAGGCAGAAGGAGAATACTCTGATCGTTTTTCGGCCACGTGTGTGTGTTA TCTCAGTGTTTCTAAGAAGCGTTTGCTACTTTAGATTTTTTATTTAAAAAAATAGTAATAATCTATTAAG TATGAGAGATGTGCAGAGAGGATTAGTGATCGAGAGCCATTTTTGCTGGTGGCAATCATATGGTACTTTT AATGGGAATATTAGAAAGGCACCGGTAATGACCTTGTTGCAGCACAAAGGAGAGAGTGTGGGGTGCCCCT GCATGTTGTCCCACCTCTTGTGACGTGTATCGTTTTGGAATTTCCAGTGGCTTGATCATGAACTACTGCA GGAATCCAGATGCTGTGGCAGCTCCTTATTGTTATACGAGGGATCCCGGTGTCAGGTGGGAGTACTGCAA CCTGACGCAATGCTCAGACGCAGAAGGGACTGCCGTCGCGCCTCCGACTGTTACCCCGGTTCCAAGCCTA GAGGCTCCTTCCGAACAAGGTAAGGAGTCTGTGGCCAGACATCTACACGCTTCGATGCTGGGATGAAAAG CCATGGAAATTCCCACTGATGCAGCCGCCTTCAATGGTAAACGGATGCTCGAGTGTTGCCTGAGTTCTAC CATGTAGGAGGAAGCCTCCGTGCACTCTCTGGGGGAGCCAGCGGAGTGATTTCTGGTGCAACGTGGTTGG GCTTTGTCTTTAGGATGGGCACAAACCCTCCAGGGGGATCGACTTCAAAATTCACCTTGTTGTAAAACGG GCTACCTCAGTGTCCCAGCCAAAATTTTTATTGTAACATGCTGTCAGGTGTGTCACTCTTTCCAAGCCAG TAAGCTTTTCCGGGGATTTCTTCAAGTAGCCAGCATTCAGAGCAATCTTCAGCATTGCAGATTCTGAGAA ATGTGGCTCTGGAGCCTGTCACCCTCGAGAAACCTAAGAGGGCTGCATTGATTCCATGTGGCCCTGGGTC TATGGAGCAGTACATGAGCTCCCAGTGCTCTAAGGCTCTTCAGCCCTAGGCTTTGAAGGGAGTGATTTCT CAGTATTCTTAAACCTCTTTCTGATGACACTTGTACCTGTGAGGGGTCTAGAGAGAAAGAGTAGTAGACT CCTACTTTACTACAATTCAGGATGCAGGGCATGAGAGGATTCCCTCTCTCCTCCAAGGGAAGAAGCTTTT GGCGTGCACACATCCCTGAGAAGCAAAGTGTCTTTGTCTTCAGTCAGATACATAGGACCGTTTTCTGCCC CATGGCCCGGAAGCCAAAGGCCTTGGCTTTCATGATCAACGGTCTAGGGAAACATGCAAAATTTCCATGT CTGTCCCAAACTCTGCCCCCGACAGCCAATTACCACCTGCAGCCCGCATTGCCAAATGCGGTGCCGTTTG CATGAAGATTCAGTAGAGTTTCCTAGAAAGGTGCTACCTCGTGAGCTCACTTTCCAATGAGGAATCTGAT CTGTTGTGTTTCTCTAAGGTGTCAGGTGAAATATTTCCAAGAACTTACTACAGTTCTAGAATGGGAGGAA TCTGTTGCTTTGGTGTTTGTTTGTTGGTCGGTTTTCTCACATCCATCTGCCTATGGATAAGGAAAAGAGA ACGGTCGTAATTCTCATAGACTCCTTTCTGGTTGTGTCACAAATGGCTTCACATGTTTCTCTATGCTCAG AGATACTCAGCTTGATTTCCCGTGTTTTCATTTCAGCACCGACTGAGCAAAGGCCTGGGGTGCAGGAGTG CTACCATGGTAATGGACAGAGTTATCGAGGCACATACTCCACCACTGTCACAGGAAGAACCTGCCAAGCT TGGTCATCTATGACACCACACTCGCATAGTCGGACCCCAGAATACTACCCAAATGCGTATGTCTTTGTTC TTTACCATAAGAGAAGAAAGGGCCAAGTGAAGTTTCTGTTACAAGAGATGTGTCTCAAGCTGAGTTCTCC GAACTCAACTTGTGACAGATGCAGATGGCGTAGCAAAATGTCTCAGGATGATTGCCTTGGAGCTAAGGGT CTGAGAGAAGGGAAATGTTAAGCTCCCTCTCCTTCCTCCTAGTTCTATTGAGCAGAAGGGAAATCTGGAG GTGAGGAGATCACATTATGAAGAAAGTCAGAATGACAAAGGACCAGACACTTAGATTACCCTTCCACAAC ACCAACTAAACGTCAATGGAGACTTTCCAGTTGGAATTCCGTTATTCTGGCTTCCACTTCCTGAAGGGAA GGTTGCGTTTGCCTTTTCTCTCTGGGTTCAAGAGGAAAGAATAGGTGCTTATTTATGGACAGGTGAATTG ATCTGTTTCTATATCTACGTATATTCCGATTGTCAGAAAAACACTCGTTCCTAAGTACCAGTGGCCTGAA GGGATACAGGTTCCCAGCAAGAGAAGATCCAAGGAAGGAAGGCAGATGAGAGTCAGCACAGAGAGGGATG CTGAAAAGTAAAAGGGATGGGTGGATGGAGAGAAGCCCGGGTCTGACCACCCAATGGCCAATATTTTGGC CACAAGCGACTACCAGAGACATGGAAAAATGGTTTCTACATGTGGGACAACAGATGGTAGAGGACCTAGA GAATTGAGAGAGGGGCAATGATGGGCTCCACTCCGCAGATGCCTTGGCTTTCTTCCTGGATACCCTTCCT GCACTGAATAGCAAGGAGATGGAGCCCAAGCAGACTGTAGCCATCTTGCTGAATGGAGGAGAGGGATTGG AGTTTGGGATGACTGTGGTAGCTGAAATTTTTCTAGGTCTGCTAGAAATAAGAACTGGTTTGTGGAGGAA AAGAGCTCTACAAATACGCATAGAAGTCTCCTCCAGTCGTTGGCCTGACATGACGCTGCCTGTGCACAGG AAATGGTTCCACGAGAAAGTGTGGCAAAGAACATTTACTGAGAAACAGCAAGTACAAGAGCACAGGAAGC TCAATAAAGAAGAGAGAGATCACATAGCACTCTGGGATACTGGAGTTCTTCCCAGCTAGACCAGAGAGTC CTCACGGAGCACATTGCCAATTCAGTGGAGACCCCAGAACAGCCGTAATTTAAAGGTACACTTAGTATAT TACTAGAATAAAGTCAGCTGCAGACAACCCCTTGCACAGCTGGAAAGCAAGTGTCCAAGCATCAAATCGG TTTCCAATCAATGAAGTGCCTGTGAGAGGAAATCTCAACTCTCTTTAGAAGTAAACAACAAAGTCGATTG CCTCAGCTATGCGGTATCCGCAGAGTGAGTCCTAAATTTAAAATCTGACTACATGTAGAAAAGCGTTTCG TGTGACCCATGACCAGGAAATAAATCGGGTAATACAAACAGGCTCAGGAATGAGAGAAATGATTAGAATT GCGTGAAAATTTGACATATCAGTATGATAACTGATTTCAAATATTTAAAAAAACAACATGCAAGAAAGCA GATATCATATCAAGAGAAATTAACAGTACAGAATAGCCAAATTAAATTAAAGAGCTAGTATAAAAAAAGT ATGTCTTAATTGAAAAAAATTACTGTATGGCCGGCTGATCAATTTAGACGTTTCAGAGGAAAACATTACC CAACACACAATTCTAGAGAACCTACAGAATGAGCTACACACACACACACACACACACACACAAACTGAAA ACACACCCATACTCACACACACGCAGAAACTCACAAGTTCTAACACACACAGACACGCGCACCCCTGAAG AAACAGTGAAATATAAAATTAAGCGAGCCTCACAGACATGTAGGAAAATATGAAAAGATTTCCTGCATGT GGGAAGCAAGTCACAGTAAAGAGCAAGGGAGTTTGGAATAGAAACAAATACCGGAATCAAGGATGGCTGA TAACTTTTCAATTACGAAGAACATTAAAAAAAATCACAGAATCGTGAAACTCAAGGGATCACATAGGGAA TTTCGGAAAAAAAACCCAACCTGTATGATGTACTTTTGTACATCACAGTTCGAAGGTAACAAGGCAAAGA TATAATAAGAAGAAACCTGTCACGAGAAACTGGAGGAAAAAGAGCTGTGTCTTCCTACAAGTACACTGAT ACAAATTGCCAATGTGTTCACCTCAGAAACACTGGAAGCCAGATACCAGGGAATATTGTTAAAATGATAA TCAGGAACAAAAAGAGATCAACCGGGAATGCTGAATCCAGCAATAAAATGCCTTGAAGATCATCCATGTC GGATAAATGCATATTGTGCACTGCCCCAAAGAAAGAAACCGGAAACTGTAAGAATTGGAAATCAGCAGGC TTATGTAACAAGAGAGGTGACCCGAAGGAATTAGGTAGAAGAAGAATTGAACAAGAAAGGAACTTTCTGC AGCCCACGTAATGAAGAATCCAGCAATTGGCAAATGTAGATAGATGTAAATGCAAAATATTTTCTTGATC AAATTTCTATATCTTTGTAAATGAGAGTTGACTACTTGAAACAAAATGATAGCAAGATATTTAACTTCAG CATATGTAGAGGTAAGAATTTGAAATGGTAGCATAAATCACGAAGGGATTAATTCGAAGTGTACCGTTGT AAGTTTCTTTACCTCATGCACGATGGTGTGTCATATTAATAAAAGGGTACTGTGCGGGTTCGAAGGGATA TTGCAAATCCTAGAGCAATCACAAAGGTTTGAACTCTGAGGTTTTTGGTATAATAAGAATAGTCCATGCA TTCAAAAGAGGGAAGCCAAGGAAGAACTAGAAGTCTTTCAAGAGCTCAGGCTCTTATACATCCAGTTGCT CATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGGTTGAGACTAGGCCACAAGTCTAGAGTCTCTAGAGA GACAGTGTTGGAACCCCATGGCCCATAATACATTTCCCATTTTCTCAGGCAGCCAGAGGTCATGAATGTG AGGATACTGGGAGGTTGGAGCAACGTTCTTGGGAGGCATAAGGAAGAGCGAATGCTTCAAGATCCCCGCA GCCCAAACTACTCGCCTGCTTTGCCCCCTAATGCATTTTTCTCTGCTGCTCCGTAGCTGTCCGACCTCTT CAGATCTCTTAGTCCACCCTGCCGTCTTCCTTTATGCCATGGGTCCCACTGTTCTTTCAACTCATCCCCC TTTCCCTCAGTCCCGGAGTAGCTGCGGCCAGCAGAGGGTAGACTGAGAGCAGGAGAGAAGGACCTGCCTA GGAACCCCTTCTAGAGATACTGCATCCTGCCTGGGAGCAAGTTTTCCAGGGCAGCTTTGAGAAGTCTTGG AGAAACAAACCTACTAAACCTGACAGACAGTAATACTATTTGCACAATGCTTTTCTGTGGGAAAGGTAGA GCCTTTTCACTACGTATTGAGTACATAGAGTGTGAGGGTTGACCTGGAACGGCTATCCTCCTGGATGACG TGTGTTTTCTGAAGAACTACATGTTCGTTGCAACTCCCACATTAGAATATGAAGTCCTACCGAGAGAGAT ACGGAGACTAGACAGATACAGATGCATTTGCATGTGAATACACAATCCCACAATACAGACGTCAAAACCC ATACCAGTTATTCCAGAGAGATGGATTGGGTAGGAGGCAGAAGGAGAATACTCTGATCGTTTTTCGGCCA CGTGTGTGTGTTATCTCAGTGTTTCTAAGAAGCGTTTGCTACTTTAGATTTTTTATTTAAAAAAAATAGT AATAATCTATTAAGTATGAGAGATGTGCAGAGAGGATTAGTGATCGAGAGCCATTTTTGCTGGTGGCAAT CATATGGTACTTTTAATGGGAATATTAGAAAGGCACCGGTAATGACCTTGTTGCAGCACAAAGGAGAGAG TGTGGGGTGCCCCTGCATGTTGTCCCACCTCTTGTGACGTGTATCGTTTTGGAATTTCCAGTGGCTTGAT CATGAACTACTGCAGGAATCCAGATGCTGTGGCAGCTCCTTATTGTTATACGAGGGATCCCGGTGTCAGG TGGGAGTACTGCAACCTGACGCAATGCTCAGACGCAGAAGGGACTGCCGTCGCGCCTCCGACTGTTACCC CGGTTCCAAGCCTAGAGGCTCCTTCCGAACAAGGTAAGGAGTCTGTGGCCAGACATCTACACGCTTCGAT GCTGGGATGAAAAGCCATGGAAATTCCCACTGATGCAGCCGCCTTCAATGGTAAACGGATGCTCGAGTGT TGCCGGAGTTCTGCCATGTTGGGGGAAGCCTCCGTGTACTCTCTGGGGGAGCCAGCGGAGTGATTTCTGG TGCAACTTGGGTGGGCTTTGTCTTTAGAATGGGCACAAACCTTCCAGGGTGATGGGCTTCACAACTCACC TCCTTCTAAAATGGGCTATCTCAGTGTCTTAGCCAAAATTTTTATTGTAACGTGCTGTCAGGTGTGTGAT TCTTTCTGTCGCAGTAAGCTTTTCTGGGGATTTCTTCAAGTAGCCAGCAGTCAGTGCAATCTTCAGCATT GCAGATTTCAAAAAATGTGGCTCTGGAGCCTGTCATCCTCGAGAAACCTAACAGGGCTGCATTAATTCCA TATGGTCCTGGGTCTATGGAGCAGTATATGAGCTCCCAATGCTCTAAGGCTCTTCAGTCCTAGGCTTTGA AGGGAGTGATTTCTCAGTGTTCTTAAACCTCTTTCTGATGGCACTTGTACCTGTGAGGGGTCTAGAGAGA AAGGTTAGTAGACTTCTCCTTTACTGCAATTCAGGATGCAGGGCATGAGAAGATTCCCTCCCTCCTCCAA GGGAAGAAGGTTTTGGCGTGCACACATCCTTGAGAAGCAAAGTGTCTTTGCCTTCAGTCAGATATATAGG ATCGTTTTCTGCCCCATGGCCTGGAAGCCAGAGGCCTTGGCTTTCATGATCAACGATCTAGGGAAACATG CAAAATTTCCATGTCTTTCCCCTCCTCTGCCCTCGACAGCCAATTACCACCTGCATCCTGCATTGCCAAA TGCAGTGCCCTTTGTATGAACATTCAGTAGAGTTTCATAGAAAGGTGCTACTTCGTGAGCGCACTTTGCA GTGAGAAGGAGTCTGTTCTGTTCTGTTTTTCTAAGGATTTCAGGTGAAATATTTCCTAGAACTTACTACA GTTCTAGATTGGTAGGAATCTGTAGGTTTGCTGTATGTTTTTTGGTTGGTTTTCTCCCATCCATCTGCCT ACAGGTAAGGGAAAGATAACGTTCGTAATTCTCATAGACTCCTTTCTGGTTGTGTCATAAATGGCTTCAC ATATTTCGTTATTCTCAGAGATACTCAGTTTATTTCTTGTGTTTTCATTTCAGCACCGACTGAGCAGAGG CCTGGGGTGCAGGAGTGCTACCACGGTAATGGACAGAGTTATCGAGGCACATACTCCACCACTGTCACTG GAAGAACCTGCCAAGCTTGGTCATCTATGACACCACACTCGCATAGTCGGACCCCAGAATACTACCCAAA TGCGTATGTCTTTGTTCTTTACCATAAGAGAAGAAAGGGCCAAGTGAAGTTTCTGTTACAAGAGATGTGT CTCAAGCTGAGTTCTCCGAACTCAACTTGTGACAGATGCAGATGGCGTAGCAAAATGTCTCAGGATGATT GCCTTGGAGCTAAGGGTCTGAGAGAAGGGAAATGTTAAGCTCCCTCTCCTTCCTCCTAGTTCTATTGAGC AGAAGGGAAATCTGGAGGTGAGGAGATCACATTATGAAGAAAGTCAGAATGACAAAGGACCAGACACTTA GATTACCCTTCCACAACACCAACTAAACGTCAATGGAGACTTTCCAGTTGGAATTCCGTTATTCTGGCTT CCACTTCCTGAAGGGAAGGTTGCGTTTGCCTTTTCTCTCTGGGTTCAAGAGGAAAGAATAGGTGCTTATT TATGGACAGGTGAATTGATCTGTTTCTATATCTACGTATATTCCGATTGTCAGAAAAACACTCGTTCCTA AGTACCAGTGGCCTGAAGGGATACAGGTTCCCAGCAAGAGAAGATCCAAGGAAGGAAGGCAGATGAGAGC CAGCACAGAGAGGGATGCTGAAAAGTAAAAGGGATGGGTGGATGGAGAGAAGCCCGGGTCTGACCACCCA ATGGCCAATATTTTGGCCACAAGCGACTACCAGAGACATGGAAAAATGGTTTCTACATGTGGGACAACAG ATGGTAGAGGACCTAGAGAATTGAGAGAGGGGCAATGATGGGCTCCACTCCGCAGATGCCTTGGCTTTCT TCCTGGATACCCTTCCTGCACTGAATAGCAAGGAGATGGAGCCCAAGCAGACTGTAGCCATCTTGCTGAA TGGAGGAGAGGGATTGGAGTTTGGGATGACTGTGGTAGCTGAAATTTTTCTAGGTCTGCTAGAAATAAGA ACTGGTTTGTGGAGGAAAAGAGCTCTACAAATACGCATAGAAGTCTCCTCCAGTCGTTGGCCTGACATGA CGCTGCCTGTGCACAGGAAATGGTTCCACGAGAAAGTGTGGCAAAGAACATTTACTGAGAAACAGCAAGT ACAAGAGCACAGGAAGCTCAATAAAGAAGAGAGAGATCACATAGCACTCTGGGATACTGGAGTTCTTCCC AGCTAGACCAGAGAGTCCTCACGGAGCACATTGCCAATTCAGTGGAGACCCCAGAACAGCCGTAATTTAA AGGTACACTTAGTATATTACTAGAATAAAGTCAGCTGCAGACAACCCCTTGCACAGCTGGAAAGCAAGTG TCCAAGCATCAAATCGGTTTCCAATCAATGAAGTGCCTGTGGGAGGAAATCTCAACTCTCTTTAGAAGTA AACAACAAAGTCGATTGCCTCAGCTATGCGGTATCCGCAGAGTGAGTCCTAAATTTAAAATCTGACTACA TGTAGAAAAGCGTTTCGTGTGACCCATGACCAGGAAATAAATCGGGTAATACAAACAGGCTCAGGAATGA GAGAAATGATTAGAATTGCGTGAAAATTTGACATATCAGTATGATAACTGATTTCAAATATTTAAAAAAA CAACATGCAAGAAAGCAGATATCATATCAAGAGAAATTAACAGTACAGAATAGCCAAATTAAATTAAAGA GCTAGTATAAAAAAAGTATGTCTTAATTGAAAAAAATTACTGTATGGCCGGCTGATCAAATTAGACGTTT CAGAGGAAAACATTACCCAACACACAATTCTAGAGAACCTACAGAATGAGCTACACACACACACACACAC ACACACACACACACTGAAAACACACCCATACTCACACACACGCAGAAACTCACAAGTTCTAACACACACA GACACGCGCACCCCTGAAGAAACAGTGAAATATAAAATTAAGCGAGCCTCACAGACATGTAGGAAAATAT GAAAAGATTTCCTGCATGTGGGAAGCAAGTCACAGTAAAGAGCAAGGGAGTTTGGAATAGAAACAAATAC CGGAATCAAGGATGGCTGATAACTTTTCAATTACGAAGAACATTAAAAAAAATCACAGAATCGTGAAACT CAAGGGATCATATAGGGAATTTCGGAAAAAAAACCCAACCTGTATGATGTACTTTTGTACATCACAGTTC GAAGGTAACAAGGCAAAGATATAATAAGAAGAAACCTGTCACGAGAAACTGGAGGAAAAAGAGCTGTGTC TTCCTACAAGTACACTGATACAAATTGCCAATGTGTTCACCTCAGAAACACTGGAAGCCAGATACCAGGG AATATTGTTAAAATGATAATCAGGAACAAAAAGAGATCAACCGGGAATGCTGAATCCAGCAATAAAATGC CTTGAAGATCATCCATGTCGGATAAATGCATATTGTGCACTGCCCCAAAGAAAGAAACCGGAAACTGTCA GAATTGGAAATCAGCAGGCTTATGTAACAAGAGAGGTGACCCGAAGGAATTAGGTAGAAGAAGAATTGAA CAAGAAAGGAACTTTCTGCAGCCCACGTAATGAAGAATCCAGCAATTGGCAAATGTAGATAGATGTAAAT GCAAAATATTTTCTTGATCAAATTTCTATATCTTTGTAAATGAGAGTTGACTACTTGAAACAAAATGATA GCAAGATATTTAACTTCAGCATATGTAGAGGTAAGAATTTGAAATGGTAGCATAAATCACGAAGGGATTA ATTCGAAGTGTACCGTTGTAAGTTTCTTTACCTCATGCACGATGGTGTGTCATATTAATAAAAGGGTACT GTGCGGGTTCGAAGGGATATTGCAAATCCTAGAGCAATCACAAAGGTTTGAACTCTGAGGTTTTTGGTAT AATAAGAATAGTCCATGCATTCAAAAGAGGGAAGCCAAGGAAGAACTAGAAGTCTTTCAAGAGCTCAGGC TCTTATACATCCAGTTGCTCATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGGTTGAGACTAGGCCACA AGTCTAGAGTCTCTAGAGAGACAGTGTTGGAACCCCATGGCCCATAATACATTTCCCATTTTCTCAGGCA GCCAGAGGTCATGAATGTGAGGATACTGGGAGGTTGGAGCAACGTTCTTGGGAGGCATAAGGAAGAGCGA ATGCTTCAAGATCCCCGCAGCCCAAACTACTCGCCTGCTTTGCCCCCTAATGCATTTTTCTCTGCTGCTC CGTAGCTGTCCGACCTCTTCAGATCTCTTAGTCCACCCTGCCGTCTTCCTTTATGCCATGGGTCCCATTG TTCTTTCAACTCATCCCCCTTTCCCTCAGTCCCGGAGTAGCTGCGGCCAGCAGAGGGTAGACTGAGAGCA GGAGAGAAGGACCTGCCTAGGAACCCCTTCTAGAGATACTGCATCCTGCCTGGGAGCAAGTTTTCCAGGG CAGCTTTGAGAAGTCTTGGAGAAACAAACCTACTAAACCTGACAGACAGTAATACTATTTGCACAATGCT TTTCTGTGGGAAAGGTAGAGCCTTTTCACTACGTATTGAGTACATAGAGTGTGAGGGTTGACCTGGAACG GCTATCCTCCTGGATGACGTGCGTTTTCTGAAGAACTACATGTTCGTTGCAACTCCCACATTAGAATATG AAGTCCTACCGAGAGAGATACGGAGACTAGACAGATACAGATGCATTTGCATGTGAATACACAATCCCAC AATACAGACGTCAAAACCCATACCAGTTATTCCAGAGAGATGGATTGGGCAGAAGGCAGAAGGAGAATAC TCTGATCGTTTTTCGGCCACGTGTGTGTGTTATCTCAGTGTTTCTAAGAAGCGTTTGCTACTTTAGATTT TTTATTTAAAAAAAATAGTAATAATCTATTAAGTATGAGAGATGTGCAGAGAGGATTAGTGATCGAGAGC CATTTTTGCTGGTGGCAATCATATGGTACTTTTAATGGGAATATTAGAAAGGCACCGGTAATGACCTTGT TGCAGCACAAAGGAGAGAGTGTGGGGTGCCCCTGCATGTTGTCCCACCTCTTGTGACGTGTATCGTTTTG GAATTTCCAGTGGCTTGATCATGAACTACTGCAGGAATCCAGATGCTGTGGCAGCTCCTTATTGTTATAC GAGGGATCCCGGTGTCAGGTGGGAGTACTGCAACCTGACGCAATGCTCAGACGCAGAAGGGACTGCCGTC GCGCCTCCGACTGTTACCCCGGTTCCAAGCCTAGAGGCTCCTTCCGAACAAGGTAAGGAGTCTGTGGCCA GACATCTACACGCTTCGATGCTGGGATGAAAAGCCATGGAAATTCCCACTGATGCAGCCGCCTTCAATGG TAAACGGATGCTCGAGTGTTGCCTGAGTTCTACCATGTAGGAGGAAGCCTCCGTGCACTCTCTGGGGGAG CCAGCGGAGTGATTTCTGGTGCAACGTGGTTGGGCTTTGTCTTTAGGATGGGCACAAACCCTCCAGGGGG ATCGACTTCAAAATTCACCTTGTTGTAAAACGGGCTACCTCAGTGTCCCAGCCAAAATTTTTATTGTAAC ATGCTGTCAGGTGTGTCACTCTTTCCAAGCCAGTAAGCTTTTCCGGGGATTTCTTCAAGTAGCCAGCATT CAGAGCAATCTTCAGCATTGCAGATTCTGAGAAATGTGGCTCTGGAGCCTGTCACCCTCGAGAAACCTAA GAGGGCTGCATTGATTCCATGTGGCCCTGGGTCTATGGAGCAGTACATGAGCTCCCAGTGCTCTAAGGCT CTTCAGCCCTAGGCTTTGAAGGGAGTGATTTCTCAGTATTCTTAAACCTCTTTCTGATGACACTTGTACC TGTGAGGGGTCTAGAGAGAAAGAGTAGTAGACTCCTACTTTACTACAATTCAGGATGCAGGGCATGAGAG GATTCCCTCTCTCCTCCAAGGGAAGAAGCTTTTGGCGTGCACACATCCCTGAGAAGCAAAGTGTCTTTGT CTTCAGTCAGATACATAGGACCGTTTTCTGCCCCATGGCCCGGAAGCCAAAGGCCTTGGCTTTCATGATC AACGGTCTAGGGAAACATGCAAAATTTCCATGTCTGTCCCAAACTCTGCCCCCGACAGCCAATTACCACC TGCAGCCCGCATTGCCAAATGCGGTGCCGTTTGCATGAAGATTCAGTAGAGTTTCCTAGAAAGGTGCTAC CTCGTGAGCTCACTTTCCAATGAGGAATCTGATCTGTTGTGTTTCTCTAAGGTGTCAGGTGAAATATTTC CAAGAACTTACTACAGTTCTAGAATGGGAGGAATCTGTTGCTTTGGTGTTTGTTTGTTGGTCGGTTTTCT CACATCCATCTGCCTATGGATAAGGAAAAGAGAACGGTCGTAATTCTCATAGACTCCTTTCTGGTTGTGT CACAAATGGCTTCACATGTTTCTCTATGCTCAGAGATACTCAGCTTGATTTCCCGTGTTTTCATTTCAGC ACCGACTGAGCAAAGGCCTGGGGTGCAGGAGTGCTACCATGGTAATGGACAGAGTTATCGAGGCACATAC TCCACCACTGTCACAGGAAGAACCTGCCAAGCTTGGTCATCTATGACACCACACTCGCATAGTCGGACCC CAGAATACTACCCAAATGCGTATGTCTTTGTTCTTTACCATAAGAGAAGAAAGGGCCAAGTGAAGTTTCT GTTACAAGAGATGTGTCTCAAGCTGAGTTCTCCGAACTCAACTTGTGACAGATGCAGATGGCGTAGCAAA ATGTCTCAGGATGATTGCCTTGGAGCTAAGGGTCTGAGAGAAGGGAAATGTTAAGCTCCCTCTCCTTCCT CCTAGTTCTATTGAGCAGAAGGGAAATCTGGAGGTGAGGAGATCACATTATGAAGAAAGTCAGAATGACA AAGGACCAGACACTTAGATTACCCTTCCACAACACCAACTAAACGTCAATGGAGACTTTCCAGTTGGAAT TCCGTTATTCTGGCTTCCACTTCCTGAAGGGAAGGTTGCGTTTGCCTTTTCTCTCTGGGTTCAAGAGGAA AGAATAGGTGCTTATTTATGGACAGGTGAATTGATCTGTTTCTATATCTACGTATATTCCGATTGTCAGA AAAACACTCGTTCCTAAGTACCAGTGGCCTGAAGGGATACAGGTTCCCAGCAAGAGAAGATCCAAGGAAG GAAGGCAGATGAGAGTCAGCACAGAGAGGGATGCTGAAAAGTAAAAGGGATGGGTGGATGGAGAGAAGCC CGGGTCTGACCACCCAATGGCCAATATTTTGGCCACAAGCGACTACCAGAGACATGGAAAAATGGTTTCT ACATGTGGGACAACAGATGGTAGAGGACCTAGAGAATTGAGAGAGGGGCAATGATGGGCTCCACTCCGCA GATGCCTTGGCTTTCTTCCTGGATACCCTTCCTGCACTGAATAGCAAGGAGATGGAGCCCAAGCAGACTG TAGCCATCTTGCTGAATGGAGGAGAGGGATTGGAGTTTGGGATGACTGTGGTAGCTGAAATTTTTCTAGG TCTGCTAGAAATAAGAACTGGTTTGTGGAGGAAAAGAGCTCTACAAATACGCATAGAAGTCTCCTCCAGT CGTTGGCCTGACATGACGCTGCCTGTGCACAGGAAATGGTTCCACGAGAAAGTGTGGCAAAGAACATTTA CTGAGAAACAGCAAGTACAAGAGCACAGGAAGCTCAATAAAGAAGAGAGAGATCACATAGCACTCTGGGA TACTGGAGTTCTTCCCAGCTAGACCAGAGAGTCCTCACGGAGCACATTGCCAATTCAGTGGAGACCCCAG AACAGCCGTAATTTAAAGGTACACTTAGTATATTACTAGAATAAAGTCAGCTGCAGACAACCCCTTGCAC AGCTGGAAAGCAAGTGTCCAAGCATCAAATCGGTTTCCAATCAATGAAGTGCCTGTGAGAGGAAATCTCA ACTCTCTTTAGAAGTAAACAACAAAGTCGATTGCCTCAGCTATGCGGTATCCGCAGAGTGAGTCCTAAAT TTAAAATCTGACTACATGTAGAAAAGCGTTTCGTGTGACCCATGACCAGGAAATAAATCGGGTAATACAA ACAGGCTCAGGAATGAGAGAAATGATTAGAATTGCGTGAAAATTTGAAATATCAGTATGATAACTGATTT CAAATATTTAAAAAAACAACATGCAAGAAAGCAGATATCATATCAAGAGAAATTAACAGTACAGAATAGC CAAATTAAATTAAAGAGCTAGTATAAAAAAAGTATGTCTTAATTGAAAAAAATTACTGTATGGCCGGCTG ATCAATTTAGACGTTTCAGAGGAAAACATTACCCAACACACAATTCTAGAGAACCTACAGAATGAGCTAC ACACACACACACACACACACACACAAACTGAAAACACACCCATACTCACACACACGCAGAAACTCACAAG TTCTAACACACACAGACACGCGCACCCCTGAAGAAACAGTGAAATATAAAATTAAGCGAGCCTCACAGAC ATGTAGGAAAATATGAAAAGATTTCCTGCATGTGGGAAGCAAGTCACAGTAAAGAGCAAGGGAGTTTGGA ATAGAAACAAATACCAGAATCAAGGATGGCTGATAACTTTTCAATTACGAAGAACATTAAAAAAAATCAC AGAATCGTGAAACTCAAGGGATCACATAGGGAATTTCGGAAAAAAAACCCAACCTGTATGATGTACTTTT GTACATCACAGTTCGAAGGTAACAAGGCAAAGATATAATAAGAAGAAACCTGTCACGAGAAACTGGAGGA AAAAGAGCTGTGTCTTCCTACAAGTACACTGATACAAATTGCCAATGTGTTCACCTCAGAAACACTGGAA GCCAGATACCAGGGAATATTGTTAAAATGATAATCAGGAACAAAAAGAGATCAACCGGGAATGCTGAATC CAGCAATAAAATGCCTTGAAGATCATCCATGTCGGATAAATGCATATTGTGCACTGCCCCAAAGAAAGAA ACCGGAAACTGTAAGAATTGGAAATCAGCAGGCTTATGTAACAAGAGAGGTGACCCGAAGGAATTAGGTA GAAGAAGAATTGAACAAGAAAGGAACTTTCTGCAGCCCACGTAATGAAGAATCCAGCAATTGGCAAATGT AGATAGATGTAAATGCAAAATATTTTCTTGATCAAATTTCTATATCTTTGTAAATGAGAGTTGACTACTT GAAACAAAATGATAGCAAGATATTTAACTTCAGCATATGTAGAGGTAAGAATTTGAAATGGTAGCATAAA TCACGAAGGGATTAATTCGAAGTGTACCGTTGTAAGTTTCTTTACCTCATGCACGATGGTGTGTCATATT AATAAAAGGGTACTGTGCGGGTTCGAAGGGATATTGCAAATCCTAGAGCAATCACAAAGGTTTGAACTCT GAGGTTTTTGGTATAATAAGAATAGTCCATGCATTCAAAAGAGGGAAGCCAAGGAAGAACTAGAAGTCTT TCAAGAGCTCAGGCTCTTATACATCCAGTTGCTCATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGGTT GAGACTAGGCCACAAGTCTAGAGTCTCTAGAGAGACAGTGTTGGAACCCCATGGCCCATAATACATTTCC CATTTTCTCAGGCAGCCAGAGGTCATGAATGTGAGGATACTGGGAGGTTGGAGCAACGTTCTTGGGAGGC ATAAGGAAGAGCGAATGCTTCAAGATCCCCGCAGCCCAAACTACTCGCCTGCTTTGCCCCCTAATGCATT TTTCTCTGCTGCTCCGTAGCTGTCCGACCTCTTCAGATCTCTTAGTCCACCCTGCCGTCTTCCTTTATGC CATGGGTCCCACTGTTCTTTCAACTCATCCCCCTTTCCCTCAGTCCCGGAGTAGCTGCGGCCAGCAGAGG GTAGACTGAGAGCAGGAGAGAAGGACCTGCCTAGGAACCCCTTCTAGAGATACTGCATCCTGCCTGGGAG CAAGTTTTCCAGGGCAGCTTTGAGAAGTCTTGGAGAAACAAACCTACTAAACCTGACAGACAGTAATACT ATTTGCACAATGCTTTTCTGTGGGAAAGGTAGAGCCTTTTCACTACGTATTGAGTACATAGAGTGTGAGG GTTGACCTGGAACGGCTATCCTCCTGGATGACGTGTGTTTTCTGAAGAACTACATGTTCGTTGCAACTCC CACATTAGAATATGAAGTCCTACCGAGAGAGATACGGAGACTAGACAGATACAGATGCATTTGCATGTGA ATACACAATCCCACAATACAGACGTCAAAACCCATACCAGTTATTCCAGAGAGATGGATTGGGCAGAAGG CAGAAGGAGAATACTCTGATCGTTTTTCGGCCACGTGTGTGTGTTATCTCAGTGTTTCTAAGAAGCGTTT GCTACTTTAGATTTTTTATTTAAAAAAAATAGTAATAATCTATTAAGTATGAGAGATGTGCAGAGAGGAT TAGTGATCGAGAGCCATTTTTGCTGGTGGCAATCATATGGTACTTTTAATGGGAATATTAGAAAGGCACC GGTAATGACCTTGTTGCAGCACAAAGGAGAGAGTGTGGGGTGCCCCTGCATGTTGTCCCACCTCTTGTGA CGTGTATCGTTTTGGAATTTCCAGTGGCTTGATCATGAACTACTGCAGGAATCCAGATGCTGTGGCAGCT CCTTATTGTTATACGAGGGATCCCGGTGTCAGGTGGGAGTACTGCAACCTGACGCAATGCTCAGACGCAG AAGGGACTGCCGTCGCGCCTCCGACTGTTACCCCGGTTCCAAGCCTAGAGGCTCCTTCCGAACAAGGTAA GGAGTCTGTGGCCAGACATCTACACGCTTCGATGCTGGGATGAAAAGCCATGGAAATTCCCACTGATGCA GCCGCCTTCAATGGTAAACGGATGCTCGAGTGTTGCCTGAGTTCTACCATGTAGGAGGAAGCCTCCGTGC ACTCTCTGGGGGAGCCAGCGGAGTGATTTCTGGTGCAACGTGGTTGGGCTTTGTCTTTAGGATGGGCACA AACCCTCCAGGGGGATCGACTTCAAAATTCACCTTGTTGTAAAACGGGCTACCTCAGTGTCCCAGCCAAA ATTTTTATTGTAACATGCTGTCAGGTGTGTCACTCTTTCCAAGCCAGTAAGCTTTTCCGGGGATTTCTTC AAGTAGCCAGCATTCAGAGCAATCTTCAGCATTGCAGATTCTGAGAAATGTGGCTCTGGAGCCTGTCACC CTCGAGAAACCTAAGAGGGCTGCATTGATTCCATGTGGCCCTGGGTCTATGGAGCAGTACATGAGCTCCC AGTGCTCTAAGGCTCTTCAGCCCTAGGCTTTGAAGGGAGTGATTTCTCAGTATTCTTAAACCTCTTTCTG ATGACACTTGTACCTGTGAGGGGTCTAGAGAGAAAGAGTAGTAGACTCCTACTTTACTACAATTCAGGAT GCAGGGCATGAGAGGATTCCCTCTCTCCTCCAAGGGAAGAAGCTTTTGGCGTGCACACATCCCTGAGAAG CAAAGTGTCTTTGTCTTCAGTCAGATACATAGGACCGTTTTCTGCCCCATGGCCCGGAAGCCAAAGGCCT TGGCTTTCATGATCAACGGTCTAGGGAAACATGCAAAATTTCCATGTCTGTCCCAAACTCTTCCCCCGAC AGCCAATTACCACCTGCAGCCCGCATTGCCAAATGCGGTGCCGTTTGCATGAAGATTCAGTAGAGTTTCC TAGAAAGGTGCTACCTCGTGAGCTCACTTTCCAATGAGGAATCTGATCTGTTGTGTTTCTCTAAGGTGTC AGGTGAAATATTTCCAAGAACTTACTACAGTTCTAGAATGGGAGGAATCTGTTGCTTTGGTGTTTGTTTG TTGGTCGGTTTTCTCACATCCATCTGCCTATGGATAAGGAAAAGAGAACGGTCGTAATTCTCATAGACTC CTTTCTGGTTGTGTCACAAATGGCTTCACATGTTTCTCTATGCTCAGAGATACTCAGCTTGATTTCCCGT GTTTTCATTTCAGCACCGACTGAGCAAAGGCCTGGGGTGCAGGAGTGCTACCATGGTAATGGACAGAGTT ATCGAGGCACATACTCCACCACTGTCACAGGAAGAACCTGCCAAGCTTGGTCATCTATGACACCACACTC GCATAGTCGGACCCCAGAATACTACCCAAATGCGTATGTCTTTGTTCTTTACCATAAGAGAAGAAAGGGC CAAGTGAAGTTTCTGTTACAAGAGATGTGTCTCAAGCTGAGTTCTCCGAACTCAACTTGTGACAGATGCA GATGGCGTAGCAAAATGTCTCAGGATGATTGCCTTGGAGCTAAGGGTCTGAGAGAAGGGAAATGTTAAGC TCCCTCTCCTTCCTCCTAGTTCTATTGAGCAGAAGGGAAATCTGGAGGTGAGAAGATCACATTATGAAGA AAGTCAGAATGACAAAGGACCAGACACTTAGATTACCCTTCCACAACACCAACTAAACGTCAATGGAGAC TTTCCAGTTGGAATTCCGTTATTCTGGCTTCCACTTCCTGAAGGGAAGGTTGCGTTTGCCTTTTCTCTCT GGGTTCAAGAGGAAAGAATAGGTGCTTATTTATGGACAGGTGAATTGATCTGTTTCTATATCTACGTATA TTCCGATTGTCAGAAAAACACTCGTTCCTAAGTACCAGTGGCCTGAAGGGATACAGGTTCCCAGCAAGAG AAGATCCAAGGAAGGAAGGCAGATGAGAGTCAGCACAGAGAGGGATGCTGAAAAGTAAAAGGGATGGGTG GATGGAGAGAAGCCCGGGTCTGACCACCCAATGGCCAATATTTTGGCCACAAGCGACTACCAGAGACATG GAAAAATGGTTTCTACATGTGGGACAACAGATGGTAGAGGACCTAGAGAATTGAGAGAGGGGCAATGATG GGCTCCACTCCGCAGATGCCTTGGCTTTCTTCCTGGATACCCTTCCTGCACTGAATAGCAAGGAGATGGA GCCCAAGCAGACTGTAGCCATCTTGCTGAATGGAGGAGAGGGATTGGAGTTTGGGATGACTGTGGTAGCT GAAATTTTTCTAGGTCTGCTAGAAATAAGAACTGGTTTGTGTGGAGGAAAAGAGCTCTACAAATACGCAT AGAAGTCTCCTCCAGTCGTTGGCCTGACATGACGCTGCCTGTGCACAGGAAATGGTTCCACGAGAAAGTG TGGCAAAGAACATTTACTGAGAAACAGCAAGTACAAGAGCACAGGAAGCTCAATAAAGAAGAGAGAGATC ACATAGCACTCTGGGATACTGGAGTTCTTCCCAGCTAGACCAGAGAGTCCTCACGGAGCACATTGCCAAT TCAGTGGAGACCCCAGAACAGCCGTAATTTAAAGGTACACTTAGTATATTACTAGAATAAAGTCAGCTGC AGACAACCCCTTGCACAGCTGGAAAGCAAGTGTCCAAGCATCAAATCGGTTTCCAATCAATGAAGTGCCT GTGAGAGGAAATCTCAACTCTCTTTAGAAGTAAACAACAAAGTCGATTGCCTCAGCTATGCGGTATCCGC AGAGTGAGTCCTAAATTTAAAATCTGACTACATGTAGAAAAGCGTTTCGTGTGACCCATGACCAGGAAAT AAATCGGGTAATACAAACAGGCTCAGGAATGAGAGAAATGATTAGAATTGCGTGAAAATTTGACATATCA GTATGATAACTGATTTCAAATATTTAAAAAAACAACATGCAAGAAAGCAGATATCATATCAAGAGAAATT AACAGTACAGAATAGCCAAATTAAATTAAAGAGGTAGTATAAAAAAAGTATGTCTTAATTGAAAAAAATT ACTGTATGGCCGGCTGATCAATTTAGACGTTTCAGAGGAAAACATTACCCAACACACAATTCTAGAGAAC CTACAGAATGAGCTACACACACACACACACACACACACACAAACTGAAAACACACCCATACTCACACACA CGCAGAAACTCACAAGTTCTAACACACACAGACACGCGCACCCCTGAAGAAACAGTGAAATATAAAATTA AGCGAGCCTCACAGACATGTAGGAAAATATGAAAAGATTTCCTGCATGTGGGAAGCAAGTCACAGTAAAG AGCAAGGGAGTTTGGAATAGAAACAAATACCGGAATCAAGGATGGCTGATAACTTTTCAATTACGAAGAA CATTAAAAAAAATCACAGAATCGTGAAACTCAAGGGATCACATAGGGAATTTCGGAAAAAAAACCCAACC TGTATGATGTACTTTTGTACATCACAGTTCGAAGGTAACAAGGCAAAGATATAATAAGAAGAAACCTGTC ACGAGAAACTGGAGGAAAAAGAGCTGTGTCTTCCTACAAGTACACTGATACAAATTGCCAATGTGTTCAC CTCAGAAACACTGGAAGCCAGATACCAGGGAATATTGTTAAAATGATAATCAGGAACAAAAAGAGATCAA CCGGGAATGCTGAATCCAGCAATAAAATGCCTTGAAGGTCATCCATGTCGGATAAATGCATATTGTGCAC TGCCCCAAAGAAAGAAACCGGAAACTGTAAGAATTGGAAATCAGCAGGCTTATGTAACAAGAGAGGTGAC CCGAAGGAATTAGGTAGAAGAAGAATTGAACAAGAAAGGAACTTTCTGCAGCCCACGTAATGAAGAATCC AGCAATTGGCAAATGTAGATAGATGTAAATGCAAAATATTTTCTTGATCAAATTTCTATATCTTTGTAAA TGAGAGTTGACTACTTGAAACAAAATGATAGCAAGATATTTAACTTCAGCATATGTAGAGGTAAGAATTT GAAATGGTAGCATAAATCACGAAGGGATTAATTCGAAGTGTACCGTTGTAAGTTTCTTTACCTCATGCAC GATGGTGTGTCATATTAATAAAAGGGTACTGTGCGGGTTCGAAGGGATATTGCAAATCCTAGAGCAATCA CAAAGGTTTGAACTCTGAGGTTTTTGGTATAATAAGAATAGTCCATGCATTCAAAAGAGGGAAGCCAAGG AAGAACTAGAAGTCTTTCAAGAGCTCAGGCTCTTATACATCCAGTTGCTCATTGAACCAGCTTCCTGGAA TGGAGGGTCTGGGGTTGAGACTAGGCCACAAGTCTAGAGTCTCTAGAGAGACAGTGTTGGAACCCCATGG CCCATAATACATTTCCCATTTTCTCAGGCAGCCAGAGGTCATGAATGTGAGGATACTGGGAGGTTGGAGC AACGTTCTTGGGAGGCATAAGGAAGAGCGAATGCTTCAAGATCCCCGCAGCCCAAACTACTCGCCTGCTT TGCCCCCTAATGCATTTTTCTCTGCTGCTCCGTAGCTGTCCGACCTCTTCAGATCTCTTAGTCCACCCTG CCGTCTTCCTTTATGCCATGGGTCCCACTGTTCTTTCAACTCATCCCCCTTTCCCTCAGTCCCGGAGTAG CTGCGGCCAGCAGAGGGTAGACTGAGAGCAGGAGAGAAGGACCTGCCTAGGAACCCCTTCTAGAGATACT GCATCCTGCCTGGGAGCAAGTTTTCCAGGGCAGCTTTGAGAAGTCTTGGAGAAACAAACCTACTAAACCT GACAGACAGTAATACTATTTGCACAATGCTTTTCTGTGGGAAAGGTAGAGCCTTTTCACTACGTATTGAG TACATAGAGTGTGAGGGTTGACCTGGAACGGCTATCCTCCTGGATGACGTGCGTTTTCTGAAGAACTACA TGTTCGTTGCAACTCCCACATTAGAATATGAAGTCCTACCGAGAGAGATACGGAGACTAGACAGATACAG ATGCATTTGCATGTGAATACACAATCCCACAATACAGACGTCAAAACCCATACCAGTTATTCCAGAGAGA TGGATTGGGCAGAAGGCAGAAGGAGAATACTCTGATCGTTTTTCGGCCACGTGTGTGTGTTATCTCAGTG TTTCTAAGAAGCGTTTGCTACTTTAGATTTTTTATTTAAAAAAAATAGTAATAATCTATTAAGTATGAGA GATGTGCAGAGAGGATTAGTGATCGAGAGCCATTTTTGCTGGTGGCAATCATATGGTACTTTTAATGGGA ATATTAGAAAGGCACCGGTAATGACCTTGTTGCAGCACAAAGGAGAGAGTGTGGGGTGCCCCTGCATGTT GTCCCACCTCTTGTGACGTGTATCGTTTTGGAATTTCCAGTGGCTTGATCATGAACTACTGCAGGAATCC AGATGCTGTGGCAGCTCCTTATTGTTATACGAGGGATCCCGGTGTCAGGTGGGAGTACTGCAACCTGACG CAATGCTCAGACGCAGAAGGGACTGCCGTCGCGCCTCCGACTGTTACCCCGGTTCCAAGCCTAGAGGCTC CTTCCGAACAAGGTAAGGAGTCTGTGGCCAGACATCTACACGCTTCGATGCTGGGATGAAAAGCCATGGA AATTCCCACTGATGCAGCCGCCTTCAATGGTAAACGGATGCTCGAGTGTTGCCTGAGTTCTACCATGTAG GAGGAAGCCTCCGTGCACTCTCTGGGGGAGCCAGCGGAGTGATTTCTGGTGCAACGTGGTTGGGCTTTGT CTTTAGGATGGGCACAAACCCTCCAGGGGGATCGACTTCAAAATTCACCTTGTTGTAAAACGGGCTACCT CAGTGTCCCAGCCAAAATTTTTATTGTAACATGCTGTCAGGTGTGTCACTCTTTCCAAGCCAGTAAGCTT TTCCGGGGATTTCTTCAAGTAGCCAGCATTCAGAGCAATCTTCAGCATTGCAGATTCTGAGAAATGTGGC TCTGGAGCCTGTCACCCTCGAGAAACCTAAGAGGGCTGCATTGATTCCATGTGGCCCTGGGTCTATGGAG CAGTACATGAGCTCCCAGTGCTCTAAGGCTCTTCAGCCCTAGGCTTTGAAGGGAGTGATTTCTCAGTATT CTTAAACCTCTTTCTGATGACACTTGTACCTGTGAGGGGTCTAGAGAGAAAGAGTAGTAGACTCCTACTT TACTACAATTCAGGATGCAGGGCATGAGAGGATTCCCTCTCTCCTCCAAGGGAAGAAGCTTTTGGCGTGC ACACATCCCTGAGAAGCAAAGTGTCTTTGTCTTCAGTCAGATACATAGGACCGTTTTCTGCCCCATGGCC CGGAAGCCAAAGGCCTTGGCTTTCATGATCAACGGTCTAGGGAAACATGCAAAATTTCCATGTCTGTCCC AAACTCTGCCCCCGACAGCCAATTACCACCTGCAGCCCGCATTGCCAAATGCGGTGCCGTTTGCATGAAG ATTCAGTAGAGTTTCCTAGAAAGGTGCTACCTCGTGAGCTCACTTTCCAATGAGGAATCTGATCTGTTGT GTTTCTCTAAGGTGTCAGGTGAAATATTTCCAAGAACTTACTACAGTTCTAGAATGGGAGGAATCTGTTG CTTTGGTGTTTGTTTGTTGGTCGGTTTTCTCACATCCATCTGCCTATGGATAAGGAAAAGAGAACGGTCG TAATTCTCATAGACTCCTTTCTGGTTGTGTCACAAATGGCTTCACATGTTTCTCTATGCTCAGAGATACT CAGCTTGATTTCCCGTGTTTTCATTTCAGCACCGACTGAGCAAAGGCCTGGGGTGCAGGAGTGCTACCAT GGTAATGGACAGAGTTATCGAGGCACATACTCCACCACTGTCACAGGAAGAACCTGCCAAGCTTGGTCAT CTATGACACCACACTCGCATAGTCGGACCCCAGAATACTACCCAAATGCGTATGTCTTTGTTCTTTACCA TAAGAGAAGAAAGGGCCAAGTGAAGTTTCTGTTACAAGAGATGTGTCTCAAGCTGAGTTCTCCGAACTCA ACTTGTGACAGATGCAGATGGCGTAGCAAAATGTCTCAGGATGATTGCCTTGGAGCTAAGGGTCTGAGAG AAGGGAAATGTTAAGCTCCCTCTCCTTCCTCCTAGTTCTATTGAGCAGAAGGGAAATCTGGAGGTGAGGA GATCACATTATGAAGAAAGTCAGAATGACAAAGGACCAGACACTTAGATTACCCTTCCACAACACCAACT AAACGTCAATGGAGACTTTCCAGTTGGAATTCCGTTATTCTGGCTTCCACTTCCTGAAGGGAAGGTTGCG TTTGCCTTTTCTCTCTGGGTTCAAGAGGAAAGAATAGGTGCTTATTTATGGACAGGTGAATTGATCTGTT TCTATATCTACGTATATTCCGATTGTCAGAAAAACACTCGTTCCTAAGTACCAGTGGCCTGAAGGGATAC AGGTTCCCAGCAAGAGAAGATCCAAGGAAGGAAGGCAGATGAGAGTCAGCACAGAGAGGGATGCTGAAAA GTAAAAGGGATGGGTGGATGGAGAGAAGCCCGGGTCTGACCACCCAATGGCCAATATTTTGGCCACAAGC GACTACCAGAGACATGGAAAAATGGTTTCTACATGTGGGACAACAGATGGTAGAGGACCTAGAGAATTGA GAGAGGGGCAATGATGGGCTCCACTCCGCAGATGCCTTGGCTTTCTTCCTGGATACCCTTCCTGCACTGA ATAGCAAGGAGATGGAGCCCAAGCAGACTGTAGCCATCTTGCTGAATGGAGGAGAGGGATTGGAGTTTGG GATGACTGTGGTAGCTGAAATTTTTCTAGGTCTGCTAGAAATAAGAACTGGTTTGTGTGGAGGAAAAGAG CTCTACAAATACGCATAGAAGTCTCCTCCAGTCGTTGGCCTGACATGACGCTGCCTGTGCACAGGAAATG GTTCCACGAGAAAGTGTGGCAAAGAACATTTACTGAGAAACAGCAAGTACAAGAGCACAGGAAGCTCAAT AAAGAAGAGAGAGATCACATAGCACTCTGGGATACTGGAGTTCTTCCCAGCTAGACCAGAGAGTCCTCAC GGAGCACATTGCCAATTCAGTGGAGACCCCAGAACAGCCGTAATTTAAAGGTACACTTAGAATATTACTA GAATAAAGTCAGCTGCAGACAACCCCTTGCACAGCTGGAAAGCAAGTGTCCAAGCATCAAATCGGTTTCC AATCAATGAAGTGCCTGTGAGAGGAAATCTCAACTCTCTTTAGAAGTAAACAACAAAGTCGATTGCCTCA GCTATGCGGTATCCGCAGAGTGAGTCCTAAATTTAAAATCTGACTACATGTAGAAAAGCGTTTCGTGTGA CCCATGACCAGGAAATAAATCGGGTAATACAAACAGGCTCAGGAATGAGAGAAATGATTAGAATTGCGTG AAAATTTGACATATCAGTATGATAACTGATTTCAAATATTTAAAAAAACAACATGCAAGAAAGCAGATAT CATATCAAGAGAAATTAACAGTACAGAATAGCCAAATTAAATTAAAGAGCTAGTATAAAAAAAGTATGTC TTAATTGAAAAAAATTACTGTATGGCCGGCTGATCAAATTAGACGTTTCAGAGGAAAACATTACCCAACA CACAATTTTAGAGAACCTACAGAATGAGCTACACACACACACACACACACACACACACACACAAACTGAA AACACACCCATACTCACACACACGCAGAAACTCACAAGTTCTAACACACACAGACACGCGCACCCCTGAA GAAACAGTGAAATATAAAATTAAGCGAGCCTCACAGACATGTAGGAAAATATGAAAAGATTTCCTGCATG TGGGAAGCAAGTCACAGTAAAGAGCAAGGGAGTTTATAATAGAAACAAATACCAGAATCAAGGATGGCTG ATAACTTTTCAATTACGAAGAACATTAAAAAAAATCACAGAATCGTGAAACTCAAGGGATCATATAGGGA ATTTCGGAAAAAAAACCCAACCTGTATGATGTACTTTTGTACATCACAGTTCGAAGGTAACAAGGCAAAG ATGTAATAAGAAGAAACCTGTCACGAGAAACTGGAGGAAAAAGAGCTGTGTCTTCCTACAAGTACACTGA TACAAATTGCCAATGTGTTCACCTCAGAAACACTGGAAGCCAGATACCAGGGAATATTGTTAAAATGATA ATCAGGAACAAAAAGAGATCAACCGGGAATGCTGAATCCAGCAATAAAATGCCTTGAAGGTCATCCATGT CGGATAAATGCATATTGTGCACTGCCCCAAAGAAAGAAACCGGAAACTGTAAGAATTGGAAATCAGCAGG CTTATGTAACAAGAGAGGTGACCCGAAGGAATTAGGTAGAAGAAGAATTGAACAAGAAAGGAACTTTCTG CAGCCCACGTAATGAAGAATCCAGCAATTGGCAAATGTAGATAGATGTAAATGCAAAATATTTTCTTGAT CAAATTTCTATATCTTTGTAAATGAGAGTTGACTACTTGAAACAAAATGATAGCAAGATATTTAACTTCA GCATATGTAGAGGTAAGAATTTGAAATGGTAGCATAAATCACGAAGGGATTAATTCGAAGTGTACCGTTG TAAGTTTCTTTACCTCATGCACGATGGTGTGTCATATTAATAAAAGGGTACTGTGCGGGTTCGAAGGGAT ATTGCAAATCCTAGAGCAATCACAAAGGTTTGAACTCTGAGGTTTTTGGTATAATAAGAATAGTCCATGC ATTCAAAAGAGGGAAGCCAAGGAAGAACTAGAAGTCTTTCAAGAGCTCAGGCTCTTATACATCCAGTTGC TCATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGGTTGAGACTAGGCCACAAGTCTAGAGTCTCTAGAG AGACAGTGTTGGAACCCCATGGCCCATAATACATTTCCCATTTTCTCAGGCAGCCAGAGGTCATGAATGT GAGGATACTGGGAGGTTGGAGCAACGTTCTTGGGAGGCATAAGGAAGAGCGAATGCTTCAAGATCCCCGC AGCCCAAACTACTCGCCTGCTTTGCCCCCTAATGCATTTTTCTCTGCTGCTCCGTAGCTGTCCGACCTCT TCAGATCTCTTAGTCCACCCTGCCGTCTTCCTTTATGCCATGGGTCCCACTGTTCTTTCAACTCATCCCC CTTTCCCTCAGTCCCGGAGTAGCTGCGGCCAGCAGAGGGTAGACTGAGAGCAGGAGAGAAGGACCTGCCT AGGAACCCCTTCTAGAGATACTGCATCCTGCCTGGGAGCAAGTTTTCCAGGGCAGCTTTGAGAAGTCTTG GAGAAACAAACCTACTAAACCTGACAGACAGTAATACTATTTGCACAATGCTTTTCTGTGGGAAAGGTAG AGCCTTTTCACTACGTATTGAGTACATAGAGTGTGAGGGTTGACCTGGAACGGCTATCCTCCTGGATGAC GTGCGTTTTCTGAAGAACTACATGTTCGTTGCAACTCCCACATTAGAATATGAAGTCCTACCGAGAGAGA TACGGAGACTAGACAGATACAGATGCATTTGCATGTGAATACACAATCCCACAATACAGACGTCAAAACC CATACCAGTTATTCCAGAGAGATGGATTGGGCAGAAGGCAGAAGGAGAATACTCTGATCGTTTTTCGGCC ACGTGTGTGTGTTATCTCAGTGTTTCTAAGAAGCGTTTGCTACTTTAGATTTTTTATTTAAAAAAAATAG TAATAATCTATTAAGTATGAGAGATGTGCAGAGACGATTAGTGATCGAGAGCCATTTTTGCTGGTGGCAA TCATATGGTACTTTTAATGGGAATATTAGAAAGGCACCGGTAATGACCTTGTTGCAGCACAAAGGAGAGA GTGTGGGGTGCCCCTGCATGTTGTCCCACCTCTTGTGACGTGTATCGTTTTGGAATTTCCAGTGGCTTGA TCATGAACTACTGCAGGAATCCAGATGCTGTGGCAGCTCCTTATTGTTATACGAGGGATCCCGGTGTCAG GTGGGAGTACTGCAACCTGACGCAATGCTCAGACGCAGAAGGGACTGCCGTCGCGCCTCCGACTGTTACC CCGGTTCCAAGCCTAGAGGCTCCTTCCGAACAAGGTAAGGAGTCTGTGGCCAGACATCTACACGCTTCGA TGCTGGGATGAAAAGCCATGGAAATTCCCACTGATGCAGCCGCCTTCAATGGTAAACGGATGCTCGAGTG TTGCCTGAGTTCTACCATGTAGGAGGAAGCCTCCGTGCACTCTCTGGGGGAGCCAGCGGAGTGATTTCTG GTGCAACGTGGTTGGGCTTTGTCTTTAGGATGGGCACAAACCCTCCAGGGGGATCGACTTCAAAATTCAC CTTGTTGTAAAACGGGCTACCTCAGTGTCCCAGCCAAAATTTTTATTGTAACATGCTGTCAGGTGTGTCA CTCTTTCCAAGCCAGTAAGCTTTTCCGGGGATTTCTTCAAGTAGCCAGCATTCAGAGCAATCTTCAGCAT TGCAGATTCTGAGAAATGTGGCTCTGGAGCCTGTCATCCTCGAGAAACCTAACAGGGCTGCATTAATTCC ATATGGTCCTGGGTCTATGGAGCAGTATATGAGCTCCCAATGCTCTAAGGCTCTTCAGTCCTAGGCTTTG AAGGGAGTGATTTCTCAGTGTTCTTAAACCTCTTTCTGATGGCACTTGTACCTGTGAGGGGTCTAGAGAG AAAGGTTAGTAGACTTCTCCTTTACTGCAATTCAGGATGCAGGGCATGAGAAGATTCCCTCCCTCCTCCA AGGGAAGAAGGTTTTGGCGTGCACACATCCTTGAGAAGCAAAGTGTCTTTGCCTTCAGTCAGATATATAG GATCGTTTTCTGCCCCATGGCCTGGAAGCCAGAGGCCTTGGCTTTCATGATCAACGATCTAGGGAAACAT GCAAAATTTCCATGTCTTTCCCCTCCTCTGCCCTCGACAGCCAATTACCACCTGCATCCTGCATTGCCAA ATGCAGTGCCCTTTGTATGAACATTCAGTAGAGTTTCATAGAAAGGTGCTACTTCGTGAGCGCACTTTGC AGTGAGAAGGAGTCTGTTCTGTTCTGTTTTTCTAAGGATTTCAGGTGAAATATTTCCTAGAACTTACTAC AGTTCTAGATTGGTAGGAATCTGTAGGTTTGCTGTATGTTTTTTGGTTGGTTTTCTCCCATCCATCTGCC TACAGGTAAGGGAAAGATAACGTTCATAATTCTCATAGACTCCTTTCTGGTTGTGTCATAAATGGCTTCA CATATTTCGTTATTCTCAGAGATACTCAGTTTATTTCTTGTGTTTTCATTTCAGCACCGACTGAGCAGAG GCCTGGGGTGCAGGAGTGCTACCACGGTAATGGACAGAGTTATCGAGGCACATACTCCACCACTGTCACT GGAAGAACCTGCCAAGCTTGGTCATCTATGACACCACACTCGCATAGTCGGACCCCAGAATACTACCCAA ATGCGTATGTCTTTGTTCTTTACCATAAGAGAATAAAGGGCCAACTGAAGTTTCTGTGACAAGAGACATG CTTCAAGCTGAGTTCTCCGAACTCAACTTGTGTCAGATTCAGATGGTGTAGCAAAATGTCTCAGGATGAT TTCCTTGGAGCTAAGGGTCTGAGAGAAGAGAAATGTTAAGCTGCCTCACCTTCCTCCTAGTTTTGTGGAG CAGAAGGGAAATGAGGAGGCGAGGAGATCACCTTATGAAGAAAGTCAGAATGACGAACCACCAAACACTT AGATTACCCTTGCCCAACACCCACTAAGCGTCAATGAAGACTTTCCAGTTGGAATTCCGTTATTCTGACT TCCAATTCCTGAAGGGAAGATTGTGTTTGCCTTTTCTGTCTGGGCTCATGAGGAAAGTTTATGTGCTTAC TTATGGACAGGTGAATTGATCTGTTTCTATTTCTACCTGTATTCCAATAGGGAGAAAATCTCTTGGTCCT AAGTACCAGTGGCCTGAAAGGATAGAGGTTCCCAGCAAGAGAAGATCCAAGGAAGGAAGGCAGATGAGAG TCAGCACAGAGAGGGATGCTGAAAAGTAAAAGGGATGGGTAGATGGATAGAAGCCCTGGTCTGACCACCC CATGGCCAATCATTTGGCCATAATCAACAACCAAAGACATGGAAAAATGGTTTCTACATGTGGGACAACA GATGGTAGAGGACCTAGAGAATTGAGAGAGGGCCAATGATGAGCTCAACTCCATAGATGCCTTGGCTTTC TTCCTGGATACCCTTCCTGCACTGAATAGCAAGGAGATGGAGCTCAAGCAGCCTGTAGCCATCTAGCTGA GCAGAGGAGAGGGATTGGAGTTTGGGATGACTCTGGTATTTTCTAGGTCCGCTACAAATAAGAACTGGTT TGTGGAGGAAAGGAGCTCTACAAATACGCATAGAAGTCTCCTCCAGTAGTTGGCCTCACATGACACTGCA TGTGCACAGAAAATGGTTCTACAGAAAGTGTGGCAAAGAACATTTACTGAGAAACAGCAACTACAAGAGA ACAGCAAGCTCAATTAAGAAGATAGAGATCACATAGCACTCTGTGTTATTGGAGTTCTTACCAGCTAGAT GAGAGAGTGCTCACGGAACACATTGCCAATTCAGTGGAGACCCCAGAACAGCCATAATTTCAAAGTACAA TTAGTATATTACTAGAATAAAGGCAGCTGCAGACAACCCCTTGCACAGCTGAAAAGCAAGTGTCCAAGCA TCAAATGGGTTTCCAATCAATGAAGTGCCTGTGAGAGGAAATCTCAACTCTCTTCAGAAGTAAACAACAA AGTCAATTGCCTCAGCTATGCGGTATCCCCAGAGTGAGTCCTAAATTAAAAATTTGACTACGTGTAGAAA AGAATTTCGTGTGATCCATGACCAGAAAATAAATCAGGCAATACAAACAGGCTCAGAAATGACATCGATA ATTAGAATTGCATGAAAATTTGACATATCAGTATGATAACTGATTTCAGATATTTAAAAAAAGTGCAACA AAGCAGGTATCATATCAAGACAAATTAATAGTATAGAATAGCCAAATCAAATTAAAGAACTATTATACAA AAAGTATGTCTTAAATGAAGAAATTACTGTATGTCCGCCTGAAAAATTTAGATGTTTCAGAAGAAAAAAT TAACCAAAAACAATTCTGCAGAACCTACAGAATGAGCCACACACACACACATTCAAAACACACCCATACA CACACACATGCAAAAACTCACAAGTTCTAACACACACACAAACACACACACACATGCACATCCCTAAAGA AATAGGGAAATATAAAATTAACCGACCCTCAGAGACATGCAGGAAAATATAAGAAGATTTCCTGCATGTG GGAAGCAAGTCACAGTAAAGAGCAAGGGAGTTTGGAGTAGATACAAATACCGGAATCACGGATGGCTGAT AACTTTTCAATTATGAAGAACGTTAGAAAAATCACAGATTCATGAAACTAAAGGGATCAAATAGGAAATT TCGAGAAAAAAAACTACATGATGCACTTCTCTACATCACAGTTCAAAGGTAACAAGGCAAGGATATAAGA AGAAGAAACATCTCACGAGAAACTGGAGAAAAAAGAGCTGTGTCTTCCTAGAGTACAGTGATACAAATTG CTAATGCGTTCACCTCAGAAACACTGGAAGCCAGATACCAGGGAATATTATTAAAATGATAATGAGGAAC AAGAAGAGATCAACCGAGAATGCTGAATCCAGCAATAAAATGCCTTGAAGATCATCCATGTTGGATAAAT GCATATTGTGCACTGCCCAAAACAAAGAAACTGGAAAGTGTAAGACTTTGGAATCAGCAGGCTTATGTAG CAACAGAGGTGACCCGAAAGAATTAGGTATAAGAAGAATAGAAGAATTGCATGAAAATTTGACATATGAC TAAGATAACTATTTCAAATATTTAAAAAAAGATGAATATGTAATAAAACAGATAAAATATCAAAAGAAAG TAACAGTATTGACTAGCCAAATCAAATTAAAGACTTAGTGTAAAAAGCTATGTCTTAAAAGAAAAAATTA CTGGATGGCTGCCTGATCAATTTAGACATTTCTGAATAGGAAACTAACCAAAAATCAATTCTACAGAACC AACTACACACATATATACACATACAACACACCCATACACACCCACGCAAAAACTCACAAGTTCACACACA CACACACACACACACAACCCTCAAGAAATAGTGAAATAGAAAACCAACCGAACCTCACAGACATGTTGCA AAATAGGAAAAGATTTCCTGCATATGGGAAGCAAGTCACAGAAAAGAGAACGGGAGATTGGAAACAGAAA CAAATACCGGAATCAAGGATGGCCGAAAACTTTTCATTGATCAAGAATATTAACAAAATCGCAAAAACAC GAAATTCAATGCATCAAATAGGCGTTTCGAAAAAAAGAAAAAATCTGGTATGATGCACTTTTGTACTTCA CATTTTCACGGTAAGAAGACAAAGATATAATAACAAGAAACTTCTTATGAGAAACTGGGGAAAAACAAGC TGTTTCTTGCTAGAAGAACAGTGATACAAATTGCTAATGCATTCTCGTCAAAAACACTGGAAGCCAGATA CCGGGAATGTTATTAATGTGGTAAACAGGAACAAGAAGAGATCAACCAAGAATGCTAAATCCAGCAATAA AATGCCTTGAAGATCATCCATGCTGCATAAATGTATGTTGTGCACTGCCCCAAACAAAGAAACCGGAAAC TGTAAGAATTTGGAATCAGCAGGCTGATGTAACAAGAGAGGTGACCCAAAGGAATTAGGTAGAAGAAGAA TAGTACAAGAAGGGAACTTTCTGCAGCCCATGTAATGAAGAACCCAGCAATTGGCAAATGTAGATGTAAA TGCAAAATATTTTCTTGACCAAATTTCTATATATTTTTAAATGAGCGTTGACTACTGGAAACAAAATGAT AGCAATATATTTAATTTTAGCATATGTAGAGGTAAGAATTTGAACAAGTAGCGTAAATCATGTAGGGAAT AATTAGAAGTGTACCATTGTAAGTTTCTTACCTCATGCACAATGGTATGTAATATTAATAAAATGTTACT GTGTGGGTTCAAGGAGATATTGCAAATCCTAGAGCAATCACAAAGTTTTGAACTCTGAGGTATATTGTAT AATAAGAATATTCCATGTATTCAAAAGAGAGAAGCCAAGGAAGAAAGAAATTTGTCACGAGTTTGGGCTC TTAGTACATCCTGTAGCTCATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGATTGACACTAGGCCACAT GTATAGAGTCTCTAGAGAGACAGTGTTTCATCCCCATGGCCCGTAATACATTTCCCATTTTCTCAGGCAG CCACAGGTCATGAATGTGAGGATAGAGAGAGGTTGGAGCAACGTTCTTGGGAGGCATAAGGAAGAGCAAA TGCTTCAAGATCCCCGCAGCCCAAACTCCTACCTGCTTTGCCCCCTAATGCAGTGTTCCTCCGTAGCTGT CCGACCTCTTCAGATCTCTTAGTCTACCCTGCCATCTTCCTTTATGCCATGGGTCCCACTGTTCTTTCAA CTCATCCCCCTTTCCCTCAGTGCAGAGTAGCTGCGGCCAGCAGAGGGTAGACTGAGAGCAGGAGAGAAGG TCCTGCCCAGGAACCCATTCTAGAGATGCTGCATTCTGCCTGGGAGCAAGTTTTCCAGGGCAGCTTTGAG AAGTCTTGCAGAAACAAACCTATTTGACCCACATGATATGGGAATGACAGAAAGTAATACAATTTGCACA GTGCTTTTCCATGGGAAAAGTAGAGCCTTTTCGCGAGGTTTTGAGTACATAGAGAGTGAAGGTTGACCTG GAAAGGTTATCCTCCTGGATCCCATGTTTTTTCTGAAGAACTACCTGTTAGTTGCAACTTGCACATTAGA ATATGAAGTCCTACCGAGAGAGATACGGAGAACTAGATAAATACAGATACTTTTGTATGTGAATAAACGA TTCCACAATACACACATCAAAATCCATACCAGTTATTCCAGAGAGATGGATTGGGCAGAAGGCAGAAGGA GAATACTCTGATCGTTTTTTGCCCACGTGTATGTATTATCTCAGTGTTTCTAAGAAGCGTTTGCTACTTT AGATTTTTTTTTATAATAATAATCTTTTAAGTATGAGAAATGTGCAGACAGGATTAGTGATTGAGAGCCA TTTGTGCTTGTGGCAATCATATGGTACTTTTATGGGAATATTAGAAAGGCACTGGTAATGACCTTGTTGC AGCACAAAGGAGAGGGTGTGGGGTGCCCCTGCATATTGTCCCACCTCTTGTGACGTGTATCGTTTTGGAA TTTCCAGTGGCTTGATCATGAACTACTGCAGGAATCCAGATCCTGTGGCAGCCCCTTATTGTTATACGAG GGATCCCAGTGTCAGGTGGGAGTACTGCAACCTGACACAATGCTCAGACGCAGAAGGGACTGCCGTCGCG CCTCCAACTATTACCCCGATTCCAAGCCTAGAGGCTCCTTCTGAACAAGGTAAGGAGCCTGTGGCCAGAA ACCTACACGTTTCGATGCTGGGATGAAAAGCCATGGAAATTCCCACTGATGCAGCAGCCTCCAATGGTAA ACGGATGCTCGAGTGTTGACTGAGTTCTGTCATGTAGGAGGAAGCCTCCGTGCACTCTCTGGGGGAGCCA GCGGATTGATTTCTGGTACAACGTTGGGTGGGCTGTGTCTTTAGAATTGGCACAAACCCTCCAGGGTGAT CGACTTCACAACTCACCTCGTTGAAAAATGGGCTATCTCAGTGTCTTAGCCAAAATTTTTATTGTAACAT GCTGTCAGATGTGTGACTCTTTCCAAGCCAGTAAGCTTTTCCTGGGACTTCTTCAATTAGCCAGCATTCA GTGCAATCTTCAGCATTGCAGATTCAGAGAAATGTGGCTCTGGAGCCTGTCACCCTTGAGAAACAGGGCT AACAGGGTTGCATTAATTCCAAATCACCCTGGTTCTATGGAGCAGTACATGAACTCCCAATGATCTATGT TTCAGGACTTCCTCAGTCATAGGTGGGCTCTGCAGCCCTAGGTTTTTAAGTGAGTGACTGCCCCGTGTTC TGGTGGCAGTTGTACCTGTGAGCGGTCTGGATAGAAAGAGTCGGAGACTTCTGTATTATTGCAACTCAGG ATGTGGGTCATGAGAGGATTTCATCTCTCCTGCAGGGGAGTAAGCTGTTCGCCTCCACCCATCCCTGATA ACTGAAGTGTCTTTGTCTGCAGTCCTAGACGAAGGACTGTTGTCTCTCCCATGGCCCAGAAGCTGAAGAC CTTGCCTTTTGTTATGAAACGTTCATTGTTTTCATGTCTGTCCGTTTCTCTGCCCCTAACACCCAATCAC CATGTATGGCCTGTACCCCCAAATGCATCGTGCTTTGCTGTTTGCTGCCCCATAGTCCTCATGAACATTC AGTAGAAATTCCCATAAATGTGCTTGCACGTGAGCACAGTTTCCATTGAGAAGCCCTCTCATTTGTCCTT TTTTTCTAAGCTTTTATGTGAAATATTTCTAAGAACTTACTACAGTTCTAAAGTGTTAGGAATTTGTTTC TTTGGTGTTTTTGTTTGTTGGTTGGTTGTTGCTTTTCTCAAGTCCATCTGCCTACAAATAAAGAAACAAG AATGTTACTTGTCATATTCTCCTGAGGTCATAATTCTCAGAGACTTTTTTCTGGTTTGTGCCATAAGTGG CTTCACATGTTTGTCTCTTCTTGGAAACACTCAGTTTGATTTCTTTTCTTTTCATTTCAGCACCAACTGA GCAAAGGCCTGGGGTGCAGGAGTGCTACCACGGAAATGGACAGAGTTATCAAGGCACATACTTCATTACT GTCACAGGAAGAACCTGCCAAGCTTGGTCATCTATGACACCACACTCGCATAGTCGGACCCCAGCATACT ACCCAAATGCGTATGTCTATTTTCTTTACCATAAGTGAAGGAAGGGTCAGTGGAAATTTCTGTTAGTAGA GTCATGCTTCAAGCTGAGTGTTCAGGACTCAAGTTGTCTCAGATGAACAGTGCATAGCAAAATGTCTCAG GAACATTGTCTTTGAGCAAAGAGTCTAAGAGAAGACAAATGTTAATCTGGCTCTCCTTCCTCCTAGTTTA ATGGAGCAGAAAGGTATCTGGAGGCAAGGATATCACATTAAGAAACAAGTCAAGATGACAAATGATGAAA CTCTTAGAGTACCCTTCCACAACACCCACTAAGGTTCAATGCAGCCTTTTCTCCTTGGAATTCTATTAAA CTAAACTCCAATTCCTGAAGTGAAGGTTCTGTTGGGGTTTTCTGTTTTGGCTTACAAGGAAAGTATATAT GTATATCTATGGAGAGGCAAATCTATCTCTTTCTATATCTACGTCTATTCCAATATGTAGAAACACAGTC GGTTCTGACCACCAGTGGTCTGAAGGGATACTGGTTGTTAGAGAATAAAAATGGCAGGAAGGCAGATGAG AGTCAGCAAAGAGAGAGATCCTGTAAAGTAAAAGGGTGGATAGATGGACAGAAGCCCAGGTCTGACCAGC CCATGGCCAGGCTTTAGGCCATAAGTGACACCAAAGACATGGAAAAATGGTTTCTACATGTTGGACAACA GACAGTAGTGGACCAAAAGAATAGTGACAGGGGGAACAATGAGATCAACTCCATAGATACCTTGGCTTTC TTCCTGGAGGCCCTTCTTGCACTGAAGAGCAAGGTGATGGAGCCCAGATGGACTGTAGCCATCTTCCTGA ATGCAGGAGAGAGATTGGAATTTGGGACTACTGTGGTAGCTAGGATTTTATAGGCCTGCTGAGAATGAGA ATGGATTTGTGGATGAAAGGAGCTCCAGGGGCACGCATAGTAGTCTCCTCGAATCTTTGGCTAAACATGA CGTTGCATGTGCCCAGAAAAAGGTTCCACAAGAAAGTAGAGAAAAGAATATATCCTGAGGAATAGCAACT GCGATTGAACAGTGAGCTCAATAAAGAGGACAGAGCCCTCATAGCATTCTGGGATACTGGAGTTCTGACC AGCTGGAGGAGAGACCTCACTGAACCTCTTGGGAATACAGTAGAGACTCCAGAAAAGTCATACTTTAGGA GTAGAATTAGTAAATTTCTAGAAAAAAAGGCAGCTCTAGACAAACCCTGGCAAAACTGAAAAGCAAGTCT CCAAGCATTAAAATCATTTCCAAGTCAATTAACTGCCTGGGAGAGGAAAACCCTCTTTAGAGGTAAACAA CAAAGTCAAGTGGCTCAGCTATGTGGTGTTCACAGTGTGAGTTCTAAATTTAAAACTTGACTACACATAG AGAAGCTTTTAGTATGAACCATGACCAGGTGAAAAATCAGTCAATACAAATAGACCTAGAAATGACAGAA ATGATTAGAATGGCAAAAAATTTGACATATCAATATGTCAACTGAGTTTTAGGTTTTAAGAAAACATGAA TACGGAATGAAGCAGATACCATATCAAGAGACAGTAACAGTATAGAAGAGCCAAATTAAATTAAAGAACT AGTATAAGAAGGTATGTCTTAAATGAAAAAATTACTGGATGTATTCCCAATGGAGTGAGATGTTTCAGAA GTAAAAACTAACTGAAAAACAATTTTATACCACCTACAGAACCAGCTACACATACACAAATGACACACAC ATATACACACATACTCACACATGCACAGGCTTAGAAACATGCACGCACACACACACACACACACACACAC ACCTCCACAAATACTAAAAAATGAAATCCACTGATCCTCACAGACAGGCGGGAAAATATAAAAAGATTTC CTGCATGTGGGTAGGAAGTCACAGAAGGAGAGGAAGGAGAGATTGCTACAGGAACAAATACTGGAAGCAA GGATAGCTAAAAACTTTTCAAATAAGAAGAATATTAAAAACCACAGATTCAAGAAGCTGAATGAATCAGA CAGGGAATTTCCAAAAAAAAAAAAAAAAAAACTGTATGATTCACTTTTGTACATCACCGTTCAACAGTCA GAAGGCAAAGATATAATAACAAGAAACATCTCATGAGAAACTGGAGGAAAAAGAGCTGTGTCTTGCTAGA AGAACAGTGATACAAATTGCTAATGCATTCTCATCAGAAACACTGGAACCCAGTTAACAGGGGATATCAT TAAAATGATAAACTAGAAAAAAAAGAGATCAAATGAGAATGCTACATCCAGCAATAAAATGCCTTGAAGA TCATCCATGTTGGATAAATGCATATTGTGCACTGCCCCAAATAAATAAACCAAAAACTAATAATTTGGAA TCAGCAGGCTTGTGTAACAAGAGATGTTGCCCAAAGAAAATTAGCTAGAAGAAGAATAGTTCAAGAGGAG AACTTTCTGCAGCCCACGTAATGAAGAACCCAGCAAATGGCAAATGTAGATGTAAATGCAAAATATTTTC TTGATCAAATTTCTATATCTTTTTAAATGAGAGTTGACTACTTGAAGCAAAATGATAGCAATATATTTAA CTTTAGCATATGTAGAGGTAAAAATTTGAACATATAGACTAAATCATGTGGGGAATAATTGGAAGTGTAC CATTGTAAGTTTCTTACCTTATCCACGATGGTATGTAATATTAATGAAAGGTTGAATTTGTGGGTCCAAA GGGATATTGTAAATCCTAAAGCAATCATAAAATTTTGAATTCTGAGGGATATTATATAATAAGAATTTTC CATGTATCCAAAAGAGGGAAGCCAAGGAAGAAAAAGAAGTCTTTCAAGTACTCAAGCTCTGAGCACATCC AGTTGCTCATTGAACCAGCTTCCTGGAATGGAGGGTCTGGGCTTGAGACTAGGTCACATGTGTAGAGTCT CTAGAGAGACAGTGTTGGATCCCCATGGCCCATAATACATTTCCCGTTTTCCCAGGCAGCCACAGGTCAC GAATGGGAGGATTCTGAGAGGTTGGAGCAATGTTCTTAGGAGGCATAAGGAGGAGTGAATGCTCTGAGAT TTCCCCAGCCTGAGGTCCTCCATAGCTGCCCGACCTCTTCAGACCTCATAGTCTGCCCAGCTGTCTCCCT TTATGCCATGAGTGCCACTGTTCTTTCAACTCATCCCCCATTCCCTCAGTCCCGGAATTGCTGTGGCCAG CAGAGGATGGACTGAGAGCAGGAGAGGAAGTCCTGACCAGGAACCCATCCTAGAGATACTGCATCCTGCC TGAAAGCTAGGTTTCCAGGGCAGCTTTGAGAAGTCTTGCAGAAAGAAACCCACTTGACCCACCTGATACG GTATCGACAGACAGGAATACTTTTTGTGCAATGGTTTTACATGCTGAACATAGAGCCTTTTGGCTACATT TTGAGTACATTGAATGAGACTGCTGGCCTGGGAAGGATATCATGCTGGATGCCATTTTTTTCTCTGGAGA ACTATGTGTTAGTTCCAACTCGCACATTACTATATGAAGTCCTACACAGAGAGATACGGAGAGCTAGACA GATAGAGATACTTTTGTATGTGCATAACCAATTCCACAATACACACGTCAAAATCCATACCAGTTATTCC AGAGAGATGGATTGGGCAGAAGGCAGAAGGAGGATATTCTGATCCCTTTTTGGCCACATGTATGTATAAT CTCAGTGTTTCTAGGAAGTGTGTGCTGCATTAGATTTTTTTTCTTTAAAAAAAGTGATAATATATTAAGT ATGAGAAATGTGCAGAGAGGATTAGAGATTGAGAGCCATTTGTCATTGTGGCAATTGTATGGTATCTCTT TTGGGAATATTTCAAAGGCACCAGTAATGACCTTGTTGTAGCAAAATATACAGTGTTCCTGCATATGTAC CCATTTTTTGTGATGTGTATTCTTTTGGAATTTCCAGTGGCTTGATCAAGAACTACTGCCGAAATCCAGA TCCTGTGGCAGCCCCTTGGTGTTATACAACAGATCCCAGTGTCAGGTGGGAGTACTGCAACCTGACACGA TGCTCAGATGCAGAATGGACTGCCTTCGTCCCTCCGAATGTTATTCTGGCTCCAAGCCTAGAGGCTTTTT TTGAACAAGGTAAGAAGTTGTGCCAGACATTTACCTGCTTGGATGCTGGGATGAAAAGCCATGGATACCC CCACTGACGCACAACCCTTCAGTGCTACACTGGTTCTCGTGTGTTGGTTCTGGGTCTGCCATGTGGGAGG AAGCCTTAGCGCACTCTCTGGGGGAGCCAGAGGTGTGATTTTTGGTGCAACCTGTGCGAGCTGTGTCTTT AGGATGGGCGGAAACCATTCTGGGTGCTCGACTTCACCACTCCCCTCATTGTAAAAGGGGCTATCTCATT GTCCTAGACAAAATTCTTATTGTAATATGCTGTCAGATGTGTGTGTCTTTCCAAGCCAGTAAACTTTTCC AGGGATTTCTTCAAGTAGACAGCATTCAGTGCAATCTTCAGCATTGCAGATTCCGAGAAATGTGGCTCTA GATCCTGTTATCCTTGAGAAACCTAACTGGGTTGCATTAATTCCATATCTCCCTGGGTCTGTGGAGTAGT ACATGAGCTCCCGAAGCTCTATCTCTCAGGTCTTTTTCAGTCCGAGGCAGGTTGTGCAGTTCTTAGCTTT GAAGGGAGTGATTTTTTCGTGTGCTTTTGCCTCTTTCTGATGGAACTTGTACCTGCGGGGGGTCTGGAGA AAAAGAGTAGTAGACTTTTGCTTTATTGCAATGCATTATGCTGGGCACGAGAGGATTCCCTATCTTATTG TAGGTGATAAGCTTTTGGCCTCCACTCATCCCTGAGAAGTGAAGTGTTGTTGCCTACAGTTTTAGCTGCA GGACTGTTGTCTGCCCCATCACCAGGAGTTTAATGCTTTCTTTTTTGAGCAATCATCTAGGGACACATGC AAGGTTTTTATATGTCCTTGCCTCCTCCCCAAAAAACCATTTTAATGCTTGGAGACTTGCTTTTCAGCTT TGCCAAATGCATCACCCTTTCTTCTATGCTGTTCCATGTCGTCATGAACACTCTGTAGAGATTCCTAGAA ATGAGCTTCCATGTTAGTGGAGTTTCCGATGAGAAGCAATCTGATATTTCTTTTCCACTAAGTTTTACAT GAAATATTTCTAAGAACTTACTACAGTTCTAGAATGGTAGGCATCTCTTACTTTCGTGTTTGTTTGTGTG TTTTCTCATGTCCATTTGCCTATTAATAAAGAATAGAGAATGGTTGTAAATCTCAGTGACTCTTTTTTGG TTTATGTCATAAATGGCTTCCTGTATTTTTCTGTTCTAGGAAATAATAAGCTTGATGTCTTCTGTTTTAA TTTCAGCACTGACTGAGGAAACCCCCGGGGTACAGGACTGCTACTACCATTATGGACAGAGTTACCGAGG CACATACTCCACCACTGTCACAGGAAGAACTTGCCAAGCTTGGTCATCTATGACACCACACCAGCATAGT CGGACCCCAGAAAACTACCCAAATGCGTACGTCTTTGTTCTTTACCATAAGCGAAGGAAGGGCCAATGGA AGTTTCTGTTAGAAGAGTCATGCTTCAAGGTGACTGCTCAGGACTCAACTTGGCTCAGATGCAGAGGAAC ATTTCCTGTGAGCAAAAGTTCTTAGAGAAGACTTTGTTTTTTTGAGACAGAGTCTTGCTTTGTTGCCCAG GCTGGAGTGCAGTGGCATGATCTCGGCTCACTGCAAGCTCCGCCTCCCGGGTTCACACCATTCTCCTGCT TCAGCCTCTCTAGCAGCTGGGACTACAGGCACCCACCACCACACCCGGCTAATTTTTTGTATTTTTAGTA GAGACAGGGTTTCACTGTTCTAGCCAGGATGGTCTTGGTCTCCTGACCTCGTGATCCGCCTGCCTCAGCC TCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCTGGCTGAGAAGACATTTTTTAAGCTGGCTCT CCTTCCTCCTAGTTTTATGGAAGCAGAAGGATATATGGAGTTGAGAAGATCTTATTAATAAAACAGCCGG GATGACAAATGACCAAAGAGTTAGAGTATCCTTCTACAACATCGGCTGAGGGTTAATACAACCTTTTCAC CTTGGAATTCTATCATTCTAAGCTCTAGTCCCTGAAGTGAATGTTGTGTTGGCCTTTTGCATCTTGGGTC ACAGGGAATTGATACTTGCACATCTATGGAGAGGCAAATCTTTTTCTATCTACTTCTTTTTCAATGGGTA CAAACACACTTGGTCCTGAGCACCAGTGGTCTGAAGAGATACGGTCTGCCCAGAGGAGAAGAACAAAGGC AGGAAAGCAGATGAGAGTCAGCAAAGGGGCGATGCTGAAAAGTAAAAGGGGCGGGTAGATGGACAGAAGC CATGATCTGGCCATTCTATGGCCAGTCTTTCGGCCATAAGTGACTACCAAAGACACGGCAAAACGGTTTC CACATGTTGAACAACAGATGCTAGAGGACCAAGAGTATTGCAAGAGGGAGAAAATGAGATCAACCCATCA ATGCCTTGGCTTTCTTCAAGGAGACCCTTCCTGCACTGAAGAGCAAGGAGATGGAGCCCAAGCTGACTGT AGCCATGTTGCTGAACAGAGGAGAGTGATTGGACTTTGGGATTACTCAGGTAGTTAGGATTTTCTAGCCA TGCTAAGAGTAAGAATGGACTTGTGGAGGATAGGAGCTCCAGGCATAGAAGTCTCCTCAAGTGTTAGTCT AAACATAAAGCAGCACTTGCATAGAAGATTTTCCACAAGAAAATATGGCAAAAAAACACCATATATTGAG GAACAACAACTACAAGGGAACAGTGAGCTTAATAAAGGTGACAGAGCTCACATAGTGCTCTGGAATATTG GAGTTTTGACCAGCTAGAGAGAAGAGACCTCATTGAAAATCTTGGGCATTCAGTAGAGACCTCAGAAAAG TCAGACTTTATGAGTAGACTTTGTATATTCCTAGAATAAAGGCAGCTCCAGAAAAAACCTAGCAAAGCTG AAAAGCAAATCTCCAAGCATTAAAATGGTGTCCTAGTCAATTAACTGCCTTCTAGAAGAAAACTCAACAC TCTTTACAGGTGAACAACAAAGTTAAGTTGCTGAGCTATGCAATATCCACAGTGTGAGTCCTAAATTTAT AACTTTACTACACATAAAAAAGCATTTAGTGTGAACCATAACCAGGAAAATAATCAGTCAATAAAAATAG AACCAGGAATGATAGAAATGATTTAAATGGCATGAGAATTTGACATATTAGTATCATAACTGCATTGCTG GATTTAAGAAAACATAAACATGGAACGTAACAGATATCATATCAAGGGAAAGTAAAAGGATAAAAGAGTC AAATCAAATTAAAGGACTATTAAAAGGTATATCTTAAATGAAAAATTCACTGGATGGTCTCCCAATCAGG TTAGTTGTTTCCAGGGAAAAAATTAACTGAAAAATAATTCAATAGAATCTACAGAAATAGCTGCACATAT ATACACACAATGGCACACGTGCACACACCCACACCCACACAGGTGTGAATCCTAGAGCCACACGAGCATT GAAACATAGAGAAGTAAAAATTGTTCATTGAGGAATATGTAGCAATGCTCAATGTGTTTTACCCTAATAA GAGCTTTTGTGATGTATGATTGAAAAACTGACACAACTGAAGAGAGAAATAGATAAGCCCACACTCTGAG TTAGAGATTTCCTTGATTCTCTCACTATGGTTATAAATCTTTCCCAAACACAACAGGCTAGAACAAATAT GCAGAAAATTAGACATAGTATCTTTGTTCTCAATAAAAACGTCGACCTATTTAACATTATACCGAACTAC CGAGTACACATTAAAGTGTGCATGGAGCATTCACTGAGGTGTACTCTACACATGACCTTCCAGCAAGTCT CCATAGATTTAAAAGAATTAAAGTCATACAGAGTGTGTCACTTTATTCTCCCAGAATAAAGTGAGATATG AATAATGAGAAGTTTGCCAGCTTCTCAAATATTTGGGAGTCATACGGTGCATTTCAAAATACTCTTTGGG ACAAAGAAAACATCACTAAGGAATTTAGAAAAGTTTTGAACTGAGTAAGAATATAACACAATTTATCCAA ACTTAGGAGATGCAGTGAATGTCTTTAGGCTTTTACATAATTTTAGATGCTCTTAGGGAAAAACAGAAGC ATGTAATAATCAAGATTTCAAACTGCAATTCTCAAAGTGTAGTCTAGAGAAACCTGAGGACCTTTGAGTA CCTTCAGAGACAGTCCATGAGGTTAAAGGACTTTGCTACGTGAAAAGTAAGATGCTATTGGCCCTTTTTA CTTTCATTTTCCAACAAGAGAAGAGGGGAGTTTTCCAGCAGTTACATAATATGTAATGGCATCATGTCTC TGATGGCTAAGAAAATGGGCAATTGTTGACTTTGTGTGTTAAAAAAATTCTCAGTGTTGGTTTCTTATAC TATAAATATTCATCTTGTGTTTTGAAAAAGAAAAGCTCTTTGGAATCCCCTATGAACAAAGACTTTGACA GTTGTTGATCTAAGACCACAGCTTAAATATCTACACAAGAAAAAAAAAAAAAGCAAATAAGAGCCAAGGA AAGCAGATGGAAGGAAGTAGTCCAAACCAGTGACATTCAGTGAACAAGAAAAGAGACCAACAAGGGAGTA AACTCTTGAAACAGAAAGTTGATTCTTTGAAAAGATCCATATGATTGAACACAGTCTGGCTAAACAAATG ACAGACCAATGAGGGTGCACAACCATCACCATCTGGAGTAACAGAGGAGAGGTGCCATTACTATAGCATC TTCCAGTTCTGAAAGCTGAAAAGAAGATTTTGAGAACAATTGTATGTGAATAAATTCAGGAATGTTAATC ATGTGGGCCAATTCCTGAGGAAGACAACAAATCAGCAAACCAGATGCTGAATAGTTAGTGTAGTCCTGTA GAGAGACATACAGAGAGGCTGACAGAGAAATATTTGTATGTGCATAAAACAATCTACAAGACACACTTCA AAATCAATCTCAGTTAATCTGGAGGAACATATTTCACAGAAGGTGGAAGGAGGGTATTCTGATCCTCTTG TACATTGTACAACATTGTACAATGTACAGAGTATAATTGTACAAGTACAATTGAAGTTGTACAAGTACAA GTGCAACTTGCACAATGTACAGAGTAAACATTGATGTTTACTCTCAATTTTCTTATGGAGCACAGATGAC TTTGGATGTGTTACAATATGAATGATAATTTGTCTTTGAGATGTTCGCAGTTGTTTAGAAGTTGAGGACC ATTTGTGCATATTATGGGACCTTTAGTGAAAATATTTCAAAGTCTCTTTTTACACTTTGTTACAGCAAAA TGTAGAGGGCGCTAAGTGCCCTTGAATCTTCTCCCATCTCTGGTGACCTGTGTTGTTTTGAAATTTGCAG TGGCCTGACCAGGAACTACTGCAGGAATCCAGATGCTGAGATTCGCCCTTGGTGTTACACCATGGATCCC AGTGTCAGGTGGGAGTACTGCAACCTGACACAATGCCTGGTGACAGAATCAAGTGTCCTTGCAACTCTCA CGGTGGTCCCAGATCCAAGCACAGAGGCTTCTTCTGAAGAAGGTAGGAAGTCTATGGCCAGACAACCACA CCCTAGGACGTTGGGATGAAAAGAGTTGCAAAATCTTAGTGATATAGAAGCCTTCCATGCTCACACAATT CCAAGTAGAATGTGGACTCAGGGTCAGCCACTGGGAAGGAACACTCAGCGCCTTCTCTGGGAGAACCAGA GCTGTGATGTTTGGTACCCTGTGAAAGGGTGGTATCTATAGGAAGGGTGCAGACCCTCTAGGGCACTGGA CTTACCACTCCCCTGGTTATTCAAAGGATCATTTTAGTGTCTTAGCCAGAAGAATATTCTAACATTTTGC CAAATTTGTGAAGATTTACCAAGCTCATGATAAGCCTTTCATGGTATTTCTTCAAGTAGTCAGTGTTCAT TGCATCTTTGGCTTTGCGGTTTCGGAGGAATGCGGTTTTTGAGTCTGTCATCCTTGAGAAACCTAATATG ACTTTTCTTAGTTCCATATACTTCTGGGTCCAGGTAGCAGTACATAGCCAACAAATGCTCCATCGTTCTG GCCTATCTCCATCTTAAGCCAGTCCTGCACAACTAGGCTTTGATGGGAGGGATCTCTCAGTGTTCTTGCC CCTCCTTCTCATGGAACATATATCTGTGTTGGTCTCTGAGAAGAAGAGTAGTGGATATCTACTTTGTTGC AATGCAGAATCCTGGGCCAAAGATACCAGCCATCCCTCCAAGGGAATAAAATTTTGGCCAGTAGCCCTCT CTGAGAGACAATTTGTCTTTGCCTACGAGTCCTAGATGCAGGACCGCTTCCTGCCCCATCTTCAAGAAGC TGAAGGCTTTGGCTTTGGAGGATCAGCAGTCTAGGGAAATGTGTGACGGTTTCATGTCTGTCCCCACTGA CAGTCAATCACCACCTACAACCTGCACAGCCTGATGCATAGCAGTCTAGTTTCCTGCCTTATTCTCAGGA ACACCCAGAAGATGTCTATATTAAAGAGCATGCACATGAGTGCAATTTTGACTGATAGGCACTCTGATCT TTCCTTTGGTGCCTGTGTTTTAAAGGAAATCTTTCTAAGAACTCGTTAAAGTTCTAGAATGCTATGAATC TTTGGGTTTTATTATTGGTATGTCCATCTGCCTGCTAGTACAGAACAGAGCATGGTAGTCTTTCTCAGAG ACAATGATCCTGTTTCAGTCACAGATTTCTTCTGATGCTTCTGTGTTCTAGAAATTACTCAGCTTGATTT CTCCTCTTTGAATTTCAGCACCAACGGAGCAAAGCCCCGGGGTCCAGGATTGCTACCATGGTGATGGACA GAGTTATCGAGGCTCATTCTCTACCACTGTCACAGGAAGGACATGTCAGTCTTGGTCCTCTATGACACCA CACTGGCATCAGAGGACAACAGAATATTATCCAAATGGGTACAACCTTGAGTTTTCTTCAAAGACAGACA GCAGCCCCCTTACATTTCTCTTGGAAGGGCCATGCTTCCAACTAACTTCTTATGACAAATTTATCTCAGA TCTGGAATGTTGGGTAGAATGTCTCAGGCTTCTTTCTTCAGGCACAGTGTCTGAAAGGAGAGAAATGTCA GGCCAGCTCTCTTTTCTCATAGTTGACAGAAGCAGGAGGATATTTGAAGGTGGTGAGTTCTCATGAATAG AAAGCTCAGGACACATGGCCACGTGCTTAGAAATAGCACCATTCCACAATGCCCACTAAAGACCAATGCA ATAGTTCAACCAGGGATTTCTGTCATTCTAATCTCCAAGTCCTGAAGTGAAGGTTGTATTAGCCATGTTC ATCTTGGGCAACAAATAAAGGATATCTATGTTGACATCCAGATCTTCCAATCACTTTCTCCTCTAACCTG TACCTGGGTTCTGAGAACAAGGTATCTGAAGAGCTATGTGTTGCCAGCACATGAGGGGCAAAAGTAGGAA GGCAGCTGAGAGTCAGGAAGTATAAAGATTCTGAAGAGTTACACATGCAGGAAGATGGACAGAAACCCAG TTCAGACCACGTCAGCGTTTCTGCCATGAAGGACTATCAAATACATAGGAAAAGTGTTTTCATAGGTTGG ACAACAGACATGACAGGCCTGAGAAAATTCAGAAAGGGAATCAAAGGAGATCAACCTTATCATGTCCCTG GCATCCTTCCTTGAGACCCTTGAAGGGCAAGCAGATGGAGCCCAGCTGACCACAGCAGTCTTGCTTAACT GAGGAGAGAGACTGGAGTTTGTGATGCCTCAGGCATCTGACGTATTCTAGGCTGGCTAAGAATGAGAGGG GATTTGTGGAGGAAAGGAGCTCCAAGAATACACACCGAAGTCTTCTCAAGGCTTTGGCTAAATACAAAGC TGCGTATGCACAAGGAGAGTTTTCACAAAGAAAGAACAATAAAGAAAAGCTACTGGGGAAAGAACAACTG CAAGGGAACAGTGAGCTCAATGGAGATGCTAGAGCTCACATAGCACTGGGGGATATTTGAGTTCTGACCA CTCAGAGGAGAGACACCTCACTGAACATCTTGGGCATTCAGTAGAGGTCAAAGAAAGCCATAATTTGGGA GTAGGATCTTCGGATTCCTAGAAATAAGGTGACTCCAGAAACACTCCAGCAACCCTTCTTCCAAGCCAGT CTAAAAGGATCCAAATGATTTCCAAGTAAATTAACTGCCTTCCAGAAAAAAGTAAACTCAACCCTCCTTA GAGGTAAGGAACGAATACAAGTTTCTCAGTTATATGACATCCCCAGAGTGCAACTTGCATTTAAAAATTT ACTAGACACAAAAGAAGTTTTCACTGTGATCCATAACTGGGAGAAAAATCACTCAACACAAATAGGCCCA GAAATAATAGAAATTATGGCATTGGCAAGAACATTTAAAATGCACCTCTGAGAACTGTGTTTCAGGAAAA TGTCAGCAAAAGCTGACCATGAGAGAAATGAATGCATAATATCAGAAAAGAAAAGAATTGAAGAGCCAAA TGGAAATTTAAAAACTGAGAAAAGTTATATCTGTAATGAGGAATTCACTGGATGGCCTTATAACCAGTTT AGATATTATGGTAGGAAAAGGTGAACGAGAAAATGATTCAATTAAAGCTAGACAAACCACAAGACAGACA GACAGACACAAATACACATACACACAATGACTGAACCAATTAATCAACAGAGCCTCAAGGACATCTAGGA AAACATCCACACATTTAATATATGTGTTAGGCAAGTCACAGAAAGAGAGGAAAAAGATAATGTGACAGAA GTTATACTTGAAGCCATGACGGCTGACAAATTTCCAAACATACAGAAAATGAGAAATTCATAGTCATGAA GCTCAATGACTCAGGTATAGATTTTTAAAGAGCAAAACTCTGATTTACTGGGGTACATCATAGTTAAATT GTCTGATTTCAAAGCTAAGAAGAAAAAAAGGGGGTTCCTATGAACAAACATTTTGACAGTTGATCTAAGA CCACAGCTTAAATATCTAGGCAAGGAAAAGCAAATAAGACACAAGGAAAGGGGATGGATGGAAATAGTCC AAACCAATGACATTCAGTGAACAAGAAAATAGACCAACAAAGGAGTAAATCCATGAAACAGAAAGTTGGT TCTTTGAAAAGATTCATGTGATTGACCACAGTCTGGCTGAACAGATGACAGACCAAGGAGGGAGTACAAC CATCACCATTTGAAGTAACAGGGGAGAGGAGCCATTGCTATACCATACTCCAGGTCTGAAAGCTGACAAG AAGATATCAAGAAAAACTGTATGTGAATAAATTCATGAATGTAGATCATGTGGATCAATTCCTTAGGTAA ACAACAAATCAGCAAACCAGATACTGAATAGATTGGGTACTCCTATAGAAAGACATACAGATAGCCAGAC AGAGAAACATTTGTACGTGCATAAAACAATCTACAAGACTCACTTCAAAATCTCTCAGTTAATCCAAAGT AACATATTTGGCAGAAGGTGGAAGGAGGGTATTCTGATCCTTTCTTGTACACATTGATGTTTTCTCTCGG TTTTCTTATGGAGTATAGACGAGTTTGGATGTGTTACAATAAGAATGATAATCTGTCTTTGAAATGTTCA CAGTTGTTTAGAAGTTGAGGACGATTTGTGATTGTTACAGGACCTTTAGTGAGAATATTTCAAAGTCACT TTTTACCACTTTGTTACAACAAAATGTAGAGGATGTCTGGTGCCCTTGTATCTTCTCCCATCTCTGGTGA ACTGTATTGTTTTGTAATTTGCAGTGGCCTGACCAGGAACTACTGCAGGAATCCAGATGCTGAGATTAGT CCTTGGTGTTATACCATGGATCCCAATGTCAGATGGGAGTACTGCAACCTGACACAATGTCCAGTGACAG AATCAAGTGTCCTTGCGACGTCCACGGCTGTTTCTGAACAAGGTAAGAAGTCTCTGGCCAGACAACCACA CCCTTGGACGTTGGGATAAAAAGAGTTGCAAAATCTTAGTGATACAGAAGCCTTCCATGCTGCACGGGAA TCTGAATGTGGACTCAGGGTCAGCCAATGGGAAGGAAGCCTCAGCGCCTTCTCTGGGGGAACCAGGGCTG AGATTTTTGGCACCCCGTGACAGGGTGGTGTCTTTAGGAAGCGTGCAGACCTTCTAGGGCACTGGATTTA CCACTCCCCTGGTTATTCAATAGATTATTTCAGTGTCCTAGTGAAAATGGATATTCTAACATCCTGCCAA ATTTGTGATGATTTACCAAGCTCATCATGAGCCTTTCCTGGTATTTCTTCAAGTAGACAGTACTCATTGC AAACTTCAGCTTTACAGTTTCAGAGGAATGTGGTTTTTGAGTCTGTCATCCTTGAGAAACCTGATATGAC TTTACTTAGTTCCATATCCTCCTGGGTCTAGGTAACAGTACATAGCCAGCAAATGCTCTATCTCCCTGTC TACCTTAATCTTAGGCAGGTGCTGCACACCTAGGCTTTGATGGAAGGGATTTCTTAGTGTTCTTGCCCCT CCTTCTCATGGAACACGTATCTGTGTTGCTGTTTGTGAAGAAGAGTAGTGGATGTCTACTTTGTTGCAAT GCAGGATCCTGGGCCCAAGATTTCCCGCCGTCCCTCCAAGGGAATAAAATTTTGGCCAGTACCCCTCTCT GAGAGACAATGTGTCTTTGCCTGGAAGTCCTAGATGGAGGACCACTTCCTGCCCCATCTTCCAGAAACTT AAGGCTTTGGCTTTGGAGGATCAGTGCTCTGGAGAAATGTGTGACGGTTTCATGTCTGCCCCCACTGACA ACCACCACCTACAGCCTGCACCGCCTGATGCATGGCACTCTGGTCTCCTGCCTTGTTCTCAGGAACACCC AAAAGAGATCTTTGCCAAAGAACAGGCACATGAGTGCAATTTTGACTGATAGGCACTCTGATCTGTCCTT TGGTGCCCAGGTTTTAAAGAAAATCTTTCTAAAAACTCATTGAAGTTCCAGAATGCTATGAATCTTTGAG CTTTGTTATTGGCATGTCCATCTGCCTACTAATGTAGAACAGAGCATGGTCGTCATTTTCAGAGATGATG TCCTGTTTCTATCATGGATTTTTTTTCTCATGCTTCTGTGTTCTGGAAATTACTCAGTTTGTTTTCTCCT CTTTGAATTTCAGCACCAACGGAGCAAAGCCCCACAGTCCAGGACTGCTACCATGGTGATGGACAGAGTT ATCGAGGCTCATTCTCCACCACTGTTACAGGAAGGACATGTCAGTCTTGGTCCTCTATGACACCACACTG GCATCAGAGAACCACAGAATACTACCCAAATGGGTATGTCTTTGAGTTTTCTCCCAAGAGAAACAGCCAC CCACTTAAATTTCTCCTGGAAGAGCCATGCTTCCAGCTAACTTCTTATGACCCAATTTCTCTCAGACCCA GAATGTTGGACAGAATGTCTCAGGCTTCTTGCTTTGGGCACAGGGTCTGAGAGGAGAGAAATGTCAGGCC AGCTCTCTTTTCTCATAGTTGATAGAAGTAGGAGGATACTTGGAGGTGGTGAGGTCTCATGAATAGAAAG CTCAGAAGAACATATGACCATGTGCTTAGAAATAGCACCATTCCACAATGCCCACTAAAGACCAGTGAAA TAGTTCAACCAGGGAATTCTGTCATTCTAATCTCCAAGCCCTGGAGTGAAGGTTGTGTTTGCCATGTTTG TCTTGGGTAACAAGTGAAGGATATCTATATTGACTTCGAGATCTTCCGATCACTTTCTCCTCTAACCTGT ATAAACACATTGGGTTCTGAGAACAAGGTGTCTGAAAAGCTATGTGTTGCCAGCCCATGAGGGGCAAAAG GAGGAAGGCAGCTGAGAGTCAGGAAGTATAGAGATGCTGAAGAGTTACACATTCAGGAAGATGGACAGAA ACCCATGTCTGGCTATGCCAGCCTTTCTGCCATGAAGGACTATCAAATACATGAGAAAACAGTTTTCACA GGTTGGACAACAGATATGGTAGGCTTGAGAGAACTGAGAAAGGGAATCAAAGGAGATCAACTTCATCATT AACCTGTCTTCCTTCCTGGACACAGTGTTGGATTGAAGGACAAGCAGATGGAGCCCAGCTGACCACAGCA GTCTTGCTTAACTGAGGAGAGAGACTGGAGTCTGCGATGCCTCAGGCAGCTGATGTGTTCTAGGCTGGCT AAGAATGAGAAGGGATTTGTGGAAGAAAGGAGCTCCAGGAATACACACAGAAGTCTCCTCAAGGCTTTGG CTAAATACAAAGCTGCGTATGCACAGGGAGAGTTTTCATAAAGAAAGAACAACAAAGAAAAGCTACTTGG GAAAGAACAACTGCAGGGGAACAGTAAGCTCAATGGAGATGCCAGAGCTCACATAGCACTGGGGGATATT TGAATTCTGACCACTCAGAGGAGAAACACCTCACTACATTTTGGGCATTCAGTAGAGACCAAAGAAAGCT GTATTTTGGGATTGGGATCATCTTATTCCTAGAATCAAGGTGACTCCAGAAAAACTCCAACAACCCTTCT TCCAAGCCAGTCTAAAAGGATCCAAATGATCTCCAAGTAAATTAACTGCATTCCACAAGAAAAAAAAAAC TCAACCCCCCTTAGAGGCAAGGGACAAATACAAGTTGCTCAGTTATATGGCATTCCTATTGCGTTACTTC TATTTAAAAATTTAATAGAGACACAAGAAGCTTTCACTGTGATACATAACTGGGAGAAAAAATCACTCAA CACAAACAGGCCCAGAAATTATAGAATTGATGACATTGGTGAGAACATTTAAAATGCACCTCTGAGAACT GTGTTTCAGGAAAATGTCAGCAAAAGCTGACCATGAGAGAAACAAAAGCAGAATAGCAAGAGAAAAGAAA AGAACCGGAGAGCCAAATGAAAATTAAAGAACTGAGAAAAGGTACATCTCTAATGAAGAACTCACTGGAT GGCCTTATCATCACTTTAGACATTACGGTAGGAAAGGTGACCTAGAAAATAATTCAATAGGAGCTACACA AATCACAGGACAGACAGACAGACCAACAGACAGAAACACACACACACACACACACACACACACACACACA CACACACACACACAAAGACTGAACCTATTAATCAACAGAGCCTCAAGGGCATCTAGGAAAAATCCACACA TTTAATATATGTGTTAGGCAAGTCACAGAAGGAGAAGAAAAAGATATCATGACAGACATTATACTTGAAG CGATGATGGCTCGCAACACGCCAAATATACAGAAAACAAGAAACTCATAGTCAAGAAGCTAAATGACTCA GGTATAGAATTTTAAAGAGCAAAACTCTATGATTTACTGGGATATATCATAGTTAAGTTGCCTCAATTCA AAGCTAAAAAGAAAAAAAGGGGGTTCCTATGAACAACAGCTTTGACAGCTGTTGATCTAAGACCACAGCT TAAATATCTAGGCAAGGAAAAGCAAATAAGGCACAAGGAAAGAGGATGGAAGGAAATAGTCCAAACCAAT GACATTCAGTGGAAAAGAAAATAGACCAACAAAGGAGTAAATCCATGAAACAGAAAGTTAGGTTCTTTGA AAAGTCTATATGATTGGCCAAAGTCTGGCTAAACAGATGACAGACCAAGGAGGGAGCATATCCATCACCA TCATGAGTAACAGGAGAGAGATGCCATTGCTATAGCATCCTCCAGGTGTGAAAGCTGAGAAGTAGATATT GAGATCAACTGTATGTAAATAAATTCATGAATGTAGATCATGTGGATGGATTGCTTAGGTAAATAACAAA TCAGCAAATCAAACACTGAATAGATCATGCAGTTTTATAGAGACTTACAGACAGCCTGACAGATAAACAT TTGTATGTACGTGAAACAATCTCCAAGACACACTTCAAAATCCCTCTCGGTTAATCCAAAGGAATGTATT TGGCAGAAGGTAGAAGGAGGGTATTCTGATCCTTTCTGGTACACATTGATGTTTTCTCTCAGTTTTCTTA TAAAGCATAGATTACTTTGAATGTGTTACAATAAGAATCATAAGCTGTCTTTGAAATGTTGACAGTTGTT TAGAAGTTGAGGACCATTTGTGAGTGTTATGGGACTTTAGTGAGAATATTTCAAATTTGCTTGTTTACAC TTTGTTACAAGAAAACATAGAGGGTGCCAGGTGGTGCTGTATCTTCTCCAATCTCTGGTGACCTGTATTG TTTTGGAATTTGCAGTGGCCTGACCAGGAACTACTGCAGGAATCCAGATGCTGAGATTCGCCCTTGGTGT TATACCATGGATCCCAGTGTCAGATGGGAGTACTGCAACCTGACGCAATGTCCAGTGATGGAATCAACTC TCCTCACAACTCCCACGGTGGTCCCAGTTCCAAGCACAGAGCTTCCTTCTGAAGAAGGTAAGAAGCCTGC AGTCAGACAACCATACCCTCGGACATTGGGATAAAAAGATTTGCAAAATCTTTGTGATGCAGAAAACTTC CATGCTGCACAGGAAGTCGAAGGTGAAGTCATGGACAGCCAATGGGAAGGAAGCTTCAGTGCCTTCTCTG GGGGGACCAGAGCTGGGATGTTGAGTGCCTTGTGAGGGATGGTGTCTTTAAAAGGGGCACAGACCCTCTA GGACACTGGATTTATCACTTCCCTGTTATCAAACGAATCATATTAGTGTCCTAGCCAAGATGGATATTCT AACATCCTGCCAAACTTGTGAAGATATACCAAGCTCCTAAGCCTGTCCAGCCCTTTCTTCAAGTAGGCAG TGTTTATTGCAGTCTTCAGCTTTACCATTTTGAAGGAATGCCATTTTTGAGGCTGTTGTTCTTGAGAAAC CTAACATGTCTTCATTAGATCCGTATTGTCCTGAGACTTTGAAGCAGTACATAGCCACCAAATTGTTTAT CTCCCCAGCCTACCTTCATCTTGGGCATGCCTTCCACACCTAGGATTTGAGGGAAGGGATTTCTCAGTGT TCTCATCCCTGCTTCTCATGGAACATTTATCTCCGTTGTTTTTTGAGAAGAAGAGTAGTGGATGTCAGCT TTCTTGTAATGAGGGATCCTGGGCCCAAGATTCCCTGTCTCCCCTCCTAGGCTATAAAATTTTGGCCTGT ACTCCTTCTCCCTGAGAGGCAATGTGTCTTTACCTACAAGTCCTAGATGCAAGATCCTTTTCTGCCCCAC ACCCCAGAATCTGAAGGCTTTTGCTTTGGAGGAGCAGTGGTCTAGTGTGCAAGGGTTTCATGTATACCCC CCACTAACAGCCAATCACCACCTATAGCCTGAACAGCTTGATGCATGGCACCCTGGTCTCCTGCCTTGTT CTCATGAACACCCAGAAGAGGTGTAAGCAAAAGACCATTCACATGAGTGTAATTTTGAAGTATAGGCACT CTGATCTGTTTTTTGTTTGTTTCTTTGTTTGTTTGTTTTCCAGGGTTGAATTAAAATATTTATGACTACT TATTAAATTTCTAGAATCCTATAAGTCTATTTGTATTTTTATTCTACATTTCAATTTGCATGCTAATATA GAAGAGTGTAAATTGTTAATCCTCAGATTATTCCACTTTGTGTGTCATAATTTTTTTCACATTTCCCTTT TCTAGGCAATACTGAGCTTGATTTTCTCTTTTAATTTCAGCACCAACTGAAAACAGCACTGGGGTCCAGG ACTGCTACCGAGGTGATGGACAGAGTTATCGAGGCACACTCTCCACCACTATCACAGGAAGAACATGTCA GTCTTGGTCGTCTATGACACCACATTGGCATCGGAGGATCCCATTATACTATCCAAATGCGTATGTCTAT CATGTTAGCCATAAAAGGAACAATAGTCAACTAAAATTTCTCTTAGCTGGCCCATGCTACAAGCTCACTT CCTAGGTCCAAATTTCTCATAGACTCAGAGTTTGTAGCAAAATGTCTCAGGAAACTTACTTTTGAGCAAA AGGTCTGAATGAAGAGAAGTTTTAGGATTGCTATCTTTCATAACAATTTGATGGAAGCAGCAGGATATAT GGAGGTGGTGAAGTCTCATTAATGTAAAGCTAAGGAGATCAAATGACCAAATGCTGAGACAAAGTATCAT TCCACAATGCCCACTAAAGGTCCATGCAGTCTTTCAACCATGCAATTCTATCATTCTATCCTCCATTCCC TGAAGTGAAATTTGTGTTTGCCATTTTTGACACGAATCAGAAGTAACAAATTCAGGCTGGGTGCAGTGGC TCAGGCCTGTGATCCCAACACTTTGGGAGGACAAGACGGGCAGATCACCAGAGGTCAGGAGTTCAAGACC AGCCTGGCTAACATGGCAAAACCCCATCTCTACGAAAAATTAAAAAATTAGCCGGTCATGGTGGTGGGTA CCTGTAATTCCAACTACTTGGGAGGCTGAGGCAGGAGAAACACTTGAGCCTGGGATTCAGAGTTTGCTGT GAGCCGAGAACATGCCACTGCACTCCAGCCTGGGTGACAGAGCAAGACTCAATCTCAAAAAAAAAAAAAA AGAAGAAGAAGAAGAAAAGAAGAAGAGGAAGAAGAAGAAGAGGAAGAAGAAGAAGAAGAAGAAGAGGAAG AGGAAGAGGAGGAGGAGGAGGAGGAGGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGA AGAAGAAGAAGAAGAAGAAGAAGAAAATAGAAATGAGTGCATATATTTATATATGAGTACTAGCCTGTAT GAACACACTGGGTTCTAAGCACCAGTTTTCTGAAGGGATATGGGTTGTCAGGCAGAGTAAAAGCAGGAAT GCAGATGAGAGTCAGGAAGTAAACAGATGTGGTGATTAAAATGGGCAGGTACATGGACAAAAAAATGCAT GTCTGACAAAAACTGGCCTCTTGCCATAAGTGAGTATGAATAATATGGAAAAACTGTTTGCACATGTTGA ACAGCAGACAGTACAACCTGAGATAGTTTAGAAAGGGAAACAAATAAGATCAACCCCATAATTACCCTTC CTAGACTTAAGGGCAAAGAGTTTTAACCAAAGCATTCCACAGCAGTCTTGCTAAACTGGGGAGAGAGACT GGAGTTTTGTTTACTAATAAAACCGAGATTTTCTAGGTTAGGTAATAATGAGAAAGTATTTGTGGAGAAA AGGAGCTCCAGGAATACACACAGAAGTCTCTTCAAGTCTCTGGCTGAACAGAAAGCTGTGTATGCACAGA AAGAGTTTCCAGAGAGAAAGGAGAACAAAGAACAGCTACTGGGGAAAGAACAACTGCTGGGGAACAGTGA GCTCAATGAAGATGCCAGAGCTCACATAGCACTGGGAGGTATTTGAGCTCTGACCAGCCTGAGGAGAGAC ACTTCATTGAACATCTTGGGCATTCAGCAAAGACCCCAAAAAACCATACTTCAGGAGTAGAATTAATGCA TTCCTAGAATAAAGTCTACTCCAGAAACACCCTAGAAAAGCTTAGAAACCAAGTCTAAAAAGATCCAAAT GATCTCCAAGTAAATTAATTGCCTGTCAGAAGAAAACAACCTCTTCAGAGGTAAACAACAAAATTAAATT GCTCAATTATATAGTATGCACAATGTGTGGCATACATTTAAAAATTTGCTAAACATACAAAAAGCATTTA GTGTGACCCATAACCAGGAGAAAAATCAGTCAATACAAATAGACCCAAAAATGATAAAAATAACAGAATT GGCAAGGAGATTTAAAATGTATGTATCATAATTGTGTTCAAGGATTTAAAGAAAGCGTGGACAAGAAATA AATAAATGGATAATATCAACAGAAAGAAAAATTGTAAAAGGACCAAATGGAGAGTCAAGAACTGAAAAAA AAGACATCTCTTTAATGAGAAAATCACTACATGGCCTTATAATCATATTAGATAGTACAGATGATAAAGC TAACTAGAAAATATTAGGGTGGTGCAAACCATAGCACGCTTATACAAAGCCTGAGAAGATAAACAGAGCC TCAAGGACATCTATGAAAATATCAAAATATTTAATATTTGTTTAAAGCAAGTCACAGAGGAAGGGAAAGA GATATTGGAACAGAAAAAATACTTGAAGCAGTGATGGCTGATGACTTTCTAAATATGGAAAAAATGATAA ACTCACATAGTCAAGAAGCTCAATGGATCAGATATAGGATTTTAAAAAGTAAAGCTGTATGATTTATTTG GACACATCATAATTAAATTGTCCATAATCAAAGATAGAAAGTAAAATCTTATTTGAAGCCCAAGGGAAAA AACATACCTTTACATAGAGTAACAGTGACACAAATGACTGATGCCTTCTCATCAGAAACAACACAAATCA GAAACAATAGAATAACACCTTTAGAGTGGTAAGAAGAAAAAAAGATCAAATCAGAAACAACAAAATAACA CGTTTAGAGTGGTAAGGAGGAAAACAAGATCAAATCAGAAACAATGGAATAACACCTTTAGAGTGTAAGA AAGAAAAAAAGATCAAATCAGGAACAACAGAATAACGCCTTCAGAGTGGTAAGAAGGAAAACAAGATAAA ATCAGAAACAATGAAATAACACCTTTAGAGTAGTAAGAAGAAGAAAAGATCAGGTCAGAAAAAATGGAAT AATATGCTAAGAAGAAAAAAAAAGATCAAGTCAGAAACAATGGAATAACACCTTTAGAGTGAAAAGAAGG AAAAAAACCCAGCAAGCTTAAACGCTATGCACAGCAAACAATTCCACTGAAAATGAATGTTACGTAAGTA CATATTCTGTCCTCCTAAAAACAAAGAACAAATAAAAGAATGTTTCATCAGCAGGATTATGTAATAAAAG ATGTGAAAGAATGCTATGTAAGTAGAAGAAAAATAATACCATATGGGAATTGGCATCAAAACCACAAAAT ACTATCAAAACAAAAAAACTTTATTGATAAATTTAACACAATATGCAAAAGAACTATACCATGTATACTA CATAACATTGGTGAGAAGAAAATTAGAAGATCTAAATAAAGACACATCATGCTTATAGATTAAAAAATCC AATGTCACTTTTCACAAAACTGATCTTTAGTTTCAACCCACACCCAAGCAGAATTCCTGCAGTCTTTTCT TGAAAACCTAACAGAATGTATATGCTAGAATCACCAAGACAATCTTTAAAAAGAATAAAAAACTTGGAAT AAAATCACAAGTTTGTGGGATAGATGCATATGGTAATATGGAAATTCTCATAAAGACACAGTAATCAAGA CATGTGGTATTGGCTGGGACGCTTGGCTGTAATCCTAACACTTTGGGAGGCCAAGATGAGAGGATTGCCT GAGATGAGGAGTTGCAGACAAGCCTGGGCAACATAGCAAGACCCTCATCTCTACAAATATTTAAAAAAAT TAGCCAGGTTTGGTGCCATGTGCCTGTAGTCCCAGCTATTCAGGAAGCTGAGGTGGGAGGATCACTGGAG CCCATGAGGTGGAGGCTGAAATGAGCCATGATTGTGCTACTGAACTTTAGCCTGGGAGACAGATTAAAAC CTTCCCTCTCTCTCTCAAACAAACAAACAAAAAATACATAGTATTGGGCAAAACATATGCAAACAAAAAC AGAAAAGGGTCAGCATAAATTTACATATATGGTCAATTTATTTTCAATACAGGTAGCAAAGCAATTTAAT GAGGAAATTTTTTTCCAAAATTGGTCTGAAACAACTGGATAGCCATAGAAAAAAACTATAACAAATGTGA CGCTTGAATCCTACTGTATGACTCAAATTAAATTAATTTGAGATAGCTCTTAGACCTCAATGTAACAGCT AATTCTGAGGCTGAAATATAAGACTGCTATGAAAAAGTATAGTATCTTATAACCTTGGAGAAGGAAAAAT TTTTTGAGGGAAGAACCAGAAAACACTAACTGTAAAAGAAAACAAATGATAATGTGGACATTCATTGAAT AAAAACTTATGCTCACCAAATATGACTGTTAAGAAAATAAATAAGTAAGTAACACACTGGAAGAAAAACA CTCTCATCCATATATCTGACAAATGGCCTGTATCCAGAGTATAGAAACATTTCTCCCACTCACTAATCAG AGGACAAACAACCTAATCAAAATGGGCAACAGGCTTGAATAGTCATTTCTTAGGAGAAGATGCACACAGA GCCAACAATCACCTGAAAAAGTGCACAACATCTTAGCCATCAAAAATCAAGAGTTATAACCCTCATAAGA TGACACTGAACATCCAGTGTACATGGATATCATTAAGAAGACACAATAATAAGTGGTGTCACCGATTTGG AGCTAGAATGTGCCACTCTCTCATATGCTGGTGGAAGTTCAAAATCATACAACAAATTAAAAAATCAGTC TGATGCTTTCTTATAAAGTTCGATAAATATGCATCTATCCTACAAACCTGTAATTCTATTCTTGAATATT TACCCCCCAAAATGAAAACATAAGTCCACAAAAATCTATATAAATATTCATAGCAGCTTTATGTTTTATA AACTCAAAATAAAAACTATTTCAATGTTTTCATCAAAAGAAAATGAAAACTATTTAAATGGTTTCATCAA AAGAAAATGAAAAAAGAATTTCCAGTATATTTATACAAAGGAATACTATTCATCAACAAGGAACAAGTTA CTGATAGTCTCAGAAGCATGAACAAACCTCAAAAATATATTAAGGAAAGAAGCCAGACGTCAAAGTGTAT AGTCTGTATGAGTCCATTCATGTGAGTTTATAGAAAACACAATTTATGGTGAAAGAAACCAATAGCATTT GACACTGGCCGTGGGAAGAGGGTAGCAGAGATTGATTGAGCAGCCACACAAGGGAGTTTCTGGGGTGGTG AAAATGTTCTGCATTGTGAGGGCAGTGTGGGCTACACAAGTATATGTATTTATCAAATCTCATCCAGCTA CATTTAAGATCTGTGCATCTCACTCTATGTGAAAATATACTCAACTGAAAAACAGAGCAGGTATCTGTTT CAGGTGCTACATCACTTGATACGTCCAGTTGTGTTAAAAACCACTGCCTAACATCCTCAAATGGGGGATC TGGGCTTGAGACTAGGTCACATGTGTAGAGTCTCTACAGAGACCGTGTTGGATTCCCATGCTCCATAATA CGTTCCAAGTTTTCTCAGACAGCCACAGGTCATGAATGTGAGGATTCTGAGAGGTTGGAGCAACGTTCTT GGGAGGCATAATGGGGAAGGCATTCTCCAAGATTCCTCCAGCCTGGGGTCTTCACCTGCTGTGCCTCTTA CTGCATTGTTTTCTGACTCATCCATAGCCACTTGACCCCTTCAGATCCCATAGTCTACCTAGCCGTCTCC CTTTATGCCTTGGGTCCCGCTGTTCTTTCAACTCATCACCCATTCCTTCAGTCCCAGAGTGGCTGCAGCC AGCAGAGGATGGACTGAGAGCAGGAGAGGAGGTCGTGCCCATGAACCCATCCTAGAGAAGCAGCATCCTG CCTGGGAGCTAGTTTTCCAGGGAAGCTTTTATAAGTCCTGTAGACCCAAACCCACTTGCTCTACCAGATA CAGTATTTATAGTAATACTATTTTCATGATTATTTTATATTGCAAATGTAGAGCATTTATGCTACACTAT GAGTAAATAGAGTAAGGGGGCTGGCATGGGAATTATATAATCTTGGATGCCACTTCTTCCTTGGGGAAAT GTATTTGAGTTCCAACTTACATATTACTATATAGTCTTATAGAGAGAGAGACAAAGAGCTAGACAGACAG AGATATCTTTGTATGTGCATTAAAAAATCTAAGATACATATTTCAAAATCTGTGTCATTTATTCTGGAGG AAAGTATTTGGCAGAAGGTGAAAGGAAGATATTCTGATCCTTTCTTGTACAGACATGTATTATCTCAGTT TTCATAGAGAGCATATACTACTTTTGATGTTTTAAAACAAAAATTATAATCTGTGATGTGTCCACAGTTG TTTAAAAGTTGAAGCTGAAGACCATTTGTGCTTGTGGCAATATTATTGTGGTATAATGGGAATATTTCAA AGGCACTTGTTAACACTTTGTTACAGCAAAATGTAGAGGGCGCTAAGTGCCCTTGAATATTCTCCCATCT CTGGTGACCTGTGTTGTTTTGAAATTTGCAGTGGCCTGACCAGGAACTACTGCAGGAATCCAGATGCTGA GATTCGCCCTTGGTGTTACACCATGGATCCCAGTGTCAGGTGGGAGTACTGCAACCTGACACGATGTCCA GTGACAGAATCGAGTGTCCTCACAACTCCCACAGTGGCCCCGGTTCCAAGCACAGAGGCTCCTTCTGAAC AAGGTAAGAAATTTGTGGTTAGACATCTATATACTGGGATGAAAAACCATGGAAAATCTTACTGATGCAG AAGCCTTCAGTGGTACACTGGAGGGTTGGTTGAGGGTCTGCAATGTGGAGGAAAGCCTCAGCGCCCTCTC TGGGGGATCCAGAACTGTGATTTTTGGCACGCTGTGAGGAGGCAGTGTCTTTAGGAAGGGCACGGTGTCT TTAGGAAGGGCACAGACCCGCCAGGGCACTGGACTTACCACTCCCCTGGTTATTAAATGGGTCATTTCAG TGTCCTAGCCAAAATGGATATTCTAACAGCCTGCCAAATATGTGAAGATTTCCAAGCCAATAAGCCTTTC CAGTGATTTAAAGTAGACTTTTTTCATTGCAATCTACAGTTTGCAGTTTCTTAAGAACATGGCCTTTGAG TATGATATCCTAGAGAAACCTAAGGAGACTGCATTATTTTTCTATTGTCCTGGGGCTGCATAGCAGGAGG TAACCAACGAATGCTGTCTCTCCCTGGCCTATCTCAGTCTTTCACAGGCTCTGTTCACCTCAGCTTTGAA GTTAGAAATTTCTAGGTGTTCTTGCCTCTTCTTCTCATGAAACCTGCATTGGCAGTGAGTCTACAGAAGA AGAGGAAGAGAATTCTGCTTTGTTACAATTCAGGACTCTGGGCACTAGAAGATTCCCTATCTCTCCTCCA AGGGAATAAGTTGTTTGTCTCTAACCCTCCTTGAGAAACAATGAGTCTTTGCCTGCACTCCTAAATGTAG GATGATTTCCTGCCCAAATTTTCAAAAGATTAAGCCTTTTGCCTTGGTATGAGCAATGGTCTAGGGAAAT GCGCAAGGGTCTTGTGTCGGCCCCTGACTGACCACCAGTCACCTCCTACAGCCTGCACCAAGGAATGCAT TGCATTCTGGTCTTCTGCCCTGTGGTTCTCATGAAAACCAGCAGAGATTCATATGATGGAGCTGCACATG AATGTAATTTCCAATGTCCAGCATTCTCCTCTGTTCTTTATCTTTAGATTTAAAAATAATGTTTCTATGA ACTTATTAAAATTCTAGAATACTATGAATCTACTGGGTCTTTTCACATCCTTTTGCTACTAGTAGAAAAA AGAATAGTAATAATTTTCAGAGGCTACTGTCCAGTATGTGACATAAATTGTCTCCCATGTTTCTCTGCTC ATGCAATTACTGAGTATGATTTATTTTATTTTAATTTCAGCACCACCTGAGAAAAGCCCTGTGGTCCAGG ATTGCTACCATGGTGATGGACGGAGTTATCGAGGCATATCCTCCACCACTGTCACAGGAAGGACCTGTCA ATCTTGGTCATCTATGATACCACACTGGCATCAGAGGACCCCAGAAAACTACCCAAATGCGTATGTATTT GATTAAAACCATAAGAGGAGCAACAGCCAACTCAAATATTGGTTAGAAGACCCATGCTTTAAGCTCACTT CCTAGGGACAAATTTCTCTTAGACTCACATTTTGGCAAAATGTCTCAGGACCTTTGCTTTTGAGCAAAGA GTCTAAGAGAAGAGAAATTTTAGGCCTGCTATTTTTCCTAATAGTTTTATGGAAGGAGTAGAATATACGG AAGTGGCGAAGTCATATTAATGTAAAGCTCAGAAGATAAATGACCAAAGCTTAAACACAGCACCATTCCA CAATGCCCACTAAAAATCAATGTCATCTTTCACTCGTGCAATTCTGTCATTCTAAATTTCAATTCCCGAA GGTTTGTTTGCCATTTTTGTCATGGGTAATAAGTAAAAAAAAAAAAATTAAGATGTGTATATATATATAT ATATATATATATATACACACACACACACACACACAAACATCTGAATATTTATATATATGTCTGAATATTT ATATACTTGTGTATAAAACTTATATTTAAATTTTTGCATAAATTTATATATTTTTAATATTTCATTAAAA ATTATATTGTTTCACTATGTATGTCTGAGTATTTTTATATATTTTAATATAACATTTTAAATATTTATAT ATAAATATTCAGGTATGTAACTGAATATTCATTTACACACACAAATATATGTGTGCATGTGTGTATATAT ATATATACCCATATATATATATATATATATATATACATATATATATATATATATATATGTATATATATAT ATATATATATATATACACACACACACACACACACATACATACAGGTATAAACACACTGGGCCTGAAGCAC CAGTGGTCTGAAAGGACATGTGTTGCCAGGACTTGAAGAGCAAAAGCAGGAAGGCGGATGAGAGTCAGGA GGTACACAAACGCTGAAAAGTAAAATGGACAAGTACATGGACAAAAAGCAGGTATAAGCATAACAGCCTT TTGGAAGTAAATGACTATAAAATATATGAAAATACTGTTTTCACAAGTTGCACAACAGATAGTAGTGTAT TGAGATAATTTAGAACAGAAAACAAATGTGATCAACCCCATAAGTGTGCTGTATTTCATCATGGATTGAA GGAAAAAGAGATGGAGCCCAAGAAGACCACAGCAGTCTTGATGAACTGAGAGACACCAGAGTTTGGGATT ACAAAGGCAGCTGGGATTTTCTACACTTGGTAATAATGAGAAAGAATTTGTGGAGATAAAGAGCTACAGT CATGTACCTAGAAGTCACCTCAGTGTAATATAAATCTGCATATGCACAGGGAGTGATTCCACAATGAAAG TAGGACAAAGAACAGCTACTGGGGAAAGAATAACTACAAGGGAACAATGAGTTCAATGGAGATGGCAGAG CTCACAAAGCACTGGGGGATATTTGAGTTCTTACCAGCTAGAAAAGAGACCTCATTGCAAATCTTGGGCA TTCAGTAGAGACCCCAGAAAAGCCACTCTTTGGAAACAGAGTTGATGTATTTTAAGAGCAAAATCTACTC CACAAAAATCCTAGCAAAATTGAAAAGCAAGTCAGAAAGACCAAAATCCTCTCAACATAAATTAGTTGCC CATCAGAAGAAAGCTTAACCTCTTCATAGGTAAACAATAAAATCAAATTGCTCAGTTATCTGGCATCCAC AATATGTGACATAAATTTAAAAATTTACTAGACATACAAGAAGCATTTAGTGTGATCCATAACCAGGAGA AAAATCATTCAATACAAATAGACCCAGAAATGACAGAAATGATAGAATTAGCAAAAACATTTAAAATATA CATATGATCATTTGATCTTGTGATCAGATATCACAAGAGAAGAAAGAGATACTTGAACAGAAAAAATGCC TGAAGCAATGATGGCTGAAAACTTTCCAAATATGAAGAAAAAAAAGCTCACAGATTCAAGAAAACTAATC AATCAGAAATATGATTTTGAAAAGTAAAAATGTATGATTTACTTTGGCAAATCTTCTTGGTTAAATTGTC TAAAATCAAAGAAAGCTAGGAAAATTTTATAAGCCAGAGGAAAAAAGATTGTTTATATAAAGGAACAGTT ACACAAATGACTGATGCCTTCTCATCAGAAACAATGAAAGTCAGAAACAATAAAGTAACATCTTTAAAGT AATAGAAGAAAAACCCAAGAGGTGAGGGATCGTGGCAGACAGGAGGCAGGACTAGATTGCAGCTCTGGAC AGAGCAGCATGCAGAGGCTCATATTGTGAATTTTAGCCCCATATTGACTGCAAGAACAGACCAGCAATCC TGAGAGGACCCACAGACCGTGTGAAGGAAGCAGACTGCTCCTGCAGGATAAGGGAGACACCCCAAATACT GTGAGTTCCCCAACTGCAGAAGTGGAAAAGGGAGGCCTTACTCCCTCAAACACACCCCACAACTGGAGAA GCTGAAAGTCTGTTTGCAGGAGAAGTTCCCAACTTTACCTGGGCCTCAGTAAATTTAGAGAGCTGAGCCA AGCAAAATATAGGGGTAGAGGAAGCAGCAGAGAAGACCTCAGAGCTTGCTGGATCCCCAAGCAGCTCATT CCTGCCTGGCACCACAGAGATCCATCAGAAGTGTGGCCAAAGGAACAGAGGGTAAAACTCCACATGGAGG ACTGCTCTACCTGAACTTTCTAACAATTTGAACAGGGGGAGAAGCCTCCTGGCCAGAACTTGGGGGAGGG CATGAATCTGGTTTGCAGACTTCACAGGTGGGGGAAGGACTAAAGCCCTTTTCTTTCACAGCTGGGAGGT GGAAAGCCTCAGGCAAGTTTTCAAGCCTGACTTTCCCCCCACCTGGAAACAGACTTGGAGCTGTTGCGGG GTTGGGGGCATGGTGGGAGTAAGACCAGCCCTTCAGTTTGCATGGGTGCTGGGTGAGGCCTGTGACTGAC AGCTTCCCTCCACTTCCCCGACAACTCAGATGACTCAGCAGAGGCAGCCATAATCCTCCTAGGTACACAA CTCCAGTGACCTGGGAACTTCACCCCCACACCATACAGAAGCTTCAGTAAGACGTGCCCAAGGAAAGTCT GAGCTCAGACACGCCTAGTCCCACCCCCAACTGATGGTCCTTCCCTACCCACCCTGGTAGCAGAAGACAA AGAGCATATAATCTTTGGAGTTCTAGGGCCCACCCACCTCTAGTCCCTCTCCACACTAGTATAGCTGATG CAGGAGGCCAACCAGCACAAAAATAGAGCATTAAACCACCAAAGCTAGGAACCCCTATGGAGTCCATTGC ACCCTCCTCCACCTCCACCAGAACAGGCACTGGTATCCACAGCTGAGAGACCCATAGATGGTTCACATCA CAGGACTCTGTACAGACAGTCCCCAGTACCAGCCCAGAGCTGGGTAGACTTGCTAGGTGGCAAGACCCAG AAGACAGGCAATAATCACTGCAGTTCAGCTCACAGGAAGCCACATCCATAGGAAAAGAGGGAGAGTACTA CATCAAGGGAACACCCCATGGGATAAAAACATCTGAACAACAGCCTTCAGCCCTACCTTCCCTCTGACAC AGTCTACCCAAATGAGAAGGAACCAGAAAACCAACCCTGGTAATATGACAAAACAAGGCTCATCACACTC CCAGTTCACCAGCAATGGATCCAAACCAAGAAGAAATCCCTGATTTACCTGAAAGAGAATTCAGGAGGTT AGTTATTAAGCTAATCAGGGAGGGACCAGAGAAAGGCAAAGCCCAATGCAAGGAAATCCAAAAAAAAAAA GGTATAAGAAGTAAAAGGTGAAATATTCAACAAAATAGATAGCTTAATAAAAAAACAATAAAAAATTCAG TAGACTTTGGACACACCTTTGGAAATGTGACATGCTCTGGAAAGTCTCAGCAATAGAACTGAACAAGTAG AAAAAATAAATTCAGAGCTCAAAGACAAGGACTTCAAATTAACCCAATCCAACAAAGACAAAGAATAAAG GATAAGAAAATATGAACAAAGCCTTCAAGATGTCTGGGATTATGTTAAATGACCAAATATAAGAATAATC GTGGCTCCTGAGGAAAAAGACAATACTAAAAGCTTGGAAAACATATTTGGGGGAATAACTGGGGAAAACT TACCTGGCCTTGCTGGACACCTAGACATGCAAATACAAGAAACACAAAGAACATGTAAATACAAGCAGCA CAAAGAACACCTGGGAAATTCATCACAAAAAGATCTTAGCCTAGGCACATTCTCATCAGGTTATGCAAAG TTAAGACGAAGGCAAGAATCTTAAGAGCTGTGAGACAGAAGCACCAGGTAATGTATAAAGGAAACCCTAT CAGATTAACAGCCAGTTTTTCAGCAGGAACTGTACAAGCTATAAAGGATTGGAGCCCTATCATAGCCTCC TCAAACAAAACAATTATCAGTCAAGAATTTTGTATCCAGCGAAAGTAAGCATCATATATGAAGGAAAGAT ACAGTCGTTTTTGGACAAACAAATGCTAAGAGAATTCACCATTACCAAGTCACCACTAGAAGAACTGCTA AAAGGAGCTCTAAATCTTGAAACAAATCCTAGAAACACATGAAAACAGAATCTCTTTAAAGCATAAATCA CACAGGACCTATAAAACAAAAGTACAAGTTAAAAAACAAAAACAAAAAACAAAACCAAAGTACGGAGGCA ATAAAGAATATGATGAATGCAGTGGCACCTCACATTTCAATGCTAAAATTGAATCTAAATGGCCTAAATG CTCCACTTAAAGGATACAAAAAGAGTTGGTGGCTGGCAAGATGGCTGAATAGGAACAGCTCCAGTCTGCC GCTCCCCGTGAGATCAACACATAGGGTGGGTCATTTCTGCATTTCCAACCAAGGTACCCGGCTCATCTCA TTGGGACTGGTTAGACAGTGGGTGCAGCCCACAGAGGGTGACCTGAAGCAGGGTGGGGTGTCACCTCACC TGGGAAGTGGAAGGGGTCAGGGAACTCCCTCCCCTAGCCAAAGGAAGCCGTGAGGGACTGTGCCGTGAAG ACCAGTGCATTCTGGCACAAATACTATGCTTTTCCCACGGTCTTTGCAACCTGAAGACCAGGAGATTCCC TTGGGTGCCTACACCACCAGGGCCCTGGATTTCAAGCCCAAAACTGGGCTGGCATTTGGGCAGACACTAA GCTAGCTGCAGGAGTTTTTTTTCATACCCCAGTGGTCCCTGGAATGCCAGCAAGACAGAACCATTCACCC CCGTGAAGAAAGGGCTGAAGCCAGGGAGCTAAGTGGTCTTTCTCAGTGGATCCCACCCCCATGGAGCCCA GCAAGCTAAGCTCCACTGGCTTGAAATTCTTGCTGCCAGCACAGCAGTCTGAAGTTGACCTGGGACGCTC AAGCTTGGTGGGAGGAGGGGTATCCACAAATACTGGGGCTTGAGTAGGAGGTTTTCCCCTCACAGTGTAA GCAAAACCGCTAGGAAGTTTGAACTGGGCAGGGTGCACTGCAGCTTGGCAAAGCCATTGTAGCAAGAGTG CCTCTCTAGATTCCTCCTCTCTGGGCAGGGCATCTCTGAAAGAAAGGCAGCAGCCCCAGTCAGAAGCTTA TAGATAAAACTCCCATCTCCCTGGGACAGAGCAACTGGAGGAAGGGGTGGCTGTGAGTGCAGCTCCAGCA GACTTAGTTTCCTGCCTGCCAGCTCTGAAAAGAGCACCAGATCCCCCAACACAGCACTAGAGCTCTGATA AGGGACAGACTGCCTCCTCAAGTGGGTCCTGGTTTCAGAAGATAATAAGAAACTCCTCTGAGCTAAAGGA GCATGTTCTAACACAATGCAAGGAAGCTAAGAACCTTGAAAAAGGTCAGAGGAATTGCTAACTACAGTAA GCAGTTTAGAGAAGAACATAAATGACCTTAGGGAGCTGAAAAACACAGCACGAGAACTTCATGACACATA CACAAGTATCAATAGCAAAATCGATCAAGTGGAAGAAAGGATATCAGAGATTGAAAATCAACTTAATGAA GTAAAGCGTGAAAACAAGATTAAGGAATAAAGAATGAAAAGGAATGAACAAATCCTCCAAGTATGGGACT ATGTGAAAAGATTGAACCTACGTTTGATTGGTGTACCTGAAAGTGATGGGAGAATGGAACCAAGTTGGAA AACACTCTTCAGGATATTATCCAGGAGAACTTCCCCAACCTAGCAAGACAGGCCAACATTCAAATTAAGG AAATACAGAGAATACCACATTCAAATTCAGGAAATACAGAGAACACCACAAAGATACTCCTCAAGAAGAG CAACCTGAAGACACATAATCGTCAGATTCACCAAGGTTGAAATGAAGGAAAAAAATGTTGAGGGCAGCCA GAGAGAAAGTTTGGGTTACCCACAAAGGGAACCCCATCAGACTAACAGTGGATCTTCCTGCAGAAACTCT ACAAGCCAGAAGAGAGTGGGAGGCCAATATTCAACATTCTTTTTTACTATTATTATACTTTAAGTTCTAG GGTACATGTGCACAAGGTGCAGGTTTGTTACATATGTATACATGTGCCATGTTGGTGTGCTGCACCCATT AACTCTTCATTTACATTAGGTATATCTCCTAATACTATCCCTCCCCACTCCCCCCATCCCATGACAGGCC CCGGTGTGTGATGTTCCCCACTCTGTGTCCATGTACTCTCATTGTTCAATTCCCACCTATGAGTGAGAAC ATTCGGTGTTTGGATTTCTGTCCTTGTGATAGTTTGCTGAGAATGATGGTTTCCAGCTTCATCCACATCC CTACAAAGGACATGAAGTCATCCTTCTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCACATTTT CTTAATCCAGTCTACCATTGATGGACGTTTGTGTTGGTTCCAAGTCTTTGCTATTGTGAATAGTGCCGCA ATAAACATATGTGTGCATGTGTCTTTATAGCAGCATGATTTATAATCCTTTAGATATATATCCAGTAATT GTATGGCTGTGTCAAATGGTATTTCTAGTTCTAAATCCTTGAGGAATCACCGCACTGTCTTCCACAATGG TTGAACTAGTTTACAGTCCCACCACCAGTGTAAAAATGTTCCTATTTCTCCACATCCTCTCTAGCATCTG TTGTTTCCTGACTTTTTAATGATCACCATTCTAACTGGTATGAGATGGTATCTCATTGTGGTTTTGATTT GCATTTCTCTGATGGCCAGTGATGGTGAGCACTTTTTCATGTGTCTCTTGACTGCATAAAAGTTTTCTTT TGAGAATTGTCTGTTAATATCCTTTGCCAACTTTTTGATGGGGTTGTTTGATTTTTTTTCTTGTAAATTT GTTTATGTTCTTTGTAGATTCTGGATATTAGCCCTTTGTCAGATGGGTAGATTGTAAAAATTTTCTCCCA TTCTGTAGCTTGCCTGTTCATTCTGAGGGTAGTTTCTTTTGCTGTGCAGAAGCTCTTTAGTTTAATTAGA TCCCATTGGTCAATTTTGGCTTTTGTTGCTATTGCTTTTGGTGATTTAGTCATGAAGTCCTTGCCCATGC CTATGTCCTGAATGGTATTGCTTAGGTTTTCTTCTAGGGTTTATATGGTTTTAGGTCTAACATTTAAGTC TTTAATCCATCTTGAATTAATTTTTATATAAGGTGTAAGGAAGGGATCCAGTTTCAGCTTTCTACATATG GCTAGGCAGTTTTCCCAGCACCATGTATTAAATAGGGAAACCTTTCCCTATTTCTTGTTTTTGTCAGGTT TGTCATAGATCAGATGGTTGTAGATGTGTGGTATTATTTCTGAGGGCTCTGTTCTGTTCCATTGGTCTAT ATCTCTGTTTTGGTACCAGTACCATGCTGTTTTGGTTACTGTAGCCTTGTAATGTAGTTTGAAGTCAGGC AGAGTGATGCCTCCAGCTTTGCTTTTTTGGCTTAGGATTGTCTTGGCAATGCATGCTCTTTTTTGTTCCA TATGAACTTTAAAGTAGTTTTTTCCAATTCTGTGAAGAAAGTCATTGGTAGCTTGATGGGGATGGCATTG AATCTATAAATTACCTTAGGCAGTATGGCCATTTTCACAATATTGATTCTTCCTATCCATGAGCATGGAA TGTTCTTCCATTTGTTTGTGTCCTCTTTTATTTCATTAAGCAGTGGTTTGTAGTTCTCCTTGAAGAGGTC CTTCCCATCCCTTGTAAGTTGGATTCCTAGGTATTTTATTCTCTTTGAAGCAATTGTGAATGGGAGTTCA TCCATGTCCCTACAAAGGACATGAAGTCATGTATGGGAATGCTTGTGATTTTTGCACATTGATTTTGTAT CTTGAGACTTTGCTGAAGTTGCTTATCAGCTTAAGGAGATTTTGGTCTGAGAAGATGGGGTTTTCTAAAT ATACAATCATGTCATCTGCAAACAGGGACAATTTAACTTCCTCTTTTCCTAACTGAATACCCTTTATTTC CTTCTCCTGCCTAATTGCCCTGGCCAGAACTTCCAACACTATGTTGAATAGGAGTGGTGAGAGAGGGCAT CCCTGTCTTGTGCCAGTTTTCAAAGGGAATGCTTCCAGTTTTTGCCCATTCAGTATGATATTGGCTATGG GTTTGTCATAAATAGCTCTTATTATTTTGAGATATGTCCCATCAATACATAGTTTATTGAGAGTTCAGCA TGGAGAGCTGTTGAATTTTGTCAAAGGCCTTTTCTGCATCTATTGAGATAATCATGTGGTTTTTGTCTTT GGTTCTGTTTATATGATGGATTACATTTATTGATTTGCATATGTTGAACCAGCCTTGCATCCCAGGGATA AAGCCAACTTGATCATGGTGGATAAGCTTTTTGATGTGCTGCTGGATTCGGTTTGCCAGTATTTTATTGA GGATTTTTGCATCAATGTTCATCATGGATGTTGGTCTAAAATTCTCATTTTTGTTGTGTCTCTGCCAGGA TTTGGTATCAGGATGATGCTGGCCTCATAAAATGAGTTAGGGAGGATTCCCTCTTTTTCTATGATTGGAA TAGTTTCAGAAGAATTGGTACCAGCTCCTCTTTGTATCTGTGGTAGAATTCGGCTATGAATCTCTCCTGG ACTTTTTTTGGTTGGTAGGCTCTTAATTATTGCCTCAATTTCAGAGCCTGTTATTGGTCTATTCAAGGAT TCAATTTCTTTCTGGTTTAGTCTTGGTAGGGTGTATGTGTCCAGGAATTTTTCCATTTCTTCTAGATTTT CTAGTTTATTTGCACAGAGGTGTTTATAATATTCTCTGATGGTAGTTTGTATTTCTGTGGGATTGGTAGT GATATCCCCTTTATCATTTTTTATTGCATCTATTTGATTCTTCTCTCTTTTCTTCTTTATTAGTCTTGCT AGTGGTCTATCAATTTTGTTGATCTTTTCAAAAAACCAGCTCCTGGATTCATTGATGTTTTGAAGGTTTT TTTGTGTCTCTATCTCCTTCAGTTCTGCTCTGGTCTTAGTTATTTCTTGCCTTCTGCTAGCTTTTTAATG TGTTTGCTCTTGCTTCTCTAGTTCTTTTAATGGTGATGTTAGGGTGTCAATTTTAGATCTTTCCTGCTTT CTCTTGTGGGCATTTAGTGCTGTAAATCTCCCCCTACACACTGCTTTAAATGTGTCCCAGAGATTCTGGT ATGTTGTGTCTTTGTTGTCATTGGTTTCAAAGAATATCTTTATTTCTGCCTTCATTTCGTTACATACCCA GTAGTCACTCAGGTGCAGGTTGTTCAGTTTCCATATAGTTGAGCAGTTTTTAATGAGTTTCTTAATCCTG AGTCCTAGTTTGATTGCACTGTGGTCTGAGAGACAGTTTGTTATAATTTCTGTTCTTTTACATTTGCTGA GGAATGCCTCACTTCCAACTATCTGGTCAATTTCAGAATAAGTGCGATGTGGTGCTGAGAAGAATGTATA TTCTGTTGATTTGGGGTGGAGAGTTCTGTAGATGTCTATTAGGTCTGCTTGGTGCAGAGCTGAGTTCAAT TCCTGGATATCCATGTTAACTTTCTGTCTCATTGATCTGTCTAATGTTGACAGTGGGGTGTTAAAGTCTC CCATTATTATTGTGTGGGAGTCTAAGTCTCTTTGTAGGTCTCTAAGGACTTGCTTTATGAATCTAGGTGC TCCTGTATTGGGTGCATATATATTTAGGATAGTTAGCTCTTCTTGTTAAATTGGTCCCTTTACCATTATG TAATGGCCTTCTTTGTCTCTTTTGATCTTTGTTAGTTTAAAGTCTGTTTTATCAGAGACTAGGATTGCAA CCCCTGCTTTTTTTGTTGTTTTCCATTTGCTTGGTAGATCTTCCTCCATCCCTTTATTTTGAGCCTATGT GTGTCTCTGCACGTGAGATGTGTCTTCAGAATACAGCACACTGATGGATCTTGACTCTTTATCCAATTTT CCAGTCTGTGTCTTTTAATTGGAGCATTTAGCCCATTTACATTTAAGGTTAATATTTTTATGTGTGAATT TGATCCTGTCATCATGATGTTCGCTGGTTATTTTGCTCATTAGTTGATGCAGTTTCTTCCTAGCATCGAT GGTTTTTACAATTTGGCATGTTTGTGCAGTGGCTGATACCGATTGTTTCTTTCCATGTTTAGTGCTTCCT TCAGGAGCTCTTGTAAGGCAGGCCTGGTGGTGACAAAATCTCTCAGCATTTGCTTGTCTGTAAAGGATTT TATTTCTCCTTCACTTATGAAGCTTAGTTTGGCTGGATATGATATTCTCAGTTGAAAATTCTTTTCTTTA AGAATGTTGAATATTGGCTGCCACTCTCTTCTGGCTTGTAGAGTTTCTGCTGAGAGATCTGCTGTTAGTC TGATGGGCTTCCCTTTGTGGGTAACCCGACCTTTCTGGTGAATCTGACAATTATGTGTCTTGGAGTTACT CTTCTCGAGGAGTATTTTTGTGGCATTCTCTGTATTTCCTGAATTTGAATGTTGGCCTGCCTTTGTAGGT TGGGGAAGTTCTCCTGGATAATATCCTGAAGAGTGTTTTCCAACTTGGTTCCATTCTCCTCGTCACTTTC AGGTACACCAAGCAGATGTAGATTTGGTCTTTTCACATAGTCCCATATTTATTGGAGGCTTTGTTCATTT CTTTTTACTCCTTTTTTTCTCTAAACTTCTCTTCTCGCTTCATTTCATTCATTTGATCTTTAATCACTGA TACCCTTTCTTCCACTTGATTGAATCAACTACTGAAACTTGTTCATGTGTCACGTAGTTCTCGTGCCATG GTTTTCAGCTCCATTAGATCATTTAAGGTCTTCTCTATGCTGTTTATTTTAGTCTGCCATTCATCTAAAC TTTTTCAAGGTTTTTAGCTTCTTTGCAATGGGTTCGAACATCCTTCTTTAGCTCGGAGAAATTTGTTATT ACAGATCGTCTGAAGCCTTCTTCTCTCAACTCATCAAAGTCATTCTCTGTCCAGCTTTGTTCTGTTGCTC GTGAGGAGCTGCGTTCCTTCGGAGGAGAAGAGGCACCCTGATTTTTAGAATTTTCAGCTGTTCTGCTCTG GTTTCTCCCCATCTTTGTGGTTTATCTACCTTTGGTTCTTGATGATGGTGATGTACAGATGGGGTTTTGG TGTGGATGTCTTTTCTGTTTGTTAGTTTTCCTTCTAACAGTCAGGACCCTCAGCTGCAGGTCTGTTGGAG TTTGCTGGAGGTCCACTCCAGTCCCTGTTTGCCTGGGTATTACCAGTGGAGGCTGCAGAACAGCAAATAT TACAGAACAGCAAATGTTGCTGCCTGATTCTTCCTCTGGAAGCTTCATCTCAGAGGGGCACCCAGCTGTA TGAGGTGTCAGTTGGCCCCTACTGGGAGGTGTCCCCCAGTTAGGCTACTCGGGGGTCACGGACCCACTTG AGGAGGCAGTCTGTCCATTCTCAGATCTCAAACTCTCTGCTGGGAGAACCACTACTCTCTTCAAAGCTGT CAGACAGGGATGTTTAAGTCTGCAGAAGTTTCTGCTGCCTTTTGTTCAGCTATGCCCTGCCCCCAGAGGT GGAGTCTACAGAGGCAGGCAGGTCTCCTTGAGCTGTGGTGGGCTCCACCCAGTTTGAGCTTCCTGGTCGC TTTGTTTACCTACTCAAGTCTCAGCAATGGCAGACGCCCCTCCCCCAGCTTTGCTGCCGCCTTGCAGTTC GGTCTCAGACTACTGTGCTAGCAGTTCAATCTCAGACTGCTGTACTAGCAGTGAGCAAGGCTCTGTGGGC ATGGGACCCTCTGAGCCATGTGCAGGATATAATCTCCTGGTGTGCCGTTTGCTAAGACCATTGGAAAAGT GCAATATTAGGGTGGGAGTGTCCCGATTTTCCGGGTACATCTGTCATGGCTTCCCTTGGCTAGGAAAGGG AATTCCCTGACCCCTTACACTTCCCGGGTGAGGCAATATCCCGCCTTGCTTCGGCTCACTCTCCGTGGGC TGCACCCACTGTCTGACAAGCCCCGGTGAGATGAACCCAGTACCTCAGCTGGAAATGCAGAAACCACCCA TCTTCTGCTTTGCTCATGCTGGGAACTGTGGACTGGAGCTGTTCCTATTCGGCCATCTTGAAACCTCCCC TCTCTCACGATCACAAGGTCCCACAATAGGCCGTCTGCAGGCTGAGGAGCAAGAAAAGCCAGTCTGAATT CCAAAACTGAAGAAATTGGAGTCTGATGTTCAAGGGCAGGAAACATCCAGTGCCAAAGAAAGATGTAGAA TATTCAACATTCTTAAAGAAAATAATTTTCAACCTAGAATTTCATATCCAGCCAAACTAAGCTTTATAAC AAAGGAGAAGTAAAATCCTTTACAAACAAGCAAATGCTGAGGAATTTTGTCAACACCAGGCCTGCCTTAC AAGAGGTCCTGAAGAAAACACTAAATATGGAAAGGAAAAACCAGTAACAGCTACTGCAAAAACATACCAA ATTGTAAACACCATCAACACTATAAAGAAACTGCATCAACTAATGGGCAAAATAGCCAGCTAGCATCATA ATGACAGGATCAAATTCACACATAACAATATTAACCTTAAATGTAAATGGGCTAAATGCCCCAATTAAAA GACACAGACTGGGAAATTGAATAAAGAGTCAAGACCCATTGGTTTGCTGTGTTCAGAAGACCCATCTCAG GGTGAAAAGACATACATGGGCTCAAAATAAAGAAATGAAGGAATATTTACCAAGCAAATGGAAAGAAAAA AAAAGCAGCGGTTGCAATCTTAGTCTTTGATGAAACAGACTTTAAACCATCAAAGATCAAAAGAGACAAA GGAGGGCATTACCTAATGGTAAAAGTATCAATGCAACAAGAAGATCTGACTGTCCTACTTATATATGCAC CCAATACAGGAGCACCCAGATTAATAAAGCAAGTTCTTAGAGACCTACAAAGAGACTTAGACTTCCACAC AAAAATAGTGGGAGACTTTAACACCCCACAGCCAATATTAGATCGACGTGACAGAAAATTAACAAGGATA TTCAGGACGTGAATTCAGCTCTGGACCAAGCTGACCTAATAGACATCTACAGAACTCGACACCACAAATC AACAGAATATACATTCTTCTCAGCACCACATTGCACTTATTCTAAAATTGACCACATAATTGGAAGTAAA ACACTTCTCAGCAAATGCCGTAGAATGGAAATCATAACAAACAGTCTCTCAGACCAAAGTGCAATCAAAC TAGAACTCAGGATTAATAAACTCACTCAAAACCACACAACTATATGGAAACTGAACAACCTGCTCCTGAA TTACTACTGGGTAAATAACAAAATTAAGGCAGAAGTAGATAAGTTCTTAGAAACCAAAGAGAACAAAGAC ACAATGTGCCAGAATCTCTGGTACACAGCTAAAGCCATGTTTAGAGGGAAATTTATAGCACTAAATGCCC ACAGGAGAAAGCGGGAAAGATCTAAAATCAACACCCTAACATCACAATTCAAAGAACCAGAGAAGCAAGA GCAAACAAATACAAAAGCTAGCAGAAGACAAGAAATAACTAAGATCAGAGCAGAACTGAAGGGGATAAAG ACACGAAAACCCTTTAAAAAATTAATAAATCCAAGAGCTGGTTTTTTGAAAAGATTAACAAAATACATAG AAGCCTAGCCAGACTAATAAAGAAGAAAATAGAGAAGAATCAAATAGACACAATAAAGAATAATAAAGGG GATATCACCAATGATGCCACAGAAATACAAACTACCATCAGAGAATACTTTAAACACCTCTATGCAAATA AAATAGAAAATCTAAAAGAAATGGATAAATTCCTGGACACATACACCCTCCCAAGACTAAACCAGGAAGA AGTCAAATCCCTGAATAGACCAATAACAAGTTCTGAAATCGAGGCAGTAATTAATAGCTTACCAACCAAA AAAAGCCCAGACCAGAGGGATTAACAGTCAAATCCTAACAGAGGTACAAAGAAGAGCTAGTACTATTCCT TCTGAAACTATTCCACACAATAGAAAAAGAGGGACTCCTGCCTAACTCATTTTATGAGGCCAGCATCATT CTGATACCAAAACCTGGCAGAGACACAACAAGAAAAGAAAATTTCAGGCCAACATCCCTGATGAACATCA ATGTGAAAATCCTCAATAAAATACTGGCAAACTGAATCCAGCAGCACATCAAAAAGCTTATCCACCATGA TCAAGTTGGCTTCATCCCTGGGATGCAAGGCTGGTTCAACATATTCAAATCAATAAACATAATCCATCAC ATAAACAGAACCAATGACAAAAACCGTATGATTATCGCAATAGACGCAGAAAAGGCCTTTGATAAAATTC AATACCCAATCATGCTAAAAACTCTTAATAAACTAGGTATTGATGGAGCATGTCTCAAAATAATAAGAGC TACTTATGACAAATGCATAGCCAATATCATACTGAATGAGCAGAAGCTGGAAGCATTCCCTTTGAAAACC AGCACAAGACAAGGATGCCCTCTCTCACCACTCCTATTCAACATAGTATTGGAAATTCTGTCCAGGGCAA TCAGGCAAGAGAAAGAAATAAAGGTATTCAAGTGGGAAGAGAGGGAGTCAAATTATTTCTCTTTGCAGAT GACATGATTGTATATTTAGAAAACTCTATCATCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAACTTCA GCAAAGTCTCAGGATACAAAATCAATGTGCAAAAATCACAAGCATTCCTATACACCAATAAGAGACACAG AGCCAAATCCTGAGTGAATTCCCATTCACAATTGCTACAAAGAGAATAAAATATACCTAGGAATCCAACT TACAAGGGATGTGAAGGACCTCTTCAAGGAGAACTACAAACCACTGCTCAAGGAAATAAGATAGGACACA AACAAATGGAAAAACATTCCATGCTAATGGATTGGAAGAATCAATATTGTGAAAATTGCCATACTGCCCA AAGTGATTTATAGATTCAATGTTATCCCCATCAAGCTACCATTGATTTCTTCACATAATTAGAAAAAACT ACTTTCAATTTCATATGGAATAGAAAAAGGGCCTGTATATCCAAGACAACCTAAGCAAAAAGAACAAAGC TGGAGGCATCATGCTATCTGACTTCAAAATATACTACAAGGCTACAGTAACAAAAACAGCATGGTATGGT ACTGGTACCAAAACAGATATATAGACCAATAGAACAGAACAGAGGCCTCAGAAATAACACCACACATCTA CAACTATTGGATCTTTGACAAACTGGACAAAAATAAGCAATGGGGAAAGGATTCCCTATTTAATAAATGG TGTTGGGAAAACTGGCTAGCCATATGCAGAAAACTGAAACTGGATCCCTTCCTTACACCTTATACACAAA TTAACTCAAGATAGATTAAAGAATTAAATGTAAGACCTAAAACCATAAAAACCCTAGAAGACACTTTGGG AGGCCGAGGTGGATGGATCACGAGGTCAGGAGATCGAGACCATCTTGGCTAACACAGTGAAAGCCCATCT CTACTAAAAATACAAAAAATTAGCTGGGTGTGGTCGTGGGCACCTGTAGTCCCAGCTACTTGGGAGGCTG AGGCAGGAGAATGGCATGAGCTGAGGAGGTTGAGCTTGCAGCAAGCCAAGATTGTGCCACTGCACTCCAG CCTGGGCAACAGAGTGAGACTCCATCAAAAAAACAAAAACAAAAACAAAAAATCAAACCCTAGAAGAAAA CATAGGCAATACCATTCAGGACATAGGCATGGGAGAAGACTTCATGACTAAAACAGCAAAACCAATGGCA ACAAAAGCCAAAATTTACAAATCAGATCTAATTAAAATAAAGAGCTTCTGCACAGCAAAAAACTCTCATC AGAGTGAAAAAGCAACCTATGGAGAAAAATTCTGTGGTCTAGCCATCTGACAAAGGGCTAATGTTTAGAA TGTACAAGCAACTTAAACAAATGTACAAGAAAAAAAAAACAACCCCATCAAAAAGTGGGCAAAGGATATG AACAGACACTTCTGACAGGAAGACCTTTATGTGGCTGACAAACATGAAAAAAGCTCATCATCACTGTTAA TTAGAGAAATGCAAATCGAAACCACAATGAGATACCATCTCATGCCCGTTAGAATGGCGATCATTAAAAA GTCAGGAAACAACAGATGCTGAAGAGGATGTGTGGAGAAAGAGGAACACATTTACACTGTTGGTGGGAGT GTAAATTAGTTCAACCATTGTGGAAGACAGTGCGGTGATTCCTCAAGGATCTAGAACCAGAAGTACCATT TGACCCAGCAATCCCATTACTGGGTATATACCCAAAGGATTATAAATCATTCTACAATAAAGACACATGC ACACGTATGTTTATTGTAGCACTATTCACAATAGCAAAGACTTGGAACCAACTGAAATGCCCATCAATGA TAGACTGGATAAAGAAAATGTGGCACATATACACTGTGGAATACTATGCAGCCATAAAACAGGATGAGTT CATGTCTTTTGCAGGGACATGGATGAAGCTGGAAACCATCATTCTCAGCAAACTAACACAAGAACAGAAA ACCAAACACCATATGTTCTCACTCATAAGTGTGAGTTGAACAATGAGAACACATGGACACAGGAAGGGGA ACATCACACACAGGGGCCTGTTGGGGAGTTGAGGCTAGGGGAGGGATTGGATTAGGAGAAATACCTAATG TAGATGATGGGTTGCTGGGTGCAGCAAACCACCATGACACGTGTATACCTATGTAACAAACCCACACATT CTACACATGTATCTCAGAACTTAAAGTATAATAATAATAAGATACAGAACTGCAGAATGAATAAGAACTC ACCAACCATCTGCTGCCTTCAGGAGACTCATTTAAGACATAAGGACTCACATAAACTTAAAGTAAATGGG TGGAAATAATAATAAGTGGTGTCACTGATGTGGAGGTAGATTATAAAACTCTTATCATATGCTGGTGGAA GATCAAAATGATAAAACGAATTAAAAAATCAGTCAGATGGTTTCTTAAAAAGTTCCATCAATATGCCTCT ATCTTACAAACCTGCAATTCTATTCCTGAATCTTTATCCCAAGGAAATGAAAAAGTAAGTCCACAAAGAG TTCTATATGAATATTTATAGGAGCTTTATTTATTATAATTCAAACTGTAAAAATAATTTCAATGTTCATC AATAACAAAATGAAAAAATAATTTGCAACCTACTGGTACACTTGAATACTATTCAGCACTGAGTATCTTA AATAGCATGGATGGAGCTCAAAAATATACTCAGGAAAGAAGCCATGTATATTCTGTATGAGTTCATTTAC ATGAGATCATTTACATTTCCTCCAAAAGAGGAAAAACTAATTTCTGTTGAAAGAAACCAATGTATTTGCC TCTGGCAGTGGTAAGGGGGTAGCACAGATTAATTGGGTAGGGACTCAAGAGAGTTTCTGGGGTCACAGAA ATGTTCCGTGTGGTGATGGGAGTTTGGGCTCCACAGGTATAGGTGTTGATCCAAAATCATCAAAAAAACA ACATTGCAGATCTGTGCATCTCACTCTGTGGGAAAGTATATCTCAACTGTAAAAAGGGCAGAAATTGCTT TTAAACGCTCAGCCTTTTAGCACATCCAGTTGCTTGGAGAACCAGCTTACTCAAATGGGGGTCTAGGCTG GAGACTAGGTCACAGGCATAGAGTCTCTAAACTTTCCCATGGCACATAATACGTTTCAGGTTTTCTCAGA GAGCTGCAGGTTAGTAATCTGAGGATTCTGACAAGTTGGGTCAACGTTCCTAGGAGGCATGAATGGGAGT GCATTCTCTAAGATCCCTCCACCCCAGGGTCCTTGCTTTCTGTGCCTCTTACTCCATTGTTTTCTGACTC CTCTGTAGCCACTCGACCTCTTCAGATCCCATTGTCTACCCAGCCATCGCCCTTTATGACTTGGGTCCCA CTGTTCTTTCATCTCATCCTCCATTCCCTCAGTTTCGGAGTGGCTGCCGCTAGCAGAGGATGGACTGAGA GCAGGAGAGGTGGTCCTGCCCAGGAACCCATCCTAGAGAAATGGCATCCTGTCTGGGAGCTAGTTTTTTA GGGCAGGTTTTATAAGTCTTGTAAAGCCAGACACACTTGATCTACCTGGTATGTTATTTACAGTAATACT ATTTTCATAATTGCTTTTCACTCTAAAAGTAGAGCCTTTTAGCTACACTGTGAGTAAATAAAGGGGCTGG CCTGGGAATGGTATCATGTTGGATGTTGTTTCTTCCCTGAAGTAATATATATCAGTTACAATTTACATGT TACTGCAGAGTCCTAGAGAGAGACACAGAGAATGAGACAGATACCAATACATTTTTATGTGCATTAAAAA AATCTAAGGCCAGGCGCAGTGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCA CGAGGTCAGGAGATTGAGACCATCCTGGCTAACACGGTGAAACCCTGTCTCTACTAAAAATACAAAAAAT TAGCCAGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCAGGAGACTGAGGCAGGAGAATGGCTTGAA CCCAGGAGGCAGACCTTGCAGTGAGCCGAGATTGCGCCACTGCACTCCAGTCTGGGCGACAGAGCGAGAC TCCGTCACAAAAAAAAAAAAAAATCTAAAATGCACTCTTCAAAATCTATGTCATTTATTCTGGAGGAATG CAGTTGGCAGAAGGAGGAAGATATTCCGAATTTTTCTTGTATACATTTATGTATGATCTCAGTTTTTTTA TGGATCATAGACCAATTTTGATATTTTAAAATAAAAATTATAATCTATCTTGGAAATTTACATGGTTCTT TAGAACTTGAGGACCGTTTTTGCTTTTCGGAATATTATTGTACCTAAAATGGGAATATTACAACGTCACT TTTTAACACTTTGTTATAACAAAGTTTAGACAGCGCTGGGTGCCCCTGAATTTTTTCCCGCCTCTTGTGA CCTGTGTTGTTTTGGAATTTGCAGTGGCCTGACCGAGAACTACTGCAGGAATCCAGATTCTGGGAAACAA CCCTGGTGTTACACAACCGATCCGTGTGTGAGGTGGGAGTACTGCAATCTGACACAATGCTCAGAAACAG AATCAGGTGTCCTAGAGACTCCCACTGTTGTTCCAGTTCCAAGCATGGAGGCTCATTCTGAAGCAGGTAA GAAGTCTGTGGCCAGATATCTACACATTTGAACATTGGGATGAAAAGAGATGGAAAATCTGACTGATGCA GAAGCCTTCCATGCTACACAGAAACTTGAGGGTATGGCAGGTGGAAAGAAGCCTCAGCACTCTCTCTGGT GGAGCAATTTTTGGCGCAACGTGCGTGGGCGGTGACTTCAGGAATGGTGCAAACCCACCTGGGCACTTGA CTTACCACTCACTTTGTTATGAAAGGGGTTATCTCGGTGTTCCAGACAAAATTCCAATTCTAACATCAGG CCAAATTTGTGCCAAATTTCACACTAGTGAGTGTTTCCAGGCATTTATTAAAATGGACAGTGTTCATTGC AATCTTCAGCATTGCAGTTGCTGAGGTATGTGGCCGCTGAGTTTGTCATCCTGGGGAAACCTAATATGAT GATATTTATTCCATCTAATCCTGGGGCTATTTGGCAGTAAATACCACAGAATACACTATTTCTCTGGCTT ATTTCAGTCTTAGGTAGGCTCTGCACACCTATGCTTGGAAGGCAGGAATTTCTTGGTGTTCTTGTGCCTT CTTCTCATGGAACGTGCATCTTTGGTGTGTGTTGAGAGGAAGGGTAGTAGACTTCTGCTTTGTTGCAATG CAGGATGCTGGAACAAGAGGATTCCCTGTCTCTACTGTAAGGGAATAAGATTTTAGCCTCCATCCTTCTC TAAGAAGCAATGTGTCTTTGCCTCCAAGTACTAGATGCAGGACCATGAACTGCCCCGTCCACCAGAAGCT TAAGGCTTTGGCTTTTCAGGAGCAATCATCTAGGGAACTGTGCAGGGTTTTCATGTCTGTCCCCTACTGA CAGCCAATCACCATACAGCCTGCATAACCTAATCCATCATCGTCTGGTTTCCTGCCTCATTGTTTTCATG AACAACCAGTAGAGAGCCATACGAAAGAGCTTGCACATGAGTCTTTGTTCCAATTGTAAGAGCACTGATA GGTCCTTTTCCCACCAGGTTTTGAATATAAAATTTCTAAGAACTTATTAAAATATTAGAATGTTATTAAT CTATTGTTTTTGCTTCAGCATGTCCTTCTGCTTGTGAGTATACTAAAGAGAACAGTCATAATTCTGAAAC TACTGTCCTGTTTGTGTCATAAATTGCTTCACATGTTTCTGCATACTAGTAGTTACTCAGCTTGATTTTG TCTATTTTCAGCACCAACTGAGCAAACCCCTGTGGTCCGGCAGTGCTACCATGGTAATGGCCAGAGTTAT CGAGGCACATTCTCCACCACTGTCACAGGAAGGACATGTCAATCTTGGTCATCCATGACACCACACCGGC ATCAGAGGACCCCAGAAAACTACCCAAATGAGTATGTCTTTGATGTTACTTGTAAGAGGAGCAACAGCCA ACTTAAGTTCCTCCTAGAAGAGCCTTGCTTCAAGCTAACTTGTTAGGACAAATTTCCCTTAGACCCAGAA GGTGTGTCAAAATGTCCAGACAACTTTGCTTTTGATCAAAGAGTCTGAGAGAATAGGTATTTTAGGCTTG CTATCTTTTCTAATAGTCTGATGGAAGCAGAAGGCTACATGGAGCTGATGAGGTCTTTTTAATATAAAGC TCAAGAGATCAAATGATCAAATACTTAGAGTGCCATTCTACAAGGCTCATAAAAGATCAATGCACTCTTT CACCCATGCAATTCTATCATTCTAACCTCCCTTCTCTGAAATGAAGGCTTTTTGCCATTTTTGTCATGGG TCACAAGTAAATAATTCACATGTATATGAGTATATATATAACCAGGTGTGTTTATTCAGACTAGTATGTA TATATATACATATATATGTTCATATAAGTTAGTATTCATATATATGTTCATATATATATGTTCATACAGA CTAGTATTCATATATATATACATATATATATACACACACATATATATATATATATATATGTTCTAGGGAA ACATGCAAGGTTTTTATGTCTGTCCCTGACTGATGACCAAATACCCTATAGCCTGCACAGCTGCAAGCTG TATAGCCATACAATTTGCAGGACACACACACATACACACACACACACACACACACACACACTAACATATA ATATAATATAATATAATATAATATAATATAATATAATATAATATAATTAATATATATAAACCTGTGTGAA CACACTGGGTTCTAAGCTCCAGTTTTCTGAAGGGATATGGGTTGCCAGGAGAGGAAGAGCAAAAGCAAGA ATGTAGATGAGAATTAGGAAGTAAACAGATATGGAGATTAAAATGGGCAGGTACATGGACAAAAAACCAG GTCTGACAAAAACTGGCTTTCTGCCATAAATGACTATAAAAGATATTAAAAAACACTTTCCACATGTTGG ACAAGAGACAGTACAGGACTGAGATAATTTAGAAAAGGAAATGAATGAGCGCAACTCCGTAACTATTATG ACTTTCTTCCTGGAGAACCTTCCTGGACTGAAGGGCAAGGAATTGGAGCCAAAGCCAACCACAGCAGTCT TGCTGAACTGAGGAAAGAGACTGGAGTTTGGGATAGCTAAGAAAATGTGTATTTTCTATGCTAGGTAATA ATGAGAAAGAATTTGTGGTGAAAAGGAGCTGAAGGAATATGCATGGAAGTCTAATATAAACTGCATATGC ACAGGGAGAAATTCTACAAAGTGGGACAGAGAACCACTACTGGGGAAAGGACAAATTCAGGGAAACAGTG AGCTCAATGGTGACGCCAGAGCTCACGTAGCACTGGGGGATACCGGGGTTCTGATCAGCCCGAGGAGAGA CACCTCATTGAACATCTCGGGCATTCAGTAGAGACCCCAGAAAAGTCATACTTTAGGAGTAGGATTTATG CCTTCTTAGAATAAAGACTACCCCAGAAACACCCTAGTAAAGCTTAAAAACCAAGTCTAAAAGGACCCAA ATGATCTCCAAGTAAATTAACTGCCTGACAGAAGAAAACTCAACCATCACTGGAGGTAAATAACATGATT ACAGTGCTCTGTAATGTTGCATTCACAAGGAGTGACATCATTTAAAAATTTATGAGGCAGGAAAAAGCAA TTAGTGTGATCCATAACTAGGAGAAAAACCAGTCAATACAAATAGACCAAGAAATAGTAGAAACGATGGA ATTGACAAAGAAATTAAAACTGTATATATGATAATTGTGTTCAAAGATTTAAAGAAAACATGAACATGAG GGAAACAAATGCAGAATATAAAAAAAAGCAAATGCGTAAAACAACCAAATGGAAATTAAAGAACTACAAA AAAGTATAACCTTAATAAAATACTCACTGGATGGCCTTAATATTAGTTTATACATTACAGAAGAAAAAGT GAACCAGAAGATAACTCAATGAAAGCCATACAATCTGTAAGACACACACACACGCACACGCGCGCGCGCG CACACACACACACACACAGAGAGAGAGAGAGAGAGAAAGAGAGAGAGAGAAAGGCTGAAAAAAATAAATA GAACCTTAAGGATATCAGTGAAAATAGCAAAAGATTTAATATATGGGTAAAGCAAGTCACAGAAGGACGG GAAGGAGATATTGGGACAGAAAAAAATACTCAAAGCAATGATGGCTGAAGACTTTACACGTATGAAGAAA ATGATAAACTCACAGTCAAGAAGCTCAATGAATCAGAAATAGTATTTTTAAAAGCAAAACTCTATGATTT ACTTGGGTACATTATAGATAAATCGTCCAACATCAAAGATAACAAGGATAATCTTATAAGCCAGAGGAAA ACAATATCATTTACATAGAGGGACAGTAATGAAAGTGACCGATGCCTTCTCCTTGGAAACAATGGCATAA CATCTTTAAAGTGATAAAGAGAAATAAAAACAGATCAACCTAGGACGACATGTCCAGCCAAAACAAACAA ATAAACAAAAAAACCCTTTAAAATAAACGTGATGTAAATACGTATTCTGCCACCTCCAGAGGAAACAAGC AAAAAAACAAAAGAATGTTTCCAAGGCAGGCTTCTGTATTAAAAGATTTTAAGGAAAGTTATTCAGGTAG AAGAAAAATAATACCAGATGGGAACTTTAATCCATACTAAGTAATGAAGAGCCCTGGAAATGGCAAATGG CAATGTCAATATAAAATACTCTTATTTATCTAATTTTTAAATGTATTTAAAGGACAATTTGTGATATTAA TTAAAATAATAGGAATATATTGTTGTTTCAACGTATGTAGTAGTAAAATTCATAAAAACAGTAGCACAAA TAATGCAGATGATAACTGGAAGTATACTGTTAATGAGTTTTTTGCATTATCCATGAAGTTATATAATATT AATAGATGGTTGAATGTGATAGTTTAAGGTGGGATATTATAAATCCTAGGACAACCAAAAAAATTTAAAC TGAGAGGAATGGATAGTAAGAGGAATAGTCCTTTTATGCAAAAGAAGGAAGAAAAAGAGGAATAAAGAAT ATAAAAGATATGGTGTAAACAGAAAATACATAGCATTATTGTAGACACAAACTGAACTACCTTATGAGTA TATTAAATATAAAAGGATTAAGCATTACAAATAAAAGGCAGAGATTGTAAATTGAATAAAAACCACAGCT AAGTGTGTTCTTTTTAGAATAAATACTCTTTAAGTGTAAAGATCTACTTTAAACACCAAAATATGAAAAA GGATATATACCATGAAAACCTGAATCATAAATAAGCTGGAGTGGTGATTAATGGATGCAGGCACTCCTAA AGACTAATAAGTGAATGTGGTCAAATTGAAGAAACAAAAGTATATACGTGCTCAATGTGCAAAAACTTTT TCTGTATACATGCTATGATCCTTTGGAAAATTAAAGTTTTAAAGCAATATCACTGACAATAGTATCAAAA CCAAAAAATATTTAGTGATAAATTTCACACACTATGCTCAAGGACTATACACCTTGCACTAGAAAACAAT GTTGAGGAAAGAATTAAAAGATCTAAATATACACCATGCTTATAGATTAAAAGACTCCATATCAGTTCTC GTGAAATTGATCTTTGGATGAAACCCACACCCAAGCACTATTGCAACAGTCCTTTTTTGGAAAAAAAAAT TGGAGGACTTATATACCTTAATATAAAGACTTATAAAAGTACAGGAATCAAGACATGTGGTATTGGCCTG GCCCCTTGGCTCATGCCTGTTACCCCAACATTTTGGGAGGCTGAGTCTGGAGGATGGCTTGAGCCCAGAT GTTCAAGACCAGCCTTAGCAACAGAGTGAGACCCTCTCTCTACAAAAAATAAACAATTAGATCGATGTGA TGACTTGCACATGTAGTTTCAGCTACTCGGAATGCTGAGGTGAGAGGATTGCTTGACTCAGGAGGTCTAG CCATGAGTGAGCATTGATCATGCCTCTGCATTCCAGCCTGGATGATGGAATGAGACACTGTCTCAAAAAA AAAAAAAAAAAAGGATATGTGTTATTGGCCAAAAAAGTATGCAAACCTAAAAAGGGATGGCCCACCACCA GACCCACATACATATATGGTAAATGGATTTTCCGTATAGATGGCAAAGCAATTCAATGGAGACAAAAATG TTTTACAAAATCATTCTGAACCATTTGGATATCCATGATACAAAACAAAAGCAGAACTTGACTTTTGCTT TTCATCTCAAATTATTTTGATATCTCTTCCACCTAAGTGTCAGAGCTAAAACTGAACCTGAAATATGAAA GTTCCATGAAAAAATATAAAATCTTCACAACCTTGGAGAAGGCAAACTTTTTTGAGGCAGGAGTCTGTAA ACACTCACTATAAAATAAAACAAATTATAATGTGGGCTTTCATGAAAACTCATGCTTACCAAAAGTCATT GTTAAGAAAATAAATAGGCAAGTAACACATGAGAAGAAAAATGCTCTCTGTCCATATATCTGACAAATGG CTTGTGTCCAGAATATAGGAACATTTCTCCCACTCACTAAACAGAGGACAAACAACTAATGGGCAACAGA TTGAATAGGCATTTCTTGGGGATAGATAGATGTACACATAGCCAATAAGCACCTGAAAAAATGTCCAGTA TCTCAGCCATGAAAAATAAAGAGTTATAATCATCATGAGATGTCACCAAACACCCAATGGACATGGATAT TATTAAGAAGACACCACAGTAACTGATGTCACTGATGTAGAGCAAGGATGTGAAACTCTCTCATATGCTG GTGAAAGTGCAAAATGATACAACCACTTTTGAAATCAGTCTGATAGTTTCTCCAAAAGTTCAATAAATGC ACTTTTACCCTACAAACCTGCAATCCTGTTTGTGAATATTTACCCCACAGAAATGGAAACATAAGTCCAC GAAGACATCTCCAAGAATATTCATAGCAGCTTTATTTTTTATAACCCCAAACTGTAGACAATTTCAATGT CAATCAATAAGAAAATGAATAAATAATTTGTGAACTAGTCATACAATGGCATACTGTTCAGCAATAAAAG GGAGCATGTTTTTGATACTCTCAAATAGTATGGAAGATGCTCAAAAATATTACATTAAAGAAAGATGCCA GATAACAAAAATGAACATTATGTATGAGTCTATTGATGTAAGGTTCCAGAAAGGTAAAACTAATTTCTGG TGAAAGAAACCAATATCATTTGCCTCTGGCCATGGGAAGAGAGTAGCAGAGATTGATTGAGCAGTAAAAC GAAGTTTTTTTCTGGGGTGATGTAAATGTCCTGTATTGTGATTGAAGTGTGAGTTACACAAGTGTACATG TTCATCAGAAGTCATCAAACTACATCTAAGATCTGTGCATTTGACTATACATGAAAATATACCTCAGTTG AAAATAGATCAATAACCTCCCTCATATACTATACTTGCTAACACAGCCAGCTGCTTGGAGAACCAGCTTG CTGGAATGGAGAATCTGGGCTTGAGACTGGGTCACATGTATAGAGTCTCTACAGAGACAATGTTGCATTC CCACGGTACATAATACATTTCAAGGTTTCTCAGACAGCCACATGTCATGAATGTGAGGATTCTGAGAGGT TGGAGCAACATTCCTGGGAGGAACGAAGGGGAGCACATTCTCCAAGATCCCCCACCACCGGGGTCCTCAC CGGCTGTGCTTTTTTTTTTTTTTTTCTTGACAGAGTCTCGCTCTGTCGCCAGGCAGGAGTGTAATGGCCC AATCTCGGCTGATTGCAGCCTCCAACTCCAGGGTTCAAGAGATTCTCCTGCCTCAGCTTCATGAGTAGCT GGGACTACAGATGTGCGCCACTGCGCCCAGCTAATTTTTGTATTTTTAGTAGAGACGGGGTTTTGCCATG TTGGCCAAGATGGTCTCGCTCTGTTGACCTCGTGATCCACCCGCCTTGGCTTCCCAAAGTGCTGGGATTA CAGGCGTGAGCCAAAGCACCCAGCCTGTGCCTCTCACTTACTCAATTGTTTTTCTGAACCCTCCATAGCT GGTGGACCTTTTCAGATCCCATAGTCTAGCCAGCCCTCTCACTTTATGCCTTGGGTCCCACTGTTCCTTC ATCTCATCCCCCTTCTGTCAGTCCCGCAGTGGCTGTGGCCAGTAGAGGATGGACTGAGAGTAGGAGAGGA GGTTCTGCCCAGGAACCCATCCTAGAGAAACAGCATCCTGCCTGGGACCTAGTCTTCCAGGTCAGCTTTT ATAAGTCTTTTAGACTCAAACTCACTTGACCCACCTGAAGTGGTATTGACAATAATGCTATTTTCATGGT TGTTTTTCACTGTAAATGCAGAGCCTTTTAGCTACACGACTAGTACAGAGAGTAAGGGAGGCTGGCCTGG GAATGATATCATCTTGGATGGCATTTCCTCCTTGGAGAAATATATGTTAGTTCCAACTCACATGTTACTA TACAGTCCTGTAGAAAGAGATACAGAGAGTTAGACAGGTATAGACGCATTTGTATATGCATAACAATCTA TAAGACACACATCAAAATCCGTATACCGGTTCCTCTAGGGGTATGTGCTTGGCAGAAGGTAGAAGGAGGG TATTCTGGTTCCTTTCTTTTGCACATTTATGTATGATCTCAGTTTTTATATGGAGCATTGATAGGGTTTG GCTATGTCCCCACCCAAAATCTCATCTTGACTTGTAATCTCTATAATCCTGATAATCCCCATGTGTCAAG GGCAGGACCAGGTGGAGGTAACTGGATCATGGGGGCAGTTTCTCCCAGGCTGTTCTCATGACAGTGAGAG AGTCTCCTGAGATCTGATGGTTTTGTAAGTGTCTGGCATTTCCCCTACTTGCACTTACTCTGTCCTGCCG CCTGTGAAGAAGGTGCCTGTTTCTCCCTTGCCTTCTGCCATGACTGTAAATTTCCAGAGGCCTCCCCAGC AATGTGGAACTGTGAGTCAATTAAAACTCTTTTCTTTGTAACTTACCCAGTCTGTCTCGGGTATTTCCTC ATAGCAATGTGAGAACGGGCTAATACAAGCATATACTACTTTTGATATTTTAAAATAAAAATTATCATCT ATCTTTGAAAGGCATGCACAAATGGGAAGTTGAGGAACATTTGTGTTGTGGCAATTGTATGATACCTTTA ATGGGAATATTTCAAAGACACTTGTTAAGACTTTGTTAGAACAAAATGTAGAGGGTGCTGGATGTCCCTG AATATTCTTCCGCCTCCTGTAACTTGTATTGCTTTGGAATTTCCAGTGGCCTGACAATGAACTACTGCAG GAATCCAGATGCCGATACAGGCCCTTGGTGTTTTACCATGGACCCCAGCATCAGGTGGGAGTACTGCAAC CTGACGCGATGCTCAGACACAGAAGGGACTGTGGTCGCTCCTCCGACTGTCATCCAGGTTCCAAGCCTAG GGCCTCCTTCTGAACAAGGTAAGAAGTCTGTGTCTTACCTTGTCTAGCACATACCTCTCTATGTGCTTGG ACAACGGGATGAAAAGACATGAAAAACCACACTGATGCAGAAGCCTTTAGTGCTACACGGGAGCTCGAGT GTTGGTTGAGGTTCTGCCATGACCAAGGAAGTCTCAGTGCCGTCCCTGGGAAAGCCAGAGCTGTGATTTT TGGCACAACTTGTGGGAGTAGTGACTTTAGGACTGGCGCAAAACCTCCAGGGTGCTCAACTTAACCACTC ACCTTATTCTAAAATGGGTTATTTCAGTGTCCCAGTCAAATTCCTATTCTAACATGCTGTCAACTGTGTG ATTATTTCCAAGCCAATAAGCATTTCCAGTAATTTCTTAAAATAGTGTTCATTGCAGTCTTCAGCGTTGT GGCTCCTGAGGGATGTGGCCCCTGATTCTGTCGTCCTAGAGAAGCCTGACATGACTGCATTGATTCTGTA TCGTCCTGGGTCTATGTGGCTGCCTGGCTGTCTGTAATCATCTGTTTTATTTTTATTTTTTTCTACAGAC TGTATGTTTGGGAATGGGAAAGGATACCGGGGCAAGAAGGCAACCACTGTTACTGGGACGCCATGCCAGG AATGGGCTGCCCAGGAGCCCCATAGACACAGCACGTTCATTCCAGGGACAAATAAATGGGCAGGTCTGGA AAAAAATGTAAGCCACTTTGATTTGGACTCTTTTTCCCTTTGCTGACAAATCTTTTCAAACAGAAGAGGG GCAGAGGAAAATACTGGAAAGACTTCAGGAGGCTAAGCGTAATTAGCCTTAGCATGGAAAGTGCAAGCAG CACAGGCCAGCAAAGCCCCACGCGTGTGGGGGTTCTCAGGCCTCTTCTCTTTTGACATTTCTTTACTGTT TCCATTGTTGGGTGCTGTTTCTCGTTTCTAGTGCTTGTCCTCTAAGCCAGGGGTCCCCACTCCAGTACTG GTACTGGTACTGGTACTGGAACTGGTAATTATCTGTGGCCTGTTAGGAACTGGGCTGCACAGCAGGAGGT GAGCTTCGGGGGAGCAAACAAAGCTTCATCTGTATTTTCTGCTGCTTCCCATCACTCTCATAGCTGCCTG AGCTCTGCCAGCTGTCAGATCAGAGGCAGCATTAGATTATCATAGCACAAACCCTATTGTGAACTGCACA TGTGAGGAATCTAGATTGCATGCTCCTTATGAGAATCTAATGCCTGATGATCTGTCATGCTTCCATCACC CCCAGATGGGACCACCTACTTGCAGGAAAATTAGCTCAGGGCTCCCACTGATTTTACCTTATGGTGAGAT GCACATTTATTTCATTATATATTACAATGTAATAATAATTGAAATAAAGTGCACGATAAATGGAAGGTAC TTGAGTCATCCTTTAACCATCGCCCCCTCACCCCAGGTGCACAGAAAAATTGCCTTTTATGAAACTGGTC TCTGGTGCCAAAAAAGTTGGGGAACCACACTGCTCTGGGTTCTAGTAGTCAGAGATGCCCTCTATGAGGC TTAAGTCAGATTTTTCTAGAAAAGATTTGGATGGGCCATCAGGTCACCATGAGACTTCCCTTAGCCTCAT GCATTCTCTGTGATGGTTTACTTTGGGGCCTATGAATAGGGAAGACTGAGATATAGGAAAAACCAAAGTG TCTGTGTTCCCCCACTCTCACACCCATGTAACATAACACTTCTCACACCAGATATGGGGGGATTTCTCCT CACACCCCAAGCGAGTCTCCAGCAGATACCAGCTGGGTGTCCTACAATGTAACTCGGTCCTGACACTCTA TCTGGAGACAGTGTCAGATCCCACAAGTTAAGGCTCAGTCCTACAAGACTGCCCCACTGCAGATGCCAAT CCCAAGTTGCAGGCTGTGACCTGTACTTCTGCCCAGCTGGATAAAGATCTGTTTTTCTATATGACCCTCC ATGGGTTTGATTACTTTGCTAGAGTGGCTCACAGAACTCAGGGAAACACGTTACTTTTATTTACCCATTT ATTATAAAAGATATTAAAAAGGATCCTGGTGAACAGCCAGGTGGAAGAGATGCACAGGGCAAGGCACGTG GGAAGGGGCTCAGAGCCTCTATGCCCTCTCCAGTGCACCAGTCCCCAGTACCCTAAGTGTTCAGCAACCC AGAAGCTCTCCAAGTGCAGTCTTGTTGGGTTTTTATGGAGGCTTCATTACAGAGGCACAGTTGATTACAT CATTGGCCATCGGTGATCGGCTCACCTTCGGCCCCTCTTCCCTCCCTGGAGGTTGGAGGGTGGGGCTGAA CAGTTCCAACCCTCAAGTCACATGGTTGGTTCCCTTGGCAACCAGCCCCTGGGGCTATCCAGGAACCCAC CAAGAGTTGCTTCATTGCAGCTCCCTTCACCCAGGAAACTCCAAGGGATTTAGGAGCTCTGTGTTAAGAA CTGGGGGGCAGAGACCCAATATACATTTCTTATTCTATCACAATATCACAGGAAGCTAAGGATGATACTG CCTTTGTGTGTCTTGGCTGTGGATGGTGCATAATGCATGGAAGTAAGCATTTCTGAATCAACAGCAAACA GGCTTTATCAGGTAGAAGACCCCTCAGCGCCCCAGGGACAAAGCTCATCAATGATGTCCCACTGTCCTCT GAGGCTCTAGCTCTAAGACCTCCAGTGGGTCAAGCTCCTGGAGAAGTGGCACATTCTCCAAAGACCCTTC AGGGTCACCACACCCTGGTTAAGGGTGTGGCCTCATAACTCCTTTTGACTATGACTGATGGCTTACAGCA TAGAAAGAAATAACTTTGTCAAAAAATATAATAATGATAGAAAGGAAGAAGGAACGCTCCCTTTTGTCTT CTAAGAATAGATGTGAAATGTGTGTGCCTTAGAATATCTTCTCCCTCTCCTGCTCCACGTGAGCTGGAGC TTACATGCCTGCTTGTTTTCAGTACTGCCGTAACCCTGATGGTGACATCAATGGTCCCTGGTGCTACACA ATGAATCCAAGAAAACTTTTTGACTACTGTGATATCCCTCTCTGTGGTAAGTTGCCTTCTGTTTTGGTAA GGAAACTGCTTCCTTAATATGGATTTGGAAAAAAAAAAGCAAAAAAAACAGAAAATGGCTTTTGAGCTGA GTGCTTCTGGGGAGGAGATGGCTGCCCTCTCCACCAGAGCCTGCTTTTCATCATGGCCACCTTGAACCTG CCCTACTATTGGCCCCATTTGTTAGGAAAACACCCGCCCCTCCCACCACACACACATAAATAAAATAAAT GTCAAATTCCCAAAGGGCAAACTTAGAGGTGATCTAATCAGCCCGGGATAGTCCCACCGAACCCTTCTTT GTCTAGCGTGGGATGCATGAAAAACAAATTTAGAGTCATTATGATGAAAAACTGTCCTCTTCTGCAGCTG AGAAGAAAAAAAAAATACGAGCAGCAGGAAACAGCTAAGCATGTAATGCACATTGTAAACCTCAGATGGC CATCCTAGGAAATCAATGAAGGGTAGTGCAGCTCTTTAGCCCCAGATGGCCTTTCTCGTAAGATTACTAC TCATGAGTCCCATTAGCGACATTGCTTAGAGACTGCTTGTTAGGTTCCTTCCTCATTGCTCTGAGACTCT TATTGGGAGTATGAGGCTTGGATCAGGGGAAGGGGAATTGACATTAGATCTTAAATGATTGGGGTAACAA ATCCATGGGGGAAAAAAAGCCACTTGTACTTGTTCCCTATTTTCTTCCTGCTGACCAATCAACTTGTCTG TCCGAGTTACAGAACACCACCCTGGACTTTTCTTTTGTGTAATTTGGTTGCTTGTGGTTGGGTCTGCCAT GTGAAGGGACCTTGAGCTGGGGGAAGAAGGTTGGCCTCCAAGTCCACTGAAGACCAGCATCCTGAGATTG CCTGGGGAGGTGGTACAGGGCAGTGATGAAGATCATGGGAGCCACACTGCCCATCGTCACATTTGGGCCA CTCCTGGGGAGAGCAAGAGGGAAGAAGGAGAGGTTAGGGTGATAGGAAAGATTCTACTTGGCCAATATTA TTATAATGTGGCATTGTGGTCTCTGGATTTAGTGTGAGTTGATAGCTGACTTTTTTCTCGAGTGGGTGCT TTTGTTCTATTTTGTCGGTGCTATTGCAGAAGCATCTTGGTGGTTCCTCTACCTCAAAGTCTCTTGATGG GGTCAGTTCCAGTTCTCCGCTTCTGGCCCCATCTAGTACACGCCACTGCCTCTCACTGCCTGGGCTCTCT ATCCTTGACAGGCTGCCTTGAATTTAAGCCCAGTCTGACTTACCTGCCTCAAACACCCACAGTAGTGCCT GGGACTCATGCACCTTTGACTCCCATGGAAGGGAAGTGCAGTAGCTTCCCAGGTGCAATTCTGCTGTCCT CACCCACATTGAGGATGTATGAGAATCAGGTTCTTAGAGATTGGAGAAAGAAGGAAGAATGGGAACAAGA TTTCTTCCAATGGACTGTGAGGTTCCCCACCTTACTTTGATGTAAGACAAGTGAGGTTAACCCCAAGCCT GGTGAGGAGGGTTCCCATCAGACACTTGGAAATCCTGAGGACTGTTTCCTGCAGAAGGATGTGGTTGGTG GGATATTCAGGTTTGACTCATGATTGAGAAAGTTAGAGCCTCTGGTTGGAGAAAGAGTTTAATAACTATT TCATTTCCACCAACACATTCAGTACGAATAATAAATAAGTAAAAATAAATAGAAACATTCAGTTTTATTT TGAATAGTAGGAGTAGGGTATAATTTCTGTAGTTACTCTTTTAGTACAATGATGCATGTTTACTGTATGT AAGGCATACTAGCAGAAATTGAGCTCAGCACTAGAAAAGATGATTGCATTCCATGCCATGCTTCTTTTTT ACAAAAGACTTCTATAGATAGATTCTCAAAACAACCCACAGCAAATGAAAAGTTATTTGGAAAACTCAGG TTCCAGATTCACTGGAGTGTAGAATCTCTGGTTGGTTGGGGAGGAATTTCCTCTTGCAGTTGTTATTAAT AATTATATGAATAATTATTAACTATATTAATATTTATAGTTTTGAAGACCTTGAAGGGCTGGAGACAACA GAGAAGCATTTTTGAACACCCTCTGTAGCCCCTGCACTGTTGTAGGCATTGATGGGTGGTACCAAAGATG GGACACTTTCCCTACCTCCAGAGACCTTGTGGGCTTGCTGCAGAGAGAAGGCAGGGAGGAGGAAAAGAAG AATAGAGGCACATGTGTGTAAATTACCCCCACAGCAGTCAGTTAGTCATGGGAGGCTCCCCAGAAGAACT GTCCTGAAGCTGGCTGAGAGAAGGCAACATTTCAACATAGGACAGTTATCCTTGCTACATAAAATCACAT ACACACATGCACATATGTCCACACACAGAGACTCACATGCAAAAGAATCCTTTGTGCCTTTCAGTAAACT TTACATGGTTTAGAAAGAACTTATATTTCCTTGAAAGGAGAGTGTCCTTTGTTGTTTACTACCACTTTTT AAACTTAGAAAGAAAAATCTAAAGAGTGTTTATGATTTTACCATTTAATTTCACCTTTGAGATGTGAAAA ACTAGTGCTTGGAATTCGTCCTGAATTAAACGACACAATTGCTAACTTGGACTCAAATGCGACTTCTTTT CCCACCTTGTGCCACAGCATCCTCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCT GGAAGCATTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTCAGAACAAGGT AAGAACAGGCCCAGAAACCATCTATACTGTCCTTCCATGTAAGCCCCACAAAACCCTTCTACATTTACAC AGAACCCACACAGCTGATGCATCAATACCTGCCTCTCTGTTTTCTGAAGGAGGAAAAAATATAGAAAAAT TAAAAAAAGTTATATTATTATAGGTTCTCTACTTGGAAAATAGCCAAAATACAAATCTTTTTCTTGATCT GGGCAGTTCCATCAAAATCTGTAGGCACAGTGATTTGCACCAAGTTCCAATACTTTTGGAAAATATTGAA GATGCTCTGAGGGTTTCTATGGATATCCATTGTCTCACTGTCAGATGAAAAGAAAGGGAAGTTTTTAGAA ATGTGACACTTTGCAGTGAGGGAGGACAAGAGCAAACTTACCTACAGTCTATCACAGGCACAGATTTTTT TTTACACTTTTGTGAATCATTGAATTCAATGCCGAGGCTATTCATCTATTCACAAACACATGAACAAATT ATGGGTTGTGATCCCCATAAATGAAGAGTAATCAGTCCGAACCCACAGAACCTGGACATTTTGGGTATCG TTTCAGTGGAACATGCAATTCGTAAGTTCAGTTTGCTTGGGTGTCTCTTAGGAAGAACACATAGGACACA GACCCATCTGCCTGCATGTTTTGCTTCCTCATCTCCTTTCTACACCAGGGCACCTGTGCTCAATTGCTGT TCTCCTCTAAAGAGACTTCCTTCTGTAAGTTTGTGAAATGCCATCGACAAACCTGATCGCATCGCATTTC ACTCTGCTGTTGAGTTGATTTTTCTTTACTTTATCGTTTGTAACTTCTTGCTCTACAGAGCTTTCACCTT CCACATATTTCAGATTCATTCTTTCCTAAACTGTGTGGTGGTCTATGTCCTCACTGACTATCAACATACT GCCATCATGCACTTCCTATCTCTATTCCTCTTCGTTGCAATCTGGCTCCAAGTGGCTCACACCATTATTC TGATCTATCAACTGCCTACACAGTCCTAGAAAGTAAGTGAGTCAAGAAACATCCCCCAAAAGTAAACTTT TCAGGTAAGATCAGAAGACCCTCATGAGTCACTGCTGCTCAGGATCGTATCTGGCTCCTTGAAGAGTGAC CTTGCATAGATCTTGTCATAAAAAATGAAAGAGACCTTGGGAAGGTCTTGGGCTGGTCACTTTTGTCAGA GTCCAGGGCTGTGGGGTGAAAGCCACAGCTATAGAGCTTCATTCTGGAGTCACTTAGCTTTGCTCTCCTG GGGACAGGCTGTGCCTATTCTTGCCTCAGGCATCAAAAAAAGTGGCACAGATGGGCCCTTCTGAAAAATC TCACTACTGGAGCACAGCTCGAAGTTTCTACTATCCTGACGTTGGGCGGTAGTCCTTTGCTTTGGGAATA TGAACATGATCAAAACTGAGTGAACTTGTCTTCCTGGCTTTCTGTACAATGAAGTAGAACAAACCATCCA ATTTGACCAAAGCCTTGGCATGTTTTCTTTCTAGGTTTGGAAAGCACTTCTGTGGAGGCACCTTAATATC CCCAGAGTGGGTGCTGACTGCTGCTCACTGCTTGAAGAAGTACGTTTAAGGGAAAACTGACATGGGGTCT TATCTTCAAGACTTTTTTCCTCCCTCTCTTCCTCCATCCCTTCTTTCTTCCCACCCTCCCCTTCCTTCCT CCCCACCTCTCTTCCTTTTCTGGAAGGAACACTAGGAACCAGGGAATGCATGCAGAATCCTGAGGCAGAA TTTCCAGGGCAATTGGATGAGAGAGGAGGGAAGTGTTTCTAGAGGGAATCTGCAGAGGGAAGACCCAGTG CAAGTGATTTTTTGGACCTGTATAAACCGCAGGACAGAGCTGTTCACTACCAGAGGCATCAATCTGTATT GCATTGCTCTAGAGCAATATCTGAGGCTGAATAATTTATAAAGAAAAGAGTTTAATTGGCACATGTTTCT GCAGGCTTTACAGGAAGCAGGATGCTGTCATCTCCTCTGCTTCTGTGTGGGCCTAAGGAAGATTACAATC ATGGTGGAGGGCAAAGTGGGAGCAGGCATGTCACATGGCCAGAGCAGGAGCAAGAGACAGAGAGAGATGG GGTGGGGGTGCTGCACAATACCAAATGACCAGACTTTGCAAGAACTAAGAGTGAGAGCTCACTGATCACC ATGAAGATGTGGCCCAAGCCATTCAAGAGGGATGCACCTCTATGATCCAAACCCCTTTCACAGGCCATAG CTCCATCACTGGGGACTACAGTTGAACACGAGATTTAGGTGGGGACAAATATACAAACTATATCACAGTC TCTGATGAAACAGATTGAGAACAGACCTTAACTGTCAGTTTCCAGCAAATTGTGAATTTTGTTTCTTGCC ACTCATAAGTCACTGATTCTGGGTGGCCGAGGGTGTCAGAGGGACAGCGCCAAGTTCATGGCACAGAGGA TACCTGAAGGGGCTGGACCATATTTTTCTCTTGACATCCTCATCTTTTCTAGGTCCTCAAGGCCTTCATC CTACAAGGTCATCCTGGGTGCACACCAAGAAGTGAACCTCGAATCTCATGTTCAGGAAATAGAAGTGTCT AGGCTGTTCTTGGAGCCCACACAAGCAGATATTGCCTTGCTAAAGCTAAGCAGGTACTCGCTCACCTGTG GTCTTCACCCCACGCTGGTGAAGATATTTGCTTTATGTCTGGGTTTTATGGGCCATGGCCACTGCATGGC AGTGGGGAGGAACTGTCTATCACATGAAAGGCTCAAGGGCTTTGGGGACAGCATCAATCTTCAACCCCAG CCCTGCCACATGTTAGTTGTGCTCTTTAAAAAGGCAGAAGGATTCGTTTCCTCACGTGGAAAAAGAGATA CCCTGTTACCCGTAAAACTTACTTAATGTTCACCAGTTCATCCACATTCATGATCAGGGAAAGGTTGTTA TTCCAGGCTAACTATTCTCCTTTCATAATAATATGCTGGAGAGAATCAAATGAGATTGCATTTCAAAGCG CTTGAAAAACCACCATATCGAGCCATGCTTAGTGTGGGCGCCTCTAATCACTGCTATTCAGGAGGCTGAC GAGGAAGAATTGCTTGAGCCCAGGACTTCAAGGCTGTAGGCAGCTATGATTGTGCCACTGCACTCCAGGC TGGGTGACAGATCAAGACCCTGTCTCAACAAAAGAAAAGAAAACAAAACAAATGAACAGAAATATTCCAC AATGTCAAAAAAAAAAAAAACCCACACAACATACAATTTACAAATGCAAATAATAATATTATTGTTGTCT TCTTTGATTTTCTCTTTCCTGGTGAAATTTTGTTTTATTAAGCCTGACAAAGTGATACCTTTGCTTACAT CACTTAAAGTTAGTCTATTTGGACCTAGGTGACAGTACAATCAGCTAAGAAACAGTATTTGTAGGAGAGG CAGGTTTGGGACAGGTGACAAGGCATGTGGGGTGCTCGCTGTGCTGGTGGCTCTGGAAGGCAGGGTGTCA ATGCAGACAGGGATGAGCATGGCCTGGTTGGGAAGGCATGGGGCAGGCAGGAGCCTGAGCTGCTCTCCTG GGCCTGGTCACAAGCCCATGGCAGCTTCTCTGGGTCTGTGAACTGAGGGGTGATGTCCTGGAATCCTCTG ACACTCTAGGAAGGAGAGAAGGGCCTTTCTGGCTCAGCCTTTATAAACAGTAGCTGATCTCCCTCTTGCT CCCCAGGGTCCTCCCCACCATCCCAGCAAATGTGCAAATACAAGATCTCTGCTCCTCATGGTCCTCAGAG AGCTGGGGTGTTCTGATGGCTTGAACAAGTCACTTAGGAAATGTGGGGTTTTGGAGGCATTCTCTGATAG GCTGATACGTTTTGAGTTTAGAGTTCCCACCGCACATCCCCACACCCCTAGAGTCTAGGGCATTTAGTGC TCCATGAGGGAACCTGTAGAGTGAGGACATCTGCATCACAGGCTGGGCCTTCTAGTGTCCAGAAGCAGAA AGTGTGTCTGCTTCAAAGTTGGTGCTAATGATGATTTTTGGTCAGAATACGGCATTTCTCATTTCCATTC CTTTATCCCCTTGAACTTACTAAAGTAGAATCAGGTCTAAAAACCAGAGTTCTAATCTTTAAGAGTCCCT GGGATTCTAAGGTATATGAATGTCCTTGGAAAACAATACCATTTAGTTCATGCAAGGTGCTTATTTCCCA TCCTCTTTCATTTGATGTCTAGCATTTTACTGCATTCTTACCACCACGGTTTAGTAACATTCACGAGGAG GAAGTGGAGGATCCAGATGGAGCAACTTGCTCTGGGCACACAAGGCATTTGCAATTTTATACCCTCTTGA TGATGTCTCAGCCAGACATTCTGCCCAGTCATCAATGCCCTCTTCAATTAATATGAAAGGACACACTTGG CATGAGATTCCAATCGTGCACAGAATATACATGAGAAGTGTGCCTTTGTCATCCCTACTTTCAAAGGCTA AGGCCACCCTCAGTTTCTTGCATGCAACTGATGCCTTTCAAATGAAACCTTACATCTGTGTAGTCCATAG GCAACCACAGGCAAATGTGAGGGTGAAACGCTGTGTTCTACATTGTTCTGTGTCAGTGAAGCAAGGCAGT GCCAGCTCAGAGGGCTCTGGGGCTTCAAGGCAGGGATGCCTGGTTGTAGGTACTGCCACTTCCAGCTGGG CAGTGAAACATAACTGCTAATACTTTCCTTACAGGCCTGCCGTCATCACTGACAAAGTAATGCCAGCTTG TCTGCCATCCCCAGACTACATGGTCACCGCCAGGACTGAATGTTACATCACTGGCTGGGGAGAAACCCAA GGTGAGATCAATTCCATTGCCCACGTAACAAATTGTTTTTGACCTTCAGTGCATGTTACAAAATGAGCAT TTTGGAGATAGTTGTACAAATTCCTACCCATGAATGTGGTCTACCCACTCCTGACTTTGCCTGGACACCT GTCTATGTCTCCATAATCAGTCTTCAAGGGACTTGGGCAAGGGGAGCGGTGCCATTTCCTTGAGTCTCTC TCTTTTTTGTTTTCAGAATCTTTTAATTTTTTTTGTAATGATTGTATGTTTCCCTTACAACAAAAACAAA CACCAGTAGAGGTCTTTGAGTCTCTTAATCATAATTTCAGCATTCATATTGCTTCCCCAGGTAAGTGGGG TTTTGACCCAGCCCTCAAGTTAAGGGTGTTAGATTATTTTTCATGTGAAATTAGACAGACTGCGTTTCTA AACATGGTGCAAAACAGTAACGACAAAAGTTGTAATTAAACTATTCTTCTTCCCAAATACCCACATGTCT AATGTGTGTGTGAGGGTGTTAGGCAGGGGACCTGAAGCTGGGGGAGAGGCAGACAGTTCCCATGGCCCCA AGTCTAGGATGGCATTTGGTATTGGTTGATGGGTGAGAGCAAGAGAGGGAATATTTTTGTGCATGATGTG GTATCAGCACCTGTACTACATTTTATGGATTCCTTCTTCTCTTTGCGGTATGCCCTGACAATAATTATAT CCGTCAGCCTTACCCCCTTGGCAGTAGGAAAACTGAAACTGTCTTAAAGTCTCAGCTCTACTTTCTCAGA GGTGCAGGCAAGGGCACTGGGAGTCTGGGGCCCTGGAAAACTGTTCTGACTCTGCCACTTGCCAGATAGA CCTGAACTAGACACGTTACCTCTTTGTACCACTTGGCTCTAATCCCTTATCTGTAAAACCAGCATTTTCA AATGGTGCTTTGCACATCAGCCTTTTGCATAAGCTTTGATTTGATAAAATGTTTTTTGTGTTTTTAAAAA GATTAAAAACCACAGGTTTAGATAATTTCAAAGTAGGCTTCCCTTTTTCTGTCATTTTCCTATTATTTTT AAAACCTCACCTCCTTGACTCCTTGTTCCCTTTTTCTGCACTGCTGAGTCTGGGAGCACTGAGGCCAGGT AAAAGGAAACTTGGCAAATGAGGGGCACCTATGGGTGTGGGAGGCTGCTCCTGGTGTTTGCATATTTTAA AATTTAAATGCTACAAACCACTGTGAGTTAGGTATTATTGTTCCTATTTTACCATTGAGGAAGCTGGGGC TCAGAGAAGGTGGAGGGTGGTACAGACAAACCTGAATTGGAACCCTGGCTCCTGCCTATGGGCTGTCAGG ACTTAGAAAAGTCGTGAGCTCTCGCTGATTGTTTCCTCAGCTGATGTGGGCTGCAGGGCTGTTATGGGGG AAATAATAAGAAAGTGCATCAAGTGCTGAGCACATCCTAAGCACTCCATCATGGCAGCTCCTACTACTAA TAAAGAATAGAATTATATCTAACATGATTCTTTCTTGCAAGTGACAGAAAATCCAACTCAAATTGGATTA AGCAAAACAAGGGAAATTCTTAGTGAGCTGCAAAGTTTTCAGGCTCACATGATGGCCCCAAATCCCAGGT CCTCCCAATCATGGAGTAGGCACTATTTGGGGGCACAAAGGTGACATTCCCATGGCTGCAGATGCTGTGG TGCTGTGGCTGTACCGGGAAAGAATAAGAAAGGCCACTCTCCCAATTATGTGAACAATAGTCTGCCCACT CTGAGAAGTCAAACTTGGGTCACAGTCCTGCCCCTGAACCCATCACTGACTGGCTCTGACCTGCACCAAT TGTTCCATGTTGGAGGTGAAGGCAAGACCCCACTAATACCCATAAGGGGCAAAAGTTAGATAGATCCTTC AAGAGGATTATGGGAGGTAGGGCAAAAAGCTGCTGGGCAGCCAGAAAGCAAACAGAGCCTCTATGATACC TCAACTGATGAAAGCATGAAGCTAAAATCATAAGGATCTGGGTGTGAGTTCTGGCTCTCCCATCTTCCAT GTGACATTGGGCAGTTATTTAATCTCTTTTAGCCTCCGCTTTCTCATCTTACATATGAGATAATTGTGAG GATTAAGATTACACATAATCATCATCATCACCGTCCACCACTACCACCATCATCCCCATCAACATCATCG CCACCACTATCATCATTCTTACTGGCACTACCATCACCATCACCACCATTCCACCACCATCACCAATATC ATCACTGTCAACATCATTACCACCATCACCATCACCACCACCATCATCATTACTACCACTACCACTACTA CCACCATCACCATCACCACCATTCCACCACCATCACCAATATCATCACTCTCAACATCATCACCATCACC ATCACCACCACCATCATCATCATTACTACCACTACCACTACTACCACCATCACCATCACCACTGTCCCAC TACTATCAGCATGACATCACCATCACCACCACCATCATCATTACCACCGCTACTACCAACATCACCATCA CCACAATTCTACTGCCATCACCATTAACATTACCACCACCATCATCACTATCACCATCACCACCATCATC ACCACTGCCATTATCACTGCCACCATCATCACTATCCTCTATATTTCCTCATCTGTATTATCATTACTAC CACCATCACTATCACCACCATCGTCACCATCATAATCACCATCAACACCATCTCCAATACCACCATCACT GTAACCATCATCACCACCACCATGATCACTATCACCATCATCACAATGATCACTGTAACCATCATTACTA CCCACCACCATCACCACTACTCCACCACCATCACCATTATCATTACCATCACCATTATCACCACCATCAT CATCACCAGCACCACCATCATCACCAGCACCACCATCACCATCACCATCATTAACACCATCACTATCACC ATTGGTTTAATCATCACCACCATCATCATAAATAAACATCACATAACCAGGGTGTAGCTGGGTGTTGACC CCAGAGCCCACTCACTGTTTCCTCTCTCCCACCCCCATCCACACATTTCTAACCACCATCCTGCACTGGG CTCCCAGTCTCCTCTGGTCTCACCCACATGTCCACTGAGAAAAGGATTTTCAGAACACCAACTAGACCAG GAGGAGCCACATACATAACTCAGGCCTGCTTATCAACTTTCTACATGTTAATAATGACATCAGATCAATG GGTGTTCTCAGCTTCTCAGAAGGAGGTCAAAATTCTCCCCCTCTCCCCTTCATGTGTCCAGACCTTCCCG GATTTGGATGTACCAAGTGCAGAGTGGTGTTGAGGCCAAGGGGCTCATCCATGTAAGTCTCATCTGCAAT CACTGGGCTGATCCCGTGGCCCTGTCTCCAGGGCGCCATCAGAGAGGGCTTCAATCCTCAGGTTACCTGT GGCCCACCCTGCCCTCAGAGGTGCCATCTCTACATTGGCCACGAGATGGCAGCACATACTCATAGACTGC ATTAATTTCCCAGCAACTCCTGGTGGGTTTTCCCTCTTATCAGGATGTTTGCCTTGCTCAGAGAGCAAAT CTGAGAGCAGTGACACCTAACTTAACTTTCAGCAAAATATTTTGAGAAGGGTGCCCCTTTACACATCTGT GCAGTCCAGGTGATGCATCCCATGCCCAATGCTCGGTAGTCAGGAGGAGCTTCCTCCATGCAGCTCTGCG GAAGAGACTCTTCCACGCTGCTCATGTAAACTCCAGATTCGGTGTCAGTTTTCTGACACCGAAGACAATG ATCTAAGTGCAGTCAAGGGCTTTGGGGAAAGCAGGAGAGAGTGCCTCAGTTCTAGCCTGTGCCATGCTTG CAAAGTTTTGCAAAATTCTAATGAGAGCTGGGCTTGCAACATTGGAAACTTGGATTATTTGTGAGAGCAC TGAGAAATCCCTGGGCATGTCCATCTGGAAAAACAGCATTTCCTCTGGCACTTTAGCAGAGGTTCTGTTT CAATTTGGCGAAGGAAATTAAGCAGTTTTTCACAAAAGAAGAACTACAACGAGGAGAATTGTCCCTAGTA TTTCTTCTCCCTAATTGTCAAGGAAGTGTAAATTAGAAAATGAATCAGGACAATTTCCACCTACTATGTT AGCTAATATTTTAAAAATTGAATATCACAAGGGTGAGGCAAAGTAATTGTTTTCCAGTGACATTTTCCAC TGTCACACCCTTTTAGAGAATAATTTGGCAATGTTACTGTGAGATAGAAATATGTCTATATAATTATGGG AACTGAGACTTCAGAAAGTAATAAGGAATAAGAATGAAATTTATGAACAAACATGTGGAAGGTTGGAAGC AAGAGTGGGGCCAACACGCATGGGGAGGAAGCATTTGGGCAGCGACTCCGCAGACCCAGACTCAAGCTGA GCTATACAACCTCCTTACGCCTCAGTTTCCTCAACTGAAGAACAGGAATGACAAGTGCCTGTTTCATAGG ACCGTTGTGAGGATTAAGTGAGATATACCACATTATGAGCTTGTGCCTGGAAAGGTTGATTCTTAGTAAA TGATGACTATTCTTTTTTATTGCAATAAAATTTATACAACATAGAGTTACTATTTTAACCATTTTTGCAG GTACCACTGAGTGGCATTCAGTACATTCACAATGGTGTGCAACCGTCACCATATTTCCAGGACATTTTTC TCATCCCCAAAGGAAACCTCATGCCCATTAAGCAGTCACTCCTCATTAAAATATTAGTTATGAAGACTGT AGCATTTTTTTAAAAACTCATGATATAACATTGATTGAAAAAATCAGTATAGGAAATTGTGCATTATGAT GTAATAGTAAAAGAAGCATATAAAAATCTGAAAAAAGTATATAAAAAGAATAGCAATTGTATTTCTCAGA CTCTCTTTACATTGTAAAAATCATTTTGATAGCTTCAAAAGAAAAGCAAAAAGTACACAAACAACAACCA ACCCCAAAGCAGCATGACAAAGCCCAGATTGTTGAATCCAGGTCTTGGGAACATAAAATCTTATATGACA TTTGCACTTTAATGGGTCAGAGAGTCCAGTGGCATTGGGAGCTGCCTTGTGTTCTGCAGCCTCACGGACA GACAGGAGGTCCAGCTCCACTGCTCTGTTCTTCTGGAATTTCCTCGTGAACAAGCTTTGGCCTCAGTAAC CATTTCTTTCATCTTTTTAAACACAGGTACCTTTGGGACTGGCCTTCTCAAGGAAGCCCAGCTCCTTGTT ATTGAGAATGAAGTGTGCAATCACTATAAGTATATTTGTGCTGAGCATTTGGCCAGAGGCACTGACAGTT GCCAGGTAAGAAAAGATCAATAGATCAAAGTCTTGTGCTCTCCCGTCTCAGTCTCAGTCCCTTAGACGTC AGTCCCAAAGTGGCAAATTCAGGAAGGTTTTGTCAGTGGAAGACCCCAGTCTAAGTGTTGCTCAGAAACT CCCCAGATCTGTCCCTGAATGCATATTCAGATCATCTAAGGAGACGTCTTGGGGCTTGAGTTCCAGATCC ATAGCAAGGGAGCCGTAAGTGCCATAACTACCTCAGGCCACTCACCTTCCTGGTGTGTGCTGGTCACCAG TGACTGAAGTGGTGGCTTTTCCAGTAGAGAGGAAGGTAGAGGGTACAGGACCGAGACAAATTACACACAC TTAACAATGATGTCCAGGCTAGCCCAGTCTAAAGGAAACACCAAGTTAGGAAGCAATGCATGCAGGATTC ACAAGGGATTATTTTTTTTCCCAGGAAAAAACTAAGTGATGTGGTTTTGTTGAATAGACTTTGCTAAGTA CTTAAGCACTGCAGATGCTTGAGTAATATGCTCATAAGTTCCTTTCTGATTTGAATTACTGGGAAAATGT ACATATGGATAAGAGAAGGATGGCATCCCATATTAAAAGGTTGGCAGCTTAAAGCTCACATGAATTTTCC CCTACCTCTGTTTAGGGTGACAGTGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAG GAGTCACTTCTTGGGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGCTCGTGTTTCAAGGTT TGTTACTTGGATTGAGGGAATGATGAGAAATAATTAATTGGACGGGAGACAGAGTGAAGCATCAACCTAC TTAGAAGCTGAAACGTGGGTAAGGATTTAGCATGCTGGAAATAATAGACAGCAATCAAACGAAGACACTG TTCCCAGCTACCAGCTATGCCAAACCTTGGCATTTTTGGTATTTTTGTGTATAAGCTTTTAAGGTCTGAC TGACAAATTCTGTATTAAGGTGTCATAGCTATGACATTTGTTAAAAATAAACTCTGCACTTATTTTGATT TGAA (SEQ ID NO: 427). By “adenine” or “ 9H-Purin-6-amine” is meant a purine nucleobase with the molecular formula C5H5N5, having the structure , and corresponding to CAS No.73- 24-5. By “adenosine” or “ 4-Amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one” is meant an adenine molecule attached to a ribose sugar via a glycosidic bond, having the structure , and corresponding to CAS No.65-46-3. Its molecular formula is C10H13N5O4. By “adenosine deaminase” or “adenine deaminase” is meant a polypeptide or fragment thereof capable of catalyzing the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase catalyzing the hydrolytic deamination of adenosine to inosine or deoxy adenosine to deoxyinosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). The adenosine deaminases (e.g., engineered adenosine deaminases, evolved adenosine deaminases) provided herein may be from any organism (e.g., eukaryotic, prokaryotic), including but not limited to algae, bacteria, fungi, plants, invertebrates (e.g., insects), and vertebrates (e.g., amphibians, mammals). In some embodiments, the adenosine deaminase is an adenosine deaminase variant with one or more alterations and is capable of deaminating both adenine and cytosine in a target polynucleotide (e.g., DNA, RNA) and may be referred to as a “dual deaminase”. Non-limiting examples of dual deaminases include those described in PCT / US22 / 22050. In some embodiments, the target polynucleotide is single or double stranded. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in DNA. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in single- stranded DNA. In some embodiments, the adenosine deaminase variant is capable of deaminating both adenine and cytosine in RNA. In embodiments, the adenosine deaminase variant is selected from those described in PCT / US2020 / 018192, PCT / US2020 / 049975, PCT / US2017 / 045381, PCT / US2021 / 016827, PCT / US2022 / 073781, PCT / US24 / 34189, or PCT / US2020 / 028568, the full contents of which are each incorporated herein by reference in their entireties for all purposes. Further non-limiting examples of adenosine deaminases include those disclosed or referenced in Rufflow, et al., “Design of highly functional genome editors by modeling of the universe of CRISPR-Cas Sequences,” bioRxiv, posted April 22, 2024, doi: 10.1101 / 2024.04.22.590591, the disclosure of which is incorporated herein by reference in its entirety for all purposes, which were designed using artificial intelligence. Further exemplary adenosine deaminase amino acid sequences include: TadA-8e (SEQ ID NO: 470), Tad1 (SEQ ID NO: 471), Tad2 (SEQ ID NO: 472), Tad3 (SEQ ID NO: 473), Tad4 (SEQ ID NO: 474), Tad6 (SEQ ID NO: 475), Tad6-SR (SEQ ID NO: 476), TadA9 (SEQ ID NO: 477), TadA20 (SEQ ID NO: 478), Staphylococcus aureus TadA (SEQ ID NO: 479), Bacillus subtilis TadA (SEQ ID NO: 480), Salmonella typhimurium TadA (SEQ ID NO: 481), Shewanella putrefaciens (SEQ ID NO: 482), Haemophilus influenzae F3031 TadA (SEQ ID NO: 483), Caulobacter crescentus TadA (SEQ ID NO: 484), Geobacter sulfurreducens TadA (SEQ ID NO: 485), Streptococcus pyogenes TadA (SEQ ID NO: 486), Aquifex aeolicus TadA (SEQ ID NO: 487), and E. coli TadA deaminase (ecTadA) (SEQ ID NO: 488). By “adenosine deaminase activity” is meant catalyzing the deamination of adenine or adenosine to guanine in a polynucleotide. By “Adenosine Base Editor (ABE)” is meant a base editor comprising an adenosine deaminase. By “Adenosine Base Editor (ABE) polynucleotide” is meant a polynucleotide encoding an ABE. By “Adenosine Base Editor 8 (ABE8) polypeptide” or “ABE8” is meant a base editor as defined herein comprising an adenosine deaminase or adenosine deaminase variant comprising one or more of the alterations listed in Table 5B, one of the combinations of alterations listed in Table 5B, or an alteration at one or more of the amino acid positions listed in Table 5B, where such alterations are relative to the following reference sequence: MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1), or a corresponding position in another adenosine deaminase. In embodiments, ABE8 comprises alterations at amino acids 82 and / or 166 of SEQ ID NO: 1. In some embodiments, ABE8 comprises further alterations, as described herein, relative to the reference sequence. By “Adenosine Base Editor 8 (ABE8) polynucleotide” is meant a polynucleotide encoding an ABE8 polypeptide. “Administering” is referred to herein as providing one or more compositions described herein to a patient or a subject. By way of example and without limitation, composition administration (e.g., injection) can be performed by intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes can be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. In some embodiments, parenteral administration includes infusing or injecting intravascularly, intravenously, intramuscularly, intraarterially, intrathecally, intratumorally, intradermally, intraperitoneally, transtracheally, subcutaneously, subcuticularly, intraarticularly, subcapsularly, subarachnoidly and intrasternally. Alternatively, or concurrently, administration can be by the oral route. By “agent” is meant any small molecule chemical compound, antibody, nucleic acid molecule, polypeptide, or fragments thereof. In an embodiment, the agent is a base editor system described herein or a component thereof. By “alteration” is meant a change in the level, structure, or activity of an analyte, gene or polypeptide as detected by standard art known methods such as those described herein. As used herein, an alteration includes a change (e.g., increase or reduction) in expression levels. In embodiments, the increase or reduction in expression levels is by 10%, 25%, 40%, 50% or greater. In some embodiments, an alteration includes an insertion, deletion, or substitution of a nucleobase or amino acid (by, e.g., genetic engineering). By “ameliorate” is meant reduce, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease. In embodiments, the disease is atherosclerosis or a cardiovascular disease. Editing of an LPa gene in a subject having atherosclerosis or a cardiovascular disease may ameliorate symptoms associated with the disease. By “analog” is meant a molecule that is not identical but has analogous functional or structural features. For example, a polypeptide analog retains the biological activity of a corresponding naturally-occurring polypeptide, while having certain biochemical modifications that enhance the analog’s function relative to a naturally occurring polypeptide. Such biochemical modifications could increase the analog’s protease resistance, membrane permeability, or half-life, without altering, for example, ligand binding. An analog may include an unnatural amino acid. By “base editor (BE),” or “nucleobase editor polypeptide (NBE)” is meant an agent that binds a polynucleotide and has nucleobase modifying activity. In various embodiments, the base editor comprises a nucleobase modifying polypeptide (e.g., a deaminase) and a polynucleotide programmable nucleotide binding domain (e.g., Cas9 or Cpf1). Representative nucleic acid and protein sequences of base editors include those sequences having about or at least about 85% sequence identity to any base editor sequence provided in the sequence listing, such as those corresponding to SEQ ID NOs: 2-11. By “BE4 cytidine deaminase (BE4) polypeptide,” is meant a base editor comprising a nucleic acid programmable DNA binding protein (napDNAbp) domain, a cytidine deaminase domain, and two uracil glycosylase inhibitor domains (UGIs). In embodiments, the napDNAbp is a Cas9n (D10A) polypeptide. Non-limiting examples of cytidine deaminase domains include rAPOBEC, ppAPOBEC, RrA3F, AmAPOBEC1, and SsAPOBEC3B. By “BE4 cytidine deaminase (BE4) polynucleotide,” is meant a polynucleotide encoding a BE4 polypeptide. By “base editing activity” is meant acting to chemically alter a base within a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is cytidine deaminase activity, e.g., converting target C•G to T•A. In another embodiment, the base editing activity is adenosine or adenine deaminase activity, e.g., converting A•T to G•C. The term “base editor system” refers to an intermolecular complex for editing a nucleobase of a target nucleotide sequence. In various embodiments, the base editor (BE) system comprises (1) a polynucleotide programmable nucleotide binding domain, a deaminase domain (e.g., cytidine deaminase or adenosine deaminase) for deaminating nucleobases in the target nucleotide sequence; and (2) one or more guide polynucleotides (e.g., guide RNA) in conjunction with the polynucleotide programmable nucleotide binding domain. In various embodiments, the base editor (BE) system comprises a nucleobase editor domain selected from an adenosine deaminase or a cytidine deaminase, and a domain having nucleic acid sequence specific binding activity. In some embodiments, the base editor system comprises (1) a base editor (BE) comprising a polynucleotide programmable DNA binding domain and a deaminase domain for deaminating one or more nucleobases in a target nucleotide sequence; and (2) one or more guide RNAs in conjunction with the polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the base editor is a cytidine base editor (CBE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE) or a cytidine or cytosine base editor (CBE). In some embodiments, the base editor system (e.g., a base editor system comprising a cytidine deaminase) comprises a uracil glycosylase inhibitor or other agent or peptide (e.g., a uracil stabilizing protein such as provided in WO2022015969, the disclosure of which is incorporated herein by reference in its entirety for all purposes) that inhibits the inosine base excision repair system. The term “Cas9” or “Cas9 domain” refers to an RNA guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and / or the gRNA binding domain of Cas9). A Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat) associated nuclease. The term “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and Schirmer, R. H., Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids can be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and Schirmer, R. H., supra). Non- limiting examples of conservative mutations include amino acid substitutions of amino acids, for example, lysine for arginine and vice versa such that a positive charge can be maintained; glutamic acid for aspartic acid and vice versa such that a negative charge can be maintained; serine for threonine such that a free –OH can be maintained; and glutamine for asparagine such that a free –NH2 can be maintained. Amino acids generally can be grouped into classes according to the following common side- chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, He; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. In some embodiments, conservative substitutions can involve the exchange of a member of one of these classes for another member of the same class. In some embodiments, non- conservative amino acid substitutions can involve exchanging a member of one of these classes for another class. The term “coding sequence” or “protein coding sequence” as used interchangeably herein refers to a segment of a polynucleotide that codes for a protein. Coding sequences can also be referred to as open reading frames. The region or sequence is bounded nearer the 5′ end by a start codon and nearer the 3′ end with a stop codon. Stop codons useful with the base editors described herein include the following: TAG, TAA, and TGA. By “complex” is meant a combination of two or more molecules whose interaction relies on inter-molecular forces. Non-limiting examples of inter-molecular forces include covalent and non-covalent interactions. Non-limiting examples of non-covalent interactions include hydrogen bonding, ionic bonding, halogen bonding, hydrophobic bonding, van der Waals interactions (e.g., dipole-dipole interactions, dipole-induced dipole interactions, and London dispersion forces), and π-effects. In an embodiment, a complex comprises polypeptides, polynucleotides, or a combination of one or more polypeptides and one or more polynucleotides. In one embodiment, a complex comprises one or more polypeptides that associate to form a base editor (e.g., base editor comprising a nucleic acid programmable DNA binding protein, such as Cas9, and a deaminase) and a polynucleotide (e.g., a guide RNA). In an embodiment, the complex is held together by hydrogen bonds. It should be appreciated that one or more components of a base editor (e.g., a deaminase, or a nucleic acid programmable DNA binding protein) may associate covalently or non-covalently. As one example, a base editor may include a deaminase covalently linked to a nucleic acid programmable DNA binding protein (e.g., by a peptide bond). Alternatively, a base editor may include a deaminase and a nucleic acid programmable DNA binding protein that associate noncovalently (e.g., where one or more components of the base editor are supplied in trans and associate directly or via another molecule such as a protein or nucleic acid). In an embodiment, one or more components of the complex are held together by hydrogen bonds. By “cytosine” or “4-Aminopyrimidin-2(1H)-one” is meant a purine nucleobase with the molecular formula C4H5N3O, having the structure and corresponding to CAS No.71-30-7. By “cytidine” is meant a cytosine molecule attached to a ribose sugar via a glycosidic bond, having the structure , and corresponding to CAS No.65-46-3. Its molecular formula is C9H13N3O5. By “Cytidine Base Editor (CBE)” is meant a base editor comprising a cytidine deaminase. Non-limiting examples of cytidine deaminase base editor amino acid sequences include amino acid sequences for BE4max (SEQ ID NO: 553), YE1-BE4 (SEQ ID NO: 554), YE2-BE4 (SEQ ID NO: 555), YEE-BE4 (SEQ ID NO: 556), EE-BE4 (SEQ ID NO: 557), R33A-BE4 (SEQ ID NO: 558), R33A+K34A-BE4 (SEQ ID NO: 559), APOBEC3A (A3A)-BE4 (SEQ ID NO: 560), APOBEC3B (A3B)-BE4 (SEQ ID NO: 561), APOBEC3G (A3G)-BE4 (SEQ ID NO: 562), AID-BE4 (SEQ ID NO: 563), CDA-BE4 (SEQ ID NO: 564), FERNY-BE4 (SEQ ID NO: 565), evolved APOBEC3A (eA3A)-BE4 (SEQ ID NO: 566), AALN-BE4 (SEQ ID NO: 567), BE4max modified with SpCas9-NG (SEQ ID NO: 568), YE1-SpCas9-NG (YE1- NG) (SEQ ID NO: 569), YE2-SpCas9-NG (SEQ ID NO: 570), YEE-SpCas9-NG (SEQ ID NO: 571), EE-SpCas9-NG (SEQ ID NO: 572), R33A+K34A-SpCas9-NG (SEQ ID NO: 573), YE1- CP1028 (YE1-BE4-CP1028, or YE1-CP) (SEQ ID NO: 574), YE2-CP1028 (YE2-BE4-CP1028) (SEQ ID NO: 575), YEE-CP1028 (YEE-BE4-CP1028) (SEQ ID NO: 576), EE-CP1028 (EE- BE4-CP1028) (SEQ ID NO: 577), R33A+K34A-CP1028 (R33A+K34A-BE4-CP1028) (SEQ ID NO: 578), BE4max (with nickase) (SEQ ID NO: 597), BE4 (SEQ ID NO: 598), BE4 with His tag (SEQ ID NO: 599), BE4max (SEQ ID NO: 600), AncBE4max 689 (SEQ ID NO: 601), and AncBE4max 687 (SEQ ID NO: 602). By “Cytidine Base Editor (CBE) polynucleotide” is meant a polynucleotide encoding a CBE. Non-limiting examples of polynucleotide sequences encoding cytidine deaminase base editors include those encoding BE4max (SEQ ID NO: 616), AncBE4max689 (SEQ ID NO: 617), and AncBE4max687 (SEQ ID NO: 618). By “cytidine deaminase” or “cytosine deaminase” is meant a polypeptide or fragment thereof capable of deaminating cytidine or cytosine. In embodiments, the cytidine or cytosine is present in a polynucleotide. In one embodiment, the cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine. The terms “cytidine deaminase” and “cytosine deaminase” are used interchangeably throughout the application. Petromyzon marinus cytosine deaminase 1 (PmCDA1) (SEQ ID NO: 13-14), Activation-induced cytidine deaminase (AICDA) (SEQ ID NOs: 15-21), and APOBEC (SEQ ID NOs: 12-61) are exemplary cytidine deaminases. Further exemplary cytidine deaminase (CDA) sequences are provided in the Sequence Listing as SEQ ID NOs: 62-66 and SEQ ID NOs: 67-189. Non-limiting examples of cytidine deaminases include those described in PCT / US20 / 16288, PCT / US2018 / 021878, 180802-021804 / PCT, PCT / US2018 / 048969, PCT / US2016 / 058344, PCT / US2020 / 062428, and PCT / US2019 / 033848, the disclosures of which are incorporated herein by reference in their entireties for all purposes. Non-limiting examples of cytidine deaminase amino acid sequences include amino acid sequences for Rat APOBEC1 (SEQ ID NO: 579), Human APOBEC1 (SEQ ID NO: 580), Human APOBEC3 (SEQ ID NO: 581), Human APOBEC3B (SEQ ID NO: 582), Human APOBEC3G (SEQ ID NO: 583), evoAPOBEC3A(eA3A) (SEQ ID NO: 584), evoCDA (SEQ ID NO: 585), evoAPOBECl (SEQ ID NO: 586), YE1 (SEQ ID NO: 587), YE2 (SEQ ID NO: 588), YEE (SEQ ID NO: 589), EE (SEQ ID NO: 590), R33A (SEQ ID NO: 591), R33A+K34A (SEQ ID NO: 592), AALN (SEQ ID NO: 593), FERNY (SEQ ID NO: 594), evoFERNY (SEQ ID NO: 595), APOBEC (SEQ ID NO: 619), Anc686 APOBEC (SEQ ID NO: 620), Human APOBEC- 3G D316R_D317R (SEQ ID NO: 621), Human APOBEC-3G chain A (SEQ ID NO: 622), Human APOBEC3-G chain A D120R_D121R (SEQ ID NO: 623), Mouse APOBEC3 (SEQ ID NO: 624), Rat APOBEC3 (SEQ ID NO: 625), Rhesus macaque APOBEC-3G (SEQ ID NO: 626), Chimpanzee APOBEC-3G (SEQ ID NO: 627), Green Monkey APOBEC-3G (SEQ ID NO: 628), Human APOBEC-3G (SEQ ID NO: 629), Human APOBEC-3F (SEQ ID NO: 630), Human APOBEC-3B (SEQ ID NO: 631), Rat APOBEC-3B (SEQ ID NO: 632), Bovine APOBEC-3B (SEQ ID NO: 633), Chimpanzee APOBEC-3B (SEQ ID NO: 634), Gorilla APOBEC-3C (SEQ ID NO: 635), Human APOBEC-3A (SEQ ID NO: 636), Rhesus macaque APOBEC-3A (SEQ ID NO: 637), Bovine APOBEC-3A (SEQ ID NO: 638), Human APOBEC- 3H (SEQ ID NO: 639), Human APOBEC-3D (SEQ ID NO: 640), Rat ABOPEC1 (SEQ ID NO: 641), Anc689 APOBEC (SEQ ID NO: 642), Anc687 APOBEC (SEQ ID NO: 643), Anc686 APOBEC (SEQ ID NO: 644), Anc655 APOBEC (SEQ ID NO: 645), and Anc733 APOBEC (SEQ ID NO: 646). By “cytidine deaminase polynucleotide” is meant a polynucleotide encoding a cytidine deaminase. Non-limiting examples of polynucleotide sequences encoding cytidine deaminase domains include those encoding Rat APOBEC1 (SEQ ID NO: 604), Anc689 APOBEC (SEQ ID NO: 605), Anc687 APOBEC (SEQ ID NO: 606), Anc686 APOBEC (SEQ ID NO: 607), Anc655 APOBEC (SEQ ID NO: 608), Anc733 APOBEC (SEQ ID NO: 609), Rat APOBEC1 (SEQ ID NO: 610), Anc689 APOBEC (SEQ ID NO: 611), Anc687 APOBEC (SEQ ID NO: 612), Anc686 APOBEC (SEQ ID NO: 613), Anc655 APOBEC (SEQ ID NO: 614), and Anc733 APOBEC (SEQ ID NO: 615). By “cytosine deaminase activity” is meant catalyzing the deamination of cytosine or cytidine. In one embodiment, a polypeptide having cytosine deaminase activity converts an amino group to a carbonyl group. In an embodiment, a cytosine deaminase converts cytosine to uracil (i.e., C to U) or 5-methylcytosine to thymine (i.e., 5mC to T). In some embodiments, a cytosine deaminase as provided herein has increased cytosine deaminase activity (e.g., at least 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold or more) relative to a reference cytosine deaminase. The term “deaminase” or “deaminase domain,” as used herein, refers to a protein or fragment thereof that catalyzes a deamination reaction. The term “detect” refers to identifying the presence, absence or amount of the analyte to be detected. In one embodiment, a sequence alteration in a polynucleotide or polypeptide is detected. In another embodiment, the presence of indels is detected. In one embodiment LPa is detected in the blood serum or a tissue of a subject. By “detectable label” is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an enzyme linked immunosorbent assay (ELISA)), biotin, digoxigenin, or haptens. By “disease” is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Exemplary diseases include cardiovascular disease. Non-limiting examples of cardiovascular diseases include aortic stenosis, atherosclerotic cardiovascular disease (ASCVD), abnormal heart rhythms, or arrhythmias, aorta disease and Marfan syndrome, congenital heart disease, coronary artery disease (narrowing of the arteries), coronary heart disease (CHD), deep vein thrombosis and pulmonary embolism, heart attack, heart failure, heart muscle disease (cardiomyopathy), heart valve disease, pericardial disease, peripheral vascular disease, rheumatic heart disease, stroke, and vascular disease (blood vessel disease). By “dual editing activity” or “dual deaminase activity” is meant having adenosine deaminase and cytidine deaminase activity. In one embodiment, a base editor having dual editing activity has both A→G and C→T activity, wherein the two activities are approximately equal or are within about 10% or 20% of each other. In another embodiment, a dual editor has A→G activity that no more than about 10% or 20% greater than C→T activity. In another embodiment, a dual editor has A→G activity that is no more than about 10% or 20% less than C→T activity. In some embodiments, the adenosine deaminase variant has predominantly cytosine deaminase activity, and little, if any, adenosine deaminase activity. In some embodiments, the adenosine deaminase variant has cytosine deaminase activity, and no significant or no detectable adenosine deaminase activity. Non-limiting examples of proteins having dual deaminase activity include those described in International Patent Application Publications No. WO 2024 / 040083 and WO 2022 / 204574, the disclosures of which are hereby incorporated by reference in their entireties for all purposes. By “effective amount” is meant the amount of an agent (e.g., a base editor, cell) as described herein, that is required to ameliorate the symptoms of a disease relative to an untreated patient or an individual without disease, i.e., a healthy individual, or is the amount of the agent sufficient to elicit a desired biological response. The effective amount of active compound(s) used to practice embodiments of the present disclosure for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an “effective” amount. In one embodiment, an effective amount is the amount of a base editor of the disclosure sufficient to introduce an alteration in a gene of interest in a cell (e.g., a cell in vitro or in vivo). In one embodiment, an effective amount is the amount of a base editor required to achieve a therapeutic effect. Such therapeutic effect need not be sufficient to alter a pathogenic gene in all cells of a subject, tissue or organ, but only to alter the pathogenic gene in about 1%, 5%, 10%, 25%, 50%, 75% or more of the cells present in a subject, tissue or organ. In one embodiment, an effective amount is sufficient to ameliorate one or more symptoms of a disease. For example, an effective amount of a base editor system described herein is administered to a patient where the administration is associated with a decrease in serum concentrations of LPa in the patient. The term “exonuclease” refers to a protein or polypeptide capable of removing successive nucleotides from either the 5′ or 3′ end of a polynucleotide. The term “endonuclease” refers to a protein or polypeptide capable of catalyzing the cleavage of internal regions in a polynucleotide. By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids. In some embodiments, the fragment is a functional fragment. By “gene” is meant a polynucleotide sequence that is transcribed as a single unit. By “guide polynucleotide” is meant a polynucleotide or polynucleotide complex which is specific for a target sequence and can form a complex with a polynucleotide programmable nucleotide binding domain protein (e.g., Cas9 or Cpf1). In an embodiment, the guide polynucleotide is a guide RNA (gRNA). gRNAs can exist as a complex of two or more RNAs, or as a single RNA molecule. “Hybridization” means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds. By “increases” is meant a positive alteration of at least 10%, 25%, 50%, 75%, or 100%, or about 1.5 fold, about 2 fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7- fold, about 8-fold, about 9-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, or about 100-fold. The terms “inhibitor of base repair”, “base repair inhibitor”, “IBR” or their grammatical equivalents refer to a protein that is capable in inhibiting the activity of a nucleic acid repair enzyme, for example a base excision repair enzyme. An “intein” is a fragment of a protein that is able to excise itself and join the remaining fragments (the exteins) with a peptide bond in a process known as protein splicing. The terms “isolated,” “purified,” or “biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings. “Purify” denotes a degree of separation that is higher than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this disclosure is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high performance liquid chromatography. The term “purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. For a protein that can be subjected to modifications, for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified. By “isolated polynucleotide” is meant a nucleic acid molecule that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the disclosure is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. In addition, the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence. By an “isolated polypeptide” is meant a polypeptide of the disclosure that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. In embodiments, the preparation is at least 75%, at least 90%, or at least 99%, by weight, a polypeptide of the disclosure. An isolated polypeptide of the disclosure may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis. The term “linker”, as used herein, refers to a molecule that links two moieties. In one embodiment, the term “linker” refers to a covalent linker (e.g., covalent bond) or a non-covalent linker. By “marker” is meant any protein or polynucleotide having an alteration in expression, level, structure, or activity that is associated with a disease or disorder. In an embodiment, the level of LPa in a sample (e.g., blood, serum, plasma, tissue) is a marker of cardiovascular disease and / or atherosclerosis. The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)). The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g., nucleotides and / or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and / or double- stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA / RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and / or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5- methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5- propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7- deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages). The term “nuclear localization sequence,” “nuclear localization signal,” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus. Nuclear localization sequences are known in the art and described, for example, in Plank et al., International PCT application, PCT / EP2000 / 011690, filed November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS described, for example, by Koblan et al., Nature Biotech.2018 doi:10.1038 / nbt.4172. In some embodiments, an NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV (SEQ ID NO: 190),KRPAATKKAGQAKKKK (SEQ ID NO: 191), KKTELQTTNAENKTKKL (SEQ ID NO: 192),KRGINDRNFWRGENGRKTR (SEQ ID NO: 193), RKSGKIAAIVVKRPRK (SEQ ID NO: 194),PKKKRKV (SEQ ID NO: 195), MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 196), PKKKRKVEGADKRTADGSEFESPKKKRKV (SEQ ID NO: 328), or RKSGKIAAIVVKRPRKPKKKRKV (SEQ ID NO: 329). The term “nucleobase,” “nitrogenous base,” or “base,” used interchangeably herein, refers to a nitrogen-containing biological compound that forms a nucleoside, which in turn is a component of a nucleotide. The ability of nucleobases to form base pairs and to stack one upon another leads directly to long-chain helical structures such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). Five nucleobases – adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) – are called primary or canonical. Adenine and guanine are derived from purine, and cytosine, uracil, and thymine are derived from pyrimidine. DNA and RNA can also contain other (non-primary) bases that are modified. Non-limiting exemplary modified nucleobases can include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5- methylcytosine (m5C), and 5-hydromethylcytosine. Hypoxanthine and xanthine can be created through mutagen presence, both of them through deamination (replacement of the amine group with a carbonyl group). Hypoxanthine can be modified from adenine. Xanthine can be modified from guanine. Uracil can result from deamination of cytosine. A “nucleoside” consists of a nucleobase and a five carbon sugar (either ribose or deoxyribose). Examples of a nucleoside include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U), deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. Examples of a nucleoside with a modified nucleobase includes inosine (I), xanthosine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), and pseudouridine (Ψ). A “nucleotide” consists of a nucleobase, a five carbon sugar (either ribose or deoxyribose), and at least one phosphate group. Non-limiting examples of modified nucleobases and / or chemical modifications that a modified nucleobase may include are the following: pseudo-uridine, 5-Methyl-cytosine, 2′-O- methyl-3′-phosphonoacetate, 2′-O-methyl thioPACE (MSP), 2′-O-methyl-PACE (MP), 2′-fluoro RNA (2′-F-RNA), constrained ethyl (S-cEt), 2′-O-methyl (‘M’), 2′-O-methyl-3′- phosphorothioate (‘MS’), 2′-O-methyl-3′-thiophosphonoacetate (‘MSP’), 5-methoxyuridine, phosphorothioate, and N1-Methylpseudouridine. The term “nucleic acid programmable DNA binding protein” or “napDNAbp” may be used interchangeably with “polynucleotide programmable nucleotide binding domain” to refer to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid or guide polynucleotide (e.g., gRNA), that guides the napDNAbp to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. A Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, for example a nuclease active Cas9, a Cas9 nickase (nCas9), or a nuclease inactive Cas9 (dCas9). Non-limiting examples of nucleic acid programmable DNA binding proteins include, Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, and Cas12j / CasΦ (Cas12j / Casphi). Non-limiting examples of Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, Cas12j / CasΦ, Cpf1, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Type II Cas effector proteins, Type V Cas effector proteins, Type VI Cas effector proteins, CARF, DinG, homologues thereof, or modified or engineered versions thereof. Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, although they may not be specifically listed in this disclosure. See, e.g., Makarova et al. “Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?” CRISPR J.2018 Oct;1:325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., “Functionally diverse type V CRISPR-Cas systems” Science.2019 Jan 4;363(6422):88-91. doi: 10.1126 / science.aav7271, the entire contents of each are hereby incorporated by reference. Exemplary nucleic acid programmable DNA binding proteins and nucleic acid sequences encoding nucleic acid programmable DNA binding proteins are provided in the Sequence Listing as SEQ ID NOs: 197-231, 232-245, 254-257, 260, and 378. In some embodiments, the napDNAbp is a (CRISPR-associated system) Cas9 endonuclease, for example, Cas9 (Csnl) from Streptococcus pyogenes (e.g., SEQ ID NO: 197), Cas9 from Neisseria meningitidis (NmeCas9; SEQ ID NO: 208), Nme2Cas9 (SEQ ID NO: 209), Streptococcus constellatus (ScoCas9), or derivatives thereof (e.g., a sequence with at least about 85% sequence identity to a Cas9, such as Nme2Cas9 or spCas9). Further non-limiting examples of nucleic acid programmable DNA binding proteins include those disclosed or referenced in Rufflow, et al., “Design of highly functional genome editors by modeling of the universe of CRISPR-Cas Sequences,” bioRxiv, posted April 22, 2024, doi: 10.1101 / 2024.04.22.590591, the disclosure of which is incorporated herein by reference in its entirety for all purposes, which were designed using artificial intelligence. In some embodiments, the napDNAbp is OpenCRISPR-1, or a variant thereof (e.g., a variant comprising a D10A amino acid alteration and / or lacking an N-terminal methionine). Further non-limiting examples of nucleic acid programmable DNA binding proteins include those disclosed in International Patent Application No. PCT / US2019 / 047996. The terms “nucleobase editing domain” or “nucleobase editing protein,” as used herein, refers to a protein or enzyme that can catalyze a nucleobase modification in RNA or DNA, such as cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine), and adenine (or adenosine) to hypoxanthine (or inosine) deaminations, as well as non-templated nucleotide additions and insertions. In some embodiments, the nucleobase editing domain is a deaminase domain (e.g., an adenine deaminase or an adenosine deaminase; or a cytidine deaminase or a cytosine deaminase). As used herein, “obtaining” as in “obtaining an agent” includes synthesizing, purchasing, or otherwise acquiring the agent. By “OpenCRISPR-1 polypeptide” is meant a protein with an amino acid sequence having at least about 85% amino acid sequence identity to SEQ ID NO: 463, or a fragment thereof that associates with a nucleic acid, such as a guide nucleic acid or guide polynucleotide, that guides the napDNAbp to a specific nucleic acid sequence. Further details relating to the OpenCRISPR-1 polypeptide are disclosed in Rufflow, et al., “Design of highly functional genome editors by modeling of the universe of CRISPR-Cas Sequences,” bioRxiv, posted April 22, 2024, doi: 10.1101 / 2024.04.22.590591, the disclosure of which is incorporated herein by reference in its entirety for all purposes. By “OpenCRISPR-1 polynucleotide” is meant a nucleic acid molecule encoding an OpenCRISPR-1 polypeptide, as well as the introns, exons, 3′ untranslated regions, 5′ untranslated regions, and regulatory sequences associated with its expression, or fragments thereof. In embodiments, an OpenCRISPR-1 polynucleotide is the genomic sequence, cDNA, mRNA, or gene associated with and / or required for OpenCRISPR-1 expression. An exemplary OpenCRISPR-1 nucleotide sequence is provided at SEQ ID NO: 464. In various embodiments, a guide RNA suitable for use in combination with an OpenCRISPR-1 polypeptide contains a scaffold having at least 85% sequence identity to a nucleotide sequence selected from the following, or fragments thereof capable of binding to an OpenCRISPR-1 polypeptide: GUUUUAGAGCUGUGUUGAAAAACACAGCAAGUUAAAAUAAGGCUUUGUCCGUAUCCAACUUGAA AAAGUGAGCACCGAUUCGGUGC (SEQ ID NO: 465); GUUUUAGAGCUGGAAACAGCAAGUUAAAAUAAGGCUUUGUCCGUAUCCAACUUGAAAAAGUGAG CACCGAUUCGGUGC (SEQ ID NO: 466); and GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCA CCGAGUCGGUGC (SEQ ID NO: 467). By “subject” or “patient” is meant a mammal, including, but not limited to, a human or non-human mammal. In embodiments, the mammal is a bovine, equine, canine, ovine, rabbit, rodent, nonhuman primate, or feline. In an embodiment, “patient” refers to a mammalian subject with a higher than average likelihood of developing a disease or a disorder. Exemplary patients can be humans, non-human primates, cats, dogs, pigs, cattle, cats, horses, camels, llamas, goats, sheep, rodents (e.g., mice, rabbits, rats, or guinea pigs) and other mammalians that can benefit from the therapies disclosed herein. Exemplary human patients can be male and / or female. “Patient in need thereof” or “subject in need thereof” is referred to herein as a patient diagnosed with, at risk or having, predetermined to have, or suspected of having a disease or disorder. The terms “pathogenic mutation”, “pathogenic variant”, “disease causing mutation”, “disease causing variant”, “deleterious mutation”, or “predisposing mutation” refers to a genetic alteration or mutation that is associated with a disease or disorder or that increases an individual’s susceptibility or predisposition to a certain disease or disorder. In some embodiments, the pathogenic mutation comprises at least one wild-type amino acid substituted by at least one pathogenic amino acid in a protein encoded by a gene. In some embodiments, the pathogenic mutation is in a terminating region (e.g., stop codon). In some embodiments, the pathogenic mutation is in a non-coding region (e.g., intron, promoter, etc.). The terms “protein”, “peptide”, “polypeptide”, and their grammatical equivalents are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. A protein, peptide, or polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof. The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. The term “recombinant” as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence. By “reduces” is meant a negative alteration of at least 10%, 25%, 50%, 75%, or 100%. In embodiments, administration of a base editor system of the disclosure to a subject is associated with a reduction in serum levels of LPa in the subject and / or a reduced incidence of coronary heart disease in the subject. By “reference” is meant a standard or control condition. In an embodiment, the reference is the level of LPa present in the blood of a subject not having a cardiovascular disease or atherosclerosis or having a low incidence of cardiovascular disease. In another embodiment, the reference is the level of LPa present in the blood of a subject having a cardiovascular disease or atherosclerosis or having an elevated risk for developing a cardiovascular disease. In another embodiment, a reference is an unedited cell. Another example of a reference is a base editor system lacking one or more alterations or one or more components of a base editor system of interest. In an embodiment, a reference is a base editor system containing a base editor polypeptide, or one or more polynucleotide encoding the same, and / or guide polynucleotide, or a polynucleotide encoding the same, that differs from that of a base editor system of interest. In one embodiment, the reference is a wild-type or healthy cell. In other embodiments and without limitation, a reference is an untreated cell that is not subjected to a test condition, or is subjected to placebo or normal saline, medium, buffer, and / or a control vector that does not harbor a polynucleotide of interest. A “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will generally be at least about 16 amino acids, at least about 20 amino acids, at least about 25 amino acids, about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, at least about 60 nucleotides, at least about 75 nucleotides, about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween. In some embodiments, a reference sequence is a wild-type sequence of a protein of interest. In other embodiments, a reference sequence is a polynucleotide sequence encoding a wild-type protein. The term “RNA-programmable nuclease,” and “RNA-guided nuclease” refer to a nuclease that forms a complex with (e.g., binds or associates with) one or more RNA(s) that is not a target for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease-RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). The term “single nucleotide polymorphism (SNP)” refers to a variation in a single nucleotide that occurs at a specific position in the genome, where each variation is present to some appreciable degree within a population (e.g., > 1%). SNPs can fall within coding regions of genes, non-coding regions of genes, or in the intergenic regions (regions between genes). In some embodiments, SNPs within a coding sequence do not necessarily change the amino acid sequence of the protein that is produced, due to degeneracy of the genetic code. SNPs in the coding region are of two types: synonymous and nonsynonymous SNPs. Synonymous SNPs do not affect the protein sequence, while nonsynonymous SNPs change the amino acid sequence of protein. The nonsynonymous SNPs are of two types: missense and nonsense. SNPs that are not in protein-coding regions can still affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of noncoding RNA. Gene expression affected by this type of SNP is referred to as an eSNP (expression SNP) and can be upstream or downstream from the gene. A single nucleotide variant (SNV) is a variation in a single nucleotide without any limitations of frequency and can arise in somatic cells. A somatic single nucleotide variation can also be called a single-nucleotide alteration. By “specifically binds” is meant a nucleic acid molecule, polypeptide, polypeptide / polynucleotide complex, compound, or molecule that recognizes and binds a polypeptide and / or nucleic acid molecule of the disclosure, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample. By “substantially identical” is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence. In one embodiment, a reference sequence is a wild-type amino acid or nucleic acid sequence. In another embodiment, a reference sequence is any one of the amino acid or nucleic acid sequences described herein. In one embodiment, such a sequence is at least about 60%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or even 99.99%, identical at the amino acid level or nucleic acid level to the sequence used for comparison. Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis.53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a functional fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double- stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the disclosure include any nucleic acid molecule that encodes a polypeptide of the disclosure or a functional fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence but will typically exhibit substantial identity. Polynucleotides having “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By “hybridize” is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol.152:399; Kimmel, A. R. (1987) Methods Enzymol.152:507). By “split” is meant divided into two or more fragments. A “split polypeptide” or “split protein” refers to a protein that is provided as an N- terminal fragment and a C-terminal fragment translated as two separate polypeptides from a nucleotide sequence(s). The polypeptides corresponding to the N-terminal portion and the C- terminal portion of the split protein may be spliced in some embodiments to form a “reconstituted” protein. In embodiments, the split polypeptide is a nucleic acid programmable DNA binding protein (e.g. a Cas9) or a base editor. The term “target site” refers to a nucleotide sequence or nucleobase of interest within a nucleic acid molecule that is modified. In embodiments, the modification is deamination of a base. The deaminase can be a cytidine or an adenine deaminase. The fusion protein or base editing complex comprising a deaminase may comprise a dCas9-adenosine deaminase fusion protein, a Cas12b-adenosine deaminase fusion, or a base editor disclosed herein. As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disorder and / or symptoms associated therewith or obtaining a desired pharmacologic and / or physiologic effect. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, reduces the intensity of, or cures a disease and / or adverse symptom attributable to the disease. In some embodiments, the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a disease or condition. To this end, the presently disclosed methods comprise administering a therapeutically effective amount of a composition as described herein. By “uracil glycosylase inhibitor” or “UGI” is meant an agent that inhibits the uracil- excision repair system. Base editors comprising a cytidine deaminase convert cytosine to uracil, which is then converted to thymine through DNA replication or repair. In various embodiments, a uracil DNA glycosylase (UGI) prevent base excision repair which changes the U back to a C. In some instances, contacting a cell and / or polynucleotide with a UGI and a base editor prevents base excision repair which changes the U back to a C. An exemplary UGI comprises an amino acid sequence as follows: >splP14739IUNGI_BPPB2 Uracil-DNA glycosylase inhibitor MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPE YKPWALVIQDSNGENKIKML (SEQ ID NO: 231). In some embodiments, the agent inhibiting the uracil-excision repair system is a uracil stabilizing protein (USP). See, e.g., WO 2022015969 A1, incorporated herein by reference. As used herein, the term "vector" refers to a means of introducing a nucleic acid molecule into a cell, resulting in a transformed cell. Vectors include plasmids, transposons, phages, viruses, liposomes, lipid nanoparticles, and episomes. Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and / or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting. As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended. This wording indicates that specified elements, features, components, and / or method steps are present, but does not exclude the presence of other elements, features, components, and / or method steps. Any embodiments specified as “comprising” a particular component(s) or element(s) are also contemplated as “consisting of” or “consisting essentially of” the particular component(s) or element(s) in some embodiments. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure. The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Reference in the specification to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. BRIEF DESCRIPTION OF THE DRAWINGS FIG.1 provides a schematic diagram showing LP(a) structure, properties, regulation, and relation to disease. Lipoprotein(a) [LP(a)] contains a lipid-rich domain, primarily cholesteryl esters, and apolipoprotein(a) [apo(a)]. Apo(a) binds to apolipoprotein B100 (apoB) via a single disulfide bond (a) at a location close the low-density lipoprotein receptor binding site of apoB (b). Apo(a) contains repeated kringle (K) structures (KIV and KV), comparable with those in plasminogen. There are 10 different subtypes of apo(a) KIV, where type 2 is present in multiple copies, resulting in a highly variable molecular mass (300–800 kDa). Apo(a) is compositionally unique among apolipoproteins with a high carbohydrate content (≈28%). Proinflammatory and proatherogenic oxidized phospholipids bind to apo(a) KIV type 10 (c) and can also be found in the lipid phase. Apo(a) contains a protease domain (d) that lacks enzymatic activity. The Lp(a) concentration is heterogeneous and, to a major extent, controlled by genetics, inversely related to the copy number variation in the LPA gene. Other factors such as ethnicity and race and medical and environmental conditions also play roles in Lp(a) regulation. Lp(a) has been associated with increased risks of atherosclerosis, thrombosis, and aortic valve calcification. FIG.2 provides a schematic diagram showing single nucleotide polymorphisms (SNPs) reported to modify Lp(a) concentrations, including multiple variants in the KIV-2 region. The exons are numbered according to the domain that they encode (1–10: KIV-1 to KIV-10, L. leader sequence, P. protease domain, 5’: 5′ UTR, 3’: 3′ UTR). For orientation, three exons carry a superscript that reports the exon number in the genome sequence hg38. SNPs that have been associated with higher Lp(a) concentrations are shown above the gene structure. SNPs that have been associated with lower Lp(a) are shown below. SNPs that prevent protein production completely (null alleles) are underlined. FIG.2 is taken from Coassin and Kronenberg, Atherosclerosis 349:17–35, 2022 (doi.org / 10.1016 / j.atherosclerosis.2022.04.003), the disclosure of which is incorporated herein by reference in its entirety for all purposes. FIG.3 provides a violin plot showing the distribution of serum LP(a) concentrations (mg / dL) in subjects containing 0, 1, or 2 (see x-axis) LP(a) polynucleotide variants containing the SNP chr6:160532610:A>G. FIG.4 provides a plot showing maximum C to T or A to G base editing frequencies measured in HEK293T cells transfected with the indicated base editor systems. In FIG.4, the following notation is used to identify each base editor system indicated along the x-axis: the first term preceding the hyphen (“-“) indicates the guide polynucleotide of the base editor system (e.g., gRNA3512), the term “ABE” or “CBE” indicates that the base editor was an “adenosine deaminase base editor” or a “cytidine deaminase base editor,” respectively, and the last term, which follows the final underscore (“_”), indicates the PAM sequence recognized by the nucleic acid programmable DNA binding protein (napDNAbp) domain of the base editor (e.g., “NGG,” where “N” indicates A, C, T, or G). The guide polynucleotides of the base editor systems of FIG.4 targeted the base editors to effect the introduction of a stop codon or to disrupt a splice site in an LPA polynucleotide in the HEK293T cells. FIG.5 provides a plot showing maximum C to T or A to G base editing frequencies measured in HEK293T cells transfected with the indicated base editor systems. In FIG.5, the following notation is used to identify each base editor system indicated along the x-axis: the first term preceding the hyphen (“-“) indicates the guide polynucleotide of the base editor system (e.g., gRNA3420), ABE or CBE indicate that the base editor was an “adenosine deaminase base editor” or a “cytidine deaminase base editor,” respectively, and the last term, which follows the final underscore (“_”) indicates the PAM sequence recognized by the nucleic acid programmable DNA binding protein (napDNAbp) domain of the base editor (e.g., “NNNRRT,” where “N” indicates A, C, T, or G, and where “R” is A or G). The guide polynucleotides of the base editor systems of FIG.5 targeted the base editors to effect the introduction of a stop codon or to disrupt a splice site in an LPA polynucleotide in the HEK293T cells. DETAILED DESCRIPTION Provided herein are base editors and guide RNAs (gRNAs) for use in editing, modifying, or altering a target polynucleotide. In particular embodiments, a base editor of the present disclosure modifies an LPA polynucleotide. In particular embodiments, a base editor of the disclosure introduces a stop codon, protective SNP, missense mutation, or indel (e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10-nucleotide acid insertion or deletion (indel)) alteration in an LPA polynucleotide, or disrupts a splice site in the LPA polynucleotide. In embodiments, the alterations are associated with a reduction in activity or levels of an LPA polypeptide and / or polynucleotide in a cell. In some embodiments, the alterations are associated with reduced incidence of atherosclerotic cardiovascular disease (ASCVD) in a subject. In some cases, the alterations are associated with a reduction in incidence of heart attack, stroke, and / or aortic stenosis in a subject. The various aspects and embodiments of the disclosure are based, at least in part, upon the discovery that base editing (e.g., disruption of splice acceptor or splice donor, or introduction of a stop codon, missense mutation, or indel alteration) can be used to reduce the expression of a LPA polypeptide associated with cardiovascular disease or to introduce to an LPA polypeptide single nucleotide polymorphisms (SNPs) to an LPA polynucleotide that were previously found to be associated with reduced risk of cardiovascular disease in a subject. In particular, reducing activity and / or expression of the LPA polypeptide or introducing protective SNPs to the polynucleotide encoding the LPA polypeptide in a subject diagnosed with or having a propensity to develop cardiovascular disease can be an effective treatment strategy. This reduction in activity and / or expression or introduction of an SNP can be effected using any of the base editing systems and methods provided herein. Accordingly, the disclosure features compositions and methods for editing an LPA polynucleotide. The edit to the LPA polynucleotide is associated with a reduction in expression of an LPA polypeptide in a cell of a subject and / or a reduction in symptoms associated with cardiovascular disease. In some embodiments, the edit to the LPA polynucleotide is associated with a reduction in LPA concentrations in the blood of a subject. In some instances, the LPA concentrations are reduced by about or at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80%. In some embodiments, the LPA concentrations are reduced to less than 100 mg / dL, 90 mg / dL, 80 mg / dL, 70 mg / dL, 60 mg / dL, 50 mg / dL, 40 mg / dL, 30 mg / dL, or 20 mg / dL. In embodiments, the methods of the present disclosure include disrupting splicing of an LPA polynucleotide transcript. For example, the base editors or base editor systems provided herein can be used for editing a nucleobase in the splice acceptor situated 5′ of an exon of the LPA polynucleotide. In some embodiments, the target sequence is a splice acceptor in the intron of an intron sequence adjacent to an exon of the LPA polynucleotide and is associated with a change in the splice acceptor compared to a wild-type splice acceptor. In some embodiments, the deamination of an A or C nucleobase in the splice acceptor results in disruption of splicing of the mRNA transcript during transcription. In some embodiments, the subject has or has the potential to develop cardiovascular disease. In some instances, the methods of the present disclosure include modifying an LPA polynucleotide to introduce a stop codon, indel, or missense mutation associated with a reduction in levels or activity of the LPA polynucleotide and / or polypeptide. The alterations can be effected by a base editor system, such as those described herein. In some cases, the methods of the present disclosure include modifying an LPA polynucleotide to introduce a single nucleotide polymorphism (SNP) known to be associated with reduced incidence of cardiovascular disease in a subject. Such SNPs may be referred to as protective alterations or variants of LPA. Non-limiting examples of such SNPs include missense variants of i significantly associated with decreased serum LPA concentrations in the United Kingdom Biobank (UKBB) (n=10) or null alleles shown previously to be associated with decreased serum LPA concentrations (n=10). In some cases, a variant may require a transversion alteration, however the corresponding transition variant may have a similar effect on serum LPA concentrations. Non-limiting examples of SNPs associated with reduced incidence of cardiovascular disease in a subject are listed in FIG.2. Non-limiting examples of protective variants of LPA are listed in Table 8. In some embodiments, the present disclosure provides base editors or nucleases that efficiently generate an intended mutation, such as a point mutation or indel, in a nucleic acid molecule (e.g., a nucleic acid within a genome of a subject) without generating a significant number of unintended mutations, such as unintended point mutations. In some embodiments, an intended mutation is a mutation that is generated by a specific base editor (e.g., an adenosine base editor or a cytidine base editor) bound to a guide polynucleotide (e.g., gRNA), specifically designed to generate the intended mutation. In some embodiments, the intended mutation is an adenine (A) to guanine (G) point mutation within the non-coding region of a gene. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation within the non-coding region of a gene. In some embodiments, the intended mutation is a mutation of a splice acceptor in the non-coding region 5′ of an exon of a gene associated with a disease or disorder. In some instances, the intended mutation is an indel mutation. In some embodiments, the intended mutation is an adenine (A) to guanine (G) point mutation in the splice acceptor in the non-coding region 5′ of an exon of a gene associated with a disease or disorder. In some embodiments, the intended mutation is a missense mutation. The intended mutation can include the introduction of a stop codon to a polynucleotide sequence. In some embodiments, the intended mutation is a mutation that disrupts normal splicing of a complete transcript of a gene, for example, an A to G change in the splice acceptor within the non-coding region located 5′ of an exon of a disease-causing or a disease-associated gene. In some embodiments, the intended mutation is a mutation in the splice acceptor that disrupts splicing of a gene transcript and results in an alternative transcript that encodes a truncated and / or nonfunctional protein product. In some embodiments, the intended mutation is an SNP known to be associated with a reduction in incidence of cardiovascular disease in a subject. In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations : unintended point mutations) that is greater than 1 : 1. In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations : unintended point mutations) that is at least 1.5: 1, at least 2: 1, at least 2.5: 1, at least 3: 1, at least 3.5: 1, at least 4: 1, at least 4.5: 1, at least 5: 1, at least 5.5: 1, at least 6: 1, at least 6.5: 1, at least 7: 1, at least 7.5: 1, at least 8: 1, at least 10: 1, at least 12: 1, at least 15: 1, at least 20: 1, at least 25: 1, at least 30: 1, at least 40: 1, at least 50: 1, at least 100: 1, at least 150: 1, at least 200: 1, at least 250: 1, at least 500: 1, or at least 1000: 1, or more. In some embodiments, editing of a plurality of nucleobase pairs in one or more genes using the methods provided herein results in formation of at least one intended mutation. In some embodiments, the formation of the at least one intended mutation is in the splice acceptor 5′ of an exon of a disease-associated gene and results in disruption of splicing of the mRNA transcript of a disease-associated gene. It should be appreciated that multiplex editing can be accomplished using any method or combination of methods provided herein. The present disclosure provides methods for the treatment of a subject diagnosed with a cardiovascular disease. For example, in some embodiments, a method is provided that comprises administering to a subject having or having a propensity to develop a cardiovascular disease, an effective amount of a nucleobase editor (e.g., an adenosine deaminase base editor or a cytidine deaminase base editor) to effect an alteration in an LPA polynucleotide sequence. CARDIOVASCULAR DISEASE Cardiovascular disease (CVD) encompasses a group of disorders of the heart and blood vessels. In many instances, CVD is associated with an increase in atherosclerosis. CVD associated diseases include coronary heart disease – a disease of the blood vessels supplying the heart muscle; cerebrovascular disease – a disease of the blood vessels supplying the brain; peripheral arterial disease – a disease of blood vessels supplying the arms and legs; rheumatic heart disease – damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria; congenital heart disease – birth defects that affect the normal development and functioning of the heart caused by malformations of the heart structure from birth; and deep vein thrombosis and pulmonary embolism – blood clots in the leg veins, which can dislodge and move to the heart and lungs. Heart attacks and strokes are usually acute events and are mainly caused by a blockage that prevents blood from flowing to the heart or brain. The most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that supply the heart or brain. Strokes can be caused by bleeding from a blood vessel in the brain or from blood clots. Symptoms of a heart attack include: pain or discomfort in the center of the chest; and / or pain or discomfort in the arms, the left shoulder, elbows, jaw, or back. Symptoms of stroke include: sudden weakness of the face, arm, or leg, most often on one side of the body, numbness of the face, arm, or leg, especially on one side of the body, confusion, difficulty speaking or understanding speech, difficulty seeing with one or both eyes, difficulty walking, dizziness and / or loss of balance or coordination, severe headache with no known cause, and fainting or unconsciousness. Rheumatic heart disease is caused by damage to the heart valves and heart muscle from the inflammation and scarring caused by rheumatic fever. Rheumatic fever is caused by an abnormal response of the body to infection with streptococcal bacteria, which usually begins as a sore throat or tonsillitis in children. Symptoms of rheumatic heart disease include: shortness of breath, fatigue, irregular heartbeats, chest pain and fainting. Human genetic studies have indicated that plasma lipoprotein(a) (LPA) is causally associated with the risk of cardiovascular disease. LIPOPROTEIN(A) Lipoprotein(a) (LPA) is a lipoprotein that has emerged as an independent risk factor for developing vascular disease (see, e.g., FIG.1). A number of SNPs reported to modify LPA concentrations are shown in FIG.2. Plasma LPA levels above the common cut-off level of 300 mg / L place individuals at risk of developing heart disease, particularly if combined with other lipid and thrombogenic risk factors. In general, LPA levels have proven challenging to regulate. LPA has a high affinity for arterial walls and displays many athero-thrombogenic properties. Ongoing research continues to highlight the clinical importance of LPA in connection with cardiovascular disease. A review of LPA biology is provided by McCormick Clin Biochem Rev.2004 Feb; 25(1): 69–80, which is incorporated herein in its entirety. Elevated LPA levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) in a subject. Increased lipoprotein(a) (LPA) can lead to heart attack, stroke, and aortic stenosis. About 1.4 billion people globally have elevated LP(a) levels, described as greater than about 50 mg / dL, and possibly higher in patients with established ASCVD. Elevated LPA levels can occur in patients with otherwise normal lipid levels. A UK Biobank analysis supported the current American College of Cardiology / American Heart Association cholesterol and primary prevention guidelines’ recommendation to use Lp(a) as a risk-enhancing factor that, if measured, would favor statin initiation among individuals at borderline (5%–7.4%) or intermediate (7.5%– 19.9%) 10-year predicted risk for ASCVD. EDITING OF TARGET GENES Exemplary guide RNA sequences that can be used to produce the polynucleotide edits described above (e.g., missense mutations, stop codons, indel mutations, introduction of single nucleotide polymorphisms, splice-site disruption mutations, etc.) are listed in Tables 1A-1 to 1C-2 below. To produce the polynucleotide edits, cells (e.g., cells in or from a subject, such as hepatocytes) of a subject are contacted with one or more guide RNAs containing one or more of the spacer sequences listed in Tables 1A-2, 1B-2, or 1C-2 below, or fragments thereof, and an endonuclease or a nucleobase editor polypeptide or complex containing a nucleic acid programmable DNA binding protein (napDNAbp) and a cytidine deaminase or adenosine deaminase. In embodiments, the base editor and / or endonuclease is introduced to the cell using a polynucleotide sequence (e.g., mRNA) encoding the base editor, such as a base editor having an amino acid sequence selected from those listed in Table 2, or an amino acid sequence having at least about 85%, 90%, 95%, 99%, or greater sequence identity to a sequence listed in Table 2 or a fragment thereof (e.g., an adenosine deaminase domain or napDNAbp domain). Tables 1A-1, 1B-1, and 1C-1 below list representative guide RNA sequences that can be used in combination with the indicated editors (e.g., endonucleases or base editors). The guide polynucleotide sequences listed in Tables 1A-1, 1B-1, and 1C-1 correspond to and contain the spacer sequences listed in Tables 1A-2, 1B-2 and 1C-2, respectively, and can be used to target the target sequences listed in Tables 1A-2, 1B-2 and 1C-2 to effect the edits listed in Tables 1A-2, 1B-2 and 1C-2. In some embodiments, the gRNA comprises nucleotide analogs. These nucleotide analogs can inhibit degradation of the gRNA from cellular processes. Tables 1A-2, 1B-2, and 1C-2 list target sequences to be used for gRNAs. Further exemplary spacer sequences suitable for use in gRNA sequences for use in the methods provided herein include fragments of any of the spacers listed in Tables 1A-2, 1B-2, and 1C-2 as well as any of the spacers provided in Tables 1A-2, 1B-2, and 1C-2 modified to include an extension or truncation at the 3′ and / or 5′ end(s). In embodiments, a spacer sequence of Tables 1A-2, 1B-2, and 1C-2 can be modified to include a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide extension or truncation at the 3′ and / or 5′ end(s). In various instances, it is advantageous for a spacer sequence to include a 5′ and / or a 3′ “G” nucleotide. In some cases, for example, any spacer sequence or guide polynucleotide provided herein comprises or further comprises a 5′ “G”, where, in some embodiments, the 5′ “G” is or is not complementary to a target sequence. In some embodiments, the 5′ “G” is added to a spacer sequence that does not already contain a 5′ “G.” For example, it can be advantageous for a guide RNA to include a 5′ terminal “G” when the guide RNA is expressed under the control of a U6 promoter or the like because the U6 promoter prefers a “G” at the transcription start site (see Cong, L. et al. “Multiplex genome engineering using CRISPR / Cas systems. Science 339:819-823 (2013) doi: 10.1126 / science.1231143). In some cases, a 5′ terminal “G” is added to a guide polynucleotide that is to be expressed under the control of a promoter but is optionally not added to the guide polynucleotide if or when the guide polynucleotide is not expressed under the control of a promoter. Variants of the spacer sequences of the disclosure comprising 1, 2, 3, 4, or 5 nucleobase alterations are contemplated. For example, variation of a target polynucleotide sequence within a population (e.g., single nucleotide polymorphisms) may require said alterations to a spacer sequence to allow the spacer to better bind a variant of a target sequence in a subject. Exemplary guide polynucleotide sequences are provided below in Tables 1A-1 to 1C-2 and exemplary base editor sequences are provided in Table 2. In the below tables, “mN” indicates a 2′-OMe modification of the nucleotide “N”, and “Ns” indicates that the nucleotide “N” is linked to the following (i.e., 3′) nucleotide by a phosphorothioate (PS). Table 1A-1. Exemplary guide polynucleotide sequences for use in targeting a base editor to introduce a single nucleotide polymorphism (SNP) to an LPA polynucleotide. In embodiments, the SNP is associated with a reduction in incidence of cardiovascular disease in a subject. In some cases, the SNP is associated with a reduction in serum concentrations of LPA in a subject and / or in a reduction in risk for coronary heart disease (CHD).

[0018] Table 1A-1 (CONTINUED). Table 1A-2. Exemplary spacer sequences and their corresponding target sequences for use in targeting a base editor to introduce a single nucleotide polymorphism (SNP) to an LPA polynucleotide. In embodiments, the SNP is associated with a reduction in incidence of cardiovascular disease in a subject. In some cases, the SNP is associated with a reduction in serum concentrations of LPA in a subject and / or in a reduction in risk for coronary heart disease (CHD).

[0019] Table 1A-2 (CONTINUED).

[0020] Table 1A-2 (CONTINUED).

[0021] Table 1B-1. Exemplary guide polynucleotide sequences for use in targeting a base editor to disrupt a splice site or introduce a start codon in an LPA polynucleotide. Table 1B-1 (CONTINUED).

[0022] Table IB-2. Exemplary spacer sequences and their corresponding target sequences for use in targeting a base editor to disrupt a splice site or introduce a stop codon in an LPA polynucleotide. Table 1B-2 (CONTINUED).

[0023] Table 1B-2 (CONTINUED).

[0024] Table 1C-1. Exemplary guide polynucleotide sequences for use in targeting a base editor to disrupt a promoter region of an LPA polynucleotide.

[0025] Table 1C-1 (CONTINUED).

[0026] Table 1C-2. Exemplary spacer sequences and their corresponding target sequences for use in targeting a base editor to disrupt a promoter region of an LPA polynucleotide. Table 1C-2 (CONTINUED).

[0027] Table 1C-2 (CONTINUED). Table 2. Exemplary base editor amino acid sequences. NUCLEOBASE EDITORS Useful in the methods and compositions described herein are nucleobase editors that edit, modify or alter a target nucleotide sequence of a polynucleotide. Nucleobase editors described herein typically include a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain (e.g., adenosine deaminase, cytidine deaminase, or a dual deaminase). A polynucleotide programmable nucleotide binding domain, when in conjunction with a bound guide polynucleotide (e.g., gRNA), can specifically bind to a target polynucleotide sequence and thereby localize the base editor to the target nucleic acid sequence desired to be edited. Polynucleotide Programmable Nucleotide Binding Domain Polynucleotide programmable nucleotide binding domains bind polynucleotides (e.g., RNA, DNA). A polynucleotide programmable nucleotide binding domain of a base editor can itself comprise one or more domains (e.g., one or more nuclease domains). In some embodiments, the nuclease domain of a polynucleotide programmable nucleotide binding domain comprises an endonuclease or an exonuclease. Disclosed herein are base editors comprising a polynucleotide programmable nucleotide binding domain comprising all or a portion (e.g., a functional portion) of a CRISPR protein (i.e., a base editor comprising as a domain all or a portion (e.g., a functional portion) of a CRISPR protein (e.g., a Cas protein), also referred to as a “CRISPR protein-derived domain” of the base editor). A CRISPR protein-derived domain incorporated into a base editor can be modified compared to a wild-type or natural version of the CRISPR protein. A CRISPR protein-derived domain can comprise one or more mutations, insertions, deletions, rearrangements and / or recombinations relative to a wild-type or natural version of the CRISPR protein. Cas proteins that can be used herein include class 1 and class 2. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 or Csx12), Cas10, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Cas12a / Cpf1, Cas12b / C2c1 (e.g., SEQ ID NO: 232), Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, and Cas12j / CasΦ, CARF, DinG, Turbo Cas9 (i.e., an SpCas9 with the amino acid alterations Q844R, V842L, F846Y, L847M, and I852F), homologues thereof, or modified versions thereof. A CRISPR enzyme can direct cleavage of one or both strands at a target sequence, such as within a target sequence and / or within a complement of a target sequence. For example, a CRISPR enzyme can direct cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. A vector that encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence can be used. A Cas protein (e.g., Cas9, Cas12) or a Cas domain (e.g., Cas9, Cas12) can refer to a polypeptide or domain with at least or at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology to a wild-type exemplary Cas polypeptide or Cas domain. Cas (e.g., Cas9, Cas12) can refer to the wild-type or a modified form of the Cas protein that can comprise an amino acid change such as a deletion, insertion, substitution, variant, mutation, fusion, chimera, or any combination thereof. In some embodiments, a CRISPR protein-derived domain of a base editor can include all or a portion (e.g., a functional portion) of Cas9 from Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquis (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); Neisseria meningitidis (NCBI Ref: YP_002342100.1), Streptococcus pyogenes, or Staphylococcus aureus. Some aspects of the disclosure provide high fidelity Cas9 domains. High fidelity Cas9 domains are known in the art and described, for example, in Kleinstiver, B.P., et al. “High- fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.” Nature 529, 490-495 (2016); and Slaymaker, I.M., et al. “Rationally engineered Cas9 nucleases with improved specificity.” Science 351, 84-88 (2015); the entire contents of each of which are incorporated herein by reference. An Exemplary high fidelity Cas9 domain is provided in the Sequence Listing as SEQ ID NO: 233. In some embodiments, any of the Cas9 fusion proteins or complexes provided herein comprise one or more of a D10A, N497X, a R661X, a Q695X, and / or a Q926X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is any amino acid.. Typically, Cas9 proteins, such as Cas9 from S. pyogenes (spCas9), require a “protospacer adjacent motif (PAM)” or PAM-like motif, which is a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system. The presence of an NGG PAM sequence is required to bind a particular nucleic acid region, where the “N” in “NGG” is adenosine (A), thymidine (T), or cytosine (C), and the G is guanosine. In some embodiments, any of the fusion proteins or complexes provided herein may contain a Cas9 domain that is capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and would be apparent to the skilled artisan. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature 523, 481-485 (2015); and Kleinstiver, B. P., et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each are hereby incorporated by reference. In some embodiments, the napDNAbp is a circular permutant (e.g., SEQ ID NO: 238). In some embodiments, the polynucleotide programmable nucleotide binding domain comprises a nickase domain. Herein the term “nickase” refers to a polynucleotide programmable nucleotide binding domain comprising a nuclease domain that is capable of cleaving only one strand of the two strands in a duplexed nucleic acid molecule (e.g., DNA). For example, where a polynucleotide programmable nucleotide binding domain comprises a nickase domain derived from Cas9, the Cas9-derived nickase domain can include a D10A mutation and a histidine at position 840. In another example, a Cas9-derived nickase domain comprises an H840A mutation, while the amino acid residue at position 10 remains a D. In some embodiments, a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain, that is, the Cas9 is a nickase, referred to as an “nCas9” protein (for “nickase” Cas9; SEQ ID NO: 201). The Cas9 nickase may be a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule). In some embodiments the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those of skill in the art based on this disclosure and knowledge in the field and are within the scope of this disclosure. Also provided herein are base editors comprising a polynucleotide programmable nucleotide binding domain which is catalytically dead (i.e., incapable of cleaving a target polynucleotide sequence). For example, in the case of a base editor comprising a Cas9 domain, the Cas9 can comprise both a D10A mutation and an H840A mutation. In further embodiments, a catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g., D10A or H840A) as well as a deletion of all or a portion (e.g., a functional portion) of a nuclease domain. dCas9 domains are known in the art and described, for example, in Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.” Cell.2013; 152(5):1173-83, the entire contents of which are incorporated herein by reference. The term “protospacer adjacent motif (PAM)” or PAM-like motif refers to a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by a nucleic acid programmable DNA binding protein. In some embodiments, the PAM can be a 5′ PAM (i.e., located upstream of the 5′ end of the protospacer). In other embodiments, the PAM can be a 3′ PAM (i.e., located downstream of the 5′ end of the protospacer). The PAM sequence can be any PAM sequence known in the art. Suitable PAM sequences include, but are not limited to, NGG, NGA, NGC, NGN, NGT, NGTT, NGCG, NGAG, NGAN, NGNG, NGCN, NGCG, NGTN, NNGRRT, NNNRRT, NNGRR(N), TTTV, TYCV, TYCV, TATV, NNNNGATT, NNAGAAW, or NAAAAC. Y is a pyrimidine; N is any nucleotide base; W is A or T. A base editor provided herein can comprise a CRISPR protein-derived domain that is capable of binding a nucleotide sequence that contains a canonical or non-canonical protospacer adjacent motif (PAM) sequence. In some embodiments, the PAM is an “NRN” PAM where the “N” in “NRN” is adenine (A), thymine (T), guanine (G), or cytosine (C), and the R is adenine (A) or guanine (G); or the PAM is an “NYN” PAM, wherein the “N” in NYN is adenine (A), thymine (T), guanine (G), or cytosine (C), and the Y is cytidine (C) or thymine (T), for example, as described in R.T. Walton et al., 2020, Science, 10.1126 / science.aba8853 (2020), the entire contents of which are incorporated herein by reference. Several PAM variants are described in Table 3 below. Table 3. Cas9 proteins and corresponding PAM sequences. N is A, C, T, or G; and V is A, C, or G. In some embodiments, the PAM is NGC. In some embodiments, the NGC PAM is recognized by a Cas9 variant. In some embodiments, the Cas9 variant contains one or more amino acid substitutions selected from D1135V, G1218R, R1335Q, and T1337R (collectively termed VRQR) of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, the Cas9 variant contains one or more amino acid substitutions selected from D1135V, G1218R, R1335E, and T1337R (collectively termed VRER) of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, the Cas9 variant contains one or more amino acid substitutions selected from E782K, N968K, and R1015H (collectively termed KHH) of saCas9 (SEQ ID NO: 218). In some cases, a Cas9 variant has specificity for the PAM 5′-NGC-3′. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135M, S1136Q, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135M, S1136Y, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, the a Cas9 variant includes one or more amino acid substitutions selected from D1135L, S1136Y, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337R of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135M, S1136Y, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135L, S1136Y, G1218K, E1219F, A1283D, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135L, S1136Q, G1218K, E1219F, E1250K, A1283D, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from D1135M, S1136Y, G1218K, E1219F, E1250K, A1283D, A1322R, D1332A, R1335E, and T1337R of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, a Cas9 variant includes one or more amino acid substitutions selected from R765A, Q768A, D1135L, S1136Y, G1218K, A1283D, E1219F, A1322R, D1332A, R1335E, and T1337K of spCas9 (SEQ ID No: 197), or a corresponding mutation in another Cas9. In some embodiments, any of the Cas9 proteins provided herein, including an SpCas9 comprises any one, two, three, four, five, six, seven, eight, nine, or ten of the following amino acid substitutions in a corresponding residue: R765A, Q768A, W1126R, R1359W, E1250K, A1239T, A1239V, A1283D, R1335D, D1135L, D1135M, D1135R, D1135W, S1136H, S1136Q, S1136Y, G1218D, G1218K, G1218R, G1218E, G1218L, E1219F, E1219K, E1219N, A1322A, A1322R, A1322K, D1332A, R1335V, T1337K, T1337T, D1332A, D1135V and T1337R. In some embodiments, a CRISPR protein-derived domain of a base editor comprises all or a portion (e.g., a functional portion) of a Cas9 protein with a canonical PAM sequence (NGG). In other embodiments, a Cas9-derived domain of a base editor can employ a non- canonical PAM sequence. Such sequences have been described in the art and would be apparent to the skilled artisan. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature 523, 481-485 (2015); and Kleinstiver, B. P., et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology 33, 1293-1298 (2015); R.T. Walton et al. “Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants” Science 10.1126 / science.aba8853 (2020); Hu et al. “Evolved Cas9 variants with broad PAM compatibility and high DNA specificity,” Nature, 2018 Apr.5, 556(7699), 57-63; Miller et al., “Continuous evolution of SpCas9 variants compatible with non-G PAMs” Nat. Biotechnol., 2020 Apr;38(4):471-481; the entire contents of each are hereby incorporated by reference. Fusion Proteins or Complexes Comprising a NapDNAbp and a Cytidine Deaminase and / or Adenosine Deaminase Some aspects of the disclosure provide fusion proteins or complexes comprising a Cas9 domain or other nucleic acid programmable DNA binding protein (e.g., Cas12) and one or more cytidine deaminase, adenosine deaminase, or cytidine adenosine deaminase domains. It should be appreciated that the Cas9 domain may be any of the Cas9 domains or Cas9 proteins (e.g., dCas9 or nCas9) provided herein. In some embodiments, any of the Cas9 domains or Cas9 proteins (e.g., dCas9 or nCas9) provided herein may be fused with any of the cytidine deaminases and / or adenosine deaminases provided herein. The domains of the base editors disclosed herein can be arranged in any order. In some embodiments, the fusion proteins or complexes comprising a cytidine deaminase or adenosine deaminase and a napDNAbp (e.g., Cas9 or Cas12 domain) do not include a linker sequence. In some embodiments, a linker is present between the cytidine or adenosine deaminase and the napDNAbp. In some embodiments, cytidine or adenosine deaminase and the napDNAbp are fused via any of the linkers provided herein. For example, in some embodiments the cytidine or adenosine deaminase and the napDNAbp are fused via any of the linkers provided herein. It should be appreciated that the fusion proteins or complexes of the present disclosure may comprise one or more additional features. For example, in some embodiments, the fusion protein or complex may comprise inhibitors, cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins or complexes. Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags , biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags. Additional suitable sequences will be apparent to those of skill in the art. In some embodiments, the fusion protein or complex comprises one or more His tags. Exemplary, yet nonlimiting, fusion proteins are described in International PCT Application Nos. PCT / US2017 / 045381, PCT / US2019 / 044935, and PCT / US2020 / 016288, each of which is incorporated herein by reference for its entirety. Fusion Proteins or Complexes with Internal Insertions Provided herein are fusion proteins or complexes comprising a heterologous polypeptide fused to a nucleic acid programmable nucleic acid binding protein, for example, a napDNAbp. The heterologous polypeptide can be fused to the napDNAbp at a C-terminal end of the napDNAbp, an N-terminal end of the napDNAbp, or inserted at an internal location of the napDNAbp. In some embodiments, the heterologous polypeptide is a deaminase (e.g., cytidine or adenosine deaminase) or a functional fragment thereof. For example, a fusion protein can comprise a deaminase flanked by an N- terminal fragment and a C-terminal fragment of a Cas9 or Cas12 (e.g., Cas12b / C2c1), polypeptide. The deaminase can be a circular permutant deaminase. In some embodiments, the deaminase is a circular permutant TadA, circularly permutated at amino acid residue 116, 136, or 65 as numbered in a TadA reference sequence. The fusion protein or complexes can comprise more than one deaminase. The fusion protein or complex can comprise, for example, 1, 2, 3, 4, 5 or more deaminases. The deaminases in a fusion protein or complex can be adenosine deaminases, cytidine deaminases, or a combination thereof. In some embodiments, the napDNAbp in the fusion protein or complex contains a Cas9 polypeptide or a fragment thereof. The Cas9 polypeptide can be a variant Cas9 polypeptide. The Cas9 polypeptide can be a circularly permuted Cas9 protein. The heterologous polypeptide (e.g., deaminase) can be inserted in the napDNAbp (e.g., Cas9 or Cas12 (e.g., Cas12b / C2c1)) at a suitable location, for example, such that the napDNAbp retains its ability to bind the target polynucleotide and a guide nucleic acid. A deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase (dual deaminase)) can be inserted into a napDNAbp without compromising function of the deaminase (e.g., base editing activity) or the napDNAbp (e.g., ability to bind to target nucleic acid and guide nucleic acid). In some embodiments, the deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) is inserted in regions of the Cas9 polypeptide comprising higher than average B-factors (e.g., higher B factors compared to the total protein or the protein domain comprising the disordered region). Cas9 polypeptide positions comprising a higher than average B-factor can include, for example, residues 768, 792, 1052, 1015, 1022, 1026, 1029, 1067, 1040, 1054, 1068, 1246, 1247, and 1248 as numbered in SEQ ID NO: 197. Cas9 polypeptide regions comprising a higher than average B-factor can include, for example, residues 792-872, 792-906, and 2-791 as numbered in SEQ ID NO: 197. In some embodiments, a heterologous polypeptide (e.g., deaminase) is inserted in a flexible loop of a Cas9 polypeptide. The flexible loop portions can be selected from the group consisting of 530-537, 569-570, 686-691, 943-947, 1002-1025, 1052-1077, 1232-1247, or 1298- 1300 as numbered in SEQ ID NO: 197, or a corresponding amino acid residue in another Cas9 polypeptide. The flexible loop portions can be selected from the group consisting of: 1-529, 538- 568, 580-685, 692-942, 948-1001, 1026-1051, 1078-1231, or 1248-1297 as numbered in SEQ ID NO: 197, or a corresponding amino acid residue in another Cas9 polypeptide. A heterologous polypeptide (e.g., adenine deaminase) can be inserted into a Cas9 polypeptide region corresponding to amino acid residues: 1017-1069, 1242-1247, 1052-1056, 1060-1077, 1002 – 1003, 943-947, 530-537, 568-579, 686-691, 1242-1247, 1298 – 1300, 1066- 1077, 1052-1056, or 1060-1077 as numbered in SEQ ID NO: 197, or a corresponding amino acid residue in another Cas9 polypeptide. A heterologous polypeptide (e.g., adenine deaminase) can be inserted in place of a deleted region of a Cas9 polypeptide. The deleted region can correspond to an N-terminal or C- terminal portion of the Cas9 polypeptide. Exemplary internal fusions base editors are provided in Table 4A below: Table 4A: Insertion loci in Cas9 proteins A heterologous polypeptide (e.g., deaminase) can be inserted within a structural or functional domain of a Cas9 polypeptide. A heterologous polypeptide (e.g., deaminase) can be inserted between two structural or functional domains of a Cas9 polypeptide. A heterologous polypeptide (e.g., deaminase) can be inserted in place of a structural or functional domain of a Cas9 polypeptide, for example, after deleting the domain from the Cas9 polypeptide. The structural or functional domains of a Cas9 polypeptide can include, for example, RuvC I, RuvC II, RuvC III, Rec1, Rec2, PI, or HNH. A fusion protein can comprise a linker between the deaminase and the napDNAbp polypeptide. The linker can be a peptide or a non-peptide linker. For example, the linker can be an XTEN, (GGGS)n(SEQ ID NO: 246),SGGSSGGS (SEQ ID NO: 330), (GGGGS)n(SEQ ID NO: 247), (G)n, (EAAAK)n (SEQ ID NO: 248), (GGS)n,SGSETPGTSESATPES (SEQ ID NO: 249). In some embodiments, the fusion protein comprises a linker between the N-terminal Cas9 fragment and the deaminase. In some embodiments, the fusion protein comprises a linker between the C-terminal Cas9 fragment and the deaminase. In some embodiments, the N-terminal and C-terminal fragments of napDNAbp are connected to the deaminase with a linker. In some embodiments, the N-terminal and C-terminal fragments are joined to the deaminase domain without a linker. In some embodiments, the fusion protein comprises a linker between the N- terminal Cas9 fragment and the deaminase but does not comprise a linker between the C- terminal Cas9 fragment and the deaminase. In some embodiments, the fusion protein comprises a linker between the C-terminal Cas9 fragment and the deaminase but does not comprise a linker between the N-terminal Cas9 fragment and the deaminase. In some embodiments, the napDNAbp in the fusion protein or complex is a Cas12 polypeptide, e.g., Cas12b / C2c1, or a functional fragment thereof capable of associating with a nucleic acid (e.g., a gRNA) that guides the Cas12 to a specific nucleic acid sequence. The Cas12 polypeptide can be a variant Cas12 polypeptide. In other embodiments, the N- or C-terminal fragments of the Cas12 polypeptide comprise a nucleic acid programmable DNA binding domain or a RuvC domain. In other embodiments, the fusion protein contains a linker between the Cas12 polypeptide and the catalytic domain. In other embodiments, the amino acid sequence of the linker is GGSGGS (SEQ ID NO: 250) or GSSGSETPGTSESATPESSG (SEQ ID NO: 251). In other embodiments, the linker is a rigid linker. In other embodiments of the above aspects, the linker is encoded byGGAGGCTCTGGAGGAAGC (SEQ ID NO: 252) or GGCTCTTCTGGATCTGAAACACCTGGCACAAGCGAGAGCGCCACCCCTGAGAGCTCTGGC (SEQ ID NO: 253). In other embodiments, the fusion protein or complex contains a nuclear localization signal (e.g., a bipartite nuclear localization signal). In other embodiments, the amino acid sequence of the nuclear localization signal is MAPKKKRKVGIHGVPAA (SEQ ID NO: 261). In other embodiments of the above aspects, the nuclear localization signal is encoded by the following sequence: ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCC (SEQ ID NO: 262). In other embodiments, the Cas12b polypeptide contains a mutation that silences the catalytic activity of a RuvC domain. In other embodiments, the Cas12b polypeptide contains D574A, D829A and / or D952A mutations. In some embodiments, the fusion protein or complex comprises a napDNAbp domain (e.g., Cas12-derived domain) with an internally fused nucleobase editing domain (e.g., all or a portion (e.g., a functional portion) of a deaminase domain, e.g., an adenosine deaminase domain). In some embodiments, the napDNAbp is a Cas12b. In some embodiments, the base editor comprises a BhCas12b domain with an internally fused TadA*8 domain inserted at the loci provided in Table 4B below. Table 4B: Insertion loci in Cas12b proteins In some embodiments, the base editing system described herein is an ABE with TadA inserted into a Cas9. Polypeptide sequences of relevant ABEs with TadA inserted into a Cas9 are provided in the attached Sequence Listing as SEQ ID NOs: 263-308. Exemplary, yet nonlimiting, fusion proteins are described in International PCT Application Nos. PCT / US2020 / 016285 and U.S. Provisional Application Nos.62 / 852,228 and 62 / 852,224, the contents of which are incorporated by reference herein in their entireties. A to G Editing In some embodiments, a base editor described herein comprises an adenosine deaminase domain. Such an adenosine deaminase domain of a base editor can facilitate the editing of an adenine (A) nucleobase to a guanine (G) nucleobase by deaminating the A to form inosine (I), which exhibits base pairing properties of G. In some embodiments, an A-to-G base editor further comprises an inhibitor of inosine base excision repair, for example, a uracil glycosylase inhibitor (UGI) domain or a catalytically inactive inosine specific nuclease. Without wishing to be bound by any particular theory, the UGI domain or catalytically inactive inosine specific nuclease can inhibit or prevent base excision repair of a deaminated adenosine residue (e.g., inosine), which can improve the activity or efficiency of the base editor. A base editor comprising an adenosine deaminase can act on any polynucleotide, including DNA, RNA and DNA-RNA hybrids. In an embodiment an adenosine deaminase domain of a base editor comprises all or a portion (e.g., a functional portion) of an ADAT comprising one or more mutations which permit the ADAT to deaminate a target A in DNA. For example, the base editor can comprise all or a portion (e.g., a functional portion) of an ADAT from Escherichia coli (EcTadA) comprising one or more of the following mutations: D108N, A106V, D147Y, E155V, L84F, H123Y, I156F, or a corresponding mutation in another adenosine deaminase. Exemplary ADAT homolog polypeptide sequences are provided in the Sequence Listing as SEQ ID NOs: 1 and 309-315. The adenosine deaminase can be derived from any suitable organism (e.g., E. coli). In some embodiments, the adenosine deaminase is from Escherichia coli, Staphylococcus aureus, Salmonella typhi, Shewanella putrefaciens, Haemophilus influenzae, Caulobacter crescentus, or Bacillus subtilis. In some embodiments, the adenine deaminase is a naturally-occurring adenosine deaminase that includes one or more mutations corresponding to any of the mutations provided herein (e.g., mutations in ecTadA). The corresponding residue in any homologous protein can be identified by e.g., sequence alignment and determination of homologous residues. The mutations in any naturally-occurring adenosine deaminase (e.g., having homology to ecTadA) that correspond to any of the mutations described herein (e.g., any of the mutations identified in ecTadA) can be generated accordingly. In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in any of the adenosine deaminases provided herein. It should be appreciated that adenosine deaminases provided herein may include one or more mutations (e.g., any of the mutations provided herein). The disclosure provides any deaminase domains with a certain percent identify plus any of the mutations or combinations thereof described herein. In some embodiments, the adenosine deaminase comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to a reference sequence, or any of the adenosine deaminases provided herein. It should be appreciated that any of the mutations provided herein (e.g., based on a TadA reference sequence, such as TadA*7.10 (SEQ ID NO: 1)) can be introduced into other adenosine deaminases, such as E. coli TadA (ecTadA), S. aureus TadA (saTadA), or other adenosine deaminases (e.g., bacterial adenosine deaminases). In some embodiments, the TadA reference sequence is TadA*7.10 (SEQ ID NO: 1). It would be apparent to the skilled artisan that additional deaminases may similarly be aligned to identify homologous amino acid residues that can be mutated as provided herein. Thus, any of the mutations identified in a TadA reference sequence can be made in other adenosine deaminases (e.g., ecTada) that have homologous amino acid residues. It should also be appreciated that any of the mutations provided herein can be made individually or in any combination in a TadA reference sequence or another adenosine deaminase. In some embodiments, the adenosine deaminase comprises an alteration or set of alterations selected from those listed in Tables 5A-5E below: Table 5A. Adenosine Deaminase Variants. Residue positions in the E. coli TadA variant (TadA*) are indicated.

[0028] Table 5B. TadA*8 Adenosine Deaminase Variants. Residue positions in the E. coli TadA variant (TadA*) are indicated. Alterations are referenced to TadA*7.10 (first row). Table 5C. TadA*9 Adenosine Deaminase Variants. Alterations are referenced to TadA*7.10. Additional details of TadA*9 adenosine deaminases are described in International PCT Application No. PCT / US2020 / 049975, which is incorporated herein by reference in its entirety for all purposes. In some embodiments, the adenosine deaminase comprises a TadA*8.20 adenosine deaminase variant further comprising an F149Y amino acid alteration. In some embodiments, the adenosine deaminase comprises a TadA*8.20 adenosine deaminase variant further comprising the amino acid alterations R147D, F149Y, T166I, and D167N (TadA*8.10+). In some embodiments, the adenosine deaminase comprises a TadA*8.20 adenosine deaminase variant further comprising the amino acid alterations S82T and F149Y (TadA*9v1). In some embodiments, the adenosine deaminase comprises a TadA*8.20 adenosine deaminase variant further comprising the amino acid alterations Y147D, F149Y, T166I, D167N and S82T (TadA*9v2). In some embodiments, the adenosine deaminase comprises one or more of M1I, M1S, S2A, S2E, S2H, S2R, S2L, E3L, V4D, V4E, V4M, V4K, V4S, V4T, V4A, E5K, F6S, F6G, F6H, F6Y, F6I, F6E, S7K, H8E, H8Y, H8H, H8Q, H8E, H8G, H8S, E9Y, E9K, E9V, E9E, Y10F, Y10W, Y10Y, M12S, M12L, M12R, M12W, R13H, R13I, R13Y, R13R, R13G, R13S, H14N, A15D, A15V, A15L, A15H, T17T, T17A, T17W, T17L, T17F, T17R, T17S, L18A, L18E, L18N, L18L, L18S, A19N, A19H, A19K, A19A, A19D, A19G, A19M, R21N, K20K, K20A, K20R, K20E, K20G, K20C, K20Q R21A, R21R, R21N, R21Y, R21C G22P, A22W, A22R, W23D, R23H, W23G, W23Q, W23L, W23R, W23H W23D W23M, W23W, W23I, D24E, D24G, D24W, D24D, D24R, E25F, E25M, E25D, E25A, E25G, E25R, E25E, E25H E25V, E25S, E25Y, R26D, R26E, R26G, R26N, R26Q, R26C, R26L, R26K, R26W, R26C, R26P, R26R, R26A, R26H, E27E, E27Q, E27H, E27C, E27G, E27K, E27S, E27P, E27R, E27L, E27V, E27D, V28V, V28A, V28C, V28G, V28P, V28S, V28T, P29V, P29P, P29A, P29G, P29K, P29L, V30V, V30I, V30L, V30F, V30G, V30A, V30M, L34S, L34V, L34L, L34M, L34W, L34G, H36E, H36V, L36H, H36L, H36N, N37N, N37H, N37R, N37T, N37S, N38G, N38R, N38N, N38E, V40I, W45A, W45W, W45R, W45L, W45N, N46N, N46M, N46P, N46G, N46L, N46R, N46V, R46W, R46F, R46Q, R46M, R47A, R47Q, R47F, R47K, R47P, R47W, R47M, R47R, R47G, R47S, R47V, R47H, P48T, P48L, P48A, P48I, P48S, P48R, P48K, P48D, P48E, P48H, P48G, P48P, P48N, I49G, I49H, I49V, I49F, I49H, I49I, I49M, I49N, I49K, I49Q, I49T, G50L, G50S, G50R, G50G, R51H, R51L, R51N, L51W, R51Y, R51G, R51V, R51R, H52D, H52Y, H52I, H52H, D53D, D53E, D53G, D53P, P54C, P54T, P54P, P54E, A55H, T55A, T55I, T55V, T55G, T55T, A56A, A56H, A56W, A56E, A56S, H57P, H57A, H57H, H57N, A58G, A58E, A58A, A58R, E59A, E59G, E59I, E59Q, E59W, E59E, E59T, E59H, E59P, M61A, M61I, M61L, M61V, M61P, M61G, M61I, L63S, L63V, L63T, L63R, L63H, L63A, R64A, R64Q, R64R, R64D, Q65V, Q65H, Q65G, Q65P, Q65F, Q65Q, Q65R, G66V, G66E, G66T, G66G, G66C, G67G, G67W, G67I, G67A, G67D, G67L, G67V, L68Q, L68M, L68V, L68H, L68L, L68G,V69A, V69M, V69V, M70V, M70L, E70A, M70A, M70M, M70E, M70T, M70v, Q71M, Q71N, Q71L, Q71R, Q71Q, Q71I, N72A, N72K, N72S, N72D, N72Y, N72N, N72H, N72G, N72M, Y73G, Y73I, Y73K, Y73R, Y73S, Y73Y, Y73H, Y73A, R74A, R74Q, R74G, R74K, R74L, R74N, R74G, R74K, R74R, I76H, I76R, I76W, I76Y, I76V, I76Q, I76L, I76D, I76F, I76I, I76N, I76T, I76Y, D77G, D77D, D77A, D77Q, A78Y, A78T, A78G, A78A, A78I, T79M, T79R, T79L, T79T, L80M, L80Y, L80I, L80V, L80L, Y81D, Y81V, Y81Y, Y81M, V82A, V82S, V82G, V82T, V82V, V82Q, V82Y, T83L, T83F, T83T, T83N, L84E, L84F, L84Y, L84I, L84L, L84M, L84A, L84T, L84S, E85K, E85G, E85P, E85S, E85E, E85F, E85V, E85R, P86T, P86C, P86P, P86L, P86N, P86K, P86H, C87M, C87I, C87S, C87N, C87P, S87C, S87L, S87V, V88A, V88M, V88V, V88T, V88E, V88D, V88S, C90S, C90P, C90A, C90T, C90M, A91A, A91G, A91S, A91V, A91T, A91C, A91L, G92T, G92M, G92A, G92Y, G92G, A93I, A93C, A93M, A93V, A93A, M94M, M94T, M94A, M94V, M94L, M94I, M94H, I95S, I95G, I95L, I95H, I95V, H96A, H96L, H96R, H96S, H96H, H96N, H96E, S97C, S97G, S97I, S97M, S97R, S97S, S97P, R98K, R98I, R98N, R98Q, R98G, R98H, R98C, R98L, R98R, G100R, G100V, G100K, G100A, G100S, G100M, G100I, R101V, R101R, R101S, R101C, V102A, V102F, V102I, V102V, D103A, V103A, V103G, V103F, V103V, F104G, D104N, F104V, F104I, F104L, F104A, F104F, F104R, G105V, G105W, G105G, G105M, G105A, A106T, V106Q, V106F, V106W, V106M, A106A, A106Q, A106F, A106G, A106W, A106M, A106V, A106R, A106L, A106S, A106B, A106I, R107C, R107G, R107P, R107K, R107A, R107N, R107W, R107H, R107S, R107R, R107F, D108N, D108F, D108G, D108V, D108A, D108Y, D108H, D108I, D108K, D108L, D108M, D108Q, N108Q, N108F, N108W, N108M, N108K, D108K, D108F, D108M, D108Q, D108R, D108W, D108S, D108E, D108T, D108R, D108D, A109H, A109K, A109R, A109S, A109T, A109V, A109A, A109D, K110G, K110H, K110I, K110R, K110T, K110K, K110A, K110l, T111A, T111G, T111H, T111R, T111T, T111K, G112A, G112G, G112H, G112T, G112R, A113N, A114G, A114H, A114V, A114C, A114S, A114A, G115S, G115G, G115M, G115L, G115A, G115F, L117M, L117L, L117W, L117A, L117S, L117N, L117V, M118D, M118G, M118K, M118N, M118V, M118M, M118L, M118R, D119L, D119N, D119S, D119V, D119D, V120H, V120L, V120V, V120T, V120A, V120E, V120G, V120D, L121D, L121M, L121N, L121K, L121L, H122H, H122N, H122P, H122R, H122S, H122Y, H122G, H122T, H122L, H123C, H123G, H123P, H123V, H123Y, Y123H, H123Y, H123H, P124P, P124H, P124A, P124Y, P124D, P124G, P124I, P124L, P124W, G125H, G125I, G125A, G125M, G125K, G125G, G125P, M126D, M126H, M126K, M126I, M126N, M126O, M126S, M126Y, M126M, M126G, N127H, N127S, N127D, N127K, N127R, N127N, N127I, N127P, N127M, H128R, H128N, H128L, H128H, R129H, R129Q, R129V, R129I, R129E, R129V, R129R, R129M, R129P, V130R, V130V, V130E, V130D, E131E, E131I, E131V, E131K, I132I, I132F, I132T, I132L, I132V, I132E, T133V, T133E, T133G, T133K, T133T, T133A, T133H, T133F, T133I, E134A, E134E, E134G, E134I, E134H, E134K, E134T, G135G, G135V, G135I, G135P, G135E, I136G, I136L, I136T, I136I , l137A, l137D, l137E, L137M, l137S, L137L, L137I , A138D, A138E, A138G, S138A, A138N, A138S, A138T, A138V, A138Y, A138A, A138M, A138L, D139E, D139I, D139C, D139L, D139M, D139D, D139G, D139H, D139A, E140A, E140C, E140L, E140R, E140K, E140E, E140D, C141S, C141A, C141C, C141V, C141E, A142N, A142D, A142G, A142A, A142L, A142S, A142T, A142N, A142S, A142V, A142E, A142C, A143D, A143E, A143G, , A143D, A143G, A143E, A143L, A143W, A143M, A143S, A143Q, A143R, A143A, A143I, L144S, L144L, L144T, L144A, L145A, L145F, L145G, L145D, L145L, L145C, L145E, L145s, C146R, S146A, S146C, S146D, S146F, S146R, S146T, S146D, S146G, S146S, S146L, D147D, D147L, D147F, D147G, D147Y, Y147T, Y147R, Y147D, D147R, D147Y, D147A, D147T, D147H, D147F, D147U, D147V, D147I, D147C, F148L, F148F, F148R, F148Y, F148A, F148T, F149C, F149M, F149R, F149Y, F149N, F149F, F149A, F149T, F149V R150R, R150M, R150D, R150F, M151F, M151P, M151R, M151V, M151M, M151E, R152C, R152F, R152H, R152P, R152R, R152P, R152Q, R152M, R152O, R153C, R153Q, R153R, R153V, R153E, R153A, R153P, Q154E, Q154H, Q154M, Q154R, Q154L, Q154S, Q154V, Q154Q, Q154F, Q154I, Q154A, Q154K, E155F, E155G, E155I, E155K, E155P, E155V, E155D, E155E, E155L, E155Q, I156V, I156A, I156I, I156L, I156F, I156D, I156K, I156N, I156R, I156Y, E157A, E157F, E157I, E157P, E157T, E157V, N157K, K157N, K157V, K157P, K157I, K157F, K157F, K157T, K157A, K157S, K157R, A158Q, A158K, A158V, A158A, A158D, A158S, A158T, A158N, Q159S, Q159Q, Q159A, Q159F, Q159K, Q159L, Q159N, K160A, K160S, K160E, K160K, K160N, K160F, K160Q, K161T, K161K, K161R, K161I, K161A, K161N, K161Q, K161S, K161T, A162D, A162Q, R162H, R162P, A162S, A162A, A162N, A162M, A162K, Q163G, Q163S, Q163Q, Q163A, Q163H, Q163N, Q163R, S164F, S164S, S164Q, S164I, S164R, S164Y, S165S, S165P, S165Q, S165A, S165D, S165I, S165T, S165Y, T166T, T166Q, T166E, T166S, T166D, T166K, T166I, T166N, T166P, T166R, D167S D167D, D167I, D167G, D167T, D167A and / or D167N mutation in a TadA reference sequence (e.g., TadA*7.10,ecTadA, or TadA8e), and any alternative mutation at the corresponding position,or one or more corresponding mutations in another adenosine deaminase. Additional mutations are described in U.S. Patent Application Publication No.2022 / 0307003 A1 U.S. Patent No.11,155,803, and International Patent Application Publications No. WO 2023 / 288304 A2, PCT / CN2022 / 143408, WO 2018 / 027078 A1, WO 2021 / 158921 A1 and WO 2023 / 034959 A2, the disclosures of which are incorporated herein by reference in their entirety for all purposes. In various embodiments, an adenosine deaminase of the disclosure lacks an N-terminal methionine. In some embodiments, the disclosure provides TadA variants comprising an alteration at an amino acid selected from one or more of L36, I76, V82, Y147, Q154, and N157 comapred to TadA*7.10. In some embodiments, the disclosure provides TadA variants comprising one or more of the following alterations relative to TadA*7.10: L36H, I76Y, V82T, Y147T, Q154S, and N157K. In some embodiments, the disclosure provides TadA variants comprising the following alterations relative to TadA*7.10: L36H, I76Y, V82T, Y147T, Q154S, and N157K. In some embodiments, the disclosure provides TadA variants comprising the following alterations relative to TadA*7.10: F84Y, A109L, A109V, A109I, A109F, A109S, A109T, A109N, V155S, V155T, V155N, F156Y, F156W, F156R, F156N, and F156Q. In some embodiments, the disclosure provides TadA variants comprising the following alterations relative to TadA*7.10: E3N, E3K, E3G, F6A, H14D, L18A, W23I, W23R, P29T, P29Y, P29Q, V35Q, L36S, N38D, G42M, N46Y, P48A, G50A, H52L, A62V, L63R, L63F, Q65R, G67N, L68V, M70I, N72Y, T79H, Y81V, V82S, M94R, G100V, V102E, V102S, R107A, A114C, G115E, M118L, D119L, H122T, P124H, P124K, P124Q, H128R, V130F, I132K, I132T, E140L, A142N, A142S, L144Q, L145R, L145N, Y147A, F149A, R152P, F156N, and K160E. In some embodiments, the disclosure provides TadA variants comprising a V82T, Y147T, and / or a Q154S mutation. In some embodiments, the disclosure provides TadA variants comprising a V82T, Y147T, and / or a Q154S mutation. In some embodiments, the disclosure provides TadA*8.8 further comprising a V82T mutation. In some embodiments, the disclosure provides TadA*8.8 further comprising a V82T, a Y147T, and a Q154S mutation. In some embodiments, the disclosure provides TadA*8.17 further comprising a V82T mutation. In some embodiments, the disclosure provides TadA*8.17 further comprising a V82T, a Y147T, and a Q154S mutation. In some embodiments, the disclosure provides TadA*8.20 further comprising a V82T mutation. In some embodiments, the disclosure provides TadA*8.20 further comprising a V82T, a Y147T, and a Q154S mutation. In embodiments, a variant of TadA*7.10 comprises one or more alterations selected from any of those alterations provided herein. In particular embodiments, an adenosine deaminase heterodimer comprises a TadA*8 domain and an adenosine deaminase domain selected from Staphylococcus aureus (S. aureus) TadA, Bacillus subtilis (B. subtilis) TadA, Salmonella typhimurium (S. typhimurium) TadA, Shewanella putrefaciens (S. putrefaciens) TadA, Haemophilus influenzae F3031 (H. influenzae) TadA, Caulobacter crescentus (C. crescentus) TadA, Geobacter sulfurreducens (G. sulfurreducens) TadA, or TadA*7.10. In some embodiments, the TadA*8 is a variant as shown in Table 5D. Table 5D shows certain amino acid position numbers in the TadA amino acid sequence and the amino acids present in those positions in the TadA-7.10 adenosine deaminase. Table 5D also shows amino acid changes in TadA variants relative to TadA-7.10 following phage-assisted non-continuous evolution (PANCE) and phage-assisted continuous evolution (PACE), as described in M. Richter et al., 2020, Nature Biotechnology, doi.org / 10.1038 / s41587-020-0453-z, the entire contents of which are incorporated by reference herein. In some embodiments, the TadA*8 is TadA*8a, TadA*8b, TadA*8c, TadA*8d, or TadA*8e. In some embodiments, the TadA*8 is TadA*8e. In one embodiment, an adenosine deaminase is a TadA*8 that comprises or consists essentially of SEQ ID NO: 316 or a fragment thereof having adenosine deaminase activity. Table 5D. Select TadA*8 Variants In some embodiments, the TadA variant is a variant as shown in Table 5E. Table 5E shows certain amino acid position numbers in the TadA amino acid sequence and the amino acids present in those positions in the TadA*7.10 adenosine deaminase. In some embodiments, the TadA variant is MSP605, MSP680, MSP823, MSP824, MSP825, MSP827, MSP828, or MSP829. In some embodiments, the TadA variant is MSP828. In some embodiments, the TadA variant is MSP829. Table 5E. TadA Variants Table 5F. TadA Variants Table 5F (CONTINUED). TadA Variants In particular embodiments, the fusion proteins or complexes comprise a single (e.g., provided as a monomer) TadA* (e.g., TadA*8 or TadA*9). Throughout the present disclosure, an adenosine deaminase base editor that comprises a single TadA* domain is indicates using the terminology ABEm or ABE#m, where “#” is an identifying number (e.g., ABE8.20m), where “m” indicates “monomer.” In some embodiments, the TadA* is linked to a Cas9 nickase. In some embodiments, the fusion proteins or complexes of the disclosure comprise as a heterodimer of a wild-type TadA (TadA(wt)) linked to a TadA*. Throughout the present disclosure, an adenosine deaminase base editor that comprises a single TadA* domain and a TadA(wt) domain is indicates using the terminology ABEd or ABE#d, where “#” is an identifying number (e.g., ABE8.20d), where “d” indicates “dimer.” In other embodiments, the fusion proteins or complexes of the disclosure comprise as a heterodimer of a TadA*7.10 linked to a TadA*. In some embodiments, the base editor is ABE8 comprising a TadA* variant monomer. In some embodiments, the base editor is ABE comprising a heterodimer of a TadA* and a TadA(wt). In some embodiments, the base editor is ABE comprising a heterodimer of a TadA* and TadA*7.10. In some embodiments, the base editor is ABE comprising a heterodimer of a TadA*. In some embodiments, the TadA* is selected from Tables 5A-5E. In some embodiments, the adenosine deaminase is expressed as a monomer. In other embodiments, the adenosine deaminase is expressed as a heterodimer. In some embodiments, the deaminase or other polypeptide sequence lacks a methionine, for example when included as a component of a fusion protein. This can alter the numbering of positions. However, the skilled person will understand that such corresponding mutations refer to the same mutation. Any of the mutations provided herein and any additional mutations (e.g., based on the ecTadA amino acid sequence) can be introduced into any other adenosine deaminases. Any of the mutations provided herein can be made individually or in any combination in a TadA reference sequence or another adenosine deaminase (e.g., ecTadA). Details of A to G nucleobase editing proteins are described in International PCT Application No. PCT / US2017 / 045381 (WO2018 / 027078) and Gaudelli, N.M., et al., “Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage” Nature, 551, 464-471 (2017), the entire contents of which are hereby incorporated by reference. C to T Editing In some embodiments, a base editor disclosed herein comprises a fusion protein or complex comprising cytidine deaminase capable of deaminating a target cytidine (C) base of a polynucleotide to produce uridine (U), which has the base pairing properties of thymine. In some embodiments, for example where the polynucleotide is double-stranded (e.g., DNA), the uridine base can then be substituted with a thymidine base (e.g., by cellular repair machinery) to give rise to a C:G to a T:A transition. In other embodiments, deamination of a C to U in a nucleic acid by a base editor cannot be accompanied by substitution of the U to a T. The deamination of a target C in a polynucleotide to give rise to a U is a non-limiting example of a type of base editing that can be executed by a base editor described herein. In another example, a base editor comprising a cytidine deaminase domain can mediate conversion of a cytosine (C) base to a guanine (G) base. For example, a U of a polynucleotide produced by deamination of a cytidine by a cytidine deaminase domain of a base editor can be excised from the polynucleotide by a base excision repair mechanism (e.g., by a uracil DNA glycosylase (UDG) domain), producing an abasic site. The nucleobase opposite the abasic site can then be substituted (e.g., by base repair machinery) with another base, such as a C, by for example a translesion polymerase. Although it is typical for a nucleobase opposite an abasic site to be replaced with a C, other substitutions (e.g., A, G or T) can also occur. Accordingly, in some embodiments a base editor described herein comprises a deamination domain (e.g., cytidine deaminase domain) capable of deaminating a target C to a U in a polynucleotide. Further, as described below, the base editor can comprise additional domains which facilitate conversion of the U resulting from deamination to, in some embodiments, a T or a G. For example, a base editor comprising a cytidine deaminase domain can further comprise a uracil glycosylase inhibitor (UGI) domain to mediate substitution of a U by a T, completing a C-to-T base editing event. In another example, the base editor can comprise a uracil stabilizing protein as described herein. In another example, a base editor can incorporate a translesion polymerase to improve the efficiency of C-to-G base editing, since a translesion polymerase can facilitate incorporation of a C opposite an abasic site (i.e., resulting in incorporation of a G at the abasic site, completing the C-to-G base editing event). A base editor comprising a cytidine deaminase as a domain can deaminate a target C in any polynucleotide, including DNA, RNA and DNA-RNA hybrids. In some embodiments, a cytidine deaminase of a base editor comprises all or a portion (e.g., a functional portion) of an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. APOBEC is a family of evolutionarily conserved cytidine deaminases. Members of this family are C-to-U editing enzymes. The N-terminal domain of APOBEC like proteins is the catalytic domain, while the C-terminal domain is a pseudocatalytic domain. More specifically, the catalytic domain is a zinc dependent cytidine deaminase domain and is important for cytidine deamination. APOBEC family members include APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D (“APOBEC3E” now refers to this), APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, and Activation-induced (cytidine) deaminase. Other exemplary deaminases that can be fused to Cas9 according to aspects of this disclosure are provided below. In embodiments, the deaminases are activation-induced deaminases (AID). It should be understood that, in some embodiments, the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localization sequence, without nuclear export signal, cytoplasmic localizing signal). Some aspects of the present disclosure are based on the recognition that modulating the deaminase domain catalytic activity of any of the fusion proteins or complexes described herein, for example by making point mutations in the deaminase domain, affect the processivity of the fusion proteins (e.g., base editors) or complexes. For example, mutations that reduce, but do not eliminate, the catalytic activity of a deaminase domain within a base editing fusion protein or complexes can make it less likely that the deaminase domain will catalyze the deamination of a residue adjacent to a target residue, thereby narrowing the deamination window. The ability to narrow the deamination window can prevent unwanted deamination of residues adjacent to specific target residues, which can reduce or prevent off-target effects. In some embodiments, an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of R33A, K34A, E63A, H102P, D104N, H121R, H122R, H122L, D124N; R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1; D316R, D317R, R320A, R320E, R313A, W285A, W285Y, and R326E of hAPOBEC3G; and any alternative mutation at the corresponding position, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor can comprise one or more combinations of mutations selected from K34A, H122L, and D124N (AALN); H102P and D104N (evoFERNY derived from FERNY); W90Y and R126E (YE1); W90Y and R132E (YE2); R126E and R132E (EE); W90Y, R126E, and R132E (YEE), or rAPOBEC1; and any alternative mutation at the corresponding positions, or one or more corresponding mutations in another APOBEC deaminase. A number of modified cytidine deaminases are commercially available, including, but not limited to, SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, VRER-BE3, YE1-BE3, EE-BE3, YE2- BE3, and YEE-BE3, which are available from Addgene (plasmids 85169, 85170, 85171, 85172, 85173, 85174, 85175, 85176, 85177). In some embodiments, a deaminase incorporated into a base editor comprises all or a portion (e.g., a functional portion) of an APOBEC1 deaminase. In some embodiments, the fusion proteins or complexes of the disclosure comprise one or more cytidine deaminase domains. In some embodiments, the cytidine deaminases provided herein are capable of deaminating cytosine or 5-methylcytosine to uracil or thymine. In some embodiments, the cytidine deaminases provided herein are capable of deaminating cytosine in DNA. The cytidine deaminase may be derived from any suitable organism. In some embodiments, the cytidine deaminase is a naturally-occurring cytidine deaminase that includes one or more mutations corresponding to any of the mutations provided herein. One of skill in the art will be able to identify the corresponding residue in any homologous protein, e.g., by sequence alignment and determination of homologous residues. Accordingly, one of skill in the art would be able to generate mutations in any naturally-occurring cytidine deaminase that corresponds to any of the mutations described herein. In some embodiments, the cytidine deaminase is from a prokaryote. In some embodiments, the cytidine deaminase is from a bacterium. In some embodiments, the cytidine deaminase is from a mammal (e.g., human). In some embodiments, the cytidine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the cytidine deaminase amino acid sequences set forth herein. It should be appreciated that cytidine deaminases provided herein may include one or more mutations (e.g., any of the mutations provided herein). Some embodiments provide a polynucleotide molecule encoding the cytidine deaminase nucleobase editor polypeptide of any previous aspect or as delineated herein. In some embodiments, the polynucleotide is codon optimized. In embodiments, a fusion protein of the disclosure comprises two or more nucleic acid editing domains. Details of C to T nucleobase editing proteins are described in International PCT Application No. PCT / US2016 / 058344 (WO2017 / 070632) and Komor, A.C., et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016), the entire contents of which are hereby incorporated by reference. Further non-limiting examples of C to T nucleobase editing proteins are described in PCT Applications No. PCT / US2020 / 062428 and PCT / US2019 / 033848, the entire contents of which are hereby incorporated by reference. Cytidine Adenosine Base Editors (CABEs) In some embodiments, a base editor described herein comprises an adenosine deaminase variant that has increased cytidine deaminase activity. Such base editors may be referred to as “cytidine adenosine base editors (CABEs)” or “cytosine base editors derived from TadA* (CBE-Ts),” and their corresponding deaminase domains may be referred to as “TadA* acting on DNA cytosine (TADC)” domains or TadA-derived cytidine deaminases (TadA-CD). Base editors containing adenosine deaminase variants having both cytidine deaminase and adenosine deaminase activity (i.e., TadA-Dual deaminases) may be referred to as TadA-based dual editors (TadDE). In some instances, an adenosine deaminase variant has both adenine and cytosine deaminase activity (i.e., is a dual deaminase). In some embodiments, the adenosine deaminase variants deaminate adenine and cytosine in DNA. In some embodiments, the adenosine deaminase variants deaminate adenine and cytosine in single-stranded DNA. In some embodiments, the adenosine deaminase variants deaminate adenine and cytosine in RNA. In some embodiments, the adenosine deaminase variant predominantly deaminates cytosine in DNA and / or RNA (e.g., greater than 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of all deaminations catalyzed by the adenosine deaminase variant, or the number of cytosine deaminations catalyzed by the variant is about or at least about 2-fold, 3-fold, 4-fold, 5-fold, 6- fold, 7-fold, 8-fold, 9-fold, 10-fold, 25-fold, 50-fold, 75-fold, 100-fold, 500-fold, or 1,000-fold greater than the number adenine deaminations catalyzed by the variant). In some embodiments, the adenosine deaminase variant has approximately equal cytosine and adenosine deaminase activity (e.g., the two activities are within about 10% or 20% of each other). In some embodiments, the adenosine deaminase variant has predominantly cytosine deaminase activity, and little, if any, adenosine deaminase activity. In some embodiments, the adenosine deaminase variant has cytosine deaminase activity, and no significant or no detectable adenosine deaminase activity. In some embodiments, the target polynucleotide is present in a cell in vitro or in vivo. In some embodiments, the cell is a bacteria, yeast, fungi, insect, plant, or mammalian cell. Examples of adenosine deaminase variants having increased cytidine deaminase activity include those described in International Patent Application Publications No. WO 2024 / 040083 and WO 2022 / 204574, the disclosures of which are hereby incorporated by reference in their entireties for all purposes. In some embodiments, the CABE comprises a bacterial TadA deaminase variant (e.g., ecTadA). In some embodiments, the CABE comprises a truncated TadA deaminase variant. In some embodiments, the CABE comprises a fragment of a TadA deaminase variant. In some embodiments, the CABE comprises a TadA*8.20 variant. In some embodiments, an adenosine deaminase variant of the disclosure is a TadA adenosine deaminase comprising one or more alterations that increase cytosine deaminase activity (e.g., at least about 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold or more increase) while maintaining adenosine deaminase activity (e.g., at least about 30%, 40%, 50% or more of the activity of a reference adenosine deaminase (e.g., TadA*8.20 or TadA*8.19)). In some instances, the adenosine deaminase variant comprises one or more alterations that increase cytosine deaminase activity (e.g., at least about 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60- fold, 70-fold or more increase) relative to the activity of a reference adenosine deaminase and comprise undetectable adenosine deaminase activity or adenosine deaminase activity that is less than 30%, 20%, 10%, or 5% of that of a reference adenosine deaminase. In some embodiments, the reference adenosine deaminase is TadA*8.20 or TadA*8.19. In some embodiments, the adenosine deaminase variant is an adenosine deaminase comprising two or more alterations at an amino acid position selected from the group consisting of 2, 4, 6, 8, 13, 17, 23, 27, 29, 30, 47, 48, 49, 67, 76, 77, 82, 84, 96, 100, 107, 112, 114, 115, 118, 119, 122, 127, 142, 143, 147, 149, 158, 159, 162165, 166, and 167, of an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or greater identity to SEQ ID NO: 1, or a corresponding alteration in another deaminase. I In some embodiments, the adenosine deaminase variant is an adenosine deaminase comprising one or more alterations selected from the group consisting of S2H, V4K, V4S, V4T, V4Y, F6G, F6H, F6Y, H8Q, R13G, T17A, T17W, R23Q, E27C, E27G, E27H, E27K, E27Q, E27S, E27G, P29A, P29G, P29K, V30F, V30I, R47G, R47S, A48G, I49K, I49M, I49N, I49Q, I49T, G67W, I76H, I76R, I76W, Y76H, Y76R, Y76W, F84A, F84M, H96N, G100A, G100K, T111H, G112H, A114C, G115M, M118L, H122G, H122R, H122T, N127I, N127K, N127P, A142E, R147H, A158V, Q159S, A162C, A162N, A162Q, and S165P of an amino acid sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or greater identity to SEQ ID NO: 1, or a corresponding alteration in another deaminase. In some embodiments, the adenosine deaminase variant is an adenosine deaminase comprising an amino acid alteration or combination of amino acid alterations selected from those listed in any of Tables 6A-6F. The residue identity of exemplary adenosine deaminase variants that are capable of deaminating adenine and / or cytidine in a target polynucleotide (e.g., DNA) is provided in Tables 6A-6F below. Further examples of adenosine deaminase variants include the following variants of 1.17 (see Table 6A): 1.17+E27H; 1.17+E27K; 1.17+E27S; 1.17+E27S+I49K; 1.17+E27G; 1.17+I49N; 1.17+E27G+I49N; and 1.17+E27Q. In some embodiments, any of the amino acid alterations provided herein are substituted with a conservative amino acid. Additional mutations known in the art can be further added to any of the adenosine deaminase variants provided herein. In some embodiments, the base editor systems comprising a CABE provided herein have at least about a 30%, 40%, 50%, 60%, 70% or more C to T editing activity in a target polynucleotide (e.g., DNA). In some embodiments, a base editor system comprising a CABE as provided herein has an increased C to T base editing activity (e.g., increased at least about 30- fold, 40-fold, 50-fold, 60-fold, 70-fold or more) relative to a reference base editor system comprising a reference adenosine deaminase (e.g., TadA*8.20 or TadA*8.19). Table 6A. Adenosine Deaminase Variants. Mutations are indicated with reference to TadA*8.20. “S” indicates “Surface,” and “NAS” indicates “Near Active Site.” Table 6A (continued). Adenosine Deaminase Variants. Mutations are indicated with reference to TadA*8.20. “I” indicates “Internal,” “S” indicates “Surface,” and “NAS” indicates “Near Active Site.” Table 6B. Adenosine deaminase variants. Mutations are indicated with reference to TadA*8.20.

[0029] Table 6C. Adenosine deaminase variants. Mutations are indicated with reference to variant 1.2 (Table 6A) .

[0030] Table 6C. (CONTINUED)

[0031] Table 6D. Adenosine deaminase variants. Mutations are indicated with reference to TadA*8.20. Table 6E. Hybrid constructs. Mutations are indicated with reference to TadA*7.10. Table 6F. Base editor variants. Mutations are indicated with reference to TadA*8.19 / 8.20. A TadA-derived cytidine deaminase (e.g., TadA-CD), according to certain embodiments, comprises an amino acid sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, and at least 99.5% identical to the amino acid sequence of SEQ ID NO: 489, wherein residue 27 of SEQ ID NO: 489 is any amino acid expect for E (glutamic acid). TadA-CDs with other sequence homologies are also possible. For example, in certain embodiments, the TadA-derived cytidine deaminase (e.g., TadA-CD) comprises an amino acid sequence that is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, and at least 99.5% identical to the amino acid sequence of SEQ ID NO: 489, wherein residue 28 of SEQ ID NO: 489 is any amino acid expect for V (valine). In another exemplary embodiment, the TadA-derived cytidine deaminase is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, and at least 99.5% identical to the amino acid sequence of SEQ ID NO: 489, wherein residue 96 of SEQ ID NO: 489 is any amino acid expect for H (histidine). In another exemplary embodiment, the TadA-derived cytidine deaminase is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 98% identical, at least 99% identical, and at least 99.5% identical to the amino acid sequence of SEQ ID NO: 489, wherein residue 26 of SEQ ID NO: 489 is any amino acid expect for R (arginine). In various embodiments, the TadA-derived cytidine deaminase comprises an alteration at one or more of positions 26, 27, 28, 48, 73, or 96 compared to SEQ ID NO: 489. As will be appreciated by those of skill in the art, TadA-derived cytidine deaminases (e.g., TadA-CD) may comprise a plurality of mutations relative to the parent adenosine deaminase (e.g., TadA-8e). In some embodiments, the deaminase of the instant application (e.g., TadA-CD) comprises mutations at residues E27, V28, and H96. In some embodiments, the disclosed deaminase further comprises at least one mutation at a residue selected from R26, M61, Y73, I76, M151, Q154, and A158, in the amino acid sequence of SEQ ID NO: 489, or corresponding mutations in a homologous adenosine deaminase. In some embodiments, the deaminase comprises at least one mutation selected from E27A, E27K, V28G, V28A, and H96N, and further comprises at least one mutation at a residue selected from R26G, M61I, Y73H, Y73S, Y73C, I76F, M151I, Q154R, Q154H, and A158S, in the amino acid sequence of SEQ ID NO: 489, or a corresponding mutation in a homologous adenosine deaminase. Other mutations are also possible. For example, in certain embodiments, the TadA-CD enzyme comprises mutations selected from E27A, V28G, and H96N, and further comprises at least one mutation selected from R26G, M61I, Y73H, Y73S, Y73C, I76F, M151I, Q154R, Q154H, and A158S, in the amino acid sequence of SEQ ID NO: 489, or corresponding mutations in a homologous adenosine deaminase. Other exemplary embodiments may include (1) deaminases comprising mutations E27K, V28G, and H96N, and further comprising at le...

Claims

CLAIMS What is claimed:

1. A method of editing a nucleobase of a lipoprotein A (LPA) polynucleotide in a cell, the method comprising contacting the LPA polynucleotide with a base editor system comprising a guide RNA, or a polynucleotide encoding said guide RNA, and a base editor comprising a fusion protein or a protein complex comprising a nucleic acid programmable DNA binding protein (napDNAbp) domain and a deaminase domain, or one or more polynucleotides encoding the base editor, wherein said guide RNA targets said base editor to effect an alteration of the nucleobase of the LPA polynucleotide.

2. A method of treating atherosclerosis and / or cardiovascular disease in a subject in need thereof, the method comprising contacting a cell of the subject with a base editor system comprising a base editor comprising a fusion protein or protein complex comprising a nucleic acid programmable DNA binding protein (napDNAbp) domain and a deaminase domain, or one or more polynucleotide encoding the base editor, and a guide RNA, or a polynucleotide encoding said guide RNA, wherein the guide RNA targets the base editor to effect an alteration of a nucleobase of an LPA polynucleotide.

3. The method of claim 1 or claim 2, wherein the guide RNA is selected from the guides listed in Tables 1B-1, 1A-1, and 1C-1.

4. The method of claim 1 or claim 2, wherein the deaminase domain is an adenosine deaminase comprising an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine and comprises one or more amino acid alterations selected from the group consisting of I76Y, V82S, Y123H, Y147R, and Q154R compared to the following amino acid sequence: TadA*7.10 MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1).

5. The method of claim 4, wherein the adenosine deaminase comprises the amino acid alterations I76Y, V82S, Y123H, Y147R, and Q154R.

6. The method of claim 5, wherein the adenosine deaminase has at least about 95% identity to SEQ ID NO:

1.

7. The method of claim 1 or claim 2, wherein the deaminase domain is a cytidine deaminase comprising an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine: ppAPOBEC1 MTSEKGPSTGDPTLRRRIESWEFDVFYDPRELRKETCLLYEIKWGMSRKIWRSSGKNTTNHVEV NFIKKFTSERRFHSSISCSITWFLSWSPCWECSQAIREFLSQHPGVTLVIYVARLFWHMDQRNR QGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPC LKISRRWQNHLAFFRLHLQNCHYQTIPPHILLATGLIHPSVTWR (SEQ ID NO: 23).

8. The method of claim 1 or claim 2, wherein alteration of the nucleobase is associated with a reduction in transcription of a polynucleotide sequence encoding the LPA protein.

9. The method of claim 1 or claim 2, wherein alteration of the nucleobase in the LPA polynucleotide disrupts a splice site.

10. The method of claim 1 or claim 2, wherein the alteration introduces a single nucleotide polymorphism (SNP) into the LPA polynucleotide, wherein the SNP is associated with reduced serum concentrations of LPA in a subject and / or reduced incidence of atherosclerosis and / or cardiovascular disease in a subject, and wherein the SNP is selected from the group consisting of, chr6:160531784:T>C, chr6:160532531:C>T, chr6:160548552:G>A, chr6:160532610:A>G, chr6:160591049:A>G, chr6:160635134:G>A, and chr6:160547886:A>G.

11. The method of claim 1 or claim 2, wherein the alteration results in a premature STOP codon.

12. The method of claim 1 or claim 2, wherein the alteration is associated with a reduction in incidence of cardiovascular disease in a subject.

13. The method of claim 1 or claim 2, wherein the base editor comprises an amino acid sequence with at least about 90% identity to a sequence listed in Table 2.

14. The method of claim 1 or claim 2, wherein the guide RNA comprises a nucleic acid sequence comprising at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of a spacer nucleic acid sequence listed in Table 1B-1, 1A-1, and 1C-1.

15. The method of claim 14, wherein the guide RNA comprises a nucleic acid sequence listed in Table 1B-1, 1A-1, and 1C-1.

16. The method of claim 1 or claim 2, wherein the method comprises altering the nucleobase of the LPA polynucleotide at a rate of greater than 50%.

17. The method of claim 2, wherein the method is associated with at least a 50% reduction of serum concentrations of LPA in the subject.

18. The method of claim 2, wherein the method is associated with a reduction of serum concentrations of LPA in the subject to less than about 50 mg / dL.

19. The method of claim 2, wherein the method is associated with at least a 10% reduction of incidence of coronary heart disease in the subject.

20. The method of claim 2, wherein the base editor system is administered to the subject using a lipid nanoparticle comprising the guide RNA and an mRNA molecule encoding the base editor.

21. A modified cell comprising an alteration in a nucleobase of a LPA polynucleotide, wherein the alteration is prepared by the method of any one of claims 1-20.

22. A base editor system comprising a fusion protein or one or more polynucleotides encoding said fusion protein, wherein said fusion protein comprises a nucleic acid programmable DNA binding protein domain (napDNAbp) and a deaminase domain, and a guide RNA, or a guide polynucleotide encoding said guide RNA, wherein said guide RNA targets said base editor to effect an alteration of a nucleobase of an LPA polynucleotide.

23. The base editor system of claim 22, wherein the guide RNA is selected from the guides listed in Tables 1B-1, 1A-1, and 1C-1.

24. The base editor system of claim 22, wherein the deaminase is an adenosine deaminase comprising an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine and comprises one or more amino acid alterations selected from the group consisting of I76Y, V82S, Y123H, Y147R, and Q154R compared to the following amino acid sequence: TadA*7.10 MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1).

25. The base editor system of claim 24, wherein the adenosine deaminase comprises the amino acid alterations I76Y, V82S, Y123H, Y147R, and Q154R.

26. The base editor system of claim 25, wherein the adenosine deaminase has at least about 95% identity to SEQ ID NO:

1.

27. The base editor system of claim 22, wherein the deaminase is a cytidine deaminase comprising an amino acid sequence with at least about 90% identity to the following amino acid sequence or a fragment thereof lacking the N-terminal methionine: ppAPOBEC1 MTSEKGPSTGDPTLRRRIESWEFDVFYDPRELRKETCLLYEIKWGMSRKIWRSSGKNTTNHVEV NFIKKFTSERRFHSSISCSITWFLSWSPCWECSQAIREFLSQHPGVTLVIYVARLFWHMDQRNR QGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPC LKISRRWQNHLAFFRLHLQNCHYQTIPPHILLATGLIHPSVTWR (SEQ ID No: 23).

28. The base editor system of claim 22, wherein alteration of the nucleobase is associated with a reduction in transcription of a polynucleotide sequence encoding the LPA protein.

29. The base editor system of claim 22, wherein alteration of the nucleobase in the LPA polynucleotide disrupts a splice site.

30. The base editor system of claim 22, wherein the alteration introduces a single nucleotide polymorphism (SNP) into the LPA polynucleotide, wherein the SNP is associated with reduced serum concentrations of LPA in a subject and / or reduced incidence of atherosclerosis and / or cardiovascular disease in a subject.

31. The base editor system of claim 30, wherein the SNP is selected from the group consisting of, chr6:160531784:T>C, chr6:160532531:C>T, chr6:160548552:G>A, chr6:160532610:A>G, chr6:160591049:A>G, chr6:160635134:G>A, and chr6:160547886:A>G.

32. The base editor system of claim 22, wherein the alteration results in a premature STOP codon.

33. The base editor system of claim 22, wherein the alteration is associated with a reduction in incidence of cardiovascular disease in a subject.

34. The base editor system of claim 22, wherein the base editor comprises an amino acid sequence with at least about 90% identity to a sequence listed in Table 2.

35. The base editor system of claim 22, wherein the guide RNA comprises a nucleic acid sequence comprising at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of a spacer nucleic acid sequence listed in Table 1B-1, 1A-1, and 1C-1.

36. The base editor system of claim 35, wherein the guide RNA comprises a nucleic acid sequence listed in Table 1B-1, 1A-1, and 1C-1.

37. A polynucleotide or set of polynucleotides encoding the base editor system of any one of claims 22-36 or a component thereof.

38. A lipid nanoparticle comprising the base editor system of any one of claims 22-36 or the polynucleotide or set of polynucleotides of claim 37.

39. A pharmaceutical composition comprising the modified cell of claim 21, the base editor system of any one of claims 22-36, the polynucleotide or set of polynucleotides of claim 37, or the lipid nanoparticle of claim 38, and a pharmaceutically acceptable excipient.

40. A kit comprising the modified cell of claim 21, the base editor system of any one of claims 22-36, the polynucleotide or set of polynucleotides of claim 37, the lipid nanoparticle of claim 38, or the pharmaceutical composition of claim 39, for use in the method of any one of claims 1-20, wherein the kit further comprises a container.

41. A guide RNA comprising a sequence listed in Table 1B-1, 1B-2, 1A-1, 1A-2, 1C-1, or 1C-2

Images